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Abstract	  
Cardiovascular disease is the leading cause of death in patients with underlying chronic 
kidney disease (CKD). Up to one third of patients presenting with an acute coronary 
syndrome have CKD stage 3-5. Outcomes following acute myocardial infarction in 
patients with underlying CKD remain poor. CKD patients are routinely excluded from 
clinical trials in novel cardioprotective strategies resulting in a paucity of prospective 
data on which to base guidelines for clinical practice.            
The aims of this work were to: 
• Establish and characterise two models of chronic uraemia in rodents: the 
subtotal nephrectomy model and the adenine diet model.  
• Determine the effects of underlying chronic uraemia on myocardial ischaemia 
tolerance. 
• Examine pharmacological cardioprotective strategies in the context of 
underlying uraemia using a PARP inhibitor 
• Investigate the cardioprotective effects of ischaemic conditioning in the 
context of uraemia. Ischaemic preconditioning and postconditioning protocols 
were used in both uraemic and non-uraemic animals in a model of acute 
myocardial infarction. 
• Preliminary work, using standard molecular biological techniques, was carried 
out in order to confirm the putative survival pathways responsible for the 
effect of preconditioning. 
• Investigate the effect of combining early and late remote ischaemic 
preconditioning to identify whether summation of these strategies could 
provide additional tissue protection in a model of acute kidney injury.  
The results demonstrate that both models develop a uraemic phenotype. Subtotal 
nephrectomy animals exhibit reduced ischaemia tolerance. PARP inhibition as a 
pharmacological post conditioning agent was shown to be ineffective at conferring 
tissue protection, whereas both ischaemic preconditioning and postconditioning were 
effective cytoprotective strategies in both non-uraemic and uraemic animals. 
Furthermore, additional benefit was seen when early and late remote preconditioning 
were summated in a rodent model of acute kidney injury. 
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This work provides a basis for future clinical trials in cardioprotection in the context of 
underlying CKD. 
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Introduction 
Heart	  disease	  in	  the	  general	  population	  
Cardiovascular disease is the leading cause of death in the western world. 
Cardiovascular disease accounts for 1 in 2.8 deaths5, and causes more deaths than 
cancer, lung disease, accidents and diabetes combined5.  Death rates from 
cardiovascular disease rose year on year peaking in the 1980s, before falling by 
approximately 20% over the last 30 years6. The incidence of cardiovascular events 
increases with age: from 3 per 1000 men aged 35-44 to 74 per 1000 from men aged 85-
947.  Coronary heart disease makes up over half of all cardiovascular events. Incidence 
rates of new coronary events in a middle aged American cohort are between 4 and 12 
events per 100 person years2, 8. Death rates from cardiac events have fallen over the last 
40 years due to medical interventions such as revascularisation therapies, heart failure 
treatments, and new pharmacological agents and also life style changes in the 
population9. However despite this, the one year mortality following an acute myocardial 
infarction (AMI) is between 8-14%4, 6. 
 
Risk	  Factors	  for	  coronary	  heart	  disease	  in	  the	  general	  population	  
Hypertension	  
Hypertension is the most prevalent risk factor for cardiovascular disease, with 30% of 
Americans having this diagnosis10. Risk factors for the development of hypertension 
include age, ethnicity, a family history of hypertension, obesity, and lower 
socioeconomic status6. Hypertension has been defined as the level of blood pressure, 
which is associated with increased morbidity and mortality when compared to the 
general population. Current guidelines for hypertension suggest that a clinic blood 
pressure of >140 systolic or >90 diastolic are indicative of hypertension in an adult 
without co-morbidities11.  
The ‘HOT’12 study demonstrated benefits in cardiovascular outcomes with BP lowering 
to a diastolic of 82.6mm/hg. However further studies have indicated that lower targets 
are associated with better outcomes in people with additional co-morbidities such as 
diabetes12 and renal disease13. Furthermore, studies looking at the cardiovascular effects 
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of antihypertensive treatment demonstrate that cardiovascular protection may go 
beyond absolute BP reduction in patients with additional co-morbidities using specific 
agents such as ACE inhibitors14 or angiotensin receptor blockers15. 
 
Smoking	  
Cigarette smoking results in a 2-3-fold risk of dying from CHD, and on average 
smokers die 14 years younger than non-smokers. If a person stops smoking within 5 
years the excess cardiovascular risk is approximately halved, and after 10 years the risk 
approaches that of life long non smokers16. 
 
Dyslipidaemia	  
There is a correlation between serum cholesterol and mortality17. The Framingham 
cohort results report that cholesterol levels remain static in men with age. Women 
however have lower cholesterol levels until menopause, when cholesterol levels rise 
and over take men at the 6th decade18. Over the last 25 years it has be well established 
that lowering of the serum cholesterol (with particular emphasis on the LDL 
component) reduces cardiovascular mortality 19 
The relative risk of coronary heart disease associated with physical inactivity ranges 
from 1.5-2.4: an increase comparable with that of smoking, hypertension or 
dyslipidaemia 20, with 12.2 % of the global burden of CVD risk is attributable to 
physical inactivity 21. 
 
Obesity	  
The obesity epidemic has yet to fully manifest itself: the prevalence of BMI-for-age 
values at or above the 95th centile in adolescents has increased from 6.1% to 17.6% 
over the last 30 years 22. Data from the NHANES database reveal that obesity was 
attributable with 13% of CVD deaths 23. Abdominal obesity is strongly associated 
with hypertension, dyslipidaemia and insulin resistance, which are themselves risk 
factors for cardiovascular disease24. 
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Diabetes	  
Underlying diabetes predisposes to CVD25 and worsens the outcome of CVD with 2-4 
times the disk of cardiovascular death compared to non-diabetic patients26. Diabetes 
confers the same risk of death as 2 of the 3 major coronary risk factors: smoking, 
hypertension and dyslipidaemia27. Furthermore diabetes tends to co-localise with other 
risk factors such as obesity, hypertension and dyslipidaemia, acting synergistically to 
increase risk further28 . 
The	  uraemic	  heart	  
Chronic	  kidney	  disease	  
Chronic kidney disease is a condition caused by loss of renal function characterised by 
elevations in serum creatinine concentrations. However the kidney does not only 
excrete creatinine: it is involved in fluid balance, acid base balance, blood pressure 
homeostasis, regulation of calcium and phosphate homeostasis, regulation of 
haemoglobin synthesis and excretion of toxic metabolites. Because of these functions, 
patients with CKD display a wide variety of physiological perturbations impacting on 
almost every organ system.  
End stage renal failure is said to occur when the kidney function declines to a level 
where the patient is severely symptomatic from renal failure and the initiation of 
dialysis is needed to alleviate the metabolic complications, without which the patient 
would die either from fluid overload or hyperkalaemia. CKD has been divided into 5 
stages29 by glomerular filtration rate (GFR), which is defined as the volume of fluid 
filtered by the glomeruli into Bowman’s space in ml/hr. CKD stage 1 and 2 represents 
no or very minimal reduction in GFR, but with urinary abnormalities such as 
haematuria or proteinuria. Stages 3-5 CKD are defined solely by GFR: stage 3 CKD: 
GFR 30-60 ml/hr, stage 4: 15-30ml/hr and stage 5 CKD is GFR is <15ml/hr or on 
dialysis.  
The incidence of CKD and ESRD has increased by 40% in the last 10 years30. The 
prevalence of CKD stages 1-5 is around 12-15% in a large western cohort 30. The 
prevalence of CKD rises with age, from 8.5% of those under 40 to almost 40% of those 
over 60 years of age31. A higher prevalence of CKD is associated with socioeconomic 
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status, a lower educational status and ethnicity, with Mexican and non-Hispanic black 
people having over twice the prevalence of CKD compared to the white population31. 
Risk factors for CKD include many of the traditional risk factors for CVD such as 
hypertension, diabetes, age, male sex, smoking and vascular disease. However, even 
after adjusting for these risk factors, underlying CKD is associated with excess 
cardiovascular risk32. Thus patients with CKD are likely to be at high risk of CVD 
already, before taking into account  additional CKD specific risk factors.  
 
Outcomes	  of	  Chronic	  kidney	  disease	  
The 5 year survival on haemodialysis is 40.3%30, which is worse than many of the most 
common cancers such as breast, colon and non-Hodgkins lymphoma. Lindner et al.33 
were the first group to report that patients with end-stage renal failure had excessive 
cardiovascular mortality.  One third of CKD patients have evidence of atheroma both at 
autopsy34 and on angiography35. However, even accounting for this, uraemic patients 
have a 4-5 times higher 1 year mortality following AMI than non uraemic patients36.  
Foley et al.37 reported that in incident haemodialysis patients, 40% had a history of 
ischaemic heart disease and heart failure and 75% had LVH on echocardiography. 
Foley at al. found that after adjusting for race, gender and age, cardiovascular mortality 
was on average 10-20 times that for an age-matched control (see Figure 1). This 
increased risk was particularly strong in the younger cohort where the cardiovascular 
mortality was over 500 times that of an age-matched control.  
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Management	  of	  CVD	  in	  the	  CKD/ESRD	  population	  
Diagnosis	  of	  CVD	  in	  CKD/ESRD	  
Difficulties exist in the diagnosis of an acute myocardial event in a CKD/ESRD patient. 
Chest pain may be absent in the context of a diabetic patient, or may occur as a result of 
anaemia. A reduction in exercise tolerance may be due to anaemia, fluid overload or 
metabolic acidosis. Resting ECG abnormalities may be due to volume overload, LVH 
or electrolyte disturbances.  
Cardiac enzyme rise, in the form of troponin, is one of the hallmarks of myocardial 
infarction. However, small elevations may be found on routine testing in patients with 
renal disease38. It is unclear whether these baseline elevations are due to low grade 
myocardial ischaemia/apoptosis or whether they represent reduced clearance of the 
troponin fragments which are detected by the troponin assay39. However, it is important 
Figure 1. Seminal figure from work by Foley et al.3 demonstrating the 
cardiovascular mortality in the general population compared to dialysis patients  
from USRDS database.  
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to note that in the context of an acute coronary syndrome (ACS), troponin 
concentrations predict death risk at 1 month regardless of creatinine clearance40.  
Given that the classical triad of symptoms, an abnormal ECG and raised cardiac 
enzymes may be less reliable in the context of CKD, along with the concern regarding 
contrast induced nephrotoxicity seen with diagnostic coronary angiograms, patients 
with CKD and CVD represent a diagnostic and management challenge. 
Therapies	  for	  CVD	  in	  CKD/ESRD	  
CKD patients are known to have the highest incidence of CVD and have the worst 
outcomes post AMI. But this group of patients often receive fewer beneficial 
interventions than non-CKD patients. They receive less aspirin, beta-blockers, ACE 
inhibitors, glycoprotein IIb-IIIa receptor antagonists, thrombolysis, and percutaneous 
coronary interventions (PCI)41-43. This therapeutic nihilism is a result of physicians 
concern regarding bleeding risk, worsening renal failure, lack of evidence for certain 
drugs and the belief that CKD patients generally have poor outcomes. The safety data 
on glycoprotein IIb-IIIa inhibitors is limited in the context of renal failure, as most 
studies excluded CKD patients from clinical trials. However, a retrospective analysis of 
mild CKD patients undergoing PCI showed no increased bleeding risk with 
glycoprotein IIb-IIIa receptor antagonists44.  
While there is the concern of hyperkalaemia and worsening GFR with the use of ACE 
inhibitors in the context of CKD, ACE inhibitor use post AMI in a CKD population was 
associated with a reduction in 30 day mortality of 36%, which is similar to non CKD 
patients43.  
After a cardiac event, patients with CKD are also at much greater risk of heart failure, 
arrythmias and sudden cardiac death. Arrhythmias, leading to sudden cardiac death is 
the most common cause of cardiovascular death in the context of CKD 45. Risk factors 
for the development of arrhythmias in dialysis patients are intradialytic blood pressure 
fall, dialysis vintage, time since prievious dislaysis session and the presence of 
diabetes45. 
 
Cardiac	  interventions	  
In hospital mortality following PCI is strongly correlated with renal function41. The role 
of PCI for AMI in the context of CKD is unclear. Early studies of angioplasty in 
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haemodialysis patients were disappointing: despite initial angiographic success patients 
had high re-stenosis rates of up to 81%46. Subsequently, procedural advances combined 
with the use of drug eluting stents reduced incidence of stent re-stenosis to 36%47. 
However a study by Dragu et al.48 suggested that PCI may lead to inferior outcomes 
when compared to thrombolysis in CKD patients. The SWEDEHEART49 study 
reported that the benefits of PCI over medical management diminished as the stage of 
CKD worsened, such that below a GFR of 30 ml/min there was no additional mortality 
benefit of PCI over medical management. It also suggested that patients with a GFR of 
<15ml/min tended to do worse in the PCI group. These data were explained by the 
increased rates of complications following PCI (bleeding and strokes) in the CKD stage 
5 group. 
Mortality following a CABG in dialysis patients is 3-4 times that of a non CKD 
patient50, 51 and dialysis is an independent risk factor for poorer outcomes following 
CABG52.  
Accurate comparison between PCI and CABG outcomes are difficult as almost all trials 
are non-randomised. A report by Keely et al.53 found that outcomes following PCI were 
superior to CABG, however, several other studies suggest that CABG may be superior 
to PCI in the CKD population54-56. The only randomised trial of PCI v CABG with a 
CKD cohort reported that a CABG resulted in reduced need for revascularisations but 
that there was no difference in mortality57. 
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Historical	  perspective	  of	  acute	  myocardial	  infarction	  
The clinical and diagnostic picture of an AMI was first described almost exactly a 
century ago by two Russian authors, Obraztsov and Strazhesko in 191058 and by an 
American Herrick in 191259.  It was impressive how prophetic Herrick was when he 
wrote ‘The hope for the damaged myocardium lies in the direction of securing a supply 
of blood through friendly neighbouring vessels so as to restore as far as possible its 
functional integrity’.  It was 30 years before Wilson et al.60 made it possible to locate 
the infarct topographically using precordial electrocardiography.  The diagnostic triad 
was completed in the 1950’s with the introduction of enzymology into clinical practice, 
which was first reported by Ladue et al.61 Although experimental models of coronary 
artery occlusion provided extensive descriptive accounts of the morphological changes 
associated with necrosis62-64, they produced relatively few insights into the molecular 
mechanisms of cell death. 
Therapeutic strategies evolved from observations that following a myocardial 
infarction, arrhythmias were one of the main causes of death within the first 72 hours65. 
Research began to focus on the use of pharmacological anti-arrhythmics and temporary 
pacemakers to improve immediate outcomes. In the 1970’s, Brunwald et al.66 produced 
a seminal paper, which highlighted the factors involved in myocardial oxygen 
consumption. This led researchers to focus on physiological and pharmacological 
interventions which could alter myocardial oxygen requirements to reduce necrosis of 
the myocardium67. At the same time, a novel concept was developed following work by 
Becker et al.68, who demonstrated that in the absence of collateral circulation, ligation 
of the left anterior descending artery resulted heterogeneous injury. They found a 
central area of necrosis with surrounding non-necrotic areas. These non-necrotic areas, 
or border areas were felt salvageable by increasing oxygen supply and/or reducing 
oxygen consumption, by reducing the work of the heart. Much of the clinical research 
in this field during the 1970’s focused on pharmacological manipulation of the oxygen 
supply/demand of the heart using vasodilators69, calcium channel blockers70, GTN71 
and β adrenoceptor blockade72, with mixed success. A reason for the failure of clinical 
studies to report positive outcomes was that the so called border areas were shown 
subsequently not to exist73, 74, and that researchers at the time had not appreciated that 
for optimal salvage, reperfusion must be employed. 
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Jennings and Reimer75 coined the term ‘wavefront’ phenomenon to describe the 
progression of cell death over time during myocardial ischaemia and put forward the 
idea that the myocardium could be salvaged by reperfusion76.  
The idea of reperfusion to salvage ischaemic tissue was first translated into clinical 
practice by Chazov et al77 in 1976, by administration of intracoronary streptokinase, and 
later by Gruntzig et al78 in 1979, who reported the first successful use of angioplasty in 
humans to treat coronary artery stenosis.  
Following a large transmural infarct, the myocardium undergoes a remodelling process 
characterised by ventricular dilation due to volume overload and scar formation in the 
necrotic area. A ventricular aneurysm may complicate dilatation with further 
impairment of systolic and diastolic function79. In the 1980’s 2 new concepts 
developed: cardiac stunning and hibernation. The concept of stunning originated from 
experiments which demonstrated that brief (5-15 minutes) coronary artery ligation, did 
not cause cell death but depressed myocardial contractility. This effect could last for 
days after the ischaemic event80. Myocardial hibernation was first described in 197881 
and describes the protective phenomenon of down regulation of myocardial 
contractility under ischaemic conditions. This serves to reduce oxygen demand during 
hypoxia, to preserve cell survival.  Thus both myocardial stunning and hibernation are 
characterised by viable myocardium with depressed function. Stunned myocardium has 
normal blood flow whereas hibernating myocardium has diminished flow82. Over the 
last 40 years attention has focused on coronary reperfusion, with timely reperfusion 
seen as the most effective way to reduce infarct size83. However, restoration of blood 
flow is not a benign process; it is associated with additional reperfusion injury (see 
iPOST chapter page 184 for discussion on the nature of reperfusion injury). 
 
Cardioprotection:	  a	  failure	  of	  translation	  	  
Historical	  aspects	  of	  cardioprotective	  strategies	  
It is 40 years since Maroko et al.67 first suggested that infarct size can be modified by 
therapeutic manipulations during ischaemia. Since then, tens of thousands of animal 
studies have been performed to identify novel cardioprotective strategies. The vast 
majority of these studies have been positive. However, many treatments such as 
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magnesium, hyaluronidase, prostacyclin, corticosteroids, trimetazidine, nitrates and 
eniporide which were shown to be protective animal models, were subsequently 
translated into clinical trials with disappointing results84.  
Despite the huge number of potentially cardioprotective strategies, which appear to 
confer protection in-vitro, or in animal work, only a few agents have been shown to 
improve outcomes in humans, such as adenosine85 and glucose-insulin-potassium 
treatment86. 
 
Preclinical	  barriers	  to	  translation	  
Several barriers exist which may account for the failure of translation. Firstly ex vivo/ 
in vitro models of disease lack physiological interactions such as an intact nervous 
system and a circulation required to ideally model ischaemia tolerance. Different 
species of animals display different tolerances to myocardial ischaemia87. Results of 
animal studies often rely on short term outcomes such as cardiac enzyme rise rather 
than a functional assessment of myocardial function at a later time point. This is an 
important failing as post infarct heart failure is a major determinant of morbidity and 
mortality following an AMI in humans. 
Critically, the vast majority of animal studies use juvenile, healthy animals. These may 
be a poor representation of the elderly diabetic, hypertensive, vasculopathic patients 
who are at increased risk of AMI. 
 
Clinical	  barriers	  to	  translation	  
Barriers at the clinical level include a lack of knowledge about the exact timing of 
ischaemia, the size of the area at risk, the extent of collateralisation of coronary vessels 
and variability in completeness of reperfusion, along with underlying co-morbidities 
and medication use in human patients. Furthermore, cardioprotective trials in the 
context of AMI are limited to treatments, which are given during ischaemia or at the 
point of reperfusion. Pre-treatment studies are impossible due to the unpredictable onset 
of an AMI.   
Clinical studies are hampered by lack of a clear method to measure infarct size. Enzyme 
release may be confounded by reperfusion status and imaging studies such as SPECT 
can be altered by the timing of the acquisition of the images, requiring 24 hour access to 
a nuclear medicine department. Cardiac MRI88 appears to provide better quantitative 
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data on tissue injury and also functional data, allowing non invasive longitudinal 
follow-up of patients, but this has yet to be implemented in routine care.  
Clinical trials have also struggled to translate infarct size reduction into a clear clinical 
benefit, such as reduced mortality or improved functional status. 
With current best management, short-term complications following AMI, while severe, 
are not very common, which requires large sample sizes to show an effect.  To improve 
the ability of a study to access hard endpoints such as mortality, a large sample size is 
required which makes these clinical trials very costly.  
Over the last 10 years several hugely expensive trials in the field of cardiovascular 
disease in the context of CKD (Choir89, CREATE90 TREAT91 AURORA92 and 4D93) 
have been published which have shown no benefit in terms of primary outcome. The 
exception to these dissapointeding studies is the recently published SHARP trial which 
demonstrated a positive outcome in terms of vascular events in a CKD cohort 94. This 
may have led to a therapeutic nihilism from large pharmaceutical companies interested 
in translational research. 
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The	   impact	   of	   underlying	   comorbidities	   on	   ischaemia	  
tolerance	  	  
Ischaemic heart disease in patients does not operate in isolation: it exists in the context 
of multiple co-morbidities such as LVH, diabetes, hypertension, senescence and 
dyslipidaemia, which affect the diseased state. Much of the characterisation of 
myocardial infarction and cardioprotection were performed in juvenile healthy animals 
with no underlying comorbidities.  However, some data exists which explore these co-
morbidities in more detail. 
Left	  ventricular	  hypertrophy	  
LVH is a physiological adaptation of the myocardium in response to exercise. 
However, pathological conditions such as anaemia, hyperthyroidism, aortic stenosis, 
obesity and arterial hypertension lead to pathological LVH, with hypertension being the 
most common causative factor95.   
Accurate estimates of the prevalence of LVH in population studies have been hampered 
by difficulty in defining the normal limits of LV size. Historically, there was marked 
variation in the methods used for measuring LVH and these were of low sensitivity96. 
The prevalence of LVH in unselected hypertensive patients has been reported as 20%, 
but this figure rises both with severity of hypertension97 and the age of the population 
studied. Tuzcu et al.98 reported that in a cohort of nonagenarians referred to a 
cardiology clinic, over 80% had evidence of LVH. From analysis of the Framingham 
cohort, with the exception of age, LVH represents the strongest traditional independent 
risk factor for future cardiovascular events99. Hypertension accelerates the development 
of atherosclerosis in coronary arteries100. LVH is associated with changes in the density, 
structure, and vasodilatory capacity of the coronary vasculature so that although 
absolute coronary flow in hypertrophied hearts may be increased, there is reduced 
cross-sectional density of endomyocardial capillaries and reduced coronary reserve 
even in the absence of detectable coronary atherosclerosis101, 102. 
Following ischaemia and reperfusion, the hypertrophied heart develops hyper 
contracture (caused by intramyocyte calcium overload during reperfusion) earlier and 
has poorer blood flow103. In addition, the hypertrophied heart recovers contractile 
function more slowly and is associated with a greater enzyme release following 
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reperfusion104. Postulated reasons for this effect include altered mitochondrial 
energetics105, changes in glucose metabolism during ischaemia106 and increased reactive 
oxygen species (ROS) production107.  
LVH is associated with increased frequency of ischaemia-induced arrhythmias. This is 
possibly due to LVH rather than hypertension per se, as lowering blood pressure before 
ischaemia using a calcium channel blocker did not alter the probability of ventricular 
fibrillation108. LVH also makes hearts more susceptible to reperfusion arrhythmias. In 
DOCA-salt hypertensive rats Baxter et al.109 demonstrated greater frequency and 
duration of reperfusion arrhythmias, an effect which resolved on resolution of the LVH 
by withdrawal of the DOCA-salt. 
Despite LVH having an impact on the bioenergetics, altered blood flow, increased ROS 
production with more arrhythmias, there have only been a few studies of myocardial 
ischaemia tolerance in hypertensive animals. These studies did not demonstrate a 
reduced ischaemia tolerance in animal models of LVH110-112. 
 
Cardiac	  failure	  and	  remodelling	  
Patients with heart failure following a myocardial are at increased risk of arrhythmias 
and sudden death.  In a dog model of healed myocardial infarction and superimposed 
heart failure, a very brief additional arterial ligation provoked fibrillation in 75% of 
animals. This could be abrogated by intrathecal clonidine, suggesting that increased 
sympathetic activity may be driving ischaemic arrhythmias113.  
Myocardial infarction can lead to cardiomegaly, with pathological structural changes 
such as fibrosis and microvascular damage114. These abnormalities would suggest that 
the failing heart would have a reduced ischaemia tolerance. However, data from 
Sharikabad et al.115 show that in an in-vitro model of post infarct congestive heart 
failure, cardiomyocytes had in increased resistance to hypoxia-reoxygenation. In vivo 
data using pacing to induce heart failure in dogs also show that there was no reduction 
in ischaemia tolerance associated with heart failure. However, care must be used when 
interpreting this data as pacing itself has been shown to confer cardio-protection116. 
 31 
Hyperlipidaemia	  and	  atherosclerosis	  
Hyperlipidaemia and atherosclerosis are important risk factors for ischaemic heart 
disease. However, animal data regarding the impact of underlying 
hypercholesterolaemia on ischaemia tolerance is conflicting. 
Rabbits fed cholesterol rich diets for 4117 and 8118 weeks have been shown to have 
reduced ischemia tolerance. This has been reported to be dependant on the inhibition of 
IL-1β and activation of caspase-1 and 3118. Experimental data show that acute 
hypercholesterolaemia in rabbits, induced by a 3 day high cholesterol diet, is associated 
with a reduction in ischaemia tolerance119. This effect was seen in the absence of 
increased atherogenesis. 
Several studies suggest that the timing of the experiment is crucial: experiments using 
LDL receptor-/- mice on high cholesterol diets for 4 weeks showed a reduced ischaemia 
tolerance, however a 12 week high cholesterol diet resulted in an increased tolerance 
compared to controls120. Furthermore, other studies in rats121 and rabbits122 demonstrate 
that long term diets rich in cholesterol alter cardiac function but do not alter ischaemia 
tolerance. 
Ferdinandy et al.96 explain this conflicting evidence by suggesting that that long term 
animal models of hyperlipidaemia may lead to extra cardiac pathological conditions, 
such as liver failure, which may alter ischaemia tolerance. 
 
Diabetes	  
Diabetes is a well recognised risk factor for the development of IHD. Ischaemic heart 
disease accounts for more than 50% of the deaths in diabetic patients in the 
Framingham cohort123. Moreover, diabetic patients were seen to have twice the 
mortality following an AMI when compared to non diabetic controls124. 
Several animal models have been used to study the effects of diabetes on myocardial 
function, with conflicting results. Tosaki et al.125 reported that streptozotocin (STZ) 
treated rats were initially more resistant to ischaemia than non diabetic controls but that 
this protective effect had worn off by 6 weeks and by 8 weeks there was even a 
deterioration in post ischaemic myocardial function. A similar temporal relation was 
seen by other groups who found that 2 weeks after the STZ injection, there was an 
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increased tolerance to ischaemia, but several weeks later the effect had disappeared126, 
127. Other models of type 2 diabetes such as the Goto-Kakizaki lean rat, which is an 
inbred strain of the Wistar rat, have shown similar increases in ischaemia tolerance 
compared to controls128. An explanation for the apparent increased ischaemia tolerance 
was suggested by Ma et al.127 who found increased capillary density (in contrast to the 
published research demonstrating a reduced capillary density seen in the uraemic 
myocardium 129), increased Akt phosphorlyation, and higher levels of nitric oxide and 
vascular endothelial growth factor in rats 2 weeks after STZ injection, with these effects 
disappearing by 6 weeks along with normalisation of ischaemia tolerance.  
While the epidemiological data strongly suggest that diabetes is a potent risk factor for 
poorer outcomes following an AMI, ex-vivo tissue from human atrial appendages 
showed no difference in injury following ischaemia when compared to non diabetic 
tissue130. An explanation for the apparent differences between experimental data and 
epidemiological data could be that diabetes is associated with other known risk factors 
for IHD, such as hypertension, heart failure, obesity and CKD without itself being 
directly cardiotoxic. However, more recently subgroup analyses of the thrombolysis in 
myocardial infarction study group were able to demonstrate that following an AMI, 
diabetes remained a risk factor for 30 day and 1 year mortality after adjustment for 
other known risk factors131.   
Senescence	  
Epidemiological studies suggest that even in the absence of diabetes, hypertension and 
hypercholesterolaemia, age itself increases cardiovascular morbidity and reduces 
myocardial performance 132, 133.  
Increased oxidative stress appears to be fundamental to the changes seen in the 
senescent myocardium134. Ageing leads to myocardial fibrosis135 and altered purine 
metabolism leading to less adenosine production in response to ischaemia136. On a 
histological level, senescence is associated with a reduction in cardiomyocyte number 
and increased variability in cardiomyocyte size leading to reduced stress tolerance137. 
Senescent mitochondria form higher levels of free radicals138, produce less ATP139 and 
display reduced membrane potentials140. Following ischaemia, senescent rat hearts 
develop a greater degree of stunning141, lower ATP levels142, more ventricular 
arrhythmias and greater cardiac enzyme release143. However, Loubani at al.144 reported 
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in an ex vivo human model of simulated ischaemia/reperfusion that no loss of 
ischaemia tolerance was seen in old hearts. 
 
Pathogenesis	  of	  Uraemic	  cardiomyopathy	  
Traditional	  risk	  factors	  	  
Traditional risk factors such as hypertension, diabetes, dyslipidaemia and smoking are 
highly prevalent in the CKD population.  
Hypertension occurs in >70% of ESRD patients. Many reasons exist for this: fluid 
overload due to the loss of urine output, activation of the renal-angiotensin system145, 
high sympathetic activity146, reduction in NO production147 and as a result of EPO 
administration148.  
Diabetes is the leading cause of ESRD and the combination of diabetes and CKD 
appears to be synergistic in terms of cardiovascular mortality30.  
Smoking is a risk factor for progression of CKD149. Dialysis patients who smoke have a 
22% greater risk in developing coronary artery disease than non smoking dialysis 
patients150. 
Dyslipidaemia is common in patients with CKD and ESRD, however unlike the general 
population, statins have not been shown to be effective in reducing cardiovascular 
endpoints in ESRD93. However more recently, a reduction in LDL cholesterol, using 
simvastatin and ezetimibe, has been shown to prevent aterosclerotic events in a CKD 
cohort151. However this did not translate into a survival advantage. 
Despite the clustering of traditional risk factors around uraemia, it appears that these 
traditional risk factors alone do not account for the morbidity and mortality seen in the 
CKD population152. Over the last 15 years, work has focused on non-traditional risk 
factors, some of which may be particularly common or unique to CKD, to explain this 
increased risk.  
Obesity	  
Obesity is an emerging risk factor for progressive renal disease. Its role goes beyond 
indirectly leading to CKD through colocalising with diabetes.  
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The percentage of obese incident dialysis patients is greater than that of the 
population average, with 63% of incident dialysis patients being classified as obese 
153. 
However somewhat paradoxically, in epidemiological studies raised BMI appears to 
be protective in ESRD patients 154. Authors have suggested that BMI is not valid in a 
co-morbid patient group as a marker of cardiovascular mortality, due to the uneven 
distribution of fat, with visceral fat being more hazardous than peripheral fat 155. 
Because of this the waist to hip ratio has been developed which has been shown to 
correlate better with cardiovascular disease in patients with co-morbidities than BMI 
156. 
The mechanism through which obesity leads to progressive CKD is thought to 
involve Adiponectin and 5’-AMP activated protein kinase (AMPK). Adiponectin is a 
protein secreted by adipocytes, which increases insulin sensitivity, reduces oxidative 
stress and inflammation 157 158. The concentration of adiponectin is inversely 
proportional to body fat 159, however the mechanism for this paradox is unclear. 
Epidemiological studies report that adiponectin and albuminuria are inversely 
correlated 160. 
Several in-vitro and in-vivo studies by Sharma et al, implicate low adiponectin in the 
pathogenesis of obesity related renal disease. The authors demonstrated that 
adiponectin knock out mice developed proteinuria and a histological pattern similar to 
obesity related CKD seen in humans. This phenotype could be ‘rescued’ with 
exogenous adiponectin 161.  
AMPK is a serine/threonine kinase which senses energy availability at the cellular 
level. In times of energy excess AMPK is inhibited 162. In chronic energy excess 
persistent inhibition of AMPK has been shown to lead to histological changes similar 
to those seen in obesity related CKD 161. The link between Adiponectin and AMPK 
has been shown by Kadowaki et al, who demonstrated that AMPK was stimulated by 
adiponectin 163. In summary it is thought that excess calorific intake leads to 
adiposity, which in turn causes an inhibiton of adiponectin which is thought to lead to 
proteinuria, podocyte effacement and glomerulosclerosis through inhibition of 
AMPK. 
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Parathyroid	  hormone,	  calcium	  and	  phosphate	  metabolism	  
Phosphate	  
Phosphate has been shown to stimulate vascular calcification in vitro164. In humans 
serum phosphate levels have been correlated with coronary artery calcification165, 
LVH166 and mortality167.   
Calcium	  
Retrospective data suggest that high calcium levels are correlated with cardiovascular 
death in dialysis patients168, 169, and that high calcium ingestion predisposes to coronary 
calcification which is an independent risk factor for CVD170. 
 
PTH	  
PTH has been implicated in the pathogenesis of LVH. In vivo, PTH causes trophic 
changes in myocytes and has been shown to be permissive in myocardial fibrosis171. 
Hyperparathyroidism has been shown in CKD patients to be an independent risk factor 
for cardiac events172, and both systolic and diastolic dysfunction173. Several studies 
have shown improvement in LV function post parathyroidectomy 174-176.  
 
Vitamin	  D	  	  
Left	  ventricular	  hypertrophy	  
It has been well established that LVH is a potent risk factor development of 
cardiovascular events and death. The vitamin D receptor (VDR) is present in the 
myocardium177. Treatment with activated vitamin D (calcitriol) has been shown to 
cause regression of LVH in dialysis patients178 and reduce QTmax and QTc 
dispersion179; both electrocardiographic features associated with a risk of sudden 
death. VDR -/- mice develop hypertension and LVH due to loss of suppression of 
rennin biosynthesis 180. In-vitro, vitamin D has been shown to inhibit myocyte 
proliferation and reduce apoptosis 181 and reduce myocyte hypertrophy in cultured 
cardiomyocytes 182. 
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Fibrosis	  
In vitro work by Artaza et al showed that incubation of a mesenchymal multipotent 
cell line with vitamin D reduced expression of collagens I and III, increased 
expression of bone morphogenic protein 2 and (both anti fibrotic factors), increased 
MMP8 (a collagen breakdown inducer) and increased follistatin (an inhibitor of the 
profibrotic factor myostatin) 181. 
Atherosclerosis/inflammation	  
Inflammatory processes play an important role in the development of a vascular insult 
183. In-vitro vitamin D analogues have been shown to inhibit the production of 
proinflammatory cytokines (IL-2, IFN-γ) and cause up regulation of the anti-
inflammatory cytokine of IL-10 in T cells 184. The net result of this is to reduce 
macrophage activation, LDL oxidation, and reduce matrix metalloproteases, which 
reduces atheroma formation and plaque rupture. VDR agonists have also been shown 
to down regulate plasminogen activator inhibitor 1, which is a potent thrombogenic 
factor in human aortic smooth muscle cells 185. 
Vascular	  calcification	  
The role of vitamin D and its analogues in vascular calcification is complex.  
Studies show that vitamin D receptor agonists can cause hyperphosphataemia and 
vascular calcification in humans: both potent mortality risk factors in ESRD 169, 186. 
High doses of oral vitamin D can induce vascular calcification in animals 187, 188. 
However in populations at increased risk of ischaemic heart disease serum levels of 
active vitamin D were inversely related to the extent of vascular calcification 189. 
Observational studies show that vitamin D analogues improve survival in dialysis 
patients 190, 191.  Work by Hsu et al reported that low doses of vitamin D, suppress 
aortic osteoblastic gene expression 192. Calcritol inhibits proliferation of vascular 
smooth muscle cells by acute influx of calcium 193. Matrix Gla protein, a potent 
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inhibitor of vascular calcification has been shown to be increased by calcitriol in-vitro 
194. 
 
Anaemia	  
Anaemia is a common consequence of CKD, due to a relative deficiency in 
erythropoietin production by the kidney. Epidemiological studies suggest that anaemia 
is an independent risk factor for the development of cardiac morbidity and mortality195.  
Anaemia results in a reduction in the oxygen carrying capacity of the blood and as such 
represents a reduction in ischaemia tolerance.  
The use of recombinant erythropoietin has revolutionised the care of renal patients over 
the last 25 years. However, despite a historical general consensus that normalising 
haemoglobin should lead to improvement in cardiovascular outcomes, several large 
randomized controlled trials controversially have failed to show a benefit89-91. 
Criticisms of the trials have focused on iron supplementation and the use of very large 
doses of ESA to get patients to target. Over the last 5 years there has been a re-
evaluation of target haemoglobin levels in dialysis and CKD patients downward from 
physiological levels to lower levels of 11-12g/dl.  
 
Autonomic	  dysfunction	  
CKD is a state of tonic increase in sympathetic outflow196, and this overactive 
sympathetic activity has been implicated in the excess cardiovascular events in dialysis 
patients197. The explanation for the increased cardiovascular mortality due to 
sympathetic over activity is suggested by data which implicate the sympathetic nervous 
system in the development of LVH198, endothelial dysfunction199 and arterial 
stiffness200. A recent pilot study in a hypertensive cohort reported that renal denervation 
not onlt resulted in a reduction in blood pressure, but also led to an improvement in 
glucose metabolism and increased insulin sensitivity 201.   
 
Homocysteine	  
Raised levels of homocysteine contribute to vascular inflammation, smooth muscle 
proliferation and vascular thrombosis202. A linear relationship between homocysteine 
levels and poor cardio-vascular outcomes has been reported203.  Homocysteine levels 
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are significantly higher in patients with renal failure than in the general 
population204,with longitudinal studies suggesting an association between homocysteine 
levels and cardiovascular disease in dialysis patients 205. However, intervention studies 
in the CKD and ESRD cohorts have yielded negative results 206, 207. 
 
Inflammation	  and	  malnutrition	  
Malnutrition is common in CKD patients, both from restrictive diets imposed on 
patients to minimise phosphate, potassium and fluid intake, along with anorexia which 
is hallmark of advanced renal failure, which may occur prior to the initiation of 
dialysis208. Inflammation is also common in dialysis patients, with as much as 50% 
showing evidence of an inflammatory response in an American cohort209. 
Hypoalbuminaemia caused by inflammation or malnutrition, (or as often in the case in 
dialysis patients both) is an independent risk factor for death in dialysis patients210. 
CRP, a marker of inflammation has been shown to be an independent risk factor both 
for death on dialysis211 and cardiovascular events in the CKD population212.  IL-6 has 
also been shown to be an independent risk factor for cardiac mortality on dialysis152.  
A mechanism by which acute phase proteins can lead to vascular disease comes from 
data which show that CRP can bind to damaged endothelial cells and activate 
complement213. IL-6 may lead to endothelial injury resulting in lipid accumulation and 
proliferation of the vascular smooth muscle cells214. 
 
Oxidative	  stress	  and	  advanced	  glycation	  end	  products	  
The mitochondrial respiratory chain, present in all cell types, is the major producer of 
oxidants in the body. The generation of physiological oxidants is an important step in 
inflammation and tissue repair215. In ESRD there exists an imbalance between the pro- 
and anti-oxidant mechanisms216. This imbalance may due to deficiencies seen in ESRD 
patients of members of antioxidant defences such as Vitamins C and E, selenium and 
glutathione peroxidase217, 218. At the same time pro-oxidant activity is increased with  
haemodialysis, inducing repetitive bouts of oxidative stress though membrane bio-
incompatibility219. Furthermore, chronic inflammation and uraemia itself is thought to 
contribute to oxidative stress215. 
Increased levels of oxidative stress have been associated with the development of 
atherosclerosis in a cross sectional study220. Vitamin E supplementation has been shown 
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to reduce the oxidative susceptibility to LDL in dialysis patients221. Vitamin E 
supplementation has also been shown to reduce all cause cardiovascular mortality in 
dialysis patients with known cardiovascular disease222, and supplementation with the 
antioxidant acetylcysteine has been shown to reduce a composite cardiovascular end-
point in a haemodialysis cohort223. 
Advanced glycation end products (AGE) are formed by the non-enzymatic oxidation 
and glycation of proteins and lipids224. AGEs normally accumulate with ageing but are 
also elevated in dialysis patients225.  In vitro data suggest AGEs lead to progression of 
atherosclerosis through production of free radicals and inflammatory cytokines226, 227. 
AGEs are also associated with arterial stiffness and diastolic dysfunction228. However, 
evidence in favour of the correlation between elevated AGEs and mortality in dialysis 
patients is conflicting229, 230. 
 
Asymmetric	  dimethyl	  arginine	  
Asymmetric dimethyl arginine (ADMA) is the most potent endogenous inhibitor of NO 
synthase known231. It opposes the anti-atherosclerotic effects of NO232 and leads to 
increased vascular resistance, hypertension, and vascular stiffness233, 234. 
Epidemiological studies demonstrate that elevated ADMA is an independent risk factor 
for all cause mortality and cardiovascular events235, 236. ADMA levels have been shown 
to correlate with LVH 232, 237 and elevated plasma levels of LDL cholesterol, 
triglycerides, glucose and homocysteine238. 
ADMA was first shown to be elevated in the context of dialysis by Vallance et al.239, 
and subsequently increased ADMA concentrations have been demonstrated even in 
very early CKD240.  
Several reasons for the excess ADMA seen in CKD patients have been proposed. 
ADMA was first proposed to be excreted by the kidneys239, however subsequently renal 
excretion has been shown to only play a minor role in ADMA excretion.  ADMA is 
metabolised by the enzyme dimethyl-diaminohydrolase (DDAH), which is present in 
the kidneys (amongst other organs)241. The activity of DDAH may be reduced in the 
context of renal failure as it is inhibited by oxidative stress215, homocysteine, 
hyperglycaemia, erythropoietin and smoking232. 
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Carnitine	  
Carnitine is a water-soluble quaternary amine which plays an important role in 
myocardial energy metabolism. Carnitine deficiency is characterised by cardiac 
hypertrophy and heart failure242. Carnitine deficiency is common in dialysis patients243, 
through loss of carnitine through the dialysis membrane 244. Carnitine supplementation 
in haemodialysis has been shown to reduce inflammation245 and LVH in dialysis 
patients246 and there is also the suggestion that carnitine supplementation may reduce 
EPO requirements in the context of renal anaemia247. 
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Aims	  of	  thesis	  
It has been established that cardiovascular disease in the context of CKD is distinct to 
that seen in the general population.  It has a different aetiology, a different phenotype, 
with a different prognosis and a different response to treatments.  
Because of this, there is a great unmet need for additional cardioprotective strategies 
in the context of uraemia to improve patient outcomes.  
The aims of this thesis are to investigate novel cardioprotective strategies in the 
context of uraemia. This will be achieved  through generation and characterisation of 
appropriate animal models of disease. Following this the models will be used to 
establish the role of underlying uraemia in myocardial ischaemia tolerance, ischaemic 
preconditioning, ischaemic postconditioning and pharmacological postconditioning 
using a PARP-1 inhibitor. 
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Chapter 2 
Animal Models of Uraemia 
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Background 
Uraemia is a multifaceted, heterogeneous syndrome involving, hypertension, LVH, 
disturbances in bone biochemistry, vascular calcification, dyslipidaemia and anaemia. 
There are several animal models that have been developed to attempt to reflect the 
complexity of this phenotype. The most widely used is renal reduction models.  
Surgical	  models	  
Surgical models of chronic anaemia involve reduction in nephron mass, this was first 
described by Chanutin and Ferris in 1932248. The reduction in nephron mass may be 
achieved using different approaches. The infarction model uses a 2 stage procedure 
whereby following a uni-nephrectomy, the remaining kidney’s renal arteries are ligated 
such that 2/3 of the kidney is infarcted and the subtotally infarcted kidney remains in 
place. The other more commonly used model is the 5/6 nephrectomy model (SNx). This 
employs a 2 stage subtotal nephrectomy model; 2/3 of one kidney is removed surgically 
followed, 2 weeks later, by a contralateral nephrectomy: leaving 1/6 of the remaining 
nephron mass in place.Histological examination of the remnant kidney reveals 
hypercellular glomerular tufts, with expansion of the glomerular volume and tubular 
atrophy249. However, when the infarction model is compared to the partial nephrectomy 
model (see below), the infarction model causes a much greater degree of variability in 
serum creatinine as a result of the greater technical difficulty than the SNx model250 and 
so is a less desirable model in the rat. The SNx model is the most commonly used 
model of chronic uraemia in the rat. 
Immune	  mediated	  CKD	  
This model relies on induction of glomerular sclerosis by injection of anti glomerular 
basement membrane (GBM) antibodies. To generate this model, rats are injected with 
rabbit anti GBM antiserum, with control animals injected with normal rabbit serum251. 
The a nti GBM serum is made by repeatedly inoculating New Zealand white rabbits 
over 2 weeks with purified rat GBM and an adjuvant. The rabbit serum (complete with 
anti GBM antibodies) is then injected intravenously into the rat252. 
This model was characterised by Nagano and colleagues251 and results in progressive 
proteinuria and uraemia with evidence of growth restriction. Histological lesions appear 
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as early as day 4, with evidence of widespread segmental necrosis, followed by cellular 
crescents at day 11. At day 44 there is severe scarring with marked fibrosis with little 
active inflammation. Biochemical disturbances include a doubling of serum creatinine 
by day 30, with hypocalcaemia and hyperphosphataemia. However, there is still 
substantial variation in the creatinine levels after 3 weeks.  The study did not examine 
the uraemic phenotype past 44 days, unlike other models of chronic uraemia. This 
model has not been widely adopted as a model of CKD, perhaps due to the complexity 
of the immune induction and due to the high variability of subsequent uraemia. There is 
no available data on the cardiac phenotype in this model. 
Adenine	  Model	  
The use of supplemental adenine to generate a model of experimental uraemia was first 
described by Yokazawa and colleagues in 1986253  and was based on previous 
observations by their group on the effects of exogenous adenine on renal function254.  
Following a diet supplemented with 0.75% adenine for 30 days, rats developed a 
uraemic phenotype. They found the rats kidneys to be larger and paler than their non-
uraemic counterparts. On histological examination of the kidneys, granuloma around 
crystalline deposits were seen in the tubules and interstitium along with evidence of 
marked fibrosis. There was also evidence of microtubular obstruction and dilatation and 
not uncommonly, hydronephrosis255.  
Biochemical analysis of the rats revealed uraemia, with creatinine values over three 
times that of controls at the 30th day and rising to almost 5 times that of control animals 
by the 50th day. The animals died between the 40th-65th day. The mechanism of adenine 
induced renal failure stemmed from the understanding of the metabolism of adenine in 
rodents (see Figure 2). Adenine, unlike other purines, is metabolised to AMP via the 
enzyme APRT254. AMP may be metabolised via adenosine, inosine, hypoxanthine, 
xanthine, urate and finally excreted as alantion254.  APRT can become saturated by 
excess adenine which is then oxidised to 2,8-dihydroxyadenine via xanthine oxidase256. 
The 2,8-dihydroxy-adenine is poorly soluble in the urine in the physiological pH range. 
The 2,8-dihydroxyadenine precipitates out in the urine causing a crystal tubulopathy 
with microtubular obstruction and granulomatous interstitial nephritis, leading to renal 
failure256. 
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Figure 2. Metabolic pathways of adenine metabolism in the Rat 1, 2 4 
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Human	  equivalent	  of	  the	  adenine	  model	  
The adenine model mimics a human disease, which causes progressive renal 
dysfunction. Adenine phosphoribosyltransferase (APRT) deficiency is an autosomal 
recessive inborn error of metabolism with a homozygous frequency of between 1 in 
50,000 to 1 in 100,000257.  It is characterised by stone formation and progressive renal 
decline. There are 2 forms of the disease. Type 1 results in the complete loss of APRT 
activity whereas type 2, seen more commonly in Japanese cohorts, results in a reduced 
affinity for adenine258.  
APRT is a purine salvage enzyme which catalyses the formation of AMP and 
pyrophosphate from 5-phosphoribosyl-1-pyrophosphate. Homozygotes for the mutation 
cannot salvage AMP from adenine and so instead, adenine is oxidized in a 2-stage 
process by xanthine oxidase to 2,8-dihydroxyadenine. 2,8-dihydroxyadenine is highly 
insoluble and when excreted in the urine forms crystals.  
 
Comparison	  between	  Adenine	  diet	  and	  SNx	  models	  
Degree of uraemia 
A SNx procedure typically generates a serum creatinine around 2-3 times that of sham 
operated controls259-261. The adenine diet however, causes a much more severe form of 
uraemia, with serum creatinine levels between 3 and 10 times that of the sham fed 
animals262-264. 
Time course of uraemia 
Uraemia is induced earlier in the adenine diet compared to SNx, with significant 
uraemia seen within 2 weeks of the commencement of the adenine diet265, whereas in 
the SNx model, a significant degree of uraemia is only seen 4 weeks after the second 
stage procedure266. 
Reproducibility 
The subtotal nephrectomy model relies on the skill of the surgeon or technician to 
achieve a reproducible reduction in nephron mass. This model takes time to learn and 
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each animal requires several hours of labour during surgery and recovery. The adenine 
diet model requires no surgical skill, and often generates a more consistent degree of 
uraemia when compared to the SNx model265. 
Calcium 
Serum calcium in SNx rats is similar to control rats259, 267-269, however 4 weeks of 
adenine diet caused a reduction in serum calcium by up to 40% when compared to 
controls263, 270, 271.  
Phosphate 
Hyperphosphataemia occurs earlier in adenine fed animals as compared to SNx animals 
and the degree of hyperphosphataemia appears to be greater in the adenine treated 
animals compared to SNx animals265. Adenine treated animals tend to have phosphate 
levels 2-3 times that of controls262-264 with SNx animals having serum phosphate levels 
between 1.1 to 2.3 times that of controls259-261.  
Hyperparathyroidism 
Both models of CKD develop marked hyperparathyroidism. SNx animals have PTH 
levels 3 to 17 times that of controls 260, 261, 268, 269, whereas adenine animals tend to have 
higher PTH levels ranging from 8.9 to 25 times that of control animals262-264. 
Furthermore, adenine treated animals had evidence of parathyroid gland hyperplasia at 
4 weeks. Again this may be explained by the higher phosphate levels and greater degree 
of renal dysfunction. There is no evidence to suggest that for a given biochemical 
profile (creatinine, calcium and phosphate), adenine treated animals have greater 
degrees of hyperparathyroidism. 
Vascular calcification 
With the SNx model it is usually necessary to supplement the diet with additional 
phosphate or calcitriol to cause vascular calcification272. However, one study has shown 
vascular calcification in the SNx model on low phosphate diets but only after 24 weeks 
following the SNx procedure273. Adenine treated rats develop vascular calcification 
within 4 weeks of starting the diet without the need for high phosphate diets274. 
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Dyslipidaemia 
Both SNx266 and adenine treated253 animals have significant elevations in total 
cholesterol. Adenine treated animals do not develop hyper-triglyceridemia253. The data 
for SNx animals is conflicting, with some authors249 noting elevation in triglyceride 
levels whereas others noted no change265. 
Anaemia 
A paper by Okada et al.275 reported that in rats, 2 weeks of adenine diet did not lead to a 
significant difference in haemoglobin when compared to a sham group. However, if 
both groups were then put on standard chow for a further 4 weeks, the adenine treated 
animals developed a significant degree of anaemia, with a 2g/dl difference in 
haemoglobin. This was despite almost total resolution in the renal dysfunction seen in 
the adenine treated group. Renal anaemia is characterised predominantly by a reduced 
production of erythrocytes due to relative deficiency of erythropoietin. The lag in 
development in anaemia is due to the life span of erythrocytes in the circulation. Rat 
erythrocytes have a half life of 14 days276, thus during the 2 week adenine diet many of 
the red cells were formed before the diet was commenced and so were not affected by 
the uraemia of the adenine diet. 
Four weeks of adenine diet has been shown to cause significant anaemia275. This 
anaemia was even more marked after a further 4 weeks off the adenine diet. Similar 
findings were seen with 6 weeks of adenine diet275. SNx animals are rendered anaemic 
following the 2 stage procedure, with a 20% fall in the haematocrit relative to non 
uraemic animals277. The SNx procedure causes anaemia through 2 ways; the first is 
blood loss during the initial 2/3 nephrectomy and the second is due to uraemia 
following a reduction in renal mass. No studies have directly compared the relative 
degrees of anaemia between the adenine model and the SNx model. However, a 
Japanese group performed 2 different experiments; 1 involving adenine induced 
uraemia278 and one using the SNx model279: Six weeks following the second stage in 
the case of the SNx model and 6 weeks following a 4 week course of adenine diet in the 
case of the adenine rats, the rats fed adenine had much lower haematocrits than the SNx 
animals.  
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Iron status 
There was no difference in serum ferritin, serum iron or transferrin in animals treated 
with 4 weeks of adenine diet when compared to controls, despite marked anaemia280. 
SNx animals however were found to have an upward trend in the levels of serum 
ferritin when compared to controls, which reached statistical significance at 15 weeks 
post 2nd stage procedure249.  This was associated with a reduction in serum transferrin, 
suggesting an inhibition in iron trafficking from macrophages to erythroid cells, leading 
to a progressive rise in ferritin levels. These effects closely resemble ‘Functional iron 
deficiency’ seen in CKD patients281. 
Urine abnormalities 
Yokozawa et al.282 reported that urinary abnormalities develop rapidly in rats on the 
adenine diet. After 1 week on the adenine diet, rodents develop polyuria with no 
associated polydipsia. Adenine treated rats also develop naturia, calciuria and 
phosphaturia. Similar findings have subsequently been replicated in SNx animals283. 
Both adenine treated animals284 and SNx rats285 have been shown to develop significant 
proteinuria. 
Blood pressure 
Work by Ataka et al.278 reported that 4 weeks of adenine diet causes marked elevation 
in serum creatinine, but did not cause hypertension. However, 6 weeks after the 
cessation of the diet, the uraemic animals began to develop significant hypertension. A 
study by Yokozawa et al.286 reported that hypertension developed after 24 days of 
adenine diet. The degree of hypertension was more marked as the duration of the 
adenine diet was increased from 24 to 36 days. The same group also found a reduction 
in renal blood flow284, with rising serum levels of ACE, angiotensin 2, and aldosterone 
in rats given the adenine diet. They hypothesised that the decreased renal blood flow 
triggered hypertension through activation of the renin-angiotensin system. SNx rats are 
significantly hypertensive at 4 weeks266 and this persists through 12 weeks266 to 25 
weeks248  after the second stage procedure. 
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LVH 
The SNx model of uraemia is associated with LVH, both as measured by heart 
weight/body weight ratio266 and on echocardiography266. Echocardiography in SNx rats 
reveals septal thickening and increased left ventricular posterior wall dimension. On 
histological examination of SNx hearts, cardiomyocyte hypertrophy was seen266.  
Cardiac hypertrophy was also demonstrated by Lacour et al.287 who reported that hearts 
from SNx animals were heavier than those of adenine or sham animals, despite SNx 
animals weighing less than the other groups. This report also suggests that significant 
LVH was not seen in adenine treated animals.  
Myocardial histology 
SNx animals develop increased myocardial fibrosis, and reduced capillary density 12 
weeks after the second stage procedure266. There is no data regarding cardiac histology 
following adenine diet. 
Death rate 
Death during induction of uraemia using the adenine diet is rare, whereas death is not 
uncommon following the 2 stage surgical procedure for SNx animals. In a study by 
Nagano et al.265 none of the adenine treated animals died during the 4 week induction 
versus 20% of the SNx animals at 4 weeks. However, if the adenine diet was continued 
for an additional 2 weeks, over 60% of the animals died275. 
Growth restriction 
Swapping animals to an adenine diet causes almost total cessation of food intake for up 
to 7 days265. Following 3 weeks of adenine diet, the animals were below their pre diet 
weights and were significantly lighter than the sham animals287. The protein intake of 
adenine rats over 4 weeks was reported to be only 65% of that of those on standard 
chow288. On cessation of the adenine diet the animals regained weight. The rate of 
weight gain depended on the duration of adenine diet. Animals who had 2 weeks of 
adenine diet regained weight rapidly such that after 4 weeks of standard diet, they 
approached the weight of the non-uraemic animals. Those animals that had 4 weeks of 
adenine diet only gained weight at the same rate as their non-uraemic controls, and 4 
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weeks later were still significantly lighter then controls. Those animals who had 6 
weeks of adenine diet put on weight more slowly than controls and so over time, the 
weight differences between the sham animals and control animals widened275. SNx 
models of uraemia report growth restriction. The mechanism of growth restriction in the 
SNx model was reported by Mehls et al.289 to be due solely to reduced food intake, as 
sham animals pair fed with the SNx animals were also found to be growth restricted 
compared to rats fed ad libitium. Work by Terai et al.265 suggests that the mechanism of 
reduced food intake may not simply be due to the palatability of the adenine diet, 
because even when adenine was administered by gavage, a reduction in food intake was 
seen when compared with methylcellulose gavage. 
Wash-out 
One of the unique advantages of the adenine model is the ability to stop the diet and 
regain renal function. The ability of the animal to recover depends on the duration of 
the adenine diet275. There is evidence of at least partial recovery of renal function on 
cessation of the diet. Shuvy et al.290 noted that 10 weeks after cessation of a 7 week 
high adenine/high phosphate diet, the renal function fell to almost to baseline, with the 
washout group having a mean serum creatinine of 115±13 mmol/l versus the control 
group 86± 16mmol/l. Some of histological features of adenine induced uraemia also 
resolved with cessation of the adenine diet, however, there was more prominent 
interstitial scaring and fibrosis in the washout group. This is unsurprising as the wash-
out group was 10 weeks older than the 7 week old uninterrupted adenine group, and 
hence has more time to develop fibrosis and scarring.  Adenine diet also caused an 
increase in apoptotic cells, which returned to baseline during the 10 week washout 
period. 
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Characterisation of 3 rodent models of chronic 
uraemia 
Three different animal models of chronic uraemia were investigated: the subtotal 
nephrectomy model, the 4-week adenine diet model and the adenine washout model. 
All models were compared with a suitable non-uraemic control group. 
The subtotal nephrectomy model is the most widely used model in the published 
literature but it is labour intensive to create with the outcomes dependant on the skill of 
the technician. The adenine and adenine washout models are attractive in that they do 
not rely on these factors and can create a more severe form of renal injury.  The 3 
models of uraemia were created so that a comparrison may be made of their different 
uraemic phenotypes.  
Methods	  
Sub-­‐total	  nephrectomy	  model	  
6-week-old Wistar rats (Charles River UK) were housed in an animal house with a 12-
hour day night cycle and had free access to standard chow and water. All procedures 
were conducted using aseptic technique and all instruments were autoclaved before use. 
The subtotal nephrectomy model was created as previously described by Raine et al.291. 
Stage	  1:	  Left	  subtotal	  nephrectomy	  
After 1 week acclimatisation, the rats were anaesthetised with inhaled 1.5% isoflurane 
(Baxter). The fur on the left flank wall was shaved and a 1cm skin incision was made 
just inferior to the lower margin of the rib cage. The flank musculature was blunt 
dissected and the parietal peritoneum was cut. The left kidney was then carefully 
externalised though the incision. The perinephric fat and renal capsule were removed. 
An arterial clamp was then placed around the renal artery and vein. 
The amount of tissue removed was crucial to the development of progressive renal 
impairment. If too little tissue was removed then the animal would not generate a 
uraemic phenotype, whereas if too much tissue was removed, following the right 
nephrectomy, the animal would subsequently become severely uraemic and have to be 
humanely sacrificed to prevent further suffering. An algorithm was developed (see 
Figure 3) to estimate how much renal parenchyma should be removed to attempt to 
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improve reproducibility. To achieve this, the weight of the removed sections of the left 
kidney were weighed and expressed as a percentage of total body weight. It was found 
that if more than 0.25% of the kidney to body weight was removed then a significant 
number of animals died or had to be sacrificed due to suffering. If the animals did 
survive up to the time of LAD occlusion, they were obviously much more uraemic than 
their other uraemic litter-mates and when analysed, had serum creatinine values 
>300umol/l. While this succeeded in generating an advanced uraemic phenotype, the 
animals were often very sick. Not infrequently these animals suffered respiratory arrests 
post anaesthetic, and those that survived this were left hypotensive post-arrest making 
them unusable for the experiment. Thus a 250g rat would require approximately 0.5-
0.62g of renal parenchyma to be removed. This value was used as a guide, because the 
absolute weight of renal tissue removed was not the only determinant of subsequent 
uraemia. The kidney is a heterogeneous organ, with the glomeruli concentrated at the 
cortex. Therefore the amount of glomeruli removed would be different depending on 
the exact location of the sections: removing the same weight of tissue from the upper 
and lower pole only would be likely to contain less glomeruli than removing many thin 
cortical sections from around the whole. Furthermore the more cuts that were made to 
the kidney in an attempt to get an exact amount of tissue removed the greater the 
likelihood of trauma to the remaining renal parenchyma and the greater the resultant 
degree of uraemia.  Taking all these factors into account, 3 sections of renal 
parenchyma were removed: the upper pole, lower pole and the lateral surface of the 
kidney. The arterial clip was removed and pressure was applied to the cut surfaces to 
promote haemostasis. Once haemostasis was established, the kidney was replaced in the 
abdominal cavity. 1ml of sterile saline was instilled into the abdominal cavity to replace 
fluid losses. The muscular layers were stitched together with 4-0 polysorb braded suture 
(Syneture), and the skin was closed using a ‘Precise’ Disposable skin stapler (3M). 
0.03ml of Vetegesic (Buprenorphine, Alstoe Animal health) was injected 
subcutaneously to provide post-operative pain relief. The rats were left to recover under 
a warming lamp and returned to their cages when fully awake.  
Stage	  2:	  Right	  Nephrectomy	  
2 weeks after the subtotal left nephrectomy, rats were anaesthetised as before, a right 
flank incision was made and the right kidney was externalised in same way as the left. 
The right renal artery and vein were tied off and the entire kidney was removed distal to 
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the ties. The abdomen was sown up, opiates were given and the animal was left to 
recover as before. 
The animals were then left for 4 weeks to develop a uraemic phenotype. 
Sham SNx animals were created in a 2 stage procedure. This was identical to the SNx 
group, except that in the first stage no renal tissue was removed and in the second stage 
the right kidney was replaced back in the abdominal cavity after it was decapsulated. 
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Figure 3 Impact of varying the amount of left renal tissue removal on subsequent 
development of renal dysfunction (r2 0.58) 
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Adenine	  Diet	  
The adenine diet model as described by Yokozawa253 was used. 6-week-old Wistar rats 
(Charles River UK) were housed in an animal house with a 12-hour day night cycle and 
had free access to water. After 1 week acclimatisation, during which time all animals 
were fed standard chow, animals were then either fed a standard pellet diet (Rat and 
mouse No.1 Maintenance diet: Special diet services UK) or the standard pellet diet with 
the addition of adenine 0.75% (Rat and mouse No.1 Maintenance diet +0.75% adenine: 
Special diet services UK). The animals were fed the adenine diet for 4 weeks to 
generate a uraemic phenotype.  Animals were fed standard chow for 4 weeks to 
generate a non-uraemic control group. 
 
Adenine	  Diet	  washout	  model	  
This model is identical to the standard adenine diet model, however at the end of 4 
weeks using the 0.75% adenine diet, it is substituted for standard chow. The animals are 
then continued on standard chow for a further 2 weeks. Control animals are fed 
standard chow for a total of 6 weeks. 
 
Characterisation	  of	  the	  uraemic	  phenotype	  
To characterise the uraemic phenotype of each model, animals were placed in metabolic 
cages. For the SNx and sham SNx groups, the animals were placed in metabolic cages 4 
weeks after the second stage of the subtotal nephrectomy (or sham subtotal 
nephrectomy in the case of the sham SNx group). The adenine diet animals were placed 
in the metabolic cages 4 weeks after starting the adenine diet, or in the case of the 
control group, 4 weeks after starting the standard chow diet. The adenine washout 
group, were placed in the metabolic cages 2 weeks after switching from adenine diet to 
standard chow, the adenine washout controls were fed standard chow for 6 weeks.  
All animals were placed in metabolic cages for 18 hours with free access to a known 
amount food and water. Food and water was weighed before and after the rats were 
placed in the metabolic cages, so that food and water intake could be calculated. Urine 
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was collected for measurement of volume. The urine was placed in a 10ml Falcon tube 
and was centrifuged at 500g for 5 minutes to remove particulate matter. The urine was 
then stored in 2ml Eppendorf tubes at -80 oC. After the animals were removed from the 
metabolic cages they were anaesthetised (for full details of anaesthesia see page 76) and 
underwent morphometry assessment (body length, tail length and tibial length). The rats 
then had venous and arterial lines inserted and a tracheostomy was performed (for full 
details of basic surgery protocol see basic surgery section p 76).  Mean arterial pressure 
and heart rate was recorded (for full details on measuring cardiovascular parameters see 
page 77). 200µl of blood was withdrawn from the arterial line in a heparinised 1ml 
syringe and analysed using an ABL 77 blood gas analyser (Radiometer Copenhagen). A 
further 1ml of blood was withdrawn from the arterial line into a 2ml Eppendorf tube 
containing 30µL heparin (5000 iu/ml) and mixed, by repeated inversion. The sample 
was spun at 6000g for 3 min at 20oC and the serum was aspirated into a new Eppendorf 
tube. The sample was then stored at -80 oC. A thoracotomy was performed (for full 
details of thoracotomy please see page 83) and the heart was quickly harvested. 
 
Histological	  assessment	  of	  left	  ventricular	  hypertrophy	  
Increased heart weight to body weight ratio in the is an indirect measure of LVH. 
Histological analysis of uraemic and non-uraemic hearts was undertaken to confirm that  
the SNx model leads to LVH. 
Hearts were harvested from SNx animals and ham SNx animals under deep anaesthesia 
and placed in 10% formalin for 10 days. The hearts were then processed by the 
histopathology department at the Royal London Hospital. The samples were embedded 
in paraffin, and sectioned into 5 um thick sections using a microtome. The hearts were 
stained using haematoxylin and eosin. The section through the widest point of the left 
ventricle was chosen as the point to measure the LV area. The cross sectional area of 
the left ventricle was calculated by subtracting the LV cavity area from the total area of 
the left ventricle in a blinded fashion using image-J software (NIH)292. This was 
repeated for each heart in the SNx group and sham SNx group. 
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Results	  
Subtotal	  nephrectomy	  model	  of	  chronic	  uraemia.	  
When compared to a sham procedure, the 2 stage subtotal nephrectomy procedure 
resulted in animals which were mildly growth restricted, with a 7% difference in mean 
weights, however there was no significance difference in body morphometry. Uraemic 
animals were polyuric and polydiptic, however no difference in food consumption was 
seen (see Table 1).   
The SNx model resulted in a mean serum creatinine 2.4 times that of shams with a 
similar elevation in serum urea concentration. The uraemic animals were hypertensive, 
anaemic with greater heart weights and a greater heart weight to body weight ratio 
which has been used as a surrogate marker for cardiac hypertrophy293. 
On biochemical analysis, this model of uraemia was associated with hypercalcaemia 
and hypercholesterolaemia but was not associated with metabolic acidosis, 
hypoalbuminaemia, hypertriglyceridaemia, hyperkalaemia or hyperphosphataemia. 
Urine analysis of uraemic animals revealed significant proteinuria, natriuresis as 
evidenced by increased fractional excretion of sodium and increased urine sodium 
excretion. 
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Table 1. Characterisation of the 2 stage subtotal nephrectomy model. Male Wistar rats 
underwent a 2 stage sham subtotal nephrectomy (sham SNx, n=10) were compared with rats 
which underwent a 2 stage subtotal nephrectomy model (SNx, n=12). All values presented as 
mean (SD), p values are results of 2-way unpaired t test using GraphPad software. Rows in 
bold type represent characteristics, which were significantly different between the 2 groups. 
*Heart weight index was calculated by dividing the weight of the heart in grams by the 
weight of the animal in kilograms.**Protein creatinine ratio is calculated by dividing urine 
protein concentration by urine creatinine concentration. §Fractional excretion of sodium is 
calculated by dividing  (urinary sodium concentration x plasma creatinine concentration) by 
(plasma sodium concentration x urinary creatinine concentration). 
 
Sham SNx SNx p
Weight (g) 408 (29.5) 378 (33.4) 0.05
Water intake (ml/hr) 1.87 (0.40) 3.34 (0.40) <0.0001
Urine output (ml/hr) 0.73 (0.21) 1.87 (0.47 <0.0001
Food intake (g/hr) 1.52 (0.20) 1.45 (0.29) 0.78
Tail length (cm) 19.4 (0.88) 18.8 (1.02) 0.18
Body length (cm) 25.2 (0.85) 24.4 (1.21) 0.08
Tibial length (cm) 5.89 (0.25) 5.87 (0.33) 0.89
Blood pressure (mm/Hg) 137 (26) 157 (19.6) 0.01
Pulse (BPM) 392 (51.6) 387 (44.7) 0.75
Heart weight (g) 1.14 (0.11) 1.31 (0.20) 0.04
Heart weight index* 2.85 (0.25) 3.44 (0.46) 0.003
Haematocrit (%) 37.8 (4.51) 27.1 (5.06) < 0.0001
Plasma bicarbonate (mmol/l) 24.8 (4.1) 26.2 (3.4) 0.2
Plasma base excess (mEq/L) 1.77 (3.65) 2.42(6.0) 0.64
Serum albumin (g/l) 27.6 (2.24) 27.5 (1.90) 0.94
Serum urea (mmol/l) 6.2 (1.34) 17.4 (4.61) <0.0001
Serum creatinine (µmol/l) 42.1 (5.41) 99.9 (30.1) <0.0001
Serum cholesterol (mmol/l) 1.85 (0.37) 2.72 (0.50) 0.003
Serum triglycerides (mmol/l) 0.83 (0.50) 0.76 (0.43) 0.72
Serum sodium (mmol/l) 141 (9.73) 143 (1.76) 0.53
Serum potassium (mmol/l) 3.88 (0.54) 4.16 (0.41) 0.27
Serum phosphate (mmol/l) 2.50 ( 0.29) 2.29 (0.29) 0.11
Serum calcium (mmol/l) 2.52 (0.12) 2.75 (0.18) 0.003
Urine protein creatinine ratio** 1.4 (0.24) 4.25 (2.62) 0.0003
Urine sodium (mmol/l) 87.6 (27.3) 44.1 (11.0) 0.002
Fractional excretion of sodium (%)§ 0.36 (0.10) 1.16 (0.58) 0.001
Urine sodium excretion (mmol/h/g) 0.15( 0.04) 0.21 (0.04) 0.003
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Adenine	  Diet	  model	  	  
4 weeks of 0.75% adenine supplementation resulted in significantly less weight gain 
than the control group, with a 31% difference in final weights (see Table 2). The 
adenine treated animals were polyuric but not polydiptic. Adenine fed animals ate just 
over 50% of the food compared to control animals.  
Adenine diet was associated with growth restriction on morphometry, with a shorter 
tail, body and tibial length than controls. Adenine treatment resulted in significant 
uraemia with serum creatinine and urea concentrations 8 times that of the control 
groups, with a similar elevation in urea concentrations. The uraemic animals were not 
hypertensive, but were significantly more bradycardic than controls. Despite no 
difference in blood pressure, the heart weight index was significantly greater than the 
control group. 
On biochemical analysis, this model of uraemia was associated with hypercalcaemia 
and hyperkalaemia but was not associated with metabolic acidosis, hypoalbuminaemia, 
hypercalcaemia, hypercholesterolaemia, hypertriglyceridaemia, or hyperphosphataemia. 
Adenine fed animals were also anaemic. Urine analysis of these uraemic animals 
revealed significant proteinuria and natriuresis as evidenced by increased fractional 
excretion of sodium and increased urine sodium excretion.  
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Table 2. Characterisation of the 0.75% adenine diet model. Male Wistar rats which were fed 
standard chow for 4 weeks (Control, n=12) were compared with rats which, were fed a diet 
containing 0.75% adenine for 4 weeks (Adenine, n=12). All values presented as mean (SD), 
p values are results of 2 way unpaired t test using GraphPad software. Rows in bold type 
represent characteristics which were significantly different between the 2 groups. 
*Heart weight index was calculated by dividing the weight of the heart in grams by the 
weight of the animal in kilograms.**Protein creatinine ratio is calculated by dividing urine 
protein concentration by urine creatinine concentration. §Fractional excretion of sodium is 
calculated by dividing  (urinary sodium concentration x plasma creatinine concentration) by 
(plasma sodium concentration x urinary creatinine concentration). 
 
Control Adenine p
Weight (g) 434 (25.6) 221(32.8) <0.0001
Water intake (ml/hr) 2.66 (0.79) 2.63 (0.51) 0.91
Urine output (ml/hr) 0.8 (0.39) 1.59 (0.4) <0.001
Food intake (g/hr) 1.50 (0.17) 0.82 (0.25) < 0.0001
Tail length (cm) 20 (0.64) 17.5 (0.65) < 0.0001
Body length (cm) 24.8 (0.75) 21.4 (0.98) < 0.0001
Tibial length (cm) 5.91 (0.29) 4.99 (0.22) < 0.0001
Blood pressure (mm/Hg) 137 (8.3) 129 (19.5) 0.19
Pulse (BPM) 397 (37.2) 296 (65.3) < 0.0001
Heart weight (g) 1.15 (0.08) 0.78 (0.13) < 0.0001
Heart weight index* 2.65 (0.24) 3.53 (0.42) < 0.0001
Haematocrit (%) 42.3 (3.54) 27.3 (5.46) < 0.0001
Plasma bicarbonate (mmol/l) 25.3 (3.4) 24.3 (1.6) 0.36
Plasma base excess (mEq/L) 2.81 (3.0) 1.83 (1.90 0.31
Serum albumin (g/l) 26.9 (2.23) 27.9 (2.30) 0.37
Serum urea (mmol/l) 5.87 (0.91) 59.3 (17.7) < 0.0001
Serum creatinine (µmol/l) 33.5 (2.70) 266 (71.5) < 0.0001
Serum cholesterol (mmol/l) 1.86 (0.37) 2.01 (0.16) 0.28
Serum triglycerides (mmol/l) 1.30 (0.86) 0.81 (0.71) 0.19
Serum sodium (mmol/l) 145 (2.36)  145 (1.93) 0.95
Serum potassium (mmol/l) 145 (2.36)  145 (1.93) 0.02
Serum phosphate (mmol/l) 2.86 (0.48) 2.66 (0.72) 0.47
Serum calcium (mmol/l) 2.22 (0.91) 2.57 (0.26) 0.02
Urine protein creatinine ratio** 1.71 (0.33) 4.57 (1.33) < 0.0001
Urine sodium (mmol/l) 76.9 (30.6) 35.7 (6.0) 0.006
Fractional excretion of sodium (%)§ 0.32 (0.07) 5.90 (1.69) < 0.0001
Urine sodium excretion (mmol/h/g) 0.139 (0.04) 0.254 (0.07) 0.007
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Adenine	  washout	  model	  	  
Four weeks of a 0.75% adenine diet followed by 2 weeks of standard chow resulted in  
rats which weighed only 73% of  the control group (see Table 3). However, during two 
weeks of standard chow, the washout rats gained more weight than in the previous four 
and there was a reduction in difference in weight between the uraemic and non-uraemic 
animals (see Figure 4). The adenine treated animals were polyuric polydiptic, however 
no difference in food consumption was seen. The adenine washout group was 
associated with growth restriction, with a shorter tail, body and tibia length. The 
adenine washout model resulted in moderate uraemia with serum creatinine and urea 
concentrations 3 times that of the control. In addition, they were also significantly 
anaemic. The uraemic animals were not hypertensive and the bradycardia seen with 
adenine treatment had resolved. Despite no difference in blood pressure, the heart 
weight index was significantly greater than the control group.  
On biochemical analysis, this model of uraemia was associated with 
hyperphosphataemia and hyperkalaemia but was not associated with metabolic acidosis, 
hypoalbuminaemia, hypercalcaemia, hypercholesterolaemia. Urine analysis of these 
uraemic animals revealed significant proteinuria, natriuresis as evidenced by increased 
fractional excretion of sodium and increased urine sodium excretion. 
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Table 3. Characterisation of the adenine washout model. Male Wistar rats fed standard chow 
for 6 weeks (Control, n=10) were compared with rats which were fed a diet containing 0.75% 
adenine for 4 weeks, followed by 2 weeks of standard chow (Ad washout, n=12). All values 
presented as mean (SD), p values are results of 2 way unpaired t test using GraphPad 
software. Rows in bold type represent characteristics, which were significantly different 
between the 2 groups. 
*Heart weight index was calculated by dividing the weight of the heart in grams by the 
weight of the animal in kilograms.**Protein creatinine ratio is calculated by dividing urine 
protein concentration by urine creatinine concentration. §Fractional excretion of sodium is 
calculated by dividing  (urinary sodium concentration x plasma creatinine concentration) by 
(plasma sodium concentration x urinary creatinine concentration).  
 
Control Ad washout p
Weight (g) 477 (35.2) 348 (22.99) <0.0001
Water intake (ml/hr) 1.88 (1.15) 3.89 (0.54) 0.008
Urine output (ml/hr) 0.89 (0.24) 2.39 (0.38) 0.003
Food intake (g/hr) 1.6 (0.08) 1.76 (0.29) 0.57
Tail length (cm) 20.2 (0.76) 17.9 (0.44) < 0.0001
Body length (cm) 24.9 (0.74) 22.7 (0.54) < 0.0001
Tibial length (cm) 5.42 (0.40) 4.79 (0.21) 0.005
Blood pressure (mm/Hg) 144 (31.1) 152 (26.6) 0.73
Pulse (BPM) 404 (12.0) 442 (33.6) 0.02
Heart weight (g) 1.43 (0.08) 1.43 (0.12) 0.95
Heart weight index* 3.02 (0.32) 4.36 (0.26) < 0.0001
Haematocrit (%) 41.6 (1.82) 20.4 (5.19) < 0.0001
Plasma bicarbonate (mmol/l) 31.6 (2.36) 28.9 (3.70) 0.23
Plasma base excess (mEq/L) 6.24 (1.36) 4.16 (3.05) 0.09
Serum albumin (g/l) 28.7 (1.00) 27.0(1.98) 0.11
Serum urea (mmol/l) 6.06 (0.69) 22.1 (11.1) < 0.0001
Serum creatinine (µmol/l) 38.4 (3.01) 112 (54.4) < 0.0001
Serum cholesterol (mmol/l) 2.18 (0.38) 3.13 (0.66) 0.009
Serum sodium (mmol/l) 142 (1.37) 144 (2.25) 0.08
Serum potassium (mmol/l) 4.02 (0.24) 5.44 (0.58) < 0.0001
Serum phosphate (mmol/l) 2.34 (0.12) 2.65 (0.34) 0.05
Serum calcium (mmol/l) 2.51 (0.11) 2.58 (0.22) 0.43
Urine protein creatinine ratio** 1.86 (0.2) 11.7 (13.3) 0.04
Urine sodium (mmol/l) 0.44 (0.07) 3.23 (1.59) <0.0001
Fractional excretion of sodium (%)§ 0.44 (0.07) 3.23 (1.59) 0.002
Urine sodium excretion (mmol/h/g) 0.20 (0.04) 0.31 (0.08) 0.02
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Figure 4. Results of weight gain in rats fed standard chow for 6 weeks (control) and rats fed a 0.75% 
adenine diet for 4 weeks followed by 2 weeks of standard chow (Adenine washout). Graph displays 
mean with error bars displaying SEM) 
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Comparison	  of	  3	  models	  of	  uraemia	  
Direct comparison of the weight gains of the 3 different models, is complicated because 
the adenine diet rats were 10 weeks old rather than 12 weeks for the SNx and washout 
models. However, the adenine washout group was still significantly lighter than the 
SNx group (see Figure 5, Figure 6 and Figure 7).  
Both the adenine and adenine washout models resulted in a greater degree of polyuria 
and polydipsia than the SNx model (p<0.01). 
The fractional excretion of sodium is the percentage of sodium filtered by the 
glomerulus, which is excreted in the urine. A FeNa of <1% in the context of uraemia 
suggests the cause of renal failure is hypoperfusion of the kidneys. The high FeNa 
compared to control animals seen in all 3 groups is consistent with tubular damage and 
reduction in nephron number.  The adenine diet model is associated with a higher FeNa 
than adenine washout group (p<0.001), which in turn has a higher FeNa than the SNx 
model (p<0.01). The urine excretion of sodium is higher in the adenine washout group 
than the SNx group (p<0.05). This could be explained by the increased sodium intake in 
the washout group from the increased food intake. There was no significant difference 
in the degree of proteinuria between the 3 groups, despite a trend towards higher 
proteinuria in the adenine washout group. Both SNx and adenine models led to similar 
degrees of anaemia, but the adenine washout model was associated with significantly 
greater anaemia than the other 2 groups (p<0.005).  
The adenine model resulted in a lower blood pressure than both the adenine washout 
and SNx models (p<0.0001). The pulse rate was also significantly lower in the adenine 
group than either the SNx group or the adenine washout group (p<0.0001). The adenine 
washout group also had a greater heart weight to body weight ratio than either the SNx 
model or adenine model (p<0.001). The SNx and adenine washout models resulted in a 
similar final concentration of creatinine and urea. However, the adenine model resulted 
in more severe uraemia with a creatinine which was over 2 times that of either of the 
other 2 models (p<0.0001). Both the adenine (p<0.01) and the adenine washout models 
(p<0.001) were associated with higher serum potassium concentrations than the SNx 
model.  
There was no significant difference in serum calcium, sodium or phosphate 
concentrations between the 3 models. This was despite the adenine washout group 
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being the only group to develop hyperphosphataemia when compared to their 
individual controls. 
Both the adenine washout and the SNx models had similar serum cholesterol 
concentrations. However, the adenine model had lower serum cholesterol than both the 
washout (p<0.001) and SNx models (p<0.05). 
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Figure 5. Comparison of the uraemic phenotype between different rodent models of chronic uraemia. 
A: Mean rat weight following a 2 stage SNx procedure, 4 weeks of 0.75% adenine diet, or 4 weeks of 
Adenine diet followed by a 2 week washout. B: Amount of food eaten per day, indexed for rat weight  
in Kg. C: Mean water intake per day indexed for rat weight in Kg. D: Urine output per day indexed for 
rat weight. E: Mean serum sodium concentration. F: Mean haematocrit values. In each group n=12. 
Graphs presented as mean with error bars as SEM. Results of 2 way ANOVA with “Bonferroni's 
Multiple Comparison Test" displayed as  *,**,***. *p=0.01-0.05, **p=0.001-0.005, ***p<0.0001. 
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Figure 6. Comparison of the uraemic phenotype between different rodent models of chronic 
uraemia. 
A: Urinary fractional excretion of sodium. B: Daily urinary sodium excetion indexed for weight of 
rat in g. C: Urine protein creatinine ratio. D: Mean arterial pressure as measured before 
throacotomy. E: Heart weight to body weight ratio calculated by dividing the heart weight in 
grams by the weight of the animal in Kg. F: Pulse rate measured beofre thoracotomy. In each 
group n=12. Graphs presented as mean with error bars as SEM. Results of 2 way ANOVA with 
“Bonferroni's Multiple Comparison Test" displayed as  *,**,***. *p=0.01-0.05, **p=0.001-0.005, 
***p<0.0001. 
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Figure 7. Comparison of the uraemic phenotype between different rodent models of chronic 
uraemia. 
A:Mean serum creatinine following a 2 stage subtotal nephrectomy procedure (SNx), 4 weeks of 
0.75% adenine diet (Adenine) or 4 weeks of adenine diet followed by a 2 weeks of standard chow. 
B:Mean serum urea in 3 models of uraemia. C:Mean serum potassium in 3 models of uraemia. 
D:Mean serum cholesterol in 3 models of uraemia. E: Mean serum calcium in 3 models of uraemia 
F: Mean serum phosphate in 3 models of uraemia. 
 In each group n=12. Graphs presented as mean with error bars as SEM. Results of 2 way 
ANOVA with “Bonferroni's Multiple Comparison Test" displayed as  *,**,***. *p=0.01-0.05, 
**p=0.001-0.005, ***p<0.0001. 
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Histological	  assessment	  of	  left	  ventricular	  hypertrophy	  
On gross inspection it was clear which hearts came from uraemic animals and which 
did not. While the hearts were grossly the same size, the LV cavity was significantly 
smaller in the uraemic animals (see Figure 8, Image 1 and Table 4). On statistical 
analysis of the images, as assessed using image-J, the SNx group had a significantly 
larger LV surface area than the sham SNx group (p=0.01). When corrected for body 
weight, this difference became even more significant as the uraemic rats were lighter 
than the non uraemic animals (p=0.003).  
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Image 1. Representative photographs of transverse sections through the non-uraemic sham SNx group (A) 
and the uraemic SNx group (B). 
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Figure 8. Graph showing the LV area in uraemic (SNx) and non uraemic (Sham 
SNx) rats. Colums reperesent median, with error bars IQR 
Table 4. Table showing results of  histological analysis  of left ventricular surface area in 
uraemic (SNx) and non uraemic (Sham SNx) rats. The top row is the LV area, the bottom row 
is the LV area corrected fro body weight. Data shown as median (IQR). The displayed p value 
is the result of a 2 tailed Mann Whitney test using GraphPad software. 
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Discussion	  
All 3 models studied share several characteristics typical of a uraemic phenotype; 
anaemia, raised serum creatinine, raised serum urea, proteinuria, natriuresis, reduced 
weight gain and increased heart weight index. The heart weight index has been used as 
a surrogate marker for LVH. The histological study confirms the finding that the SNx 
model of chronic uraemia leads to the development of LVH. However the lack of 
adenine samples of myocardial histology to demonstatate presence of absence of LVH 
is a limitation. 
Adenine animals have been shown to develop vascular calcification after 4 weeks274. 
Vascular calcification widens the pulse pressure294, which may cause the MAP to fall 
despite elevated systolic pressures. Thus in the context of potential vascular 
calcification, a normal mean arterial pressure may miss combined systolic hypertension 
and relative diastolic hypotension. 
An ideal animal model of chronic uraemia should reflect all aspects of the uraemic 
phenotype, and while these 3 models display many aspects seen in patients with CKD 
such as cardiac hypertrophy, growth restriction (commonly seen in the paediatric 
nephrology population), anaemia, proteinuria, loss of urinary concentrating ability (in 
the form of polyuria and a high FeNa), some important aspects are not represented in 
these models. Uraemia is associated with acidaemia caused by a reduction of hydrogen 
ion excretion by the renal tubules. None of these models were associated with a low 
plasma bicarbonate. Hypocalcaemia and hyperphosphataemia are hallmarks of uraemia 
leading to hyperparathyroidism, and vascular calcification. Only the washout model 
demonstrated significant elevations in serum phosphate. An explanation for this could 
be due to the increased food (and hence phosphate) intake during the washout phase. 
No model led to significant hypocalcaemia and interestingly, both the adenine and SNx 
models but not the adenine washout model was associated with hypercalcaemia. This is 
not a feature of the models in the published literature. A mechanistic explanation for the 
hypercalcaemia seen in these animals is difficult to explain, given the fact that both 
models showed similar levels of hypercalcaemia. The SNx animals had the same diet as 
the sham SNx animals effectively ruling out a dietary cause for the higher calcium. 
Tertiary hyperparathyroidism could lead to hypercalcaemia, however this is invariably 
associated with (and triggered by) hyperphosphataemia, which the rats did not display.  
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The development of a uraemic phenotype is dependant on 2 factors, the degree of 
uraemia and the duration to which the animal is exposed to uraemia.  These factors may 
explain some of the differences seen in these models. While the 4-week adenine model 
represents the model with the highest serum creatinine, the haematocrit is similar to the 
SNx model. Relative erythropoietin deficiency caused by reduced nephron mass or 
damage to renal endothelial cells leads to a reduction in red cell production which in 
turn leads anaemia. Thus despite the SNx group having significantly better renal 
function, the animals have had underlying renal failure for longer. The duration of 
uraemia also explains the adenine washout group having the lowest haematocrit. The 
duration of uraemia may also explain the increased cardiac hypertrophy seen in the 
adenine washout group. 
There are two possible explanations for the finding that 0.75% adenine diet leads to a 
reduction in food intake. Firstly it could be that as with humans, uraemia is associated 
with anorexia with resultant weight loss, or secondly, it could be that the adenine is 
unpalatable for the rats. If the lack of food intake was solely due to uraemia, then one 
would expect the food intake to gradually decrease over the 4 weeks of adenine diet and 
then gradually increase when placed back on standard chow as the uraemia partially 
resolves. However work by Terai et al.265 reported that when rats were commenced on 
0.75% adenine diet the rats stopped eating for up to 7 days. In addition during the 
washout experiment when the rats were placed back in cages with standard chow, 
despite being uraemic, they vigorously ate the standard pellets. This all suggests that 
adenine is very unpalatable and importantly part of the phenotype of the adenine diet 
may be related to starvation.  
The bradycardia seen with the adenine diet model, which resolves after 2 weeks of 
standard chow, has not been reported in the published literature. This could explain 
both the bradycardia and its resolution on a normal diet. The cardiovascular effects of 
starvation has been studied in a human anorexic cohort. Starvation is known to cause 
bradycardia, and hypotension295, which has been partly explained through an increased 
vagal tone296.   
Bradycardia could also be caused by increased levels of adenosine generated as adenine 
is metabolised (see Figure 2). Alterations in purine metabolism in the adenine model of 
chronic uraemia is investigated later (see section entitled: Investigation of the 
bioenergetics of the uraemic heart, page 118 for further details).  
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Future work 
1) Replication of the cardiac histology study to include an adenine treated cohort and 
also an adenine washout group. This would provide confirmatory data on whether 
adenine induced uraemia (unlike the renal reduction model) lead to LVH. In additon 
further analysis of the histological specimens for presence of fibrosis and capillary 
density would provide valuable information on whether diefferences in the ischaemia 
tolerance of the models were linked to histological differences. 
2) Further investigation of the apparent hypercalcaemia seen in the uraemic animals is 
needed. Additional work should include analysis of animla serum for PTH and FGF-23, 
as an explanation for hypercalcaemia.   
3) Further investigation into the bradycardia seen with the adenine treated groups but 
not the SNx or Adenine washout groups. The bioenergetics of adenine treatment will 
be examined in a later chapter see p118. In addition to dissect whether adenine leads 
to bradycardia directly through chronotropic metabolites or indirectly through 
anorexia. Further experiments could be done comparing adenine treated animals with 
pair fed controls. If it were a direct effect of adenine supplementation then the pair fed 
animals would not be bradycardic relative to the adenine fed rats, whereas if the 
bradycardia was merely an effect of starvation then both groups would be expected to 
have similar heart rates. 
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Chapter 3  
Reversible LAD Ligation as a Model of 
Myocardial Infarction in the Rodent 
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Methods	  
Basic	  Surgery	  
Six-week-old male Wistar Rats (Charles Rivers UK) were obtained and after 1 week 
acclimatisation in an animal house with a 12-hour day night cycle and free access to 
water and standard chow, they underwent protocols to generate uraemia (see methods 
section page 52 for details on creation of the SNx model of uraemia and page 55 for 
details on creation of the adenine model). 
Rats were anaesthetised using an IP injection of Thiopental Sodium (Link 
Pharmaceuticals), the dose of anaesthetic required was optimised to ensure that the 
animals were anaesthetised rapidly, without causing respiratory depression and without 
requirement for additional anaesthetic. The dose used was 73mg/kg for the uraemic 
animals and 87mg/kg for the control animals. 
Once the animals were anaesthetised they were placed on a homoeothermic control unit 
(Harvard Apparatus) and their temperature was measured using a rectal digital 
thermometer. Throughout the experiments the heating mat temperature was adjusted to 
maintain core temperature 370C +/- 1 0C. After removal of the skin over the anterior 
surface of the neck, the cervical musculature was blunt dissected to reveal the trachea. 2 
sutures were placed around and behind the trachea 5mm apart. Between the 2 sutures 
approximately 70% of the circumferential length of the trachea was cut using 
Castroviejo angled spring scissors (Harvard Bioscience). The trachea was cannulated 
using Portex tubing (Smiths Medical Watford UK) internal diameter (ID) of 1.67mm 
and tied in place using the 2 sutures. If necessary any bronchial secretions were 
aspirated using a 10ml syringe connected to a length of Portex (ID 1.67mm) tubing. 
The right carotid artery was exposed using careful dissection of the cervical 
musculature, a suture was tied at the cranial end of the artery and an arterial clip was 
placed at the caudal margin. Again using Castroviejo angled spring scissors, a small 
incision was made in the artery and the artery was cannulated using a length of Portex 
tubing (internal diameter 0.58mm) connected to a 2ml syringe filled with heparinised 
saline (15iu/ml). Once the catheter was in place the arterial clamp was removed and the 
catheter was tied in place. The external jugular vein was dissected out and tied off 
cranially using sutures as described above, and cannulated caudally using a length of 
Portex tubing (ID 0.4mm). The venous line was used for giving anaesthetic and also for 
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fluid administration. Rats were given saline at a rate of 1ml/kg every 30mins 
throughout the experiment. 
Measurement	  of	  mean	  arterial	  pressure	  (MAP)	  and	  heart	  rate	  (HR)	  
The arterial line was connected to pressure transducers (BP domes MLA 844 ADI 
instruments), which were then connected to the Powerlab/85p system via bridge amps 
(all supplied by ADI instruments).  The setup was calibrated at the start of each 
experiment using a mercury sphygmomanometer attached to the BP domes and inflated 
to pressures of 90 and 150 mmHg. The arterial pressure wave was displayed on a 
computer monitor using PowerLab Chart software. MAP and HR were recorded at 
regular times during the experiment, the precise timings varied depending on the 
experimental protocol. If in the rare circumstance the rat’s MAP did not recover to 
higher than 80 mmHg post thoracotomy then the rat was humanely terminated, without 
proceeding to myocardial ischaemia.   
Ventilation	  
Rats were ventilated using small animal ventilators (Harvard). The minute volume  
(defined as the ventilatory volume/minute required to maintain carbon dioxide 
homeostasis) that a rat requires is 575 cm3 /min/kg (range 460-900 cm3)297. Rats were 
ventilated at 70 breaths per minute (BPM) and the tidal volume (Vt) altered according 
to the weight. Thus a 300g rat would have a minute volume of 172.5 cm3 and, when 
breathing at a rate of 70 BPM the Vt would be 2.46 cm3.  
 
Ventilator	  Calibration	  
To ensure that the Vt as displayed on the ventilators was actually the Vt given to the 
rats, each ventilator was calibrated. 1 litre measuring cylinders were filled with water 
and then quickly submerged under water. Tubing from the ventilators was placed under 
the water and the ventilators were turned on. Ventilators were set at varying rates (60, 
70, 80 BPM) and at varying Vt and the amount of water displaced was recorded (see 
Figure 9). This was repeated three times and the average volume of water displaced was 
recorded. It was found that each ventilator gave slightly different Vt. These small 
differences in Vt would over the course of a lengthy experiment result in significantly 
different total ventilatory volumes. The delivered Vt was plotted against the measured 
 78 
Vt and a normogram was plotted for each ventilator (see Figure 10). Different 
ventilators gave consistently different readings, thus the Vt on each ventilator depended 
on the weight of the animal and the ventilator used. Using this method, we were able to 
readily set the ventilatory properties to ensure the animals respiratory parameters were 
kept in the physiological range.   
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Figure 9. Ventilator calibration. The Harvard ventilator was set at 70BPM with varying Vt, and the 
volume of water displaced over 60s was recorded. 
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Figure 10. Individual normograms for 3 different Harvard small animal 
ventilators. Note should be made of the differing scales, thus to deliver a Vt of 
2.5ml ventilator 1 was set to 2.4ml, ventilator 2 to 3ml and ventilator 7 was set 
to 3.8ml.  
 81 
Individual normograms were created for each individual ventilator, which were verified 
on serial arterial blood gas (ABG) testing.  After 15 minutes stabilisation on the 
ventilators, 200ul of arterial blood was withdrawn into a heparinised syringe and 
analysed using an ABL 77 blood gas analyser (Radiometer Copenhagen).  
If arterial blood gases demonstrated a significant respiratory acidosis or alkalosis, the 
minute volume was adjusted using the Vt or respiratory rate. After 15minutes the ABG 
was repeated to ensure normal physiological parameters.  
Supplemental oxygen was delivered to the rats from an oxygen cylinder. The amount of 
oxygen delivered was controlled using a tap and measured using an oxygen sensor 
(TED 200T7 Teledyne industries). The oxygen flow rate was adjusted during the course 
of the experiment to maintain a pO2 of 10-14 kPa as measured on ABG. ABGs were 
routinely taken at the following time points: 1) 15 minutes after ventilation, 2) Pre-
occlusion and 3) at the end of reperfusion, at which time up to 1ml of blood was taken 
and stored for further analysis. Further ABGs were occasionally taken if a rat was 
unexpectedly hypotensive during the experiment (See Figure 11 for schematic 
representation of full experimental setup). 
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Figure 11. Schematic representation of experimental setup for the rat model of myocardial infarction 
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Thoracotomy	  
To ensure the rats were deeply anaesthetised their foot pad was squeezed using forceps 
to elicit a pain response. If there was any evidence of a pain response, a further 0.05ml 
of Thiopental Sodium was administered IV, using the internal jugular line. After a delay 
of several minutes, the procedure was repeated to ensure adequate anaesthesia before 
the thoracotomy was commenced. 
An incision was made just inferior to the lower border of the sternum and the skin was 
blunt dissected off the anterior thoracic wall up to the superior margin of the sternum. 
The animals were placed on a metal conductive plate attached to an Electrosurgery 
system (PromhoVet). Using diathermy forceps and a diathermy electrode a left 
parasternal thoracotomy was performed involving the lower 6 ribs. The parietal pleura 
was then carefully dissected away to reveal the thoracic cavity. The cavity was held 
open using a rodent thoracic spreader (see Image 2). The thymus was lifted clear of the 
heart and held in place by an arterial clamp, while the pericardial membrane was 
carefully removed. 
A 6-0 Mersilk round bodied curved needle suture (Ethicon) was used to snare the left 
anterior descending artery (see Image 3). The position of the suture was approximately 
2mm inferior to the junction of the left atrium with the left ventricle. 
Correct suture placement was critical: if the suture was placed too high it could snare 
the left main stem artery rather than the LAD. This would lead to a massive infarction, 
associated with fatal ischaemic arrythmias. If the suture was placed too low down the 
LV there was a greater chance of missing the LAD, which meant that when the 
occluder was tightened the distal myocardium was not rendered ischaemic. The correct 
placement of the suture was extremely challenging: the LAD was rarely visible, the 
heart was beating at 400 BPM with the chest cavity moving at 70 breaths/minute and 
the difference between placing the suture too high or too low was less than 5mm. 
LAD	  occlusion	  
After the thoracotomy the rat was removed from the metal conductive plate and left to 
recover. A 2 cm section of Portex tubing ID1.67mm was cut. The tip of the section of 
tubing was held briefly over a candle flame so that the edge would flare out to make a 
suitable occluder.   
 84 
The occluder was threaded over the suture and then pulled so that the LAD artery was 
occluded between the suture material and the occluder. The degree of pressure applied 
was critical; too little pressure and the LAD did not fully occlude, too much pressure 
may cause damage to the LAD, impairing reperfusion. To ensure the pressure was 
correct the tension was increased until the area at risk turned pale (see Image 5). At this 
point the occluder was locked in place using a straight mosquito forceps (Harvard). The 
area at risk (AAR) was regularly checked to ensure that the area of ischaemia remained 
distinct from the surrounding tissue.  
At the end of ischaemic time, the mosquito forceps were released reopening the LAD 
artery. Reperfusion was confirmed by noting a prompt hyperaemic colour change in the 
previously ischaemic AAR (see Image 4) and reperfusion arrhythmias were noted. The 
animals were then left for the duration of the reperfusion time (generally 2 hours, but 
the exact reperfusion time depended on the individual experimental protocol). During 
this time the animals MAP, HR and temperature were recorded and saline boluses were 
given every 30 minutes. 
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Image 2. Photograph of a rat post thoracotomy with pericardial membrane removed and thymus retracted 
 
Image 3. 6-0 Mersilk suture placed 2-3mm inferior to atrio-ventricular junction . ECG electrodes attached 
to muscle wall for measurement of ischaemic changes and arrythmias. 
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Image 5. LAD occluded using portex snare. The white arrow indicates the pale area representing the 
area at risk. 
 
Image 4. After the tubing is unclamped the area at risk (white arrow) becomes markedly hyperaemic 
indicating reperfusion. 
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Harvesting	  
At the end of reperfusion, 1ml of blood was taken and spun in a centrifuge at 9900rpm 
for 4 minutes. The plasma was aspirated and frozen for future analysis. The LAD was 
briefly re-occluded as before. Following this, 2mls (2% w/v) of Evans blue dye  (Sigma 
Pharmaceuticals) was then infused through the venous line until the whole animal 
developed a blue tinge. At this point, only the area of the heart which was ischaemic 
remained red. This was defined as the AAR. The heart was cut away from the animal 
and placed in ice-cold isotonic saline to ensure rapid cooling and termination of 
myocardial contractility. During this time the clamp remained on. After several minutes 
the heart was removed from the ice cold saline and the clamp was taken off. The heart 
was then placed inside a 2ml syringe whose end had been removed. Care was taken to 
ensure that the heart was orientated within the syringe so that the LV apex was towards 
the end of the syringe. The syringe plunger was then used to extrude the heart slowly so 
that 2 mm sections were exposed at the tip. These were then carefully sliced off and 
placed into a Petri dish containing ice-cold saline. This process continued until the point 
at which the suture was visible. The remainder of the heart was removed and weighed. 
For each section the right ventricle was removed using a scalpel and placed with the 
remainder of the heart above the suture point. After this the red areas of tissue (AAR) 
were cut from the blue stained tissue (perfused LV). These tissues were weighed to 
define the AAR expressed as a percentage of the total LV. 
Determination	  of	  Infarcted	  tissue	  
Nitro Blue Tetrazolium (NBT) solution was made up using 5 mg of NBT (Sigma-
Aldrich Gillingham UK) dissolved in 10ml Saline. NBT is reduced in the presence of 
an intact dehydrogenase enzyme system to form a dark blue formazan298. In infarcted 
tissue, these dehydrogenase pathways are not intact and so the tissue remains red/pink. 
In this way, viable and infarcted tissue may be distinguished from each other.   
The AAR tissue was cut into 2mm cubes and incubated at 370C with 10ml of the NBT 
solution for 30 minutes. After 30 minutes the sections were then removed from the 
NBT solution washed in saline and separated according to their colour. Those samples 
that remained pink/red were considered infarcted tissue and those, which were stained 
blue, were considered viable.  Both collections of tissue were weighed and the infarct 
was expressed as a percentage of the red to blue tissue by weight. 
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Detection	   of	   myocardial	   ischaemia	   and	   reperfusion	   using	  
electrocardiography	  and	  blood	  pressure	  analysis. 
During the LAD experiments, 3 electrocardiogram electrodes were attached to the rats 
allowing continuous recording of the ECG. The positions of the attachments were on 
the left and right side of the thoracotomy and on the left foot. The electrodes were 
connected to a Powerlab/85p system via bridge amps (ADI instruments), and displayed 
using Powerchart software (ADI instruments). 
Analysis of the ECG trace assisted with determination of ischaemia and reperfusion. 
ST segment elevation in response to infarction was first described by Kjekshus et al.299, 
and is a very early indicator of myocardial ischaemia. 
Measurements of the trace were made before LAD occlusion, to ensure that there was 
no evidence of myocardial ischaemia before the occlusion of the LAD artery and then 
during ischaemia and reperfusion. Typical ECG findings in a single rat during 
ischaemia and reperfusion are shown below (see Figure 12 A-I). Pre-occlusion (A), no 
ST segment changes were seen indicating that there was no progressive myocardial 
ischaemia during the thoracotomy or during the placement of the suture around the 
LAD artery. Two minutes after LAD occlusion (B), ST segment elevation developed 
indicative of myocardial ischaemia. Over the next 5 minutes (C), the ST segments rose 
to almost the same height as the QRS complex. Ten minutes after LAD ligation (D) the 
animal developed ventricular tachycardia, with widely spaced complexes on the ECG 
and loss of cardiac output, with the MAP and calculated pulse rate falling from 80 to 
almost undetectable levels. 1 minute later (E), there was evidence of ventricular 
fibrillation and after a further 4 minutes (F), in this animal there was spontaneous 
cardioversion to sinus rhythm with restoration of cardiac output. While in sinus rhythm 
there was persistent elevation of the ST segments (G), which persisted until reperfusion. 
At reperfusion (H), there was a further loss of cardiac output with a grossly abnormal 
ECG, which lasted for 30 seconds. Finally, 10 minutes after restoration (I) of flow in 
the LAD, there is normalisation of the ST segments indicating reperfusion. 
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Figure 12. A-I. Recordings from Power Chart system during LAD ligation experiment. ECG trace is 
shown in red (top), MAP recording in the middle (green) and calculated pulse rate at the bottom 
(pink) 
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Figure 13. MAP and pulse recording during a 
single LAD ligation experiment.  Note is made 
of the drop in MAP following occlusion of the 
LAD, the ischaemic arrhythmias which generally 
occur 4-7 minutes post occlusion and subside 
after 10 minutes, and the reperfusion arrhythmias 
which occur around 30 seconds after the 
occluder is released. 
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Observer	   bias	   and	   variability	   in	   the	   measurement	   of	   infarct	  
size	  
Measurement of infarct size using NBT to stain viable myocardium black relies on a 
subjective decision by the investigator.  Not infrequently, the tissue sections are not 
either dark blue/black nor are they pink, but somewhere in-between. In addition, an 
individual section of tissue may be heterogeneously stained. This is not surprising as 
within the myocardium, infarction is not a homogenous process but depends on the 
microenvironment and the diffusion distance between the capillaries and the myocytes. 
Other methods to measure infarct size includes such as	  triphenyltetrazolium	  chloride 
(TTC) staining and planometry300, which stains viable tissue a reddish brown colour, 
leaving infarcted tissue pale. The advantage of planometry over staining using NBT is 
that the heart section images are stored as an image, which facilitates blinded scoring of 
the hearts. This still relies on observers deciding subjectively the staining of an area.  
Factors that influence the accuracy of the estimation are the size and number of sections 
of tissue. Too few a number and each section is likely to contain both infarcted and 
viable tissue making correct allocation into non-viable or viable difficult. If this 
happens, the section of tissue can be cut divided again into viable and non-viable areas. 
However, if the tissue is sliced into very small sections, additional damage will be done 
during sectioning such that viable tissue may not stain darkly using NBT.  
Because uraemic animals were visibly smaller than their non-uraemic counterparts, 
blinding between the groups was impossible. Furthermore, in later work using 
conditioning strategies the operator was performing the intervention so was not blinded 
to the outcome. To address this weakness throughout the course of the entire research 
project animals were chosen at random and re-counted by a blinded second researcher 
to ensure that there was no bias between the groups. As part of the quality control 
several samples were recounted by the same observer to ensure that any inter-observer 
variability was not due to intra-observer variability. 
After the pieces of heart were counted and weighed, the sections were resuspended in 
saline and recounted; 7 results were recounted. The intra-observer variability in these 
experiments was small with a median absolute variability of 0.57% (IQR 0.3-1.1%) and 
a median relative variability of 1.7% (IQR: 1.5-5.2).  
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The inter-observer variability was calculated on the basis of 165 results. Several steps in 
this process could introduce bias. Firstly the calculation of the area at risk was 
considered. The area at risk was calculated by briefly drying and weighing the 
nonperfused tissue (red) and the remainder of the left ventricle (blue). The area at risk 
was expressed as percentage of total LV area. When the pieces of heart were dried 
before weighing, more vigorous drying could alter the weight and hence the AAR. The 
average absolute difference in weight of tissue between the 2 observers was 0.024g 
(SD=0.03); the relative difference between the 2 observers was 10.7% (sd=15.2). There 
was no tendency for one observer to dry out the hearts more than the other. In 73/165 
occasions, one observer made the heart tissue heavier and in 85/165, the other observer 
made the heart heavier, with 7 occasions when both observers got exactly the same 
result. 
Measurement of infarct size required 2 steps: a judgement as to whether the tissue was 
viable or non-viable. The second was weighing the groups of heart sections. There was 
no significant difference in the measurement of the infarct sizes between the 2 
observers. The mean absolute inter-observer variability of infarct size estimation was 
6% (SD=7.5) and the mean relative inter-observer variability was 13% (SD=20.1). 
There did not appear to be any consistent trend in observer bias, as observer 1 judged 
the infarct size greater than observer 2 in 52% of the samples, while observer 2 judged 
the infarct size greater in 47% of the samples, with both observers getting exactly the 
same infarct size to 2 decimal places was 1%. 
To identify whether the variability depended on the degree of injury, the inter-observer 
variability was plotted against mean infarct size (see Figure 14 B). This shows that the 
absolute variability was highest when the infarct size was approximately 50%. This is 
not surprising, as when the infarct size approaches 50%, more sections of heart are 
likely to contain a mixture of viable and non viable tissue making the labelling of that 
section more challenging. If the infarct is very large or very small then there will be few 
pieces of tissue that contain a significant mix of viable and non viable tissue which 
explains why the absolute variability is reduced at extremes of infarct sizes. When the 
relative inter-observer variability (Figure 14A) is plotted against mean infarct size, 
variability decreases as infarct size increases. Again this is unsurprising, as at small 
levels of infarct, a single discrepancy may cause a large difference in infarct size 
estimation. 
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A second question regarding variability was: did the variability change over the 3 years 
of research? One would expect with researcher experience the degree of variability 
would narrow. However, (see Figure 14 C+D) there was no trend seen in either absolute 
or relative observer variability over time. This would suggest that it is an inherent error 
of the method of the model.  
The intra-observer variability is approximately 8 times less than the inter-observer 
variability suggesting that despite multiple recounting, there is an intrinsic small error in 
this model and that there does not appear to be a bias in between observers. These 
results suggest that the lowest absolute difference in infarct sizes detectable is 6%. 
Therefore, any therapies which are known to have less than an absolute 6% effect size 
will not be detectable in this model. 
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Figure 14. A: Graph showing how relative inter-observer variability varies with infarct size. B: Graph 
showing how absolute inter-observer variability varies with infarct size. C: Graph showing how 
absolute inter-observer variability varies over time. D: Graph showing how relative inter-observer 
variability varies over time. Graphs show mean with SEM as error bars. 
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Chapter 4 
 Ischaemia Tolerance of the Uraemic Heart 
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Background	  
It has been almost 40 years since Lindner et al.33 suggested a link between renal 
function and increased cardiovascular mortality. Subsequently, there has been a great 
effort in the scientific community to describe the excess risk through epidemiological 
studies37. It is clear that CKD patients have a high incidence of acute myocardial events 
and following an acute event, CKD patients have much poorer outcomes than in the 
general population301. The increased incidence of CVD in CKD has been discussed in 
the introductory chapter, but one possible explanation for the very poor outcomes 
following a cardiac event is that for a given insult the uraemic heart generates a larger 
infarct size. This theory has been difficult to prove in humans as the infarct size is 
dependent on the ischaemic area or the area at risk (AAR)302 and this has proved 
difficult to measure. Several strategies have been used to attempt to indirectly quantify 
the AAR including 99mTc-sestamibi303, contrast echocardiography304, angiographic 
scoring systems305 and cardiac MRI306. While all methods have their limitations, 
gadolinium cardiac MRI appears to offer the best special resolution with good 
correspondence to histological necrosis306. 
In vivo animal studies afford the opportunity to measure the area at risk precisely 
allowing researchers to accurately investigate tolerance to ischaemia. In 2004, Dikow et 
al.307 reported for the first time that experimental uraemia was associated with a reduced 
tolerance to ischaemia. They created a model of chronic uraemia using the standard 5/6 
nephrectomy model and found that uraemic animals had a 33% greater infarct size than 
pair fed non-uraemic animals, with no differences in the AAR. They then went on to 
demonstrate that this increase was independent of hypertension, sympathetic activity 
and salt intake. Further work by the same group has replicated the data308, however 
there has not been any further work published by other groups replicating these data or 
extending the findings to other models of chronic uraemia.   
Abnormalities	   of	   the	   uraemic	   heart	   which	   confer	   a	   reduced	   ischaemia	  
tolerance	  
Uraemic	  Left	  Ventricular	  Hypertrophy	  
Uraemia is associated with LVH. In a study by Greaves et al.309 echocardiography was 
normal in only 37% of CKD and 29% of haemodialysis patients, with LVH being the 
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major abnormality. Levin et al.310 undertook a prospective study using 175 CKD 
patients and found the prevalence of LVH increased from 26.7% in those with a 
GFR>50ml/min, to 45.2% in those with a GFR <25ml/min. Parfrey at al, 195,  examined 
a incident dialysis cohort of 432 patients. They found that at initiation of dialysis only 
16% of patients had a normal echocardiogram, with LVH being the most common 
abnormality. Furthermore those patients with incident LVH had an increased risk of 
subsequent heart failure and death. 
LVH in uraemia has been independently associated with de novo IHD, heart failure and 
mortality37. LVH has been shown to increase with the dialysis vintage even in 
normotensive patients311, and persists after transplantation312. 
The explanation of the high prevalence of LVH in CKD is multifactorial. CKD patients 
are anaemic, hypertensive, fluid overloaded, with sympathetic overactivity. Anaemia 
has been shown to be an independent risk factors for LVH in early renal disease313 and 
ESA treatment used to raise haematocrit has been shown to partially reverse LVH314. 
Sodium and water retention or arterio-venous shunting from arterio-venous fistulas 
leads to volume overload and ventricular dilation. In addition, London et al.294 proposed 
that loss of aortic elasticity leads to LVH directly due to the inherent stiffness of the 
vessels, increasing afterload and indirectly due to an increased pulse wave velocity. The 
pressure wave, which is generated by the heart, reflects off branching points in 
peripheral arteries and travels back towards the heart. In health, this wave travels more 
slowly and reaches the heart in diastole. However, when the aorta is stiff, the wave 
travels more rapidly and reaches the left ventricle during systole, increasing the after 
load294, 315.  
In contrast to the general population, the evidence for blood pressure as the driving 
force for LVH in CKD patients is unclear as it is known that CKD patients develop 
LVH even in the absence of hypertension316. Studies of patients with essential 
hypertension have shown LVH regression and mortality benefits with good blood 
pressure control317, however these mortality benefits have not been shown in dialysis 
patients. 
The difficulty of hypertension research in the field of ESRD comes from the difficulty 
in measuring a standard blood pressure in an ESRD cohort. 
It is difficult to extrapolate the usual clinical BP measurements in haemodialysis 
patients to published research studies because usual systolic and diastolic pressures 
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both pre- and postdialysis are significantly higher by about 14/5 mmHg than if 
measured according to standardized American Heart Association criteria318.  
In addition BP varies between predialysis, intradialysis, post dialysis and interdialysis 
readings. It is currently unclear which BP data set is the best measure of LVH, 
however has been shown showed that 24 hour ambulatory BP recording on non 
dialysis days provided better prognostic information about future cardiac events 319 
and better correlation with LVH 320 when compared to pre and post dialysis BP 
recordings.  
Studies on the regression of LVH using antihypertensive therapy have been 
conflicting 321 322 however more frequent HD323 or accurate control of volume 
status324 may lead to attenuation of progressive LVH associated with HD. In addition 
indirect evidence for good blood pressure control comes from work in the Tassin 
centre in France325,  where meticulous blood pressure control, along with multiple 
other interventions in a highly motivated patient group undergoing long hours of 
dialysis led to improved survival. An epidemiological study by Foley et al.326 suggest 
that blood pressure control on dialysis and cardiovascular mortality have a U shaped 
relationship with those patients with low and high blood pressure having the greatest 
death rate. This is thought to be due to heart failure patients with low blood pressure 
and very high mortality rates confounding the data.  
 
Coronary	  vascular	  disease	  
Uraemic patients are known to have a high prevalence of atheroma. However, in 
addition to intimal atheromatous disease, the media of the coronary arteries is 
significantly thickened in the context of uraemia, so that the lumen is narrowed both 
from atherosclerosis and increased medial thickness327.  The plaques associated with 
uraemia differ in composition compared to those in non-uraemic patients, with evidence 
of increased calcification328. This calcification may partly explain the early poor 
outcomes of angioplasty in uraemic patients, with a 1 year re-stenosis rate of 70%328. 
The TIMI trial329 demonstrated that the presence of coronary collaterals was associated 
with smaller infarct sizes. Sezer et al.330 have shown that uraemia is associated with 
poor coronary collateral vessel development. 
Uraemia is also associated with impairment of vasodilatation due to resistance to the 
vasodilatory effects of nitric oxide331, and also in response to lower levels of NO 
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produced during the uraemic state332.  Uraemia is also associated with increased 
production of endothelin-1 which triggers increases in intimal and medial thickness333.  
In addition to the changes seen in the coronary arteries, arterioles are also thickened in 
response to uraemia, an effect which appears to be independent of hypertension334. This 
proliferation appears to be dependant on renin-angiotensin335 and endothelin336. The 
uraemic changes in the coronary vasculature may explain the reduction in the coronary 
reserve seen in patients with uraemia337. 
 
Capillary	  rarefaction,	  cardiomyocyte	  hypertrophy	  and	  myocardial	  fibrosis	  
In experimental uraemia there is a reduction in the density of capillaries in the 
myocardium338. There is also an expansion of the cardiomyocyte volume339.  These 
findings suggest that capillary growth does not keep pace with the cardiomyocyte 
hypertrophy seen in uraemia, resulting in a greater diffusion distance of oxygen from 
the capillaries to centre of the myocyte. This distance is crucial because diffusion is 
related to the inverse square of the distance, thus small changes in distance have a large 
impact on ischaemia tolerance. This capillary mismatch appears to be specific to 
cardiac muscle with sparing of skeletal muscle340.  
The histological findings seen in experimental uraemia replicate those seen in humans. 
Post-mortem examination of dialysis patients’ myocardium revealed capillary length 
density was only 50% of that seen with controls, with a myocyte diameter double that 
of controls, and volume density of non-vascular interstitium was 60% higher than 
controls129. The mechanism for these histological changes seen with uraemia is thought 
to involve the renin-angiotensin system, sympathetic over reactivity and endothelin, as 
pre-treatment of uraemic animals with an ACE inhibitor341,  moxonidine341, 
metoprolol342 and an endothelin receptor blocker343 abrogated the histological changes 
associated with uraemia. Critically, these changes were in the absence of a significant 
reduction in blood pressure.  
Uraemia (along with diabetes and hypertension) is associated with myocardial fibrosis, 
and was first noted in the context of uraemia over 60 years ago344. While myocardial 
fibrosis was reduced with calcium antagonists and ACE inhibitors in models of 
hypertension, this was not the case in uraemic models345 suggesting that there may be 
different pathways which generate fibrosis in uraemia. In addition myocardial fibrosis 
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increases diffusion distance and has been shown to predispose to malignant 
arrhythmias346. 
 
Metabolic	  effects	  
Uraemic hearts display a marked reduction in myocardial energy supply, with a basal 
reduction in phosphocreatine/ATP ratio. During ischaemia, the phosphocreatine/ATP 
ratio falls291. The fact that uraemic hearts start out at a lower phosphocreatine ratio than 
controls may help explain the reason that uraemic hearts are less tolerant to ischaemia 
than control hearts. 
During anaerobic glycolysis, more glucose is required to create high-energy molecules 
than under aerobic conditions. In uraemia, insulin mediated glucose uptake by 
cardiomyocytes is diminished347. Dikow et al.308 showed that by restoring glucose 
uptake, using a glucose and insulin infusion, uraemic hearts regain their lost ischaemia 
tolerance. This effect was specific to uraemia, with no increase in ischaemia tolerance 
in sham-operated animals given glucose and insulin.  
	  
Anaemia	  and	  Erythropoietin	  
Erythropoietin (epo) production is stimulated by hypoxia and anaemia through 
hypoxia-inducible factor-1 430. However the relationship between epo levels and 
anaemia in the context of CKD is not straightforward. As GFR falls, minimal anaemia 
develops which leads to a compensatory increase in of epo levels such that in early 
CKD epo levels are inversely related to haemoglobin, however as GFR falls further 
epo production cannot keep pace with haemoglobin levels and the epo level does not 
rise further and in those patients with stage 4-5 CKD absolute epo levels may be 
lower for a given degree of anaemia than those with normal renal function 431.  
Exogenous erythropoietin is known to have cardioprotective effects 432 and has been 
shown to confer cardioprotection by acting through the same pathways as classical 
ischaemic preconditioning: JAK/STAT 432, Akt 433 and PKC 434 (see p124 for full 
discussion of IPC). The role of endogenous epo in ischaemia tolerance is limited to 
remote ischaemic preconditioning (see p235 for more details on remote ischaemic 
preconditioning), as the myocardium does not produce epo unlike renal tissue. 
Erythropoietin has been implicated in remote ischaemic preconditioning of the heart 
 103 
by the kidneys 435. In addition hypoxic preconditioning has been shown to confer 
cardioprotection through epo dependent pathways 436.  
Anaemia in the context of mild CKD could lead to a epo driven pro-survival state in 
which uraemic hearts are rendered resistant to subsequent injury, however against this 
is evidence from epidemiological studies which show that anaemia is a risk factor for 
poor outcomes following a cardiac event 437. In addition longstanding anaemia is 
deleterious to the heart due the resultant LVH that leads to a reduced ischaemia 
tolerance. Therefore it is unlikely that a small pro-survival effect of increased epo 
levels in early CKD in response to anaemia outweighs the deleterious effects of 
anaemia, LVH and uraemic cardiomyopathy on the ischaemic tolerance of the 
uraemic heart. 
 
Sympathetic	  overactivity	  
Uraemia is associated with an increase in sympathetic overactivity348. Increased 
sympathetic activity has been associated increased myocardial injury following AMI67, 
with pharmacological blockade of β-adrenoceptors forming the cornerstone in acute 
cardioprotection following AMI over the last 40 years349.  
 
Inflammation	  
Inflammation, common in the context of CKD209, has been widely reported to increase 
the incidence of cardiovascular disease but there is little evidence for the direct role of 
inflammation in the reduction of ischaemia tolerance. However, a study by Griselli et 
al.213 demonstrated in a rat model of LAD ligation, that direct injection of human CRP 
resulted in a 40% increase in infarct size. This effect was thought to involve 
complement activation, as the increase was blocked in the presence of cobra venom, 
which depleted complement.  
Aims	  
The aim of this work was to confirm the previously published work in the SNx model 
of chronic uraemia 307 and to determine whether this effect was seen in a more severe 
model of chronic uraemia, the adenine model. 
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Methods	  
Experiment	   1:	   Myocardial	   Ischaemia	   tolerance	   in	   an	   adenine	   model	   of	  
chronic	  uraemia.	  
Six-week-old male Wistar Rats (Charles Rivers UK) were obtained and after 1 week 
acclimatisation in an animal house with a 12-hour day night cycle and free access to 
water and standard chow, the animals were divided into 2 groups. The first group were 
fed a diet containing 0.75% adenine for 4 weeks, the second group were fed standard 
chow for 4 weeks to create a uraemic and non-uraemic group (for full details of the 
method for creation of the adenine model see page 55). At the end of the 4-week 
feeding, both groups underwent an experimental myocardial infarction procedure (see 
page 76-87 for full details on procedure). Briefly the rodents were anaesthetised, 
ventilated and underwent a thoracotomy following which, a suture was passed around 
the LAD artery. The LAD artery was occluded for 25 minutes to induce myocardial 
ischaemia, followed by 2 hours reperfusion. At the end of 2 hours reperfusion, the heart 
was harvested and the AAR and infarct size was calculated. 
Experiment	   2:	   Myocardial	   ischaemia	   tolerance	   in	   a	   subtotal	   nephrectomy	  
model	  of	  chronic	  uraemia.	  
Six week old male Wistar Rats (Charles Rivers UK) were obtained and kept in an 
animal house with a 12 hour day night cycle and free access to water and standard chow 
for 1 week. All animals then underwent a 2 stage SNx procedure or sham SNx 
procedure (for full methods see ‘Sub-total nephrectomy model’ page 52 )  
4 weeks later, both groups underwent an experimental myocardial infarction procedure 
as above (see methods section on page 75 for full details).  
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Experiment	   3:	   The	   effect	   of	   altering	   the	   duration	   of	   ischaemia	   on	  
subsequent	   infarct	   size	   in	   a	   rodent	   model	   of	   experimental	   myocardial	  
infarction.	  
Six week old male Wistar Rats (Charles Rivers UK) were obtained and housed in an 
animal house with a 12 hour day night cycle and free access to water and standard chow 
for 4 weeks. 
Four weeks later, the rats underwent an experimental myocardial infarction procedure 
as above (see page 75 for full details on procedure). The animals were divided into 2 
groups. The first group underwent 25 minutes of LAD ligation, whereas the second 
group underwent 145 minutes of LAD ligation. There was no reperfusion period. After 
25 minutes or 145 minutes the hearts was harvested and the area at risk and infarct size 
was calculated. 
 106 
Results	  
Myocardial	  ischaemia	  tolerance	  in	  an	  adenine	  model	  of	  chronic	  uraemia.	  
Adenine treated animals had similar blood pressures when compared to non-uraemic 
animals, however, they had lower pulse rates at all time points during the experiment 
(see Figure 15). Calculation of the area under the curve (AUC) for heart rate for each 
rat revealed a significant bradycardia when compared to non-uraemic animals 
(p<0.002). Pressure rate product (PRP), calculated by multiplying the heart rate by the 
mean arterial pressure, unsurprisingly had a similar result to the heart rate, with the 
AUC for the PRP being significantly lower in the adenine treated groups compared to 
the non uraemic group (p<0.05).  
In keeping with previous work, 4 weeks of adenine diet resulted in animals which were 
growth restricted and weighed almost 50% less than their non uraemic counterparts 
(p<0.0001). They were anaemic (p=0.0002), with a creatinine 6 times that of the control 
fed animals (p=0.0002) (see Figure 16 and Table 5).  
Despite this uraemic phenotype, following 25 minutes LAD ligation and 120 minutes 
reperfusion there was no significant difference in the infarct size when compared to non 
uraemic controls, with the adenine treated rodents and standard chow fed rodents 
having infarct sizes of 49.3% and 50.2% respectively. Both groups had similar AAR 
measurements of 47.1% and 42.2% in the control and adenine groups respectively.    
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Figure 15. Graph showing the change in cardiovascular parameters during 
the course of the LAD ligation experiment in control and adenine fed 
rodents.  The top graph shows mean arterial pressure changes over time. 
The middle graph demonstrates heart rate changes over time and the bottom 
graph demonstrates changes in pressure rate product over time.  Data points 
represent mean with SEM as error bars.  
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Figure 16. Results of experiment 1: Myocardial ischaemia tolerance in the Adenine model of 
chronic uraemia. These graphs show the effects of 4 weeks of adenine diet on the weight, 
haematocrit, and renal function of the rodents. Following 25 minutes of LAD ligation both 
groups had similar AAR and infarct sizes. Data displayed as mean with error bars as SEM. 
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Table 5. Tabular results of experiment 1: Myocardial ischaemia tolerance in the 
Adenine model of chronic uraemia. Data shown as mean with (SD). P values are  the 
results of an unpaired t-test using GraphPad Software. 
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Myocardial	  ischaemia	  tolerance	  in	  a	  subtotal	  nephrectomy	  model	  of	  chronic	  
uraemia	  
SNx animals tended to have a higher blood pressure during the experiment, however 
this did not reach statistical significance (see Figure 17). The uraemic animals also 
tended to have marginally higher heart rates during the experiment, and this too did not 
reach statistical significance. However, the uraemic animals did have a significantly 
higher PRP compared to the non-uraemic animals (p=0.02). 
In keeping with previous work, the SNx model of uraemia resulted in rats that were 
growth restricted (p=0.02), anaemic (p=0.0003) and had a serum creatinine over 2.5 
times that of sham operated animals (p<0.0001) (see Figure 18 and Table 6 ). Following 
25 minutes of LAD ligation with 2 hours reperfusion, the sham operated group had a 
mean infarct size of 47.2% and the SNx group had a significantly higher mean infarct 
size of 62.3%, a relative increase of 32% (p=0.03). The AAR for both groups was 
similar.  
The	  effect	  of	  altering	  the	  duration	  of	  ischaemia	  on	  subsequent	  infarct	  size	  in	  
a	  rodent	  model	  of	  experimental	  myocardial	  infarction	  
25 minutes of ischaemia without reperfusion resulted in a small median infarct size of 
3.5%. Increasing the duration of ischaemia to 145 minutes increased the infarct size to 
82.8%, which despite the small group size was significant (p=0.04). Both groups had 
similar AAR (see Table 6). 
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Figure 17. Graph showing the change in cardiovascular parameters during 
the course of the LAD ligation experiment in the SNx model of uraemia and 
sham operated non uraemic rodents.  The top graph shows mean arterial 
pressure over time. The middle graph demonstrates heart rate changes over 
time and the bottom graph demonstrates changes in pressure rate product 
over time.  Data points represent mean with SEM as error bars.  
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Figure 18. Results of experiment 2: Myocardial ischaemia tolerance in the SNx model of 
chronic uraemia. These graphs show the effects a subtotal nephrectomy procedure on the 
weight, haematocrit, and renal function of the rodents. Following 25 minutes of LAD ligation 
both groups had similar AAR and however the SNx group had a significantly larger mean 
infarct size (p<0.05). Data displayed as mean with error bars as SEM. 
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Table 6. Tabular results of experiment 2: Data shown as mean with (SD). 
 p values are the results of an unpaired t-test using GraphPad Software. 
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!
Figure 19. Results of experiment 3: Top graph represents the area 
at risk, following LAD ligation for 25 minutes or 145 minutes. 
Data presented as median with IQR. Middle: graph shows the 
infarct size results from the 2 groups. Bottom: Table showing the 
AAR and infarct sizes, with p values displayed as results from 2 
tailed Mann-Whitney test using GraphPad software. 
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Discussion	  
These experiments demonstrate that the SNx model of uraemia is associated with larger 
infarct sizes when compared with a non-uraemic group, and that the adenine model of 
chronic uraemia, while exhibiting a more severe uraemic phenotype, is not associated 
with a reduced ischaemia tolerance.  
Several reasons exist which may explain these findings. Dikow et al.307 reported that 
antihypertensive treatment in a SNx group lowered blood pressure to that of a non 
uraemic group, but did not alter the reduced ischaemia tolerance or the heart weight to 
body weight ratio. One could argue that the common finding in their work is that 
increased heart weight to body weight ratio, a surrogate marker for LVH, is the driving 
force behind the reduced ischaemia tolerance. Indeed the group of animals which had 
the highest infarct size, was the group of animals with the greatest heart weight to body 
weight ratio.  
There is conflicting data on the effect of hypertension and LVH on ischaemia tolerance, 
with some authors reporting that it was hypertension per se111 rather than LVH which 
was responsible. Others suggest that diastolic dysfunction in addition to LVH was 
required for a reduced ischaemia tolerance350. In humans, a hallmark of uraemic 
cardiomyopathy is LVH with diastolic dysfunction351 and this  phenotype has also been 
shown in the SNx rodent model352. It may be that diastolic dysfunction in addition to 
LVH is required to cause a reduction in ischaemia tolerance. There is no published 
work on the diastolic dysfunction in an adenine model of chronic uraemia.  
Both the adenine treated animals and the uraemic SNx animals had evidence of 
increased heart weight to body weight ratio (see results section chapter 3). However this 
is only a surrogate marker of LVH, and while this marker was used in work by Dickow 
et al307, their uraemic and non uraemic animals did not have as great a disparity in 
weight. It is likely that the adenine treated animal’s heart weight to body weight ratio is 
schewed by their profound cachexia and they may be mislabelled as having LVH when 
infact they had a non-hypertrophied heart but were profoundly cachexic. It is a 
weakness of this experiment that LVH was not measured directly (either hisoloogically 
or using echocardiographic data) to confirm the presence of LVH in adenine treated 
animals. 
 
 116 
Another possible explanation for the lack of increased infarct size in the adenine treated 
groups was directly starvation. It has been shown that switching rats to an adenine diet 
causes them to stop eating for up to 1 week265. Our previous data show that the adenine 
diet results in a reduction in the amount of food consumption and a failure to gain 
weight (see Figure 4). The adenine fed rats in this current experiment weighed 50% less 
than their non-uraemic counterparts. There is evidence that in the context of  acute 
myocardial ischaemia, starved rats develop less ischaemic arrhythmias and better LV 
function on reperfusion353, along with smaller infarct sizes than non starved controls354, 
an effect which is thought to be due to increased levels of myocardial glycogen in 
response to starvation353. 
PRP is a measure of myocardial oxygen consumption355. In this work, the adenine 
treated rodents had a significantly lower PRP than their non uraemic controls, while the 
SNx treated rodents had a significantly higher PRP than their controls. Reducing 
myocardial oxygen demand during ischaemia/reperfusion had been one of the corner 
stones of cardiovascular research during the 1970’s. Seminal papers demonstrated 
factors which increased oxygen demand led to larger infarcts and factors which reduced 
oxygen demand, such as β-blockade, were cardioprotective66, 67, 69.  
The third experiment while small in size is informative in two ways. Firstly, it would 
appear that 25 minutes of ischaemia by itself does not cause large amounts of 
irreversible damage to the myocardium. This is important because it leaves scope for 
subsequent cardioprotective strategies aimed at intervening at the point of reperfusion. 
The second important point of this experiment was that myocardial ischaemia for 145 
minutes, in the absence of reperfusion, leads to infarct sizes in excess of 80%. The 
duration of ischaemia was chosen as it represented the total duration of the ischaemia 
and reperfusion durations. This protocol was chosen because there was a concern that 
despite release of the LAD occluder, occasionally the distal myocardial tissue did not 
reperfuse and was, in effect, rendered ischaemic for 145 minutes. The term ‘no reflow’ 
injury has been has been used to describe this phenomenon356.  There are several causes 
of ‘no reflow’ injury. Firstly microthrombi and atheromatous plaque contents shower 
down-stream during plaque rupture, obstructing distal small arteries and arterioles357. 
The second mechanism is in-situ microvascular occlusion due to endothelial swelling, 
tissue oedema and neutrophil infiltration which occurs in response to ischaemia357. 
These processes may be enhanced by reperfusion358. A further, often temporary 
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phenomenon, is distal coronary arterial spasm which may occur as a direct result of 
embolisation of particulate matter359 . 
If no reflow occurs in this model, the subsequent infarct size is greater than 80%. This 
result may explain occasional results during the standard protocol of 25 minutes 
ischaemia and 120 minutes reperfusion where there is an unexpectedly large infarct size 
of 80-100%.  
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Investigation	   of	   the	   bioenergetics	   of	   the	   uraemic	   heart	   in	   2	  
models	  of	  chronic	  uraemia	  
Background	  
ATP is required for all functions in the cell. In the heart, the amount of ATP present in 
the cell is enough only for a few beats360 and therefore, myocytes continually re-
synthesise large amounts of ATP. The concentration of ATP within a myocyte is 
maintained a constant level despite large changes in energy demand. Although the 
primary source of ATP re-synthesis is though fatty acid oxidation in the mitochondria, 
the myocardium responds to altered energy demands by utilising alternative pathways 
such as glycolysis, and phosphotransferase reactions from creatine kinase and adenylate 
kinase360. ATP generation from the reaction of phosphocreatine and ADP to form ATP 
and creatine, catalysed by creatine kinase, can generate ATP 20 times faster than fatty 
acid oxidation by mitochondria361. Because of this, phosphocreatine is considered the 
primary energy reserve compound in the heart362. 
 
Effect	  of	  co-­‐morbidities	  on	  myocardial	  bioenergetics	  
The	  hypertensive	  failing	  heart	  
In both animals and humans, the hypertensive heart is associated with a fall in the ATP 
concentration, the total creatine pool and the phosphocreatine pool363. The 
phosphocreatine (PCr) falls more than ATP concentration, which leads to a fall in the 
PCr/ATP ratio. This reduction in the PCr/ATP ratio may lead to a reduction in 
ischaemia tolerance363. 
The	  uraemic	  heart	  
Raine et al.291 studied the cardiac bioenergetics of uraemic rats using the SNx model. 
They found reduced basal phosphocreatine levels, with unchanged ATP levels. They 
concluded that the reduced phosphocreatine/ATP ratio indicated a reduced myocardial 
energy supply. They also found that ADP concentrations were doubled in uraemic 
animals. High levels of ADP have been shown to have an adverse effect on the 
myocardium364 by inhibiting ATPase activity365. The group then went on to investigate 
whether this bioenergetic failure resulted in reduced ischaemia tolerance. They found in 
a model of simulated ischaemia, phosphocreatine fell to a lower level in uraemic hearts 
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than control hearts and more inosine was released by the uraemic hearts. Inosine release 
has been shown as a marker of ischaemic damage in vitro366. Therefore, they concluded 
that bioenergetic failure associated with uraemia led to a reduced ischaemia tolerance. 
 
Adenine	  metabolism	  in	  the	  rat	  
A striking feature of the adenine treated rats is their bradycardia. There are 2 possible 
explanations for this bradycardia. The first is starvation367, due to the unpalatability of 
the adenine diet, and the second is due to systemic effects of metabolites of adenine 
adenine diet. Starvation has been shown in human studies of anorexia to lead to 
bradycardia through increased vagal tone296. The uraemic rats consume excess adenine 
as part of their supplemented diet. Due to the saturation of the APRT, adenine is 
metabolised to the insoluble 2,8-dihydroxy-adenine (see Figure 2). The excess adenine 
initially gets converted to AMP. It is only when APRT is saturated that 2,8 dihydroxy-
adenine will form, leading to deposition of insoluble crystals in the renal tubules and 
subsequent uraemia. AMP is metabolised into adenosine by 5’ nucleotidase, and also to 
ADP by adenylate kinase. 
The cardiovascular effects of increased adenosine are bradycardia, hypotension and 
coronary vasodilatation368.  Exogenous adenosine has been shown, in an in vitro model, 
to increase both adenosine and ATP levels in isolated rat cardiomyocytes369 and  has 
been shown to be cardioprotective in human clinical trials85, 370. Furthermore, adenosine 
is involved in the tissue protection seen with ischaemic preconditioning371-374, remote 
ischaemic preconditioning375-377 and postconditioning 378-381. 
Thus the consequences of excess adenine ingestion in the rat would be increased 
formation of AMP, adenosine and ADP before any 2,8 dihydroxy-adenine is formed.  
Therefore, this excess dietary adenine has 3 possible effects; uraemia from the insoluble 
2,8 dihydroxy-adenine crystals, increased nucleotide pool leading to preserved 
bioenergetics and increased adenosine leading to bradycardia, relative hypotension and 
an improved ischaemia tolerance.   
The aim of this experiment was to investigate these possibilities, which could explain 
the differences seen between the adenine model and the SNx model. 
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Methods	  
6-week-old male Wistar rats were divided into 4 groups. One group was fed standard 
chow for 4 weeks (control), the second group was fed 0.75% adenine diet, the third 
group underwent a sham SNx procedure and the fourth group underwent a SNx 
procedure. Four weeks after group 1 and 2 were started on their control or adenine 
diets, the animals were anaesthetised, ventilated and underwent a thoracotomy 
procedure as in the previous experiments. 15 minutes after the thoracotomy, the hearts 
were very rapidly harvested and immediately dropped in liquid nitrogen and were 
stored at -80OC until used. 4 weeks after the second stage nephrectomy or sham 
procedure, groups 3 and 4 underwent myocardial harvesting and storage as above.  
The hearts were processed by crushing them using a mortar and pestle under liquid 
nitrogen and the powdered sample was weighed. A solution of 9% perchloric acid 
(Sigma) and 1% cyclic xanthine monophosphate (cXMP) was added to the triturated 
tissue in the ratio of 1ml: 100mg tissue. The samples were then further agitated with a 
sonicator for 3 minutes and spun at 3000rpm in a centrifuge for 10 mins. The 
supernatant was aspirated and divided into 500 uL aliquots. 
5 molar potassium carbonate (Sigma) was added in a 1:5 ratio to the aliquots to 
precipitate out protein-perchorate complexes (this ratio was chosen to reliably give a 
final supernatant pH of 7.5-8). The solution was spun at 13000 rpm for 10 minutes. The 
supernatant was then aspirated and transferred to 1.5 ml ependorf for storage.  
Nucleotide, phosphocreatine and creatine concentrations were determined by high-
performance liquid chromatography (HPLC). HPLC apparatus comprised of a PU-2089 
Quarternary Low Pressure Gradient Pump and MD-2010 Photometric Diode Array UV/ 
Vis Detector (195-650nm) from Jasco Instruments (UK) Ltd. The pump was connected 
to an AS-2055 autosampler and separations were performed on a reversed phase AceTM  
C18 column (4.6 mm x 15 cm, 5 µm particle size) from Hichrom Ltd. (Theale, Reading, 
UK). Peak area was calculated by EZChrome Elite software and concentrations 
determined against reference material standard curves. 
For ion-pair reversed-phased HPLC determination, the method of Perrett et al.382 was 
used to assay the nucleotides, but slightly modified. Briefly, the mobile phase consisted 
of 2 % methanol, 98 % buffer (83.3 mmol/L orthophosphoric acid H3PO4 titrated to pH 
5.8 with triethylamine). 10 µL of sample was injected onto the column with a flow rate 
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of 0.6 mL/min and a cycle time of 20 min. The column was cleaned at the end of each 
working day with 100 % methanol for 30 min and the autosampler injector was cleared 
with distilled water. Values were quantified against known standard concentrations of 
XMP. Each sample was processed twice and a CV of less than 10 % was accepted. The 
identification of each target molecule was confirmed by adding exogenous standard 
material (all from Sigma Aldrich Chemical Company) to samples.  
 
Results 
The hearts from groups 1 and 2 were crushed and analysed at the same time and the 
hearts from groups 3 and 4 were crushed and analysed at the same time.  However, 
groups 1 and 2 were processed at a different time from groups 3 and 4 and therefore, 
groups 1 and 2 were considered separately from groups 3 and 4. 
In this experiment, the SNx model (n=10) and sham SNx model (n=8) were similar in 
terms of myocardial adenine concentration, phosphocreatine/ATP, total adenine 
nucleotide pool, ATP/ADP, phosphocreatine/creatine and hypoxanthine (see Table 7A). 
Adenine treated animals (n=9) and control fed animals (n=9) were similar in terms of 
myocardial adenine concentration, total adenine nucleotide pool, ATP/ADP, 
phosphocreatine/creatine and hypoxanthine (see Table 7B). However, phosphocreatine/ 
ATP in the adenine group was higher in the adenine treated group, which approached 
significance (p=0.06). 	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Table 7. Results of bioenergetic study of sham SNx and SNx animals (A) and control fed and adenine 
fed rats (B). Data presented as median (IQR) with p values the results of a Mann-Whitney test using 
GraphPad software. 
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Discussion	  
The most striking differences in this experiment is the significant differences between 
groups 1 and 2 and groups 3 and 4. These differences are unlikely to be explained by 
the fact that the sham SNx animals were 2 weeks older than the control fed animals. It 
is more likely that this represents a difference in harvesting, storage and processing of 
the samples. Hearts from the first 2 groups were analysed at a different time from hearts 
from group 3 and 4, with different durations at being stored at -80OC. It may be that 
despite storage in a -80OC, there was degradation of the high-energy phosphates in 
groups 1 and 2.  
The sham SNx and SNx groups were similar in all measures of myocardial 
bioenergetics. This goes against previous data291, which reported a reduced 
phosphocreatine/ATP ratio and an increase in ADP concentration in an SNx model. 
Measurement of adenosine is challenging due to its short half-life. Therefore, in this 
experiment, hypoxanthine a down stream metabolite of adenosine was used as a 
surrogate measure. In these experiments, the SNx and sham SNx groups had similar 
levels of hypoxanthine. The adenine group had a no significant elevation of 
hypoxanthine compared to the control fed group (p=0.09).  This result does not fully 
exclude small differences in adenosine concentrations between the adenine and control 
fed animals because it is presumes that the metabolism of adenosine, through inosine to 
hypoxanthine, is the same in both groups. Adenosine is also metabolised to AMP via 
adenosine kinase. Significant increases in adenosine would be expected to lead to 
increased AMP concentrations. High levels of AMP would lead to increased ADP 
formation at the expense of ATP by the adenylate kinase reaction383.  This would also 
lead to an increase in the total adenine nucleotide pool, with a reduction in the 
ATP/ADP ratio. However, these results do not support this; the total adenine nucleotide 
pool and the ATP/ADP ratio were similar between the groups. Taken together, these 
results do not support the hypothesis that adenine diet leads to increased adenosine 
levels, suggesting that the bradycardia seen with the adenine diet is caused by 
starvation. 
There was only a trend towards a higher phosphocreatine/ATP ratio in the adenine 
group, which did not reach statistical significance.  These data do not suggest that the 
differences in ischaemia tolerance seen in the SNx and adenine treated animals are due 
to altered cardiac bioenergetics. 
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Chapter 5  
Ischaemic Preconditioning of the Uraemic 
Heart 
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Background	  
Following AMI, the size of an infarct is a critical determinant of prognosis384. The need 
for novel cardioprotective strategies is particularly important in patients with underlying 
additional risk factors such as diabetes, the metabolic syndrome or renal failure. 
Diabetic385 and metabolic syndrome patients386 have twice the mortality following AMI 
or CABG compared to controls.  CKD patients are at even greater risk, with up to 15 
times the in-hospital mortality following AMI compared to patients with normal renal 
function41, 387. 
Ischaemic preconditioning was first reported in a landmark paper by Murry et al388. It 
had followed on from earlier research which found that, contrary to expectations, 
repeated brief episodes of ischaemia and reperfusion did not lead to necrotic injury but 
resulted in a retardation in the fall of ATP when the heart was subsequently rendered 
ischaemic389. Murry et al reported that in anesthetised, open-chest dogs, four cycles of 5 
minute coronary artery occlusion followed by 5 min of reperfusion, before the onset of 
40 min of coronary occlusion and 4 days of reperfusion, resulted in a reduction in 
infarct size of 75% compared to controls. Ischaemic preconditioning (IPC) has become 
the ‘gold standard’ to which other cardioprotective strategies are compared390. The 
work by Murry et al. has generated a huge research effort over the last 25 years to 
elucidate the mechanisms involved and translate these findings into clinical practice. 
The phenomenon of IPC exerts robust and reproducible protection and appears to be a 
ubiquitous endogenous protective mechanism. It has been shown to confer 
cardioprotection in rodents, pigs, rabbits, ferrets, guinea pigs, sheep and man, and in a 
diverse variety of organs including the brain, gut, skin, skeletal muscle, retina, bladder 
and liver391. In addition to its anti-apoptotic and anti-necrotic tissue protective effects, 
IPC also reduces ischaemic arrythmias392, 393, attenuates endothelial dysfunction394 and 
reduces cardiac stunning395. 
The IPC stimulus elicits 2 distinct windows of cardioprotection. The first results in 
immediate protection which wanes over several hours, and the second ‘delayed 
window’ starts 12-24 hours later and lasts for 2-3 days396. 
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Mechanism	  of	  the	  cardioprotective	  effects	  of	  IPC 
Reperfusion	  injury	  salvage	  kinase	  (RISK)	  pathway.	  
The RISK pathway was first described in the mid 1990s, as a collection of pro-survival, 
anti-apoptotic protein kinases which were specifically activated at the time of 
myocardial reperfusion to confer profound cardioprotection397.  The main constituents 
of the RISK pathway are the PI3K-Akt and the MEK 1/2-Erk 1/2 signalling cascades. 
These may be activated by many disparate stimuli, of which IPC is one398. Over 30 
other substances have been shown to activate the RISK pathway such as insulin, 
erythropoietin, atorvastatin, adenosine, angiotensin II, glucagon-like peptide-1, volatile 
anaesthetics, opiates and atrial natriuretic peptide399.  
Activation of the PI3K-Akt or the MEK1/2-Erk 1/2 pathways results in a number of 
responses which led to cell survival, such as inhibition of proapoptotic proteins, 
inhibition of mitochondrial cytochrome c release, caspase inactivation and activation of 
eNOS and PKC. 
Inhibition	  of	  proapoptotic	  proteins	  
Activation of the RISK pathway leads to phosphorylation of the pro-apoptotic protein 
BAD, which results in its sequestration from its mitochondrial target, thus preventing 
apoptosis400. Bax is a pro-apoptotic protein which translocates to the mitochondria in 
response to an apoptotic stimulus to cause cytochrome c release either directly, or via 
opening of the mitochondrial permeability transition pore, a crucial end effector in cell 
death401. Activation of the RISK pathway inhibits the mitochondrial translocation of 
Bax, preventing apoptosis402. The pro-apoptotic protein BIM is upregulated when Erk 
1/2 or PI3K-Akt are inhibited403. Activation of the RISK pathway also leads to 
degradation of the pro-apoptotic protein p53404. 
Inhibition	  of	  mitochondrial	  cytochrome	  c	  release	  
Cytochrome c release from mitochondria is a potent apoptotic stimulus. Work by 
Kennedy et al.405 showed that Akt inhibited this release and prevented cell death. 
Inhibition	  of	  caspases	  
Caspases are a collection of intracellular enzymes, which are crucial to effective 
apoptosis. Both ERK1/2406 and Akt407 have been shown to inhibit caspase activation. 
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Activation	  of	  eNOS	  
Nitric oxide is a cytoprotective molecule which acts through inhibition of the 
mitochondrial permeability transition pore (mPTP) opening408. Akt has been shown to 
activate eNOS409. 
Activation	  of	  protein	  kinase	  C	  
Protein kinase C, a potent cytoprotective enzyme family, is activated following a 
preconditioning stimulus to inhibit the mitochondrial permeability channel (mPTP)410. 
The	  Survivor	  Activating	  Factor	  Enhancement	  (SAFE)	  pathway	  
Over the last decade it has become clear that activation of the RISK pathway is not the 
only way to lead to tissue protection through preconditioning. TNFα deficient mice 
were able to precondition in response to exogenous adenosine, but were unable to 
respond to IPC411. This indicates that there are other pathways  which involve TNFα, 
that can confer tissue protection. The involvement of the pro-inflammatory TNFα in 
preconditioning is somewhat surprising as TNFα has been thought to contribute to 
reperfusion injury, and is expressed in cardiomyocytes following ischaemia412. There is 
conflicting evidence for the role of TNFα in myocardial protection. Smaller infarct 
sizes have been seen in TNFα deficient mice 413 and the addition of TNFα neutralising 
antibodies reduces infarct size in rabbits414. However, other work has demonstrated that 
exogenous TNFα protected myocytes in vitro415 and that mice deficient in TNFα and 
its cell surface receptors develop larger infarct sizes416. Furthermore, it has been shown 
that an IPC protocol leads to increased expression of TNFα411. 
TNFα is thought to exert its role by binding to one of the two TNFα receptors on the 
cell surface417, and possibly the mitochondria418, suggesting a pathway capable of 
delivering the TNFα from the surface to the mitochondria. The multiple receptors for 
TNFα may explain the apparent conflicting results of its role in cell survival, as it is 
known that the 2 cell surface receptors have differing actions, with receptor 1 activation 
leading to increased cell death, and receptor 2 activation leading to cytoprotection419.  
TNFα preconditioning activates the sphingolipid pathway, protein kinase C and the 
mitochondrial potassium ATP dependent channel420 and finally the mPTP421.  
The signal transduction pathway of TNFα involves TNFα binding to its receptor which 
in turn trans-phosphorylates 2 Janus kinases (JAK). The activated JAK proteins then 
activate STAT proteins. The STAT family consists of several different members which 
are activated by JAK to form homo and heterodimers which translocate to the nucleus 
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and alter gene transcription422. Evidence for the role of the JAK-STAT pathway in IPC 
comes form experiments which demonstrate that IPC activates the JAK-STAT pathway 
and that inhibition of this pathway abolishes the tissue protection seen with IPC423. 
Furthermore STAT-3 cardiomyocyte specific knock out mice cannot respond to an IPC 
stimulus424. Downstream targets of STAT activation, in the context of IPC, are the 
activation of antiapoptotic gene Bcl-2, decreasing transcription of the pro-apoptotic 
gene Bax and phosphorylation and inactivation of the proapoptotic factor Bad. These 
effectors are thought to inhibit mPTP opening425. 
The effect of STAT activation following IPC to confer tissue protection may be too 
rapid a response to rely on de-novo transcription of antiapoptotic factors. The 
mechanism and targets for these non-genomic effects is currently unknown. 
Furthermore, these 2 paths may not be entirely separate entities and there may exist 
some cross-talk between the pathways. Evidence in favour of this comes from 
experiments which show that STAT-3 phosphorylation is dependant on PI3K activation 
in a model of pharmacological preconditioning426 and that STAT-3 knock-out mice did 
not phosphorylate Akt in response to an IPC stimulus424. 
Mitochondrial	  potassium	  ATP	  channel	  
The mitochondrial potassium ATP (KATP) channel appears to be both a mediator and 
effector of the cardioprotection seen with IPC, as antagonism of the mitochondrial KATP 
channel before the IPC stimulus abolished the cardioprotective effect and antagonism of 
the mitochondrial KATP at reperfusion also abolished the effect of IPC427.  The 
mechanism by which opening of the  KATP channel leads to tissue protection is unclear. 
The effect may involve a reduction in calcium overload seen during ischaemia428 or an  
indirect antiapoptotic effect through the reduction in cytochrome c release, caspase 
activation and cleavage of poly(ADP-ribose) polymerase429. 
 
The	  mitochondrial	  permeability	  transition	  pore	  
The downstream effectors of the RISK pathway, and perhaps the SAFE pathway,  
converge on the mPTP. The mPTP was first characterised in the late 1970s by Haworth 
and Hunter and is thought to be a voltage and Ca2+ dependant high conductance 
channel located in the inner mitochondrial membrane438, 439. 
During an episode of myocardial ischaemia and reperfusion, the fate of the 
cardiomyocyte is dependant on preserving the function of the mitochondria, as they are 
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the critical mediators of survival and death in this setting440. The major effector 
pathway of cardiomyocyte cell death following IR injury is through mitochondrial 
dysfunction arising from the formation of the mPTP. The opening of the mPTP at the 
time of reperfusion triggers a series of events which culminates in apoptotic or necrotic 
cell death425. 
Opening of the channel causes a rapid increase in permeability to solutes up to 
1.5KDa441. This leads to a collapse in the inner mitochondrial membrane potential 
causing ATP depletion, respiratory inhibition and eventual swelling and rupture of the 
mitochondrial membrane. This results in cytochrome C leaking into the cytoplasm425, 442 
and triggering apoptosis425. 
At reperfusion the intracellular pH is rapidly restored which together with a burst in 
ROS and regeneration of ATP, remove the physiological inhibition of mPTP opening. 
The removal of the inhibitors combined with the continued presence of high calcium 
levels promote optimal conditions for mPTP opening443.  
The role of the mPTP in preconditioning was suggested by work by Hausenloy et al.444 
who showed that pharmacological inhibition of the mPTP opening at the point of 
reperfusion resulted in a significant reduction in infarct size.  Subsequently, ischaemic 
preconditioning has been shown to inhibit mPTP opening to confer tissue protection445. 
The precise mechanism though which IPC results in inhibition of mPTP opening is not 
fully elucidated. IPC may inhibit mPTP opening indirectly by producing an intracellular 
milieu which favours mPTP closure, or directly via members of the RISK pathway. 
IPC had been shown to reduce cytosolic and mitochondrial calcium concentrations in 
rat hearts446. ROS generation during myocardial ischaemia and a further ROS burst at 
reperfusion have also been shown to trigger for mPTP opening83. 
Myocardial ischaemia leads to cellular ATP depletion and ADP production, which in 
turn leads to mPTP opening. IPC was first described as a protocol which preserves 
myocardial ATP levels during ischaemia388. There is indirect evidence that IPC can 
alter the pH normalisation on reperfusion, because infusion of alkaline sodium 
bicarbonate at the time of reperfusion abolishes the beneficial effect of IPC447. Opening 
of the mPTP may also be inhibited directly by components of the RISK pathway such 
as PKC448, mitochondrial K-ATP channel449, glycogen synthase kinase-3β450 and eNOS 
(though PKC-ε)451. The effect of inhibition of mPTP opening in the context of 
myocardial infarction has been shown in humans. Piot et al.452 reported that 
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administration of ciclosporin (a known mPTP inhibitor) in the context of an acute 
myocardial infarction led to a reduction in subsequent infarct size. 
Ischaemic	  conditioning	  in	  human	  studies	  
Epidemiological data suggest that IPC may be effective in the context of myocardial 
injury. Patients with underlying chronic angina (which could be thought of as an 
endogenous IPC protocol) have less injury following CABG surgery than those with no 
angina453. A possible explanation for this, above and beyond transient reduction of 
flow, is that coronary microembolisation resulting from plaque rupture has been shown 
to trigger a preconditioning response several hours later in a TNF-α dependant 
mechanism454. 
The major drawback of IPC is that the timing of the myocardial ischaemia must be 
known, which limits its clinical translation to elective surgical procedures. The first 
human study confirming the protective effect of IPC was reported in 1993 by Yellon et 
al.396 in a small study (n=14) in patients undergoing cardiopulmonary bypass. Yellon et 
al. found that following the bypass procedure the IPC group had higher levels of tissue 
ATP than the control group. Since the work by Yellon et al. there have been 32 clinical 
human clinical trials using ischaemic preconditioning to confer cardiac protection. 
These trials have invariability shown beneficial effects. However, these trials tend to be 
small, with the largest individual trial including only 86 patients393. Unfortunately, these 
trials have lacked the duration of follow up and size required to be powered for 
mortality outcomes and it is these outcomes which are needed cause change in routine  
clinical practice. Pharmaceutical companies are unlikely to fund large trials in 
ischaemic conditioning if there is no profit for their shareholders as it is impossible to 
patent IPC.  
There have been no human clinical trials in IPC in the heart over the last 7 years. At 
first this suggests that interest in preconditioning, as a translational strategy, may have 
waned. However, clinical trials in preconditioning have moved from ischaemic 
preconditioning to pharmacological preconditioning, remote ischaemic preconditioning 
and post conditioning, as each additional expansion of the field lends to greater clinical 
translatability. 
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Effect	  of	  underlying	  co-­‐morbidities	  on	  IPC	   
Hypercholesterolaemia	  
Hypercholesterolaemia is one of the most prevalent risk factors for coronary artery 
disease. Hypercholesterolaemia has been noted to block the pacing induced 
cardioprotection in rabbits fed high cholesterol diets. When these animals were placed 
back on a standard diet, the serum lipids normalised with a return of the effectiveness of 
IPC455. However Ilodromitis et al.456 have shown that IPC was still effective in 
hypercholesterolemic rabbits.  In rats, hyperlipidaemia has been shown to abolish the 
effect of IPC in the isolated rat papillary muscle457. Hypercholesterolaemia has been 
shown to abolish the effect of delayed IPC by preventing the upregulation of 
tetrahydrobiopterin, an essential cofactor for activation of nitric oxide synthase458. 
Another suggested mechanism of the IPC limiting effect of hypercholesterolaemia is 
suggested by work which shows that IPC decreases the formation of peroxynitrite459 
and hypercholesterolaemia enhances the formation of peroxynitrite460. Thus excessive 
generation of peroxynitrite by hyperlipidaemia may lead to a resistance to IPC. 
Hypercholesterolaemia also blocks preconditioning induced inhibition of cardiac matrix 
metalloproteinase-2461 and has been shown to inhibit the opening of the mitochondrial 
ATP sensitive potassium channel (KATP)462, the opening of which is a major 
mechanistic component of IPC. 
The hypercholesterolaemia-induced abrogation of the cardioprotective effect of IPC 
was also observed in a clinical study in which hypercholesterolaemia attenuated the 
anti-ischemic effect of preconditioning in humans during coronary angioplasty463. 
	  
Hyperglycaemia	  
Conflicting evidence exists as to whether the diabetic myocardium can be 
preconditioned. Some studies report that diabetes is not a barrier to IPC464, 465, but the 
majority of studies report that the diabetic heart466, 467 and the acutely hyperglycaemic 
heart468 are resistant to IPC.  Tsang et al.128 reported that diabetic hearts could be 
preconditioned, but that they had a higher threshold for preconditioning. The diabetic 
animals required 3 cycles of IPC to achieve significant tissue protection, whereas the 
non-diabetic controls required only 1 cycle. A lower basal level of phosphorylated Akt 
in the diabetic animals was postulated as the cause for the resistance to IPC. 
Administration of anti-diabetic agents has been reported to restore protection in a 
 132 
genetic model of diabetes469. IPC was abolished in a diabetic sheep model of 
myocardial stunning which was reported to be due to KATP channel dysfunction470. 
Underlying diabetes has been shown to inactivate eNOS, generate ROS leading to 
endothelial dysfunction which, may also be responsible for the loss of response to 
IPC471.A human  ex vivo study by Ghosh et al.130 reported that hearts from patients with 
diabetes, or those with poor cardiac function, were unable to respond to preconditioning 
and this effect appeared to be mediated through a failure of mitochondrial ATP channel 
opening. 
	  
Post	  infarction	  remodelling	  
Ischaemic preconditioning has been shown to fail to reduce infarct size in post-infarcted 
remodelled hearts472. However, pharmacological preconditioning using the KATP 
channel opener diazoxide remained unaffected in the contest of remodelled hearts, 
suggesting that the impairment to preconditioning in the context of post 
infarction/remodelling was upstream of the KATP channel.  
	  
Hypertension	  
There is conflicting evidence for the role of hypertension in resistance to IPC. 
Some authors report that hypertensive rats could still be preconditioned112, 373, however, 
more recently others report that hypertension abolished the cardioprotective effects of 
IPC473 and cardiac hypertrophy attenuated the response to IPC in guinea pigs474. The 
mechanism by which hypertension may abolish the effects of IPC are unknown. 
	  
Ageing	  
The ageing heart has a diminished functional and adaptive reserve capacity and a 
reduced ischaemia tolerance475. There is conflicting evidence for the impact that ageing 
has on the ability of the myocardium to respond to IPC. Przyklenk et al.476 reported that 
there was no loss of the effect of IPC in old rabbits, although other authors report that 
IPC did not minimise the post-ischemic myocardial dysfunction in senescent, isolated 
perfused rat hearts477, nor the necrotic cell death and contractile dysfunction in hearts 
from 22 month old rats478. In humans, a study in ‘elderly’ patients (70-90 years) 
undergoing cardiac surgery reported that this group had no increased resistance to 
IPC144. 
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In further evidence of the effects of age on IPC potency, Schulman et al. reported that 
‘middle aged’ rats had a resistance to IPC, which could be overcome with an increased 
number of cycles of IPC, however, elderly rats were unable to be preconditioned479. 
Tani et al.480 explored the mechanism of resistance to IPC in year old rats. They found 
that these rats were resistant to IPC and this effect was mediated by a reduction in PKC 
activation. 
	  
Obesity	  
Zucker rats display a blunted response to an IPC signal, an effect which was mediated 
through enhanced oxidative stress and reduced activation of mitochondrial KATP 
channels481. 
	  
Hyperhomocysteinemia	  
Hyperhomocysteinemia has been associated with the pathogenesis of many 
cardiovascular pathologies482. Hyperhomocysteinemia has been associated with a 
resistance to IPC483. This effect is thought to be mediated through loss of opening of the 
KATP channels in response to IPC484. 
	  
Medication	  use	  
Concomitant use of medication may alter the effect of IPC. Indeed many common 
medications frequently used by patients presenting with an acute myocardial infarct 
have been shown to interact with the RISK pathway including statins485, insulin486, 
EPO487 and glucagon-like peptide-1 agonists488. 
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Aims	  
There is no published literature on the effects of underlying uraemia on the ability of 
the heart to respond to a preconditioning signal. The rat models of chronic uraemia 
share several of the co-morbidities which have been associated with resistance to IPC, 
such as hypertension, LVH and hyperlipidaemia. 
The ability of the uraemic heart to respond to a preconditioning signal is a vitally 
important issue to address. Up to one third of patients presenting with an acute coronary 
syndrome have CKD stages 3-541, 49, 489, and yet patients with CKD are routinely 
excluded from trials in cardioprotection490, 491. 
This study seeks to answer 2 questions: 
Can the uraemic heart be preconditioned? 
If the uraemic heart can be preconditioned, is there an increased threshold to 
preconditioning seen in the context of underlying chronic uraemia? 
This study seeks to investigate the effects of cardioprotection through IPC in 2 different 
rats models of chronic uraemia, and in addition to investigate the possible mechanisms 
involved. 
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Methods	   	  
Myocardial	  ischaemic	  preconditioning	  in	  the	  subtotally	  nephrectomised	  rat 
Six week old male Wistar Rats (Charles Rivers UK) were obtained and after 1 week 
acclimatisation in an animal house with a 12 hour day night cycle and free access to 
water and standard chow. All animals then underwent a 2 stage SNx procedure (see 
Reversible LAD ligation as a model of myocardial infarction in the rodent page 75). 
Four weeks after the second stage procedure, the animals were anaesthetised, ventilated 
and underwent a thoracotomy procedure (see page 76-83).  15 minutes following the 
thoracotomy, the animals were divided into 2 groups.  The first group (control) were 
left for a further 30 minutes before undergoing a reversible 25-minute LAD ligation 
(see page 83- 87 for full details of LAD ligation, harvesting and infarct measurement). 
The second group (IPCx3) underwent 3 cycles of 5 minutes LAD ligation followed by 5 
minutes reperfusion as a preconditioning stimulus, before finally undergoing a further 
25 minutes LAD ligation. After the 25-minute LAD ligation, both groups were 
reperfused for 120 minutes. At the end of the reperfusion, the hearts were harvested and 
infarct size was quantified using Evans blue to delineate the area at risk (AAR) and 
NBT to stain non-infarcted tissue (see page 87 for methods). 
Myocardial	  ischaemic	  preconditioning	  in	  the	  adenine	  diet	  treated	  rat	  
Six week old male Wistar Rats (Charles Rivers UK) were placed on 0.75% adenine diet 
(Rat and mouse No.1 Maintenance diet +0.75% adenine: Special diet services UK) for 
4 weeks. At the end of 4 weeks, the animals underwent a similar experimental protocol 
as above, with the animals split into 2 groups. The IPC group underwent 3 cycles of 5 
minutes ischaemia and reperfusion immediately before 25 minutes LAD ligation and 
the control group did not undergo the IPC protocol. 
Resistance	   to	   myocardial	   ischaemic	   preconditioning	   of	   the	   subtotal	  
nephrectomised	  rat	  
Rats that had undergone a 2 stage subtotal nephrectomy or a sham SNx procedure, to 
create a group of uraemic and non uraemic animals, underwent basic surgery and 
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thoracotomy in the standard manner. Both groups underwent an IPC protocol consisting 
of 1 cycle of 5 minutes LAD ligation and 5 minutes reperfusion before undergoing 35 
minutes of myocardial ischaemia. After two hours reperfusion, the heart and infarct size 
was measured as before. 
Resistance	   to	   myocardial	   ischaemic	   preconditioning	   of	   the	   adenine	   diet	  
treated	  rat	  
In this experiment rats were divided into 2 groups. The first group of animals were 
given standard chow for 6 weeks. The second group, adenine ‘washout’, were given  
0.75% adenine diet for 4 weeks, at the end of this 4 week period they were placed back 
on standard chow for a further 2 weeks. At the end of the 6-week period, each group 
underwent either 1 cycle of IPC or a sham IPC procedure. Subsequently, they 
underwent 25 minutes of myocardial ischaemia followed by 2 hours reperfusion. At the 
end of this time, the hearts were harvested and infarct size was measured as before.   
Analysis	  of	  the	  mediators	  of	  IPC	  in	  uraemic	  and	  non	  uraemic	  animals	  
To investigate the underlying mechanisms a further set of experiments were performed 
(see Figure 24). Male Wistar rats were divided into 4 groups. The first group underwent 
a sham 2 stage subtotal nephrectomy procedure to generate a non-uraemic control 
group. The second group underwent a 2-stage subtotal nephrectomy procedure. The 
third group were placed on standard chow for 4 weeks and the fourth group were 
treated with 4 weeks of 0.75% adenine diet. All animals underwent basic surgery, a 
thoracotomy procedure, and a needle was passed around the LAD artery as in previous 
experiments. Each group then underwent an IPC protocol or a sham procedure. At the 
end of the IPC or sham protocol the LAD was briefly occluded and Evans blue dye was 
perfused via the venous line to delineate the area of the heart exposed to IPC (or sham 
IPC). The heart was rapidly removed from the chest cavity and cooled in ice-cold saline 
for 20 seconds. The myocardial territory exposed to IPC was quickly cut away from the 
rest of the heart and rapidly snap frozen in liquid nitrogen and stored at -80oC until 
further use.  
Tissues for western blot were ground with a mortar and pestle under liquid nitrogen and 
subsequently polytron-homogenised (3x 30sec bursts with 1min intervals on ice) in a 
mammalian protein extraction buffer (GE healthcare; 10:1 v/w) supplemented with the 
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following inhibitors: 1mM EDTA, 0.5mM DTT, 1% v/v protease inhibitor cocktail 
(Sigma), 1mM NaF, 5µM fenvalerate (Calbiochem), 1mM Na3VO4 and 1% v/v 
phosphatase inhibitor cocktails I and III (Sigma). The tissue homogenate was incubated 
for 10 minutes on ice and then centrifuged at 5000g for 10 minutes at 4oC. The 
supernatant was aliquoted and stored at -80oC until further use. Protein concentrations 
were determined using the Bicinchoninic Acid assay (BCA, Pierce), with bovine serum 
albumin (BSA, Sigma) as the protein standard. 
Lysates (40µg of protein) were subjected to SDS-polyacrylamide gel electrophoresis 
using the NuPAGE electrophoresis system (Invitrogen) under reducing conditions as 
previously described492. The ECLplus chemiluminescence detection kit (Amersham 
Pharmacia) was used to visualise protein bands. The following antibodies (from Cell 
Signalling) were used: rabbit anti-phspho-p44/p42 MAPK (Thr202/Tyr204), rabbit 
anti-p44/p42 (total ERK), mouse anti-phospho AKT (Ser473), rabbit anti-AKT (total 
AKT), mouse anti-phospho-STAT-3 (Tyr705), rabbit anti-STAT-3 (total STAT-3) and 
peroxidase-conjugated secondary antibodies. 
Arterial	  blood	  gas	  analysis	  
During the experimental procedures, arterial blood gas (ABG) measurements were 
taken at 3 time points. Additional ABGs were occasionally taken if an animal was 
unexpectedly hypotensive during the experiment. The baseline ABG was taken after the 
animals had been put on the ventilator to ensure that the animals were receiving the 
correct minute volume and fractional inspired O2. The second routine ABG was taken 
during pre-occlusion to ensure that there had not been a change in ventilatory 
requirements after the thoracotomy, when the compliance of the lungs was altered due 
to loss of mechanical resistance from the thorax. Finally, an ABG was taken at the end 
of the experiment to access further changes in ventilatory, acid base and haemostasis 
parameters.
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Figure 20. Schematic representation of experiment 1: Myocardial ischaemic preconditioning of the 
Subtotally nephrectomised rat 
Figure 21. Schematic representation of experiment 2: Myocardial ischaemic preconditioning of the 
Adenine diet treated rat. 
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Figure 22. Schematic representation of experiment 3:  Resistance to myocardial ischaemic 
preconditioning of the subtotally nephrectomised rat 
 140 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 cycle of 5 
minutes of 
ischaemia/ 
reperfusion 
25 minutes 
LAD 
occlusion 
120 minutes 
reperfusion 
!"#$%$#&
'()*+,-./&
!"#$%$#&
'()*+,-./&
0.)$")1"&
2+,(&
0.)$")1"&
2+,(&
31,-4&56&
7,$.1,8&
31,-4&96&
7,$.1,8&:;7&
31,-4&<6&
!"#$%$#&
()*+,-.&
31,-4&=6&
!"#$%$#&
()*+,-.&:;7&
Figure 23. Schematic representation of experiment 4:  Resistance to myocardial ischaemic 
preconditioning in the adenine diet treated rat. 
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Figure 24. Schematic representation of experiment 5: Analysis of 
the mediators of IPC in uraemia 
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Results	  
Experiment	   1.	   Myocardial	   ischaemic	   preconditioning	   in	   the	   subtotal	  
nephrectomised	  rat	  
Cardiovascular	  parameters	  
3 cycles of preconditioning did not significantly alter mean arterial pressure, pulse rate 
or rate pressure product (see Figure 25). 
	  
Arterial	  blood	  gas	  analysis	  
Both groups were similar in terms of plasma pH, pCO2 and base excess during the 
course of the experiment. However, the pO2 was significantly higher in the control 
group than the IPC group. Haematocrit (HCT), pO2, pCO2 and pH measurements 
remained stable during the experiment, however, the base excess fell during the 
experiment from a median baseline of 4 and 3.1 mEq/l in the SNx control and SNx 
IPCx3 groups respectively to  -0.1 and -2.6 mEq/l at the end of reperfusion in the SNx 
control and SNx IPCx3 groups respectively. This result was highly significant on 
Kruskall-Wallis testing (p<0.0001). Furthermore, the baseline HCT was higher in the 
IPC group compared to the control group. This difference was not seen in the pre 
occlusion or end reperfusion samples (see Figure 26). 
	  
Infarct	  size	  	  
The 2-stage subtotal nephrectomy procedure results in moderate uraemia with serum 
creatinine measurements approximately 2.5 times that of historical non uraemic 
controls. The 2 groups were similar in weight, creatinine and AAR. However, 3 cycles 
of IPC led to an 88% reduction in median infarct size (p=0.002), (see Figure 27 and 
Table 8). 
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Figure 25. Analysis of cardiovascular parameters of experiment 1. Graph shows how mean arterial 
pressure (top), heart rate (middle) and rate pressure product, calculated by multiplying blood 
pressure by pulse (bottom) vary during the course of the experiment in uraemic animas with and 
without an IPC protocol. Data points represent median with error bars as IQR. 
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Figure 26. Graph demonstrating changes in arterial blood gas measurements during 
experiment 1. 
The 2 experimental groups were SNx animals which underwent 3 cycles of IPC (SNx 
IPCx3) or did not (SNx control). Plasma pH, pO2, pCO2, Base excess and haematocrit 
were measured at 3 time points.: baseline, pre occlusion and at the end of reperfusion. All 
data expressed as medians with error bars representing IQR, calculated using GraphPad 
software. 
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Table 8. Results of experiment 1. Data presented as median (IQR). Statistical 
significance is presented as the results of a Mann-Whitney test using 
graphPad software. 
 
SNx SNx IPCx3 p 
Animals (n) 10 4
Weight (g) 375 (370-383) 335 (320-395) 0.11
Hematocrit (%) 27 (25.5-28.5) 33.5 (28.8-36.8) 0.03
Creatinine (!mol/l) 83.5 (74-93.3) 88.7 (85-90.9) 0.18
Area at risk (%) 44.4 (41.3-49.5) 37.5 (33.9-46.4) 0.31
Infarct size (%) 61.1 (54.2-70.5) 7.1 (6.0-8.7) 0.002
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Figure 27. Results of experiment 1. Columns represent medians with IQR as error bars. 
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Experiment	   2:	   Myocardial	   ischaemic	   preconditioning	   in	   the	   adenine	   diet	  
treated	  rat	  
Cardiovascular	  parameters	  
At baseline, both uraemic groups were similar in terms of blood pressure, pulse and 
PRP (see Figure 28). The adenine groups which had undergone 3 cycles of IPC had a 
tendency to have higher blood pressure and PRP, however, during reperfusion this did 
not reach statistical significance (p=0.25).  
	  
Arterial	  blood	  gas	  analysis	  
Due to a defective arterial blood gas analyser at the time of this experiment, there was 
an incomplete data set for experiment 2 (see Figure 29). Only the baseline arterial blood 
gas parameters were available for analysis. Given that at baseline both groups of 
animals has been treated identically, it is unsurprising that both groups were similar in 
terms of plasma pH, pO2, pCO2, base excess and haematocrit. 
	  
Infarct	  size	  
4 weeks of 0.75% adenine diet resulted in severe uraemia in both groups, with serum 
creatinine values 7 times that of historical controls (see Figure 30 and Table 9). 
3 cycles of 5 minutes LAD ischaemia/reperfusion before 25minutes LAD ligation, led 
to a reduction in median infarct size by 33% when compared to no IPC (p<0.05). The 
median area at risk was similar in the non-preconditioned and preconditioned groups 
(p=0.4). The group that underwent preconditioning were heavier than the non-
preconditioned group (p=0.05). However, there was no significant difference in the 
degree of anaemia or serum creatinine in the groups.    
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Figure 28. Analysis of cardiovascular parameters of experiment 2. Graph shows how mean arterial pressure 
(top), heart rate (middle) and rate pressure product (bottom) vary during the course of the experiment, in 
Adenine treated animals undergoing an IPC or sham protocol. Data points represent median with error bars 
as IQR. 
 
 149 
Figure 29. Graph showing baseline ABG measurements in experiment 2. Data expressed as median 
with IQR as error bars. 
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Adenine Adenine IPCx3 p 
Animals (n) 8 8
Weight (g) 220 (203-225) 238 (213-243) 0.05
Hematocrit (%) 24 (23-33) 22 (21-25) 0.07
Creatinine (!mol/l) 250 (235-267) 285 (180-336) 0.9
Area at risk (%) 46.1 (36.4-52.3) 40.0 (33.5-46.3) 0.4
Infarct size (%) 43.7 (28.5-69.5) 29.4 (7.7-32.1) <0.05
Table 9. Results of experiment 2. Data presented as median (IQR). Statistical 
significance is presented as the results of a Mann-Whitney test using 
graphPad software. 
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Figure 30. Results of experiment 2. Columns represent medians with IQR as error bars. 
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Experiment	   3:Resistance	   to	   myocardial	   ischaemic	   preconditioning	   of	   the	  
subtotal	  nephrectomised	  rat	  
Cardiovascular	  parameters	  
Analysis of heart rate, blood pressure and pressure rate product revealed no significant 
differences between the preconditioned and non-preconditioned uraemic animals (see 
Figure 31). 
 
Arterial	  blood	  gas	  analysis	  
There was no significant difference in plasma pH, pO2, pCO2 or base excess between 
the sham SNx group and the SNx group during the course of the experiment (see Figure 
32). At baseline testing, the non-uraemic group had a significantly higher haematocrit 
than the uraemic group, although this difference disappeared during the course of the 
experiment. There was no significant change in ventilatory parameters over time during 
the experiment, however plasma base excess fell during the experiment, from a median 
of 2.2 and -0.3mEq/l in the sham SNx and SNx groups respectively at baseline to -5 and 
-6.7 mEq/l in the sham SNx and SNx groups at the end of reperfusion. This was highly 
significant on  Kruskall-Wallis testing (p<0.0001). 
 
Infarct	  size	  	  
Compared with a sham procedure, a 2 stage subtotal nephrectomy resulted in a uraemic 
phenotype similar to previous experiments (see Figure 33 and Table 10). The uraemic 
animals had 2.5 times the serum creatinine concentrations that of sham animals (p= 
0.0003) and they were anaemic (p<0.01). Following 1 cycle of IPC and 35 minutes 
LAD ligation, both groups had similar area at risks (p=0.16). However, the uraemic 
group had a significantly smaller median infarct size compared to the non-uraemic 
group (p<0.01).  
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Figure 31. Analysis of cardiovascular parameters of experiment 3. Graph shows how mean arterial 
pressure (top), heart rate (middle) and rate pressure product, (bottom) vary during the course of the 
experiment involving uraemic (SNx) and non uraemic (Sham SNx) animals undergoing an IPC 
protocol. Data points represent median with error bars as IQR. 
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Figure 32. Graph demonstrating changes in arterial blood gas measurements during experiment 3. 
The 2 experimental groups were SNx animals and sham SNx animals, both groups underwent a single 
cycle of IPC. Plasma pH, pO2, pCO2, Base excess and haematocrit were measured at 3 time points.: 
baseline, pre occlusion and at the end of reperfusion. All data expressed as medians with error bars 
representing IQR, calculated using GraphPad software. 
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Sham IPCx1  SNx IPCx1 p
Animals (n) 9 9
Weight (g) 370 (332.5-386.5) 337.5 (316.3-352.5) 0.13
Hematocrit (%) 47 (44-49) 37.8 (36.5-40) <0.01
Creatinine (!mol/l) 37.9 (32.3-42.7) 93.2 (89.6-117.9) 0.0003
Area at risk (%) 45.4 (35.2-51.8) 37.2 (32.6-42.9) 0.16
Infarct size (%) 32.1 (22.9-46.6) 18.1 (7.2-23.6) <0.01
Table 10. Results of experiment 3. Data presented as median (IQR). 
Statistical significance is presented as the results of a Mann-Whitney test 
using graphPad software. 
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Figure 33. Results of experiment 3. Columns represent medians with IQR as error bars. 
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Experiment	   4:	   Resistance	   to	   myocardial	   ischaemic	   preconditioning	   of	   the	  
adenine	  diet	  treated	  rat	  
Cardiovascular	  parameters	  
Analysis of heart rate, blood pressure and pressure rate product revealed no significant 
differences between any of the 4 groups (see Figure 34). 1 cycle of preconditioning did 
not significantly alter the cardiovascular parameters of MAP, pulse rate or PRP, nor did 
underlying uraemia. 
	  
Arterial	  blood	  gas	  analysis	  
All groups had similar pH concentrations, with the exception of the control group (see 
Figure 35) which remained more alkalotic during the course of the experiment with a 
larger AUC for pH (p<0.02). There was no significant change in the partial pressure of 
oxygen or CO2 during the course of the experiment and there was no significant 
difference in pO2 or CO2 between the 4 groups.  As in the other experiments, a fall in 
base excess was seen following thoracotomy. However, in this experiment the results 
did not reach statistical significance. All groups had similar degrees of base excess at 
each time point during the experiment.   There was no change in haematocrit over time 
in any of the individual groups. Both non-uraemic groups had similar haematocrit levels 
to each other, as did both uraemic groups. However, when the adenine groups were 
compared to both the control groups, adenine treatment was associated with a 
significant degree of anaemia (p<0.0001). 
	  
Infarct	  size	  	  
Animals treated with 4 weeks of 0.75% adenine diet followed by 2 weeks of standard 
chow were over 30% lighter than animals fed standard chow for 6 weeks (see Figure 36 
and Table 11). The adenine washout groups were also significantly more anaemic with 
a reduction of over 45% in haematocrit (p<0.0001). Adenine washout resulted in serum 
creatinine concentrations that were over three times that of standard chow fed animals 
(p=0.0006).  
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Within the uraemic and non-uraemic groups respectively, there was no difference in 
weight, HCT or serum creatinine. At the end of the experiment, all 4 groups had similar 
area at risks. In non-uraemic animals, 1 cycle of IPC led to a reduction in the median 
infarct size of 50%. In the adenine washout groups, 1 cycle of IPC reduced infarct size 
by 31%. To establish how much of the difference seen between the 4 groups was 
attributable to underlying renal failure and how much was attributable to 
preconditioning, a 2 way ANOVA was performed using Graphpad software. The results 
indicated that the effects of IPC were independent of uraemia and that underlying 
uraemia accounted for <0.1% of the total variance, whereas IPC counted for 39% of the 
total variance.   
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Figure 34. Analysis of cardiovascular parameters of experiment 4. Graph shows how mean 
arterial pressure (top), heart rate (middle) and rate pressure product,(bottom) vary during the 
course of the experiment. Experimental groups are adenine diet washout groups with and 
without IPC, and standard chow fed animals with and without IPC. Data points represent 
median with error bars as IQR. 
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Figure 35. Graph demonstrating changes in arterial blood gas measurements during experiment 4. 
The 4 experimental groups were: animals fed standard chow for 6 weeks (control), animals fed standard 
chow for 6 weeks and has 1 cycles of IPC (Control IPCx1), animals fed 0.75% adenine diet for 4 weeks 
followed by 2 weeks of standard chow (adenine washout) and finally animals fed 0.75% adenine diet for 4 
weeks followed by 2 weeks of standard chow who had 1 cycle of IPC. All animals then underwent 25 
minutes of LAD ligation and 2h reperfusion. Plasma pH, pO2, pCO2, Base excess and haematocrit were 
measured at 3 time points: baseline, pre occlusion and at the end of reperfusion. All data expressed as 
medians with error bars representing IQR, calculated using GraphPad software 
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Control Control IPCx1 Adenine washout Adenine washout IPCx1 p 
Animals (n) 11 7 11 7
Weight (g) 498 (453-517) 510 (490-550) 342 (322-350) 350 (318-364) <0.0001
Hematocrit (%) 44(42-45) 43 (41-44) 23.5 (22-27.5) 22 (19-23) <0.0001
Creatinine (!mol/l) 40.5 (38.6-41.8) 39.6 (34.7-41.7) 137.1 (86-150.2) 119.7 (83.8-162.5) 0.0006
Area at risk (%) 52.6 (45.8-66.5) 49.8 (37.6-59) 43.1 (38.6-60.5) 47.2 (37.3-68.8) 0.69
Infarct size (%) 61.8 (47.8-73.8) 31.7 (9.1-37.7) 61.6 (52.8-67.9) 42.5 (12.4-48.8) 0.002
Table 11. Results of experiment 4. Data presented as median (IQR). Statistical significance is presented as 
the results of a Kruskal-Wallis test using GraphPad software. 
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Figure 36. Graphical representation of experiment 4. Columns represent medians with error bares IQR. Significance 
testing results of Dunns post testing following a 2 way Kruskall Wallis test. P values: * p<0.05, ** p<0.01, *** 
p<.0001.  
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Investigation	  of	  the	  signalling	  pathways	  of	  myocardial	  IPC	  
The	  SNx	  model	  of	  chronic	  uraemia	  
This experiment had 4 groups of rodents. Sham SNx animals, sham SNx animals that 
had undergone IPC, SNx animals and SNx animals that had undergone IPC. Heart 
homogenates were analysed for components of the RISK and SAFE pathways and for 
each group, 5 homogenates were processed.  
When the SNx model is compared to the sham SNx model, there is no difference in the 
basal activity of components of the RISK pathway or STAT activation. Preconditioning 
leads to significant ERK phosphorlyation in both the sham SNx animals and SNx 
animals in all 5 replicates. A similar effect is seen with STAT-3 in both groups, an 
effect which is consistent across replicates. There is no clear pattern across the 5 
replicates studied for the impact of IPC on Akt phosphorylation. In group 1, IPC 
appears to lead to Akt phosphorylation in the sham animals but a relative reduction in 
phosphorylation in the SNx animals. In group 2, Akt does not appear to be affected by 
IPC in either the sham or SNx animals. In groups 3 and 4, IPC inhibits phosphorylation 
of Akt in the sham animals and activiates in the SNx animals. In group 5, IPC appears 
to lead to increased phosphorylation of Akt in both the SNx and sham groups (see 
Figure 37 and Figure 38). 
 
The	  adenine	  model	  of	  chronic	  uraemia	  
This experiment had 4 groups: non uraemic control  animals, control animals with IPC, 
adenine animals and adenine animals which had undergone IPC. 16 rats were used in 
the experiment with 4 animals in each group. There was no difference in the basal 
activity of ERK1/2 or STAT-3 phosphorylation between the uraemic and non uraemic 
rats. IPC consistently resulted in increased phosphorylation of ERK and STAT in both 
uraemic and non-uraemic rats (see Figure 39).  
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Figure 37. Results of western blots investigating the effects of IPC in SNx (ureamic) and non uraemic 
sham SNx animals (Sham).. Gels were probed for STAT-3, pSTAT-3, Akt, p-Akt, p-ERK 1/2 and ERK 
1/2.  Each experiment was repeated 5 times. This figure represents the first 4 replicates (see for the 5th 
replicate)  
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Figure 38. Results of western blots investigating the 
effects of IPC in uraemic and non uraemic animals. 
Gels were probed for STAT-3, pSTAT-3, Akt, p-Akt, 
p-ERK 1/2 and ERK 1/2., this figure represents the 
fifth replicate. See the previous figure for replicates 
1-4. 
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Figure 39. Results of western blots investigating 
the effects of IPC in adenine (Ad) and control 
fed (Con) animals.  Gels were probed for p-ERK 
1/2, ERK 1/2, pSTAT-3 and STAT-3.  Each 
experiment was repliciated 4 times, with each 
lane representing a different homogenate. 
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Discussion	  
This is first time that the effect of uraemia on cardioprotection from IPC has been 
studied. The results show that IPC is a potent cardioprotective strategy in both non 
uraemic and uraemic rats, with the suggestion of even greater tissue protection in the 
context of the SNx model of uraemia. 3 cycles of IPC reduced infarct sizes by 88% in 
the SNx model and 33% in the adenine model, with 1 cycle of IPC reducing infarct size 
by 31% in the adenine wash out group.   
In experiment 3, the duration of the ischaemic insult was lengthened from 25 to 35 
minutes. It is known that the duration of the ischaemic insult is critically important 
when investigating the effects of preconditioning, too small an injury and the beneficial 
effects of preconditioning are not seen, however too long an insult may cause 
irreparable damage which cannot be modified by ischaemic conditioning493.  The 
reason for lengthening the ischaemic period was an attempt to generate a larger infarct 
in the control group, such that any small beneficial effect of only 1 cycle would be more 
easily demonstrable. Despite the longer duration of ischaemia, both groups displayed 
significant reductions in infarct sizes when compared to historical controls. 
Interestingly, despite a reduction in ischaemia tolerance the uraemic animals appeared 
to develop a smaller infarct size in response to 1 cycle of preconditioning when 
compared to the non-uraemic animals. The reason for this is unclear. There is no 
difference in the basal activity of cardio-protective mediators (Akt/ERK/STAT) in the 
SNx group. One could argue that due to the lower haematocrit of the uraemic group, 
less thrombus is generated during manipulation of the LAD artery during the IPC 
protocol leading to less ‘no reflow’ injury during reperfusion. However, the adenine 
washout group had a much lower haematocrit than the SNx animals and those animals 
did not show greater cardio-protection than their control fed partners. When comparing 
the relative effects of IPC between the adenine and SNx groups, it appears that IPC 
confers greater protection to the SNx group. The relative reduction in infarct size 
following 3 cycles of IPC is almost two and a half times that in the SNx group 
compared to the adenine group. This may be due to a greater degree of uraemia 
conferring resistance to the beneficial effects of IPC. However, from this work even 1 
cycle of IPC was enough to significantly protect all groups studied.  
During the first experiment (SNx v SNx IPCx3) the pO2 was significantly higher in the 
control group than the IPC group. This unexpected result may have been due to 
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difficulty in accurately titrating the delivered oxygen to the animals. The amount of 
oxygen delivered was controlled by a gas tap, which was difficult to finely adjust. The 
result is also surprising as at any one time, 2-3 rats were being operated on, with each 
rat receiving the same FiO2. Furthermore, during each experimental day both IPC and 
non IPC animals were operated on. The impact of supra-physiological oxygen is 
unlikely to be cardio-protective and it may enhance oxidative stress leading to an 
increased oxidative burst494 and tissue injury. The high partial pressure of oxygen in the 
control group could have contributed to injury. This may make the impact of IPC in this 
experiment more significant than it actually is. However, it is unlikely to have made 
such a large impact as to alter the conclusions from this experiment, and in all other 
experiments there was no significant difference in the oxygenation between any of the 
groups and yet protection was still seen.  
These results show that across all experiments, ventilatory parameters were generally 
similar between groups and were not altered by any cardio-protective strategies. 
However, across all groups, the base excess fell progressively during the course of the 
experiments. This effect is seen during all LAD ligation experiments and is not 
surprising given the inherent tissue damage caused during thoracotomy along with the 
associated fall in blood pressure, which is likely to be due to altered respiratory 
physiology due to removal of the rib cage.  
Analysis of the signalling mechanisms involved in IPC 
All eight experimental groups (sham SNx, sham SNx IPC, SNx, SNx IPC, control, 
control IPC, adenine and adenine IPC) had myocardial homogenates run on western 
blots for ERK 1/2, Akt and STAT-3. However, the Akt and p-Akt gels for all 4 adenine 
groups did not demonstrate specific binding for Akt or p-Akt and therefore were 
excluded from the analysis.  
This work fits nicely with the published literature on the effect of IPC on the RISK and 
SAFE pathways of myocardial protection. STAT-423, ERK1/2398 and Akt398 have all 
been shown to be activated, following an IPC protocol, leading to tissue protection. 
This current series of experiments have shown that the signalling cascades appear to be 
unaffected by underlying uraemia, with both uraemic and non uraemic models 
phosphorylating ERK and STAT in response to IPC.  
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The results of Akt phosphorylation are difficult to interpret and do not show a clear 
trend in either the non uraemic or uraemic groups. It is important to remember that the 
function of Akt is not solely as a link in signal transduction chain for IPC from the cell 
surface to the mPTP.  A possible explanation for the variability in the p-Akt results is 
that phosphorylation of Akt (as with other mediators) is a dynamic phenomeon. Akt 
phosphorylation is inhibited during ischaemia398, and rises on reperfusion such that 5-
10 minutes after the IPC protocol, the p-Akt is significantly higher than at baseline495.  
It could be that the variability of the results is due to the differential speed of 
phosphorylation of Akt during the brief reperfusion or that uraemia alters the rate of 
Akt phosphorylation during reperfusion or de- phosphorylation during ischaemia. This 
is speculative and further work needs to be done on the dynamics of Akt 
phosphorylation in the context of uraemia during IPC, with a greater delay between the 
end of preconditioning and harvesting to ensure more homogenous results.  
In both uraemic models, SNx and adenine treated rats did not differ in terms of basal 
levels of phosphorylated STAT-3 or ERK 1/2. SNx rats had no significant basal 
increase in phosphorylated Akt (p-Akt) when compared to sham animals. This is in 
contrast to work by Tsang et al.128 which showed that compared to non diabetic rats, 
diabetic rats had lower levels of p-Akt at baseline. They also found that p-Akt rose with 
subsequent IPC cycles. Tsang et al. proposed that lower basal levels of phosphorylated 
cardio-protective mediators in diabetic rats could explain the apparent resistance to IPC 
seen in such animals. This work was repeated by the same group in an ex vivo model, 
using human atrial appendages in diabetic and non diabetic patients with similar 
results496. 
The finding that underlying uraemia does not alter the basal levels of cardioprotective 
mediators concurs with their hypothesis because the uraemic rats did not have lower 
levels of p-Akt and did not display a resistance to preconditioning.  
 
 
 
 170 
Conclusions	  
These experiments demonstrate that in multiple models of chronic uraemia, renal 
dysfunction, unlike diabetes, dyslipidaemia or senescence, does not lead to a resistance 
to the cardio-protective effects of IPC. 
This work paves the way for translational research in the field of cardio-protection in 
CKD patients, who have high rates of cardiovascular disease, with poor outcomes 
following AMI and in whom standard therapies do not appear to be as efficacious or 
perhaps even deleterious. This cohort represents the ideal group to study, as their event 
rate following AMI is much higher than the general population meaning that smaller 
studies could still be powered for event based out comes.  
In essence, CKD patients have the most to lose from CVD and this work suggests that 
they may have the most to gain from preconditioning strategies. 
 
 
Future	  work	  
Future work should investigate the effect of underlying uraemia on the ability of the 
myocardium to respond to a remote ischaemic preconditioning signal. This work is 
currently the subject of on going research by my colleague Dr Conor Byrne.
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 Chapter 6 
The Anti-arrhythmic effect of 
Preconditioning in Uraemic Models of 
Myocardial Ischaemia 
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Background	  
The anti-arrhythmic effect of conditioning strategies have been widely documented in 
the published literature497-502. The mechanism through which preconditioning inhibits 
arrhythmias is unclear. Work by Matejikova et al.503 suggest that the effect is not 
dependant on a functioning PI3K/Akt system. They report that administration of a 
PI3K/Akt inhibitor abolished the cardioprotective effect of preconditioning but did not 
alter the anti-arrhythmic effects of preconditioning. Miura et al.504 found that inhibition 
of bradykinin, prostaglandin or adenosine did not affect the anti-arrhythmic effects of 
IPC. However, subsequently work by Drimov et al.505 reported that bradykinin 
antagonists abolished the anti-arrhythmic effects of IPC, that infusion of bradykinin 
mimicked the anti-arrhythmic effect of IPC and that both these effects could be 
abrogated by a sarcolemmal specific KATP inhibitor. The fundamental difficulty with 
identifying a specific mechanism for the anti-arrhythmic effects of IPC is that 
interventions which may lead to increased ischaemia tolerance may indirectly lead to a 
reduction in reperfusion arrhythmias by virtue of the fact that there is less tissue 
damage. 
Patients with CKD have a high prevalence of cardiac arrhythmias. Sudden cardiac 
death attributed to arrhythmias is the single largest cause of death in dialysis patients506. 
The explanation for this is thought to involve fluid and electrolyte shifts during dialysis, 
combined with underlying coronary vascular disease, LVH, myocardial fibrosis and 
heart failure507-509.  
It is unknown whether underlying uraemia has an impact on the anti arrhythmic effects 
of IPC. 
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Methods	  
During the IPC experiments all animals had continuous monitoring of cardiovascular 
parameters using the Powerlab/85p system (ADI instruments), which were displayed on 
a monitor using LabChart software (ADI instruments). The timing of each intervention 
during the experiment was recorded on the LabChart software for later analysis. 
After the experiments the blood pressure and heart rate trace could be analysed for 
evidence of arrhythmias. For the purposes of analysis, an arrhythmia was defined as a 
disturbance in the mean arterial pressure (MAP) trace lasting greater than 2 seconds. 
This time period was chosen so as to exclude occasional ectopic beats, which were 
unlikely to alter tissue perfusion. Asystole was defined as any period whereby the blood 
pressure was unrecordable (MAP <20mm/hg) for 2 seconds or greater. This may be 
caused by true asystole (no mechanical activity in the heart) or pulseless ventricular 
tachycardia or ventricular fibrillation. True asystole was uncommon and was almost 
invariably a terminal event.   
Arrhythmias occurring during the first 30 seconds following LAD occlusion were 
excluded from analysis, as brief arrhythmias were not uncommon immediately after 
occlusion. These were often due to repositioning of the heart in the thoracic cavity 
using forceps to get good visualisation of the area at risk, rather than due to ischaemic 
arrhythmias. 
The duration of arrhythmias (including asystole) occurring during preconditioning, 
reperfusion or during the index ischaemia were recorded. In addition, the delay between 
the onset of ischaemia/reperfusion and the onset of arrhythmias were recorded for each 
animal.  
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Results	  
In the SNx model of uraemia, during experimental myocardial infarction, 3 cycles of 
IPC resulted in a reduction in the duration of arrhythmias during the 25 minute index 
ischaemia (i25). This result approached marginal statistical significance (p=0.06). There 
was a significant reduction in the duration of reperfusion arrhythmias following IPC, 
from a median of 20 seconds to 9.5 seconds in the SNx IPC group (p=0.03). IPC did not 
alter the time to develop the first ischaemic arrhythmia, the duration of asystole, the 
time to develop the first reperfusion arrhythmia or the total duration of all arrhythmias 
(see Table 12 and Figure 40). 
In the adenine model of chronic uraemia, 3 cycles of IPC resulted in a reduction in the 
duration of arrhythmias during i25 (p=0.05) and led to a trend in reduction in 
reperfusion arrhythmia duration (p=0.06). IPC had no effect on the time to develop 
ischaemic or reperfusion arrhythmias, nor did it have any effect on the duration of 
asystole or the total duration of arrhythmias (see Figure 41 and Table 12).  
Next, the effect of underlying uraemia on the anti-arrhythmic effect of IPC was 
considered (see Table 12 and Figure 42). SNx animals and sham SNx animals did not 
differ in the response to an IPC protocol in terms of the duration of ischaemic 
arrhythmias, reperfusion arrhythmias or total duration of all arrhythmias, nor did 
uraemia have an effect on the delay in development of ischaemic arrhythmias following 
IPC. 
Finally, the anti-arrhythmic effect of IPC was investigated in an adenine washout model 
of uraemia with non uraemic controls (see Figure 43 and Table 13). The adenine 
washout group had significantly less arrhythmias than the control animals following 1 
cycle of IPC (p=0.001). When asystole duration was considered, no adenine washout 
animals developed asystole during ischaemia. This result was highly significant using 
Dunn’s multiple comparison after a Kruskall-Wallis test (p<0.0001). Furthermore, IPC 
reduced the duration of asystole in the control group (p<0.005). Neither uraemia nor 
IPC appeared to alter the delay between the start of ischaemia and the first ischaemic 
arrhythmia.  
The duration of the ischaemic, reperfusion and combined arrhythmias was investigated 
in the Adenine washout experiment (see Table 13). On Kruskall-Wallis testing, all 3 
durations were significantly different. To establish the individual impact of uraemia or 
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IPC or both on these durations, a further 2 way ANOVA was performed. IPC reduced 
the duration of i25 arrhythmias in both uraemic and non uraemic animals (p=0.04) and 
there was no interaction between IPC and uraemia. Uraemic animals had a shorter 
duration of ischaemic arrhythmias when IPC was accounted for and this result 
approached borderline significance (p=0.08).  Similar results were seen with 
reperfusion arrhythmias. IPC reduced the duration of reperfusion arrhythmias in both 
uraemic and non uraemic animals (p=0.04) and there was no interaction between IPC 
and uraemia. Uraemic animals had a shorter duration of reperfusion arrhythmias after 
IPC was accounted for (p= 0.02). Finally, when all arrhythmias were considered 
together, IPC did not alter the duration of these arrhythmias (p=0.1). When IPC was 
accounted for, uraemia was still associated with a reduction in total duration of 
arrhythmias when compared to control fed animals (p=0.003). 
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Table 12. Tables showing impact of IPC strategies on arrhythmia duration during reversible LAD 
occlusion.  Top table: The anti-arrhythmic effect of 3 cycles of IPC in an SNx model of chronic 
uraemia. Middle table: The anti-arrhythmic effect of 3 cycles of IPC in an Adenine model of chronic 
uraemia. Bottom table: The effect of underlying uraemia on the anti-arrhythmic effects of IPC. 
Definitions: preconditioning arrhythmias: all arrhythmias which occur during the preconditioning 
cycles, i25/i35 arrhythmias: arrhythmias which occur during the 25 or 35 minute ischaemic period, 
reperfusion arrhythmias: arrhythmias which occur on reperfusion following 25 or 35 minutes 
ischaemia. Results presented as median (IQR). p values are expressed as results of Mann-Whitney test 
using GraphPad software. 
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Table 13: Anti-arrhythmic effect of 1 cycle of IPC in control and adenine washout groups. Results presented as 
median (IQR). p values are expressed as the results of a 2-tailed 1 way ANOVA except in row 1 when the Mann-
Whitney test was used.  
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Figure 40. Box (IQR) and whisker plots (max/min) showing the 
anti-arrhythmic effect of 3 cycles of IPC in an SNx model of 
chronic uraemia. Figures show the effects of IPC on the ischaemic 
arrhythmias (top), reperfusion arrhythmias (middle) and total 
duration of all arrhythmias (bottom).  
 179 
Figure 41. Box (IQR) and whisker plots (max/min) 
showing the anti-arrhythmic effect of 3 cycles of IPC in 
an adenine model of chronic uraemia. Figures show the 
effects of IPC on the ischaemic arrhythmias (top), 
reperfusion arrhythmias (middle) and total duration of all 
arrhythmias (bottom). 
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Figure 42. Box (IQR) and whisker plots (max/min) 
showing the effect of underlying uraemia on the anti-
arrhythmic effects of 1 cycle of IPC. Figures show the 
effects of underlying uraemia on the duration of 
preconditioning arrhythmias (top), index ischaemic 
arrhythmias (middle) and total arrhythmia duration 
(bottom). 
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Figure 43. Box (IQR) and whisker plots (max/min) showing the effect 
of one cycle of IPC and underlying uraemia on the anti-arrhythmic 
effects of 1 cycle of IPC. The adenine groups had 4 weeks of adenine 
diet followed by a 2-week washout period; the control groups had 6 
weeks of standard chow. The Figures show the effects of uraemia and 
IPC on the duration of ischaemic arrhythmias (top), reperfusion 
arrhythmias (middle) and total duration of arrhythmias (bottom). 
 182 
Discussion	  
This analysis confirms the published literature that ischaemic preconditioning is anti-
arrhythmic, both in reducing the duration of ischaemic and reperfusion arrhythmias and 
reducing the duration of asystole.  
IPC did not delay the appearance of ischaemic arrhythmias during any of the 
experiments, nor did underlying uraemia appear to have an effect on this delay.  
Underlying uraemia does not appear to be a barrier to the anti-arrhythmic properties of 
IPC, with both the SNx and adenine treated groups developing significantly shorter 
durations of arrhythmias following IPC when compared to uraemic animals, which did 
not undergo IPC. 
With regards to the anti-arrhythmic effects of IPC in the published literature, authors 
have not analysed the extent or duration of the arrhythmias which occur during the 
preconditioning protocol itself. During IPC, particularly after the first ischaemic 
episode, long periods of arrhythmias are common. These were often in excess of that 
seen during subsequent ischaemic or reperfusion arrhythmias. It is known that inducing 
tachycardia510 or myocardial dys-synchrony511, with the use of external pacing, can 
induce cardio-protection through preconditioning. Clearly induction of arrhythmias is 
not the only mechanism through which hearts can be protected, but it is interesting to 
note that IPC produces lengthy periods of reduced or desynchronised cardiac output 
caused by VF/VT during the cycles of ischaemia/reperfusion. This loss of output may 
render the myocardium transiently ischaemic which may directly contribute to the 
reduction in infarct size. When all arrhythmias are considered, not just those that occur 
during the index ischaemic event, IPC no longer reduces the total duration of 
arrhythmias.  
Therefore, this work suggests that IPC does not reduce the total arrhythmia duration, 
but brings arrhythmias forward in time to a point before lethal injury where they can 
potentially act as an additional preconditioning stimulus. 
In the SNx model, uraemia does not appear be pro-arrhythmogenic in the context of 
IPC when compared with sham operated animals. Both uraemic and non uraemic 
animals develop similar durations of arrhythmias in response to 1 cycle of IPC followed 
by 35 minutes of LAD ligation. The adenine washout model, however, appears to 
confer a resistance to arrhythmias with a shorter duration of ischaemic arrhythmias, 
reperfusion arrhythmias and total duration of arrhythmias seen when compared to 
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control fed animals. This occurs both with and without an IPC protocol and appears to 
be independent of IPC. A possible explanation for this result could be due to the 
starvation or anorexia seen with the adenine model. Starvation has been shown in a rat 
model to increase myocardial glycogen content, protect against ischaemic 
arrhythmias353 and led to a reduction in infarct size354. However, the model used a 
washout period of 2 weeks following the adenine diet, during which time the animals 
gain weight faster than their non uraemic counterparts. This points against the animals 
being in a starvation state. To investigate this apparent effect, further studies could be 
performed with longer washout periods to ensure that the metabolic effects of the 
adenine supplementation have resolved.  
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Chapter 7 
Ischaemic Postconditioning of the Uraemic 
Heart 
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Background	  
17 years after Murry et al.388 reported their seminal finding of IPC, Zhao et al.512 
reported, in an open-chest dog model of reversible LAD ligation, that interruption of 
reperfusion by 3 cycles of 30 seconds LAD occlusion/reperfusion could reduce the 
subsequent infarct size by 44%. In addition, they found that postconditioning (iPOST) 
caused a reduction in tissue oedema, neutrophil accumulation and endothelial damage.  
This had followed on from work performed by their group showing that gradual 
reperfusion reduced infarct size513, 514. Other groups showed that maintaining a lower 
pH by staged reperfusion led to reduced stunning515. This finding had huge potential to 
overcome the main limitation of IPC, which was that the preconditioning stimulus had 
to take place before the ischaemic insult, thus limiting clinical translation of IPC to 
elective operations. 
The prerequisite for rescuing ischaemic myocardium and reducing mortality is the early 
reinstitution of coronary flow. However, the idea that reperfusion itself contributes to 
lethal injury was first proposed by Jennings et al.76 in 1960. At the time, this was 
considered highly controversial with different authors arguing that reperfusion merely 
augmented the effects of lethal ischaemic injury516, 517. Evidence that reperfusion itself 
can cause lethal injury is suggested by many experiments which show that 
pharmacological interventions, such as administration of PARP inhibitors518, 
adenosine519 bradykinin520 or opiates521 at the onset of reperfusion, can lead to a 
reduction in infarct size.  
Factors which determine the response to iPOST are the duration of the index ischaemia, 
the delay between the beginning of reperfusion and the onset of iPOST, the duration 
and number of reocclusions. If the ischaemic period is too long522 or too short523, 
iPOST loses its protective effect.  
There is even data suggesting that when the index ischaemic time is short, iPOST may 
be directly injurious and lead to higher infarct sizes493. These data suggest there is a 
certain degree of injury, which may be insult and species specific, which is amenable to 
cell salvage through iPOST. 
Data suggest that the time delay from the point of reperfusion before commencement of 
iPOST is crucial to ensure cardioprotection. In rats524, a 60 second delay following 
reperfusion abolished protection. However, this appeared to be species specific with 
rabbits still gaining a reduction in infarct size after a delay of up to 60 seconds525. 
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Larger animals appeared to be more resistant to a delay in the initiation of iPOST; a 60 
second delay still lead to cardio-protection in dogs526 and a 180 second delay still lead 
to cardioprotection in pigs527.  
Too few cycles and/or too brief a cycle may reduce the ‘dose’ of iPOST. The precise 
duration and number of cycles again appears to be species specific. In pigs, 4 cycles of 
iPOST did not lead to cardioprotection, however when the number was increased to 8 
cycles, protection was seen528, while in rabbits 3 cycles of post conditioning with  
duration of 20 seconds but not 10 seconds, resulted in cardioprotection529. It is unclear 
whether the need for a longer cycle duration was because the number of cycles was 
only 3.  
The beneficial effects of iPOST are, like IPC not limited to the heart. iPOST has been 
shown to confer tissue protection in the brain530, kidney531 and liver532. 
Mechanisms	  
The mechanisms of tissue protection from iPOST has relied on knowledge gained from 
research into the mechanisms of IPC, with multiple simultaneous endogenous (and 
exogenous) extracellular triggers acting in an autocrine/paracrine fashion to activate 
cytoprotective pathways resulting in tissue protection. The general approaches which 
have been used to elucidate the mechanism of protection include the assessment of the 
effectiveness of ischaemic postconditioning under specific pharmacological antagonism 
or inhibition, modification or loss of postconditioning in receptor or autacoid deficient 
mice and the induction of protection by exogenous autacoids or by selective synthetic 
agonists when given immediately prior to, or at the onset of reperfusion533.  
 
Triggers	  of	  postconditioning	  
Adenosine	  
Adenosine receptor activation by endogenous or exogenous adenosine to confer 
cytoprotection through iPOST has been demonstrated using a combination of 
pharmacological antagonism and gene deletion studies533, 534. 
Opioids	  
Zatta et al.521 reported that iPOST led to opioid production, that opioid inhibitors 
blocked iPOST and exogenous opioids mimicked the effects of iPOST. 
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Bradykinin	  
Exogenous bradykinin given at reperfusion mimics iPOST520. Bradykinin inhibitors 
abrogate the effects of iPOST535 and bradykinin knockout mice do not respond to an 
iPOST signal536. 
Acidosis	  and	  calcium	  overload	  
Reperfusion leads to rapid normalisation of myocardial pH at the expense of Na+ and 
Ca+ overload537. Postconditioning had been shown to delay pH recovery in rats538 which 
has been shown to inhibit mPTP opening539. 
Effectors	  of	  postconditioning	  
RISK	  pathway	  
The RISK pathway has been shown to be involved in tissue protection following IPC. 
The RISK pathway was initially thought not to be involved in iPOST because the 
components of the RISK pathway were believed to be activated before ischaemia rather 
than during reperfusion. However, Hausenoly et al.398 showed that inhibiting 
components of the RISK pathway during the first 15 minutes of reperfusion abolished 
the protection seen with IPC. Further evidence for the role of the RISK pathway comes 
from data which show that mice given an ERK inhibitor (but not a PI3 inhibitor) were 
rendered refractory to iPOST540. The importance of the RISK pathway in iPOST has 
also been shown in humans. Using an ex vivo experiment in human atrial tissue, 
Yellon’s group were able to show that hypoxic postconditioning improved recovery of 
contractile function, which was dependant on intact PI3 kinase and MEK1/2 
pathways541. 
Skyschally et al.542 showed that the intracellular signal transduction of iPOST may 
involve non RISK pathways. They reported that an iPOST protocol in pigs conferred 
cardioprotection but did not result in a greater degree of up regulation in components of 
the RISK pathway (Akt, ERK and GSK-3β) when compared to a sham iPOST protocol. 
Furthermore, the protective effects of iPOST may remain even in the face of inhibition 
of the PI3 kinase or ERK1/2 pathways543.  
 
Survivor	  Activating	  Factor	  Enhancement	  Pathway	  
The survivor activating factor enhancement (SAFE) pathway comprises STAT-3 and 
TNFα. Lacerda et al.544 have shown that TNFα administered at the time of reperfusion 
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confers subsequent cardioprotection, which is mediated via binding of TNFα to the 
TNF receptor-2, and is independent of the RISK pathway. However, this protection was 
dependant on STAT-3 activation. The JAK-STAT pathway conveys extracellular stress 
signals from the cytokine receptors on the plasma membrane to the nucleus, resulting in 
transcription of proteins involved in cardioprotection. Inhibition of the STAT pathways 
at the point of reperfusion has been shown to abolish the effects of iPOST545. 
Both the SAFE and RISK pathways appear to converge on mitochondria to achieve 
their cytoprotective effects546. 
 
Protein	  kinase	  C	  and	  G	  
Both inhibition of protein kinase C547 and inhibition of protein kinase G have been 
shown to abolish the effects of iPOST, however the signalling mechanisms remain 
unclear. 
 
Mitochondrial	  permeability	  transition	  pore	  
Like preconditioning, the mPTP is thought to be the end common effector for the 
cardioprotective pathways in iPOST548, 549.  
 
Inflammation	  
Postconditioning may also inhibit reperfusion injury by reducing neutrophil adherence 
to the vascular endothelium, inhibit activation of the coronary endothelium, reduce 
production of ROS and pro-inflammatory cytokines512, 550.   
 
Human	  trials	  in	  iPOST	  cardioprotection	  
The first work to translate the animal data into human trials was a small proof of 
concept study by Staat et al.302, which showed a 36% reduction in the area under the 
curve of CK release in an iPOST cohort when compared to controls. They also found 
that there was a significantly higher ‘blush grade’ in the iPOST group, indicative of less 
‘no reflow’, which is in line with the original findings by Zhao et al512 who found that 
iPOST had a protective effect on endothelial function. 
The benefits of iPOST have been shown to persist for up to 1 year. A small open label 
randomised study (n=38), demonstrated that 4 cycles of balloon inflation, in the context 
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of primary PCI, resulted in a 40% reduction in infarct size leading to an improved 
ejection fraction  at 1 year551. These findings are in agreement with retrospective data 
which report that in 433 patients who underwent four or more balloon inflations in the 
context of AMI had smaller infarct sizes than those with 3 or less552. 
There have been 15 human clinical trials in cardioprotection with iPOST. However they 
have been small with an average size of 58 patients. Four have been in children 
undergoing cold cardioplegia for correction of tetralogy of Fallot and all have shown 
less inotrope requirement and shorter ITU stay553. Three of these studies looked at 
cardiac enzymes as a marker for myocardial injury and all have shown a benefit554-556. 
Of the 11 trials in adults, 7 have only looked at short-term outcomes such as ST 
resolution557, cardiac apoptosis558 or cardiac enzyme rise302, 559, 560. One used cardiac 
MRI at 1 week to access infarct size561 and another used SPECT at 1 week562. Three 
studies had echo data at 8 weeks563-565, and 1 study used SPECT at 6 and 12 weeks and 
an echo at 1 year to confirm cardiac protection551. 
Comorbidities	  
The published literature, almost without exception, shows that when iPOST is delivered 
in a timely manner with an appropriate study protocol, it is a potent cytoprotective 
strategy. While the published human clinical trials have shown benefit, the trials have 
generally been small, with little long term outcome data and were not powered to show 
a mortality benefit, in addition they have also not demonstrated the same magnitude of 
tissue protection seen in the animal literature.  A possible reason for the failure of 
widespread translation from the animal literature to clinical practice could be that 
patients who present with a cardiac event differ from juvenile healthy animals.  Patients 
who present with an AMI are likely to be elderly, dyslipidaemic and with vascular 
disease, and many are diabetic.  
 
Gender	  
The role of gender in iPOST is unclear. One study in rats indicated that the effect of 
iPOST was smaller in female than male rats523. However, in another, the effect of 
iPOST depended on gender and duration of ischaemia; female rats did not 
postcondition when the ischaemia duration was 25 minutes, but did respond when the 
duration was 20 minutes, unlike male rats who were protected at both time points566. 
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Dyslipidaemia	  
Underlying dyslipidaemia has been shown to attenuate the protective effects of iPOST. 
A study by Iliodromitis et al.456 reported in a rabbit model that underlying 
hypercholesterolaemia attenuated the protective effects of iPOST. 
Hypercholesterolaemia has also been found to attenuate the effects of iPOST in the 
pig527 and rat567. 
 
Senescence	  
Aging appears to cause resistance to the effects of iPOST.  Isolated perfused hearts 
from older mice (20-24 months old) could not respond to an iPOST protocol unlike 
adult (3-4 month) mice. The mechanism by which senescence resulted in a loss in 
ability to respond to iPOST was investigated by Przyklenk et al.540. They showed that 
older mice did not phosphorylate ERK in response to an iPOST stimulus and had higher 
basal levels of MAP kinase phosphatase-1 (MKP-1), which is thought to have a primary 
role in ERK dephosphorylation. Due to increased dephosphorylation of ERK by MKP-
1 in old mice, iPOST was not able to confer protection. The role of MKP-1 in iPOST 
was confirmed by showing that inhibiting MKP-1 reinstated the cytoprotective effects 
of iPOST in older mice540.  
 
Diabetes	  
Streptozotocin treated mice were unable to respond to an iPOST protocol due to a loss 
of iPOST mediated ERK phosphorylation. However the beneficial effects of iPOST 
were regained if they were rendered euglycaemic with a islet cell transplant 2 weeks 
before the cardiac ischaemia568. 
 
Obesity	  
Ob/ob mice, characterised by hyperglycaemia, hypercholesterolaemia, left ventricular 
hypertrophy and higher body weight were found to have both a reduced ischaemia 
tolerance and a failure to respond to iPOST569. 
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Coronary	  artery	  stenosis	  
30% of patients who present with AMI already have significant coronary artery disease. 
Oikawa et al.570 reported that rats with experimental coronary artery stenosis were 
unable to respond to iPOST, due to a failure to upregulate ERK and Akt.  
 
Medication	  use	  
Patients who present with AMI are often on multiple medications, which may have an 
effect on the ability to postcondition. Chronic use of statins571, beta-blockers572 and 
drugs which block the mitochondrial KATP channel573, have been shown to render the 
heart resistant to iPOST. Furthermore, nicorandil, a KATP channel opener and a common 
drug used in patients with ischaemic heart disease, has been shown to mimic 
postconditioning when given in the context of AMI574. It is unknown whether chronic 
treatment with nicorandil may render the heart resistant to iPOST via the K ATP 
pathway. Up to 30% of patients presenting with ACS have underlying CKD stage 3-541, 
49, 489. The impact of CKD on resistance to iPOST is currently unknown. 
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Methods	  
40 male Wistar rats, which had undergone a 2 stage, subtotal nephrectomy procedure or 
sham procedure (as described in the methods section) to generate uraemic and non 
uraemic groups were used. 4 weeks after the second stage, the rats underwent reversible 
LAD occlusion (see methods section for full details of experimental protocol). After 25 
minutes of LAD occlusion, the occluder was loosened to begin reperfusion. The animal 
then either underwent a postconditioning protocol comprising 5 cycles of 10 seconds 
ischaemia followed by 10 seconds reperfusion, or they did not. This meant that there 
were 4 experimental groups. Group 1 (sham control) were animals which had 
undergone a sham SNx procedure and no iPOST. Group 2 (sham iPOST) were  animals 
which had undergone a sham SNx procedure and iPOST. Group 3 (SNx control) were 
animals which had been made uraemic with an SNx procedure, but had not undergone 
an iPOST protocol. Group 4 (SNx iPOST) were animals which had been made uraemic 
with an SNx procedure and had undergone an iPOST protocol. Following this, the 
animals underwent a 2-hour reperfusion period at the end of which blood was taken for 
analysis and the heart was harvested and processed for infarct size determination in the 
standard manner (see methods section for full details of harvesting and infarct size 
quantification). 
Exclusions	  
During the experiment, one animal died during basic surgery (uraemic group). 3 
animals had no area seen at the end of the experiment and were excluded (2 uraemic,1 
sham). 1 animal (sham) died during ischaemia,  6 animals died during reperfusion (4 
had not undergone iPOST of which 3 were uraemic, 2 had undergone iPOST of which 
one was uraemic). This left group 1 with 9 animals, group 2 with 8 animals, group 3 
with 6 animals and group 4 with 6 animals for analysis.  
Measurement	  of	  arrhythmias	  
Arrhythmias were measured in the same was as in the work in IPC (see methods 
section the arrhythmia experiments in the IPC chapter).  
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Quantification	  of	  Serum	  Troponin	  by	  ELISA	  
Serum troponin was quantified using a high sensitivity rat cardiac troponin-I (cTni) 
ELISA kit (cat no 2010-2-HSP Life diagnostics, Pennsylvania USA).  
Technique	  
Before the thoracotomy and at the end of reperfusion, 1ml of blood was withdrawn 
from the arterial line into a 2ml Eppendorf tube containing 30µL heparin (5000 iu/ml) 
and mixed by repeated inversion. The sample was spun at 6000g for 3 min and the 
serum was aspirated into a new Eppendorf tube. The sample was then stored at -80OC.  
After equilibration of the kit components to room temperature, cardiac troponin stock 
solution was prepared and serial dilutions were made to generate standards which were 
carefully pipetted into the wells. Serum samples were prepared, in the case of the pre-
thoracotomy samples, by diluting 100µl of the sample with 3 volumes of plasma 
dilutent.  It was found, after some trial and error, that the post reperfusion samples 
required a 1 in 32 dilution step before further dilution with plasma dilutent, to avoid 
going over the top of the standard cure, due to much greater troponin levels post-
reperfusion. 100µl of the appropriately diluted pre and post samples were added to the 
wells. 100µl of troponin HRP conjugate was added to each well and left on an orbital 
shaker (150 RPM) at room temperature for 60 minutes. The incubation mixture was 
then emptied from the wells and the wells washed with a provided wash solution. This 
was repeated 6 times to ensure all non bound HRP conjugated antibodies were 
removed. 100µl of tetramethylbenzidine, a HRP substrate, was added to all wells and 
the plate was again incubated at room temperature on an orbital spinner at 150 RPM for 
20 minutes. The reaction was terminated with a stop solution of HCL, turning the wells 
from blue to yellow. A Dynex revelation 4.25 plate reader was used to quantify the 
absorbance at 450nm. 
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Results	  
Baseline	  characteristics	  	  
The uraemic animals (SNx) had 4 times the serum creatinine and serum urea compared 
the non uraemic (sham) animals (see Table 14). The SNx groups were growth restricted 
(P<0.0001), anaemic (p<0.0001), hypoalbuminaemic (p=0.004), hypertensive (p=0.03), 
acidaemic (p=0.02) and hypercalcaemic (p=0.009). While the heart weights between 
the two groups did not differ significantly, the LV mass index (a surrogate marker for 
LVH) was higher in the uraemic groups (p=0.005) . 
Cardiovascular	  Parameters	  
Over the course of the experiment, the blood pressure fell in all groups, as a result of 
anaesthesia, blood loss during thoracotomy, mechanical ventilation with impairment of 
cardiac output during ischaemia and cardiac stunning during reperfusion parameters 
(see Figure 44). There was a further, temporary fall in the blood pressure 5-10 minutes 
after the beginning of ischaemia and at reperfusion, which was caused by arrhythmias. 
Pulse rate did not change significantly during the experiment, with the exception of 
during arrhythmias. The rate pressure product fell, in line with blood pressure, during 
the experiment. There was no significant difference between the cardiovascular 
parameters of the 4 groups during the experiment.  
Arrhythmias	  	  
In all groups, ischaemic arrhythmias developed around 5 minutes after the start of 
myocardial ischaemia (see Figure 45).  The groups did not differ in terms of duration of 
ischaemic arrhythmias or duration of asystole during ischaemia. iPOST did not appear 
to delay the onset of reperfusion arrhythmias, which occurred 20 seconds after the 
beginning of reperfusion. There was no difference in the duration of reperfusion 
arrhythmias or duration of reperfusion associated asystole. 
Troponin	  concentration	  	  
Baseline serum troponin was higher in the uraemic animals (p=0.02) compared to non-
uraemic animals (see Figure 46). The baseline level of serum troponin was strongly 
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correlated (r=0.72) with underlying renal function. 25 minutes of ischaemia with 2h 
reperfusion resulted in a 2000 fold increase in troponin compared to baseline. There 
was no significant difference in serum troponin levels between uraemic and non 
uraemic animals following myocardial infarction. Troponin release was significantly 
correlated with infarct size (r=0.4755,p=0.0079)   
Postconditioning was associated with a reduction in serum troponin, both in the uraemic 
and non uraemic groups. There was a 75% reduction in the median serum troponin 
level in the non uraemic group following iPOST (p=0.02) and in the uraemic group, 
there was a 69% reduction (p=0.04).  
 
Infarct	  size	  
The median area at risk was similar between all groups; sham control (40.1%), sham 
iPOST (43.1%), SNx control (45.1%) and SNx iPOST (47.3%). In non uraemic 
animals, iPOST resulted in a significant reduction (P<0.01) in infarct size of 49% 
(median infarct size 61.4 and 31.2 in the control and iPOST groups respectively).  In 
uraemic animals, iPOST caused a 69% reduction in infarct size (p<0.01), with median 
infarct sizes of 63.7% and 19.4% for the control and iPOST groups respectively. 
Comparing the infarct size of non uraemic and uraemic animals following iPOST 
revealed that uraemic animals had lower infarct sizes, a result which approached 
borderline statistical significance (p=0.051). To confirm that underlying uraemia had no 
impact on the ability of the heart to respond to a preconditioning stimulus, a 2 way 
ANOVA was performed, which confirmed that iPOST (in either uraemic or non 
uraemic models) led to a highly significant degree of tissue protection (p<0.0001), but 
that uraemia per se did not affect the result (p=0.29), with uraemia accounting for less 
than 2% of variability seen between the groups.  
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Sham (n=17) SNx (n=12) p
Weight (g) 435 (24.7) 392 (20.9) <0.0001
Initial MAP (mm/hg) 144 (14.6) 158 (22.0) 0.03
Initial pulse (BPM) 398 (28.3) 365 (70.4) 0.07
Haematocrit (%) 40.3 (4.21) 28.1 (6.41) <0.0001
Plasma HCO3 (mmol/l) 28.3 (3.46) 25.3 (3.31) 0.02
Creatinne (umol/l) 33.4 (10.7) 143 (89.4) <0.0001
Urea (mmol/l) 5.3 (1.13) 26.7 (22.7) <0.0001
Albumin (g/l) 25.4 (1.88) 23.1 (2.31) 0.004
Phosphate (mmol/l) 1.97 (0.24) 1.88 (0.44) 0.45
Calcium (mmol/l) 2.39 (0.16) 2.55 (0.17) 0.009
Heart weight (g) 1.20 (0.15) 1.51 (0.73) 0.1
LV index 0.28 (0.03) 0.51 (0.67) 0.005
Table 14. Baseline characteristics, in uraemic (SNx) and non uraemic (sham) male Wistar rats. Values 
presented as mean (SD), p value calculated using unpaired t-test. 
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Figure 44. Figure showing the change in mean heart rate (top), blood pressure (middle) 
and pressure rate product (bottom) over time during the experiment in the 4 groups. 
Data points represent mean with error bars representing SEM.   
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Figure 45. Figure showing the results of analysis of arrhythmias during myocardial ischaemia/reperfusion. Box 
and whisker graph with line (median), box (IQR) and whiskers (Max/Min). A: Time taken after the beginning 
of ischaemia to develop the first arrhythmia. B: Total duration of all arrhythmias during 25 minutes of 
ischaemia. C: Duration of asystole during 25 minutes of ischaemia. D: Time taken to develop 1st reperfusion 
arrhythmia. E: Total duration of reperfusion arrhythmias. F: Duration of reperfusion asystole. One way 
ANOVA testing (Kruskall-Wallis) revealed no significant variability in the medians between the 4 groups. 
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Figure 46. Results of baseline troponin quantification. 
The top figure shows the correlation between baseline serum troponin levels and 
underlying renal function. R value is the Spearman’s rank correlation coefficient, with  p 
value to result of a student t-test. The bottom figure shows pre-ischaemia (baseline) 
troponin levels in non uraemic  (sham) and uraemic (SNx) rats.  p value results of 
MannWhitney test  calculated using GraphPad software.   
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Figure 47. Results of serum troponin levels. Top figure shows the effect of 
iPOST on serum troponin levels following myocardial ischaemia in both non 
uraemic and uraemic animals, with a 1 way ANOVA (Kruskall-Wallis) 
statistic of p<0.01. The effect of iPOST on serum troponin levels was 
compared within the uraemic and non uraemic groups and displayed on the 
figure, as results of a Mann-Whitney test. Bottom figure showing correlation 
between infarct size as measured using NBT assay and serum troponin levels.  
r value is the Spearman’s rank correlation coefficient, with  p value to result 
of a student t-test. 
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Figure 48. Box and whisker plot showing median (line within box), IQR (box) and whiskers (Max/Min 
values). Infarct size, expressed as a % of AAR (top) and area at risk (bottom) following reversible LAD 
ligation in the 4 groups.  p values result from the Mann-Whitney test calculated using GraphPad software. 
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Discussion	  
This is the first time that the impact of underlying chronic uraemia on the ability to gain 
cytoprotection from iPOST has been studied. This study used the SNx model as the 
model of uraemia. The reason this was chosen over the adenine model is that the SNx 
model of uraemia is much more widely published, in addition we had already 
demonstrated that the SNx model had a reduced ischaemia tolerance, and therefore may 
more closely resemble the human cardiac phenotype.  
This study confirms that unlike diabetes, senescence or obesity, underlying uraemia did 
not abolish the effects of postconditioning, as measured by infarct size and troponin 
release.  
The use of serum troponin as a cardiac biomarker is useful, as unlike the method for 
assessing infarction using NBT to identify an intact LDH system, it allows for 
assessment of tissue injury without requiring the myocardium to be destroyed. This 
would enable additional measurements to be made on the heart, such as histology. 
However, serum troponin estimation appears to have a greater degree of variability than 
infarct size estimation using the NBT method. The interquartile ranges expressed as a 
percentage of the median for the troponin data are around 4 times that of the infarct size 
data. 
To help improve the correlation between troponin concentrations and infarct size, it is 
possible to perform repeated troponin measurements over time to generate a graph, the 
integral of which may be a better marker of infarct size than a single troponin 
estimation.  
In this experiment there was no significant difference in the infarct size of the sham 
SNx control group and the SNx control group.  This is in contrast to previous work 
which shows that uraemia leads to a reduced ischaemia tolerance. The reason for this 
is that this experiment used much smaller groups than in the experiment specifically 
investigating the role of uraemia in ischaemia tolerance. Smaller groups were used in 
this experiment because the expected effect size of iPOST was much greater than the 
effect size of underlying uraemia. This meant that this experiment was under powered 
to detect a difference in the ischaemia tolerance of uraemia per se. 
The results of this work suggest that uraemic animals may derive even greater benefit 
from postconditioning than non uraemic animals. The uraemic iPOST group had a 
lower infarct than the non uraemic iPOST group (p=0.051). This effect has also been 
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seen with preconditioning in SNx animals by me (see Table 10).  A possible 
explanation for this is that uraemic animals are significantly more anaemic than their 
non uraemic counterparts. Direct manipulation of the vessel, during pre or 
postconditioning with interruption of flow down stream, is likely to cause 
microvascular occlusion and no reflow injury. Because the uraemic animals have a 
lower haematocrit, they may be less likely to generate as much microvascular 
thrombus, leading to less no reflow injury.  Furthermore, iPOST is not a totally benign 
procedure. If the ischaemia time is too low, iPOST may actually increase infarct size493. 
It could be that this is specific to short ischaemic times or it could be that the deleterious 
effects of iPOST are only uncovered when there is a small index ischaemia injury, and 
hence little for iPOST to salvage in its traditional role.  
 
Arrhythmias	  
iPOST has been shown to inhibit reperfusion arrhythmias in dogs550 and rats501, 
although the mechanism for this effect is unknown. However, it does not appear to be 
mediated via the MPTP, PI3-Kinase, KATP or adenosine pathways575. The results from 
this work do not support this. However the variability in the timing, duration and 
severity of the arrhythmias may have overshadowed a small difference. 
 
Future	  directions	  
1) This work suggests that uraemia is not an absolute barrier to postconditioning. 
However, it is still unknown whether uraemia results in a relative resistance to 
iPOST. Future work should address this issue by reducing the number of 
postconditioning cycles to the minimum number, which confers protection in the 
non uraemic animals, and then repeat that protocol in uraemic animals to identify 
whether underlying uraemia causes any resistance to iPOST.  
2) Remote ischaemic post conditioning has been shown to be beneficial in rats380, 
however the role of underlying CKD has not been studied.  
3) These results suggest that there may perhaps be some additional benefit, or perhaps 
loss of harm, when the response to iPOST is compared in uraemic and non uraemic 
animals. This finding needs further testing to confirm its presence. However, a 
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possible explanation for this could be that the lower haematocrit in the uraemic 
animals leads to less no reflow injury following iPOST. The hypothesis that 
anaemia in isolation results in less injury is difficult to test, since venesection to 
render a rat anaemic will lead to up regulation of erythropoietin which is known to 
be tissue protective 576. Rendering an animal chronically anaemic will also lead to 
LVH, which may alter the hearts response to ischaemia.   
One solution to identify whether a low haematocrit results in reduced 
microvascular occlusion during the postconditioning protocol would be to harvest 
the heart for histology and quantify microthrombi in both non uraemic and uraemic 
animals following myocardial infarction with and without iPOST. 
Additionally, the adenine model of CKD could be used to assess this effect 
because in earlier work in IPC, adenine animals did not appear to derive greater 
protection from preconditioning than non uraemic controls. 
4) This novel finding that uraemic animals, unlike diabetic or dislipidaemic animals, 
can respond to postconditioning is important when designing future clinical trials 
in postconditioning and this work suggests that patients with underlying CKD 
should not be excluded from clinical trials in postconditioning. 
 
5) Additional work into cardiac biomarkers other than troponin for evaluation of 
tissue injury in the context of myocardial infarction would help to identify whether 
these would provide a more powerful surrogate marker for tissue damage in the rat 
than troponin. Rat serum should be analysed for myosin light chain and fatty acid 
binding protein and the results compared with troponin 
 
6) In this current work, only SNx animals were studied. Future work could compare 
the effects of different models of underlying uraemia on the ability of the uraemic 
heart to respond to a preconditioning signal. 
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Chapter 8 
     Evaluation of the effect of AZ12785452: 
a PARP-1 Inhibitor in a SNx Rodent Model 
of Myocardial Infarction 
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Background	  
Poly (ADP-ribose) polymerase 1 (PARP-1) is the most abundant isoform of the PARP 
family577. PARP-1 is a DNA damage sensor and signalling molecule. It binds to 
damaged DNA and catalyzes the cleavage of NAD+ into nicotinamide and ADP-ribose 
to form long branches of ADP-ribose polymers on glutamic acid residues of a number 
of target proteins including histones and PARP-1 itself 578. 
Until recently it was thought that PARP activation was primarily triggered by 
recognition of DNA breaks577, 579. However, studies have provided evidence that PARP-
1 activity can be modulated by other factors such as vitamin D580, caffeine581 as well as 
calcium, magnesium, histones and ATP582. Furthermore, the degree to which PARP is 
activated by DNA breakage may be regulated by other factors such as ERK1/2583. 
All cells exposed to DNA damaging agents can enter three major pathways based on 
the intensity of the trigger579. Moderate injury causes PARP-1 activation leading to 
DNA repair by signalling cell cycle arrest and by interacting with DNA repair enzymes. 
This allows cells to survive without passing on mutated genes. More severe DNA 
damage triggers an apoptotic cell death pathway during which caspases inactivate 
PARP-1 by cleaving it into two fragments, preventing the loss of cellular ATP, which is 
required for the process of apoptosis. Very extensive DNA damage causes an over 
activation of PARP. Activated PARP rapidly depletes the cell of NAD+, eventually 
resulting in ATP depletion and death by necrosis. Thus PARP activation, in the face of 
different severities of insult, can act to repair the cell, send the cell on an apoptotic 
pathway or through over activation, cause necrotic cell death. Pharmacological 
inhibition of PARP could switch cells from a necrotic to an apoptotic death or if the 
injury was only moderate, prevent apoptosis occurring578. PARP-1 also facilitates the 
action of apoptosis inducing factor (AIF). AIF is translocated from the mitochondria to 
the nucleus and induces DNA fragmentation584.  
PARP is also thought to increase expression of proteins involved in inflammation. The 
absence of functional PARP-1 (either genetic or pharmacological) leads to a reduction 
in pro-inflammatory mediators, including cytokines, chemokines, adhesion molecules, 
and enzymes (e.g., iNOS)585. PARP is also involved in the JNK, p38 MAP-kinases and 
STAT-1 signalling cascades578. 
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PARP-­‐1	  inhibitors	  in	  myocardial	  ischaemia	  reperfusion	  injury	  
Reperfusion injury is associated with a surge of reactive oxygen species and reactive 
nitrogen species586 along with local activation of leucocytes leading to further 
inflammation and ROS generation to form a so-called ‘respiratory burst’587. The burst 
of reactive oxygen and nitrogen leads to coronary endothelial dysfunction, myocardial 
stunning, cellular calcium overload and cell death588. In the rat, inhibition of PARP in 
the context of myocardial ischaemia/reperfusion has been shown to be cytoprotective in 
several studies589-591. 
 
Animal data 
The cytoprotective effect of PARP inhibition in the context of AMI has been studied in 
several species: mouse592, rabbit593, pig594 and rat (discussed below). A study Zhao et 
al.595 used 3-aminobenzamide (3-AB) as a PARP inhibitor in a LAD ligation model in a 
rodent. They found that the inhibitor reduced PARP activation and reduced AIF 
expression. These results are interesting in 2 ways; firstly they used a permanent 
ligation model, so that there was no reperfusion phase, which is the phase thought to 
trigger PARP activity. Furthermore, the PARP inhibitor was given IP, after occlusion 
and it is unclear how the drug acted on the ischaemic myocardium, since by definition, 
there was no blood supply to that area. However, Bowes et al.589 reported a significant 
reduction in infarct size, in an ex vivo rodent model of reversible LAD occlusion using 
the same drug as an inhibitor of PARP. Liaudet et al.591 demonstrated in a rat model of 
reversible myocardial ischaemia, PARP activation in the reperfused myocardium, 
which persisted for 23h. The PARP activity was reduced by 3-AB, which lead to a 
significantly lower infarct size. Wayman et al.596 demonstrated that 5-
aminoisoquinolinone inhibited PARP activity in vitro and in vivo in a rat model of 
reversible LAD occlusion. They also found that administration of 5-
aminoisoquinolinone 1 minute before reperfusion resulted in a reduction of infarct size 
of 50% when compared to control animals. 
Human	  studies	  
Toth-Zsamboki et al.597 analysed serum, plasma and leucocyte samples from patients 
presenting with a STEMI, and followed their progress through angioplasty to recovery. 
 208 
They reported that following successful angioplasty (reperfusion) there was a rapid 
increase in reactive oxygen/reactive nitrogen species, oxidative DNA damage, 
activation of PARP-1 and AIF translocation from the mitochondria to the nucleus. 
These observations support the theory that ischaemia/reperfusion injury in acute 
myocardial infarction is capable of activating PARP-1. 
Morrow et al.598 reported the first human clinical trial on PARP inhibitors in the context 
of myocardial infarction. The study was a phase II randomised single blind multicentre 
placebo-controlled trial in patients with STEMI undergoing primary PCI, using the drug 
INO-1001 as a PARP inhibitor. This was a small (n=40) trial with only a short follow 
up (30 days). Importantly, renal disease (defined as a serum creatinine of >2mg/dl) was 
an exclusion criteria. The group found that INO-1001 was safe and efficacious at 
inhibiting PARP in an ex vivo experiment. There was also a trend towards reduced 
inflammatory response in the form of lower CRP and IL-6 levels. 
The	  role	  of	  PARP	  in	  preconditioning	  
Liaudet et al.599 reported that PARP-1 deficient mice had smaller infarcts following 
LAD ligation than wild type animals. They showed that an ischaemic conditioning 
protocol did not confer cardioprotection in the PARP-1 deficient mice, unlike wild type 
and even appeared to be deleterious with  a 60% increase in infarct size seen following 
preconditioning in the PARP-1 deficient mice.  
These findings were replicated using 3-AB as a pharmacological inhibitor of PARP-1 in 
rats with similar results. In addition they found that both 3-AB and IPC reduced PARP 
activation in the myocardium of rats that underwent myocardial infarction. However 
when 3-AB was combined with IPC, no inhibition of PARP activity was seen. IPC 
alone was associated with generation of reactive nitrogen species and a small elevation 
in PARP activity. The authors speculated that the small elevation in PARP after IPC 
might be involved in the mechanism of IPC.  
There are several hypothesises which can be used to explain the effects of IPC on 
PARP. Liaudet et al.599 hypothesise that IPC triggers low level PARP activity which 
through auto-ribosylation, leads to auto-inhibition. Evidence in support of this 
hypothesis comes from their data showing that 3-AB given before IPC nullifies the 
cytoprotection of IPC. This hypothesis also explains the finding that IPC alone activates 
PARP and that 3-AB given after IPC does not reduce the cytoprotective effects of IPC. 
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Another hypothesis to explain the effect of IPC on PARP is that purines formed during 
the myocardial ischaemia of IPC, such as inosine and hypoxantine, are present at 
concentrations which can inhibit PARP directly600. Garnier et al.601 reported in an in 
vitro model of cerebral ischaemia, that ‘chemical ischaemia’, a model of IPC, led to 
PARP-1 cleavage with resultant cytoprotection. The authors report that IPC triggers 
caspase activation which in-turn cleaves PARP-1 into an inactive form, rendering the 
cells resistant to subsequent injury.  
Exclusion	  of	  CKD	  patients	  from	  clinical	  trials	  
The sole clinical trial using PARP inhibitors in the setting of cardiovascular disease 
excluded patients with underlying renal dysfunction598. Clinically, PARP inhibition has 
been studied more widely in the field of cancer and there have been several trials 
published. In these trials patients were either excluded unless they had ‘adequate renal 
function’602-604, of if their GFR <50%605. In others renal function data was not 
reported603.  
PARP	  inhibition	  and	  CKD	  
Swierczynski’s group have published several papers on N-methyl-2-pyridone-5-
carboxamide (2PY). 2PY is one of the end products of NAD degradation and is 
normally excreted in the urine. In health, the serum concentration of 2PY is low, 
however in uraemic patients, the serum level of 2PY is elevated by as much as 20 
fold606, 607. The concentration of 2PY is found to negatively correlate with GFR. 
Another potential reason for elevated levels of 2PY in uraemia is through excessive 
metabolism of NAD608. The authors suggest that increased oxidative stress associated 
with renal failure leads to greater PARP activation metabolising more NAD into 
nicotinamide and subsequently to 2PY. The group also found increased levels of 2PY in 
the serum and tissues in rats that had been rendered uraemic by a SNx procedure609. 
Interestingly the group found that 2PY was able in inhibit PARP-1 in an in vitro assay 
in a dose dependant manner607. Furthermore, when 2PY was added to endothelial cells 
treated with peroxynitrite to simulate oxidative stress, there was a reduced depletion of 
NAD and ATP when compared to controls, indicative of PARP inhibition610. 
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Aims	  
The role of underlying CKD in the outcome of PARP inhibition in the context of 
myocardial ischaemia reperfusion is unknown. This experiment sought to investigate 
the role of PARP inhibition as a pharmacological conditioning agent in the context of 
uraemia. 
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Methods	  
Six week old male Wistar Rats (Charles Rivers UK) were obtained and after 1 week 
acclimatisation in an animal house with a 12 hour day night cycle and free access to 
water and standard chow. All animals then underwent a 2 stage SNx procedure (see 
methods section for details on subtotal nephrectomy procedure page 52). Four weeks 
after the second stage procedure, they were anaesthetised, had venous and arterial lines 
inserted and had a tracheostomy performed and were placed on a ventilator (see 
methods section for full details of basic surgery and ventilation page 76). The animals 
then underwent a reversible LAD ligation procedure (see page 83 for full details of 
reversible LAD ligation technique).  The duration of ischaemia was 30 minutes with a 
2-hour reperfusion period.  
5 minutes before the end of the 30 minutes ischaemia, AZ12785452 (Astra Zeneca 
UK), a PARP inhibitor or  vehicle (10% DMSO) was infused. AZ12785452 was made 
up in 10% DMSO at a concentration of 1mg/ml. The infusion was initially at a rate of 
1ml/kg/min for 1 minute followed by 0.12ml/kg/min for the remainder of the 
experiment (124 minutes). At the end of the experiment the infarct size and area at risk 
were measured as before. 
	  
Quantification	  of	  serum	  troponin	  	  
For	  method	  of	  measurement	  of	  serum	  troponin	  	  (see	  methods	  section	  page	  193)	  
Preparation	  of	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  sample	  
At the end of the reperfusion period 1 ml of non-heparinised blood was drawn via the 
arterial line into an EDTA tube (max 5mM final concentration). One ml of 
blood/EDTA was then transferred from the EDTA tube to a 1.5 ml Eppendorf tube and 
mixed, by repeated inversion, with 0.25 ml of solution D (1.6 volumes of OptiPrep™ 
(Sigma) to 1 volume of solution B (0.85% {w/v} NaCl, 30 mM Tricine NaOH, pH 
7.4)). A volume of 100 µL of Solution C (0.85% (w/v) NaCl, 10 mM Tricine NaOH, 
pH7.4) was layered on top and the Eppendorf tube was spun at 1300g for 30 min at 
20OC. Approximately 600µL of PBMCs were collected from the semi clear overphase 
and transferred to a new 2ml Eppendorf tube. The collected material was washed by 
diluting with 2 volumes of cold phosphate buffered saline and spun at 500g for 10 min 
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at 4oC. The supernatant was poured off and the PBMC cell pellet was frozen and stored 
at -80oC. The samples were sent to AstraZeneca for quantification of PARP activation. 
 
Histological	  evaluation	  
12 animals, 6 in each group, had hearts harvested for histology. At the end of the 2 hour 
reperfusion period, the hearts were quickly excised and placed in ice-cold saline for 2 
minutes. The organs were then immersed in 10ml of Formalin (Sigma) for storage. The 
samples were sent to AstraZeneca R+D for histological analysis and quantification of 
PARP activation. 
The hearts were sectioned and stained with haematoxylin and eosin, and underwent 
immunohistochemistry for PAR (the product of PARP activation). The antibody used 
was mouse anti rat PAR at 1.25ug/ml (Abcam Cambridge UK). The sections were also 
stained for with an iostype specific control antibody, mouse IgG3 (Abcam Cambridge 
UK). The histology sections were analysed by an independent histopathologist in a 
blinded fashion. 
Analysis	  of	  PARP	  activity	  in	  PBMC	  pellets	  
PBMC pellets were lysed in extraction buffer. Extraction buffer (7ml) was prepared 
using 6.694ml of PBS, 1 mini-complete protease inhibitor tablet (Roche), 70µl of 1% 
igepal CA-630 (Sigma), 1.4ul of 200µM DTT (Sigma), 100µl of PI cocktail 1 (Sigma) 
and 100µl of PI cocktail 2 (Sigma).  The cell lysate (5µg of protein) was then incubated 
in PCR 8-strip tubes (VWR 3925-550-000), in a cooling block with 2µl of reaction 
buffer (250µl of 1M Tris, 1µl 1M DTT, 20µl of 1M magnesium chloride, 729µl MilliQ 
water) and 2µl of 250µM PARG inhibitor (Calbiochem 118415), the main enzyme 
responsible for degrading PARP. MilliQ water was added to ensure a final volume of 
8µl/sample. 
1µl of 1mM NAD (Sigma) solution was mixed with 1µl of DNA stock solution. DNA 
stock solution was made using 2 oligonucleotides which have been shown to activate 
PARP611. The DNA stock solution was made by adding equal amounts of the 
oliconucleotides to a buffer (100mM NaCl, 10mM Tris pH=7.4, 1mM EDTA pH=8) 
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and then diluted to a final concentration of 100ng/µl. The solution was then boiled 
and left to cool at room temperature. 
The NAD/DNA mix was added into the lids of the PCR strip, the lid was closed and 
the strip spun down to start the reaction. The strip was then transferred to a pre-cooled 
PCR block, which was heated up to 30OC for 5 minutes and then cooled to 4OC ready 
for use. 150µl of ELISA buffer (PBS with 2% BSA) was added and mixed.  
A commercial ELISA kit (HT PARP in vivo Pharmacodynamic Assay II, Trevigen 
cat# 4520-096-K) was then used to quantify PARP. Serial dilutions from a supplied 
PAR standard were performed to generate PAR standards. 50µl of the standards were 
added in triplicate to the first 3 rows of the plate. Then 50µl of samples and 50µl of 
Jurkat Cell lysate standards (as a positive control, and to monitor assay drift between 
experiments) were added to the plate in triplicate. The plate was covered with sealing 
film and left overnight to equilibrate. The plate was then washed 4 times with PBST 
solution and 50µl of diluted ‘PAR polyclonal detecting antibody’ was added to each 
well and the plate was incubated for 2h. After incubation, the plate was washed 4 
times in PBST. 50µl of diluted goat anti-rabbit IgG-HRP conjugate was then added to 
each well and the plate was incubated at room temperature for 60 minutes. After this 
incubation the plate was washed a final time. ‘PeroxyGlow’ A+B solutions (supplied 
with the kit) were mixed and 100µl of this solution was added to each well and the 
chemiluminescent readings were taken immediately.   
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Results	   	  
Baseline	  characteristics	  
The groups did not differ in terms of weight, serum creatinine, serum urea, serum 
phosphate, serum calcium, serum albumin, haematocrit and plasma bicarbonate (see 
Figure 51 and Table 15). There was no difference in initial blood pressure or heart rate 
between the 2 groups. Both groups were similar in terms of left ventricular weight and 
LV weight expressed as a percentage of body weight, which is a surrogate marker for 
LVH.  
Infarct	  size	  and	  troponin	  estimation	  	  
There was no difference in tissue injury as measured by infarct size or troponin 
quantification between the 2 groups (see Table 15 and Figure 49). Infarct size was 
52.0% and 53.3% for the vehicle and AZ12785452 treated groups respectively. While 
the AAR was not significantly different, there was a trend towards a larger AAR in the 
AZ12785452 treated group (48.0 v 53.01, p=0.07). Serum troponin concentration 
corrected for weight of infarcted tissue was similar between the 2 groups, with means of 
437 ng/ml/g and 402 ng/ml/g in the vehicle and AZ12785452 groups respectively. 
Cardiovascular	  parameters	  	  
There were no significant differences between the MAP, heart rate or pressure rate 
product between the 2 groups (see Figure 50).  
Histology	  	  
The histological changes associated with AMI reperfusion injury in both vehicle and 
AZ12785452 treated animals were analysed (see Image 6). There was evidence of 
neutrophil infiltration, oedema accumulation, fibrin accumulation, myocyte necrosis 
and haemorrhage. The samples were scored qualitatively on 5 aspects of myocardial 
injury (see Table 16). All samples had evidence of all variables.  
Samples were also stained using immunohistochemistry for the presence of PAR (see 
Image 7). Neutrophils, both intravascular and intermyocyte, were seen to stain 
strongly for PAR in both groups. There was a light staining of myocytes in areas of 
infarction/inflammation but this was also seen in the negative isotype control 
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indicating non-specific binding. Areas of leak, oedema and intravascular thrombi/red 
blood cells showed some light staining but again, this was seen in both the positive 
and the negative sections. There was no difference in PAR staining between the 
vehicle and AZ12785452 treated groups. 
Analysis	  of	  PARP	  activity	  in	  PBMC	  sample	  	  
PAR is the product of the PARP enzyme, and its concentration in this assay is 
proportional to underlying PARP activity.  In this experiment (see Figure 49 A), 
there was a trend in reduction in PAR concentration in the AZ12785452 treated animals 
compared to vehicle treated animals (mean 2.85 v 2.03 pg/ml), but this did not reach 
statistical significance (p=0.33).  
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Vehicle (n=13) AZ12785452 (n=16) P value
Weight (g) 415.2 (24.4) 406.4 (24.5) 0.35
MAP (mm/hg) 151.6 (22.2) 155.5 (19.0) 0.62
Pulse (BPM) 398.5 (34.6) 422.4(48.5) 0.16
Hamatocrit (%) 31.77 (3.24) 32.25 (2.67) 0.65
Bicarbonate (mmol/l) 28.47 (4.08) 27.42 (3.00) 0.44
Creatinine (µmol/l) 86.86 (18.18) 82.61 (16.93) 0.54
Urea (mmol/l) 17.88 (3.50) 17.68 (4.33) 0.9
Albumin (g/l) 25.1 (1.38) 24.91 (2.01) 0.78
Calcium (mmol/l) 2.6 (0.11) 2.61 (0.145) 0.84
Phosphate (mmol/l) 1.84 (.018) 1.80 (0.23) 0.57
LV weight (g) 1.45 (0.20) 1.40 (0.15) 0.17
LV weight/body weight 0.359 (0.05) 0.345 (.043) 0.41
Infarct size (%) 52 (17.5) 53.3 (22.2) 0.86
Area at risk (%) 48 (10.51) 56.01 (12.07) 0.071
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Figure 49. A: results of PAR ELISA, corrected for protein loading. B results of Troponin 
ELISA corrected for weight if infarcted tissue. 
Table 15. Results of reversible LAD ligation a SNx rodent model. All values given 
as mean (SD). All samples normally distributed as confirmed by the Shapiro-Wilk 
normality test and the D'Agostino & Pearson omnibus normality test. p value 
presented as results of unpaired 2 tailed T test using GraphPad Prism 5 software. 
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Figure 50. Graphs showing differences in MAP (top), heart rate (middle) and pressure 
rate product (bottom) over time between the vehicle treated group and the AZ12785452 
group. Graph shows mean with SEM as error bars. 
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Figure 51. Results following reversible LAD ligation in a uraemic rodent model of acute myocardial 
infarction. Rats were either given AZ12758452 (n=13) or vehicle (10% DMSO) (n=16). 
Bar graphs showing mean with SEM as error bar.   
A:  The AAR at risk is similar between the 2 groups. B: Infarct size is similar between the 2 groups. C: 
Serum creatinine measured before myocardial ischaemia is size is similar between the 2 groups. D: Serum 
urea measured before myocardial ischaemia is size is similar between the 2 groups. E: Serum albumin 
measured before myocardial ischaemia is size is similar between the 2 groups. 
F: There is no difference in weight between the 2 groups. 
 
 219 
!" #"
$"%"
&"
'"
'"
&"
Image 6. H+E staining of uraemic myocardium following reversible LAD ligation experiment. A: 
Pericardial neutrophilia in right ventricular wall. B: → indicate areas of oedema and fibrin accumulation. 
C: → indicates areas of myocyte necrosis. D: → indicate neutrophils in blood vessels, § indicate 
intermyocyte neutrophils, ‡ indicate areas of haemorrhage. 
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Image 7. Myocardium stained using immunohistochemistry for PAR. A: Low power view of myocardium 
stained for PAR: ‡ inflammatory cells staining strongly for PAR, → weak staining of myocytes. B: Low 
power view of myocardium stained with isotype control.‡ No staining of inflammatory cells, → weak 
staining of myocytes. C: High power view of myocardium stained for PAR. ‡ inflammatory cells staining 
strongly for PAR. D: high power view of myocardium stained with isotype control.‡ No staining of 
inflammatory cells. 
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Vehicle (n=6) AZ12785452 (n=6) p
Pericardial neutrophilic inflammation 6 6 ns
Myocardial neutrophilic inflammation, periphery of left ventricle wall 6 6 ns
Myocyte degeneration and necrosis, left ventricle wall 6 6 ns
Intermyocyte oedema and fibrin accumulation 3 6 0.18
Haemorrhage, left ventricle wall 6 6 ns
Table 16. Qualitative measurement of histological features of myocardial injury following a reversible LAD 
experiment. Data are shown as number of rats (n=6 in each group). There was no significant difference 
between the groups using a 2 tailed Fishers exact test, performed by GraphPad software. 
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Discussion	  
 
This experiment sought to use a PARP-1 inhibitor as a pharmacological 
postconditioning strategy to reduce myocardial reperfusion injury in the context of 
uraemia. 
Histology	  
Myocardial infarction generated neutrophilic inflammation in the pericardium and in 
the myocytes of the left ventricular wall, along with degeneration and necrosis of the 
myocytes in the left ventricular wall. Pre-reperfusion infusion of AZ12785452 did not 
appear to affect this pathology.  Anti-PAR antibodies stained the inflammatory cells 
strongly but not the myocytes. Non-specific staining of the inflammatory cells was 
excluded using the isotype control antibody. Infusion of AZ12785452 did not appear 
to affect the staining of PAR. 
PAR	  ELISA	  
AZ12785452 infused at a rate of 1mg/ml resulted in a non-significant reduction in 
PAR concentration.  The failure of the PAR ELISA to detect a significant inhibition 
of PARP could be due to inherent variability associated with the technique, which 
requires multiple complex steps resulting in high levels of variability and leading to a 
type 2 error. This could be improved with greater sample numbers. It was not possible 
to generate multiple PBMC samples from the experiment because the delineation of 
the area at risk using Evans blue dye requires a significant cardiac output. If large 
volumes of blood were withdrawn before harvesting, the cardiac output and blood 
pressure would be too low to satisfactorily perfuse the myocardium and hence stain 
the perfused area. This would lead to an overestimation of the non perfused area 
which would in turn lead to an underestimation of the infarct size, since some 
perfused tissue would be misclassified into viable non-perfused tissue. As a result,  
only relatively small volumes of blood could be withdrawn before harvesting and this 
in turn meant that only 1 small PBMC pellet was produced from each rat.  
The lack of PARP inhibition could also be because AZ12785452 did not inhibit 
PARP. However, the same batch of AZ12785452 was used by Kapoor et al.  in our 
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lab (see Figure 52), in their unpublished work on non uraemic animals, which resulted 
in tissue protection and therefore, this is an unlikely explanation.  
This experiment suggests that AZ12785452 infused at a concentration of 1mg/ml did 
not confer cardioprotection, as measured by serum troponin, histological scoring or 
infarct size in a uraemic rodent model of reversible LAD ligation. There are several 
possible explanations for this unexpected result.  The first is that the concentration of 
AZ12785452 given may not have been optimal. The dose used was chosen based on the 
best available evidence. AZ12785452 has been shown in our lab to be cardioprotective 
in a rat model of reversible LAD ligation. Kapoor et al. investigated AZ12785452 
induced cardioprotection in the non-uraemic rat. Several concentrations of 
AZ12785452 were given to identify the optimal cytoprotective protocol. Infusion of 
0.04mg/ml and 4mg/ml did not result in cardioprotection. Concentrations of 
AZ12785452 of 0.2mg/ml and 1mg/ml protected the myocardium with 1mg/ml giving 
the greatest degree of protection. Therefore, this was the reason the concentration of 
1mg/ml was chosen in the experiments involving uraemic rats. However, the 
experimental protocol and rat phenotype used by Kapoor et al. differed from this work  
(see Table 17). The rats used in work done by Kapoor et al. were younger (6-7 weeks 
vs. 11-12 weeks) and weighed less (285g vs. 425g). They had not undergone a 2 stage 
SNx procedure, and were therefore not uraemic. The duration of ischaemia was 25 
minutes in work done by Kapoor et al, rather than the 30 minutes as in this work. The 
initial plan for the experimental protocol had been to employ a 25-minute ischaemic 
phase with a 120-minute reperfusion period. However, analysis of the first 6 uraemic 
rats that underwent LAD ligation (5 treated with vehicle and 1 with AZ12785452) 
revealed a median infarct size of 46.4 (IQR: 24.9-67.8) with a median AAR of 55.2% 
(IQR: 46.6-65.9). This infarct size was lower than in past experiments. Given that 5/6 
rats were given vehicle and that the hypothesis was that AZ12785452 would lead to 
cardioprotection it was felt that to have the best chance of detecting a protective effect 
of AZ12785452 the injury should be increased. To do this, the ischaemia time was 
lengthened to 30 minutes. 
Kapoor et al. demonstrated that there is a complex relationship between AZ12785452 
concentration and cardioprotection. At small doses, no cardioprotection was seen. It is 
easy to surmise that at these dosages not enough PARP was inhibited at the time of 
reperfusion to cause a difference in protection. At higher doses, more PARP was 
inhibited and cardioprotection was seen. However when AZ12785452 was given at 
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the highest concentration of 4mg/ml, the cardioprotection was lost. It is difficult to 
imagine how inhibiting PARP more fully would lead to less protection. Unless at high 
concentrations despite inhibition of PARP, AZ12785452 led to increased injury due 
to a different toxic effect. Thus it may be that in uraemic animals, the threshold for a 
toxic dose is lower than in non uraemic animals, or the threshold for a cytoprotective 
response is higher than in non uraemic animals. To fully explore the tissue protective 
effects of AZ12785452, further studies should be considered using different 
concentrations of AZ12785452. 
A further possible explanation of this result could be due to N-methyl-2-pyridone-5-
carboxamide (2-PY), which has been shown to be an endogenous inhibitor of PARP 
whose concentration is inversely proportional to renal function. This would suggest 
that renal failure is associated with a state of endogenous PARP inhibition, and that 
any additional exogenous PARP inhibition may not be as effective. This could 
provide a further reason why the dose response relationship for AZ12785452 may be 
different in uraemia. There are several problems with this argument. Firstly, the thrust 
cardiovascular research in the context of CKD over the last 40 years has repeatedly 
demonstrated that underlying CKD is potent risk factor for cardiovascular disease. 
Additionally, if 2-PY significantly inhibited PARP at concentrations seen in the SNx 
model then it might be expected that the uraemic myocardium would have a greater 
ischaemia tolerance than the non uraemic myocardium; a phenomenon which has 
been disproved by us (see results section page) and others307. Finally, despite a much 
larger sample size in the uraemic animal experiment  (13 and 16 in each arm) 
compared to work done by Kapoor (n=8 in each arm), there was much greater 
variability in the baseline characteristics of the uraemic animals. The blood pressure, 
pulse and PRP data had significantly greater variability in the uraemic group (see 
Table 17). There was also significantly greater variability in the AAR and infarct 
sizes in the uraemic animals when compared to the non uraemic animals. Kapoor et 
al. found that at a concentration of 1mg/ml, AZ12785452 caused a relative reduction 
in infarct size by 21.3%. If AZ12785452 conferred an equal reduction in uraemic 
animals, then at this level of variability the number of animals (m) needed in each arm 
to have an 80% power to detect a relative risk reduction of 21.3%, with a p value of 
5% is given by the formula612 
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include (a) the number of participants you can reasonably expect to recruit in the given time
period within available resources, and (b) mathematical calculation. The final figure calculated
indicates the minimum number of participants required to reliably answer the research question.
There are many packages dedicated to performing sample size/power calculations. It is often
possible to perform such calculations within standard statistical software, and stand-alone
packages are available for this purpose (for details of these, see sample size software). However,
if you do not have access to any dedicated packages, the examples listed below will possibly help
you to do your own calculations by hand. We have included the most commonly encountered
clinical trial scenarios - the comparison of two equal-sized, concurrently studied groups where
the primary outcomes are either proportions (e.g. percentage responding to treatment) or means
(e.g. average blood pressure). The methods listed below are extracts from Mark Woodward’s
book (see reference texts), which includes a whole chapter on sample size determination.
One of the most important decisions to make before calculating a sample size is to define a
clinically important treatment effect, ! (or delta), which should not be confused with a
statistically significant treatment effect – neither one implies the other and the distinction
between them is important. Of course, since you are embarking on a study, you would expect
your new intervention to be an improvement, but can you estimate by how much reliably or
realistically? If not, another way to come up with an estimate is to consider what observed
treatment effect would make you change your current clinical practice. For example, if your trial
was looking at a treatment to lower blood pressure, you might argue that an average lowering of
systolic BP of 5mm Hg is clinically important; however, you might decide that an average
lowering of systolic BP of 10mm Hg would be clinically important and necessary before you
would possibly think about prescribing this treatment.
Before proceeding, you also need to set two parameters:
1. the statistical significance level, alpha ( "), typically 5% (sometimes written " =0.05);
also known as the false-positive rate.
2. the power – adequate power for a trial is widely accepted as 0.8 (or 80%). Power is
defined as 1- #, where # , the false-negative rate, in this case would be 0.2 (or 20%).
Where the primary outcome is a (continuous) measurement such as blood pressure, you also need
an estimate of the natural variability in the population, usually the standard deviation, s.
top
Basic formula
The number of participants required in each intervention group, m, is given by:
                                                                             2
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where z(1- " /2) and z(1- # ) represent percentage points of the normal distribution for statistical
significance level and power, respectively (see Table 1 for typical values), and $ represents the
standardised difference (i.e. the treatment difference divided by its standard deviation).
 
 
 
Where δ is the effect size (absolute difference in infarct size =11.08%), s is the 
standardised difference, Ζ(1-α/2)  is the significance level (1.96) and Z(1-β) is the power 
(0.8416), m= 50.4. 
Thus to demonstrate a 21% relative infarct size reduction with a mean SD of 19.9 
would require over 100 rats, which is prohibitive in terms labour and expense. 
This variability strikes at the heart of translational research. As research seeks to 
better represent human disease through animal models, more complex development of 
animal models are needed. This complexity generates variability, requiring a much 
larger sample size to show a difference. This variability in baseline characteristics 
rather than being a hindrance in animal work, perhaps is merely an indication of a 
better model of human disease, with the same inherent variability seen in clinical 
studies.  
Future	  directions	  for	  study	  
1) A different concentration of AZ12785452 should be tried, to exclude a different 
dose response effect in uraemic animals. 
2) Use of different PARP inhibitors in the SNx model, such as 3-aminobenzamide, 
which has been widely reported to inhibit PARP and cause cardioprotection in 
rodents, or INO-1001which has been studied in a phase 2 clinical trial in humans 
in the setting of AMI. This would confirm that that the loss of cardioprotection is 
not specific to AZ12785452. 
3) The impact of chronic PARP administration to SNx animals. Given that the SNx 
procedure leads to an inflammatory state with renal fibrosis and 
glomerulosclerosis, PARP inhibition may protect against this progressive cardiac 
phenotype. This would be akin to the work done in the diabetic animal models 613-
616.  
!"#$#%!%&'%(&)#*%+,%-"#%./$0123%
 226 
 
 
 
 
 
 
 
 
 
Figure 52. Results of unpublished work performed by Dr Kapoor, Dr Patel and Professor 
Thiemermann: researchers in our group. (A)Area at risk and (B) infarct size of rats subjected to 
regional myocardial ischaemia  (25min) and reperfusion (2h) and pre treated with either vehicle 
(control, 10 % DMSO 1ml/kg i.v.,(n = 8), or 2 cycles of IPC (5 min) followed by LAD occlusion 
(25min) and reperfusion (2 h) and pre-treated with vehicle (IPC, 10% DMSO 1 ml/kg i.v.,  n = 8), or 
rats subjected to regional myocardial ischaemia (25 min) and reperfusion (2 h) and pre-treated with 
AZ12785452 (0.04 mg/ml i.v., n = 8); AZ12785452 (0.2 mg/ml i.v., n = 8); AZ12785452 (1 mg/ml 
i.v., n = 8) or AZ12785452(4mg/ml i.v., n=8). P<0.01 vs. control Group, P<0.001 vs. control Group. 
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A
Kapoor et al (n=48) SNx Animals (n=29) p F test
Weight (g) 282 (40) 410 (24) <0.0001 **
MAP (mm/hg) 107 (24.5) 122.7 (36.68) 0.02 **
Pulse (BPM) 420 (36.7) 411(38.7) 0.28 ns
PRP 57951 (28995)  51826 (17608) 0.26 **
AAR (%) 54.5 (8.3) 52.4 (11.9) 0.37 *
B
Kapoor et al (n=8) SNx animals* p F test
Vehicle 68.5 (4.4) 52 (17.51) 0.02 **
AZ12785452 53.88 (7.2) 53.3 (22.2) 0.948 **
Table 17. 
A: comparison of Kapoor et al. data with SNx data in terms of weight, MAP, pulse, pressure rate product 
and area at risk. SNx animals are heavier and have higher MAP (at occlusion). Importantly there is 
greater intra-group variability in the SNx animals AAR, MAP, PRP. There is a greater variability in 
weight in the Kapoor et al data.  
  
B: comparison of Kapoor et al data with SNx Data. Kapoor et al: infarct size of non uraemic 6-7 week 
old male Wistar rats undergoing 25 minute LAD ligation, with infusion of either vehicle (n=8) or 
AZ12785452 (n=8) with 2h reperfusion. SNx animals: infarct size of 11-12 week old male Wistar rats  
who have undergone a 2 stage SNx procedure to generate a model of chronic uraemia who then 
underwent 30minutes of LAD ligation , with infusion of either vehicle (*n=13) or AZ12785452 (*n=16) 
with 2h reperfusion. The 2 groups treated with AZ12785452, had similar infarct sizes, however the non 
uraemic vehicle treated group had a significantly larger infarct size than the SNx group. There was 
significantly greater variability of infarct size in the SNx groups compared with the Kapoor et al. data. 
 
Data in cells represent mean (SD), p value shown is a result of an unpaired 2 tail T-test. F test results 
show if the standard deviations are significantly different. Statistical analysis performed by GraphPad 
Prism 5. 
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Summary and Conclusions 
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Summary  
The results of described in this thesis can be summarised as follows: 
Characterisation	  of	  animal	  models	  of	  uraemia	  
3 models of rodent models of chronic uraemic were developed: the SNx model, the 
adenine diet model and the adenine washout model. All 3 models displayed many 
features of the human uraemic phenotype; anaemia, raised serum creatinine, raised 
serum urea, proteinuria, natriuresis, reduced weight gain, increased heart weight index 
and growth restriction.  
Myocardial	  ischaemia	  tolerance	  of	  the	  uraemic	  heart	  
The SNx model, but not the adenine diet model of chronic uraemia resulted in 
reduced myocardial ischaemia tolerance in a model of reversiable LAD ligation. No 
underlying differences in bioenergetics were found between these models to explain 
the observed difference in ischaemia tolerance. 
Ischaemic	  preconditioning	  of	  the	  uraemic	  heart	  	  
This work demonstrated that an IPC protocol confers  a profound reduction in infarct 
size and arrhythmias. This experiment reported the novel finding that unlike 
dyslipidaemia and senescence, underlying uraemia did not abolish the effects of 
postconditioning as measured by infarct size and troponin release in 3 different rodent 
models. In addition, underlying uraemia did not confer an increased resistance to IPC. 
The role of the RISK and SAFE pathways in the intracellular signal transduction 
cascade of IPC were confirmed, along with the finding that underlying uraemia did 
not appear to significantly alter these pathways. 
Ischaemic	  postconditioning	  of	  the	  uraemic	  heart	  
This experiment reported the novel findings that unlike senescence and diabetes, 
underlying uraemia did not abolish the effects of postconditioning as measured by 
infarct size and troponin release. 
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The	  effect	  of	  the	  effect	  of	  AZ12785452:	  a	  PARP-­‐1	  inhibitor	  in	  an	  SNx	  rodent	  
model	  of	  myocardial	  infarction	  
Infusion of AZ12785452 immediately before reperfusion such that it acts at the point 
of reperfusion and as such acts as a pharmacological postconditioning mimetic, in a 
uraemic rodent model of AMI did not result in an alteration of reperfusion injury as 
measured by NBT staining, troponin release or histological analysis.  
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The	  failure	  and	  future	  of	  translation	  of	  ischaemic	  conditioning	  
For an intervention to have a good chance of clinical translation, an intervention 
should be effective in all species studied and can be replicated in different laboratories 
and in different experimental models. Conditioning strategies (IPC, RIPC, iPOST) 
represent ideal interventions, which fulfil all of the above criteria, and yet in the 25 
years since IPC was reported, these procedures have not become part of routine 
clinical practice. 
The apparent simplicity of the induction of ischaemic conditioning is a double-edged 
sword.  As ischaemic conditioning cannot be patented by a pharmaceutical company, 
researchers employing ischaemic conditioning can save time and money because 
there are no associated drug costs and less pharmaceutical regulations are involved. 
This has lead to a rapid translation of small, single centre trials, which while they 
have almost been universally positive, have lacked the duration and size to provide 
clinicians with the evidence they need to change their practice. 
Pharmaceutical companies are unlikely to fund large trials in ischaemic conditioning 
if there is no profit for their shareholders. Without this industry funding, ischaemic 
conditioning trials have generally been small and underpowered for the mortality 
outcomes needed to force a change in routine clinical practice.  
This thesis suggests that the ideal cohort to study novel therapeutic cardioprotective 
strategies are CKD patients. They are a group of patients hugely burdened by 
cardiovascular disease, with much poorer outcomes following  cardiovascular events 
and who have been routinely excluded from clinical trials in cardioprotective 
strategies. Through reduced ischaemia tolerance, they are at risk of greater tissue 
injury for a given insult. Several standard therapies used for the general population 
have been shown to be less effective or even harmful in the CKD/ESRD cohort.  
This thesis concludes that underlying CKD is not a barrier to ischaemic 
preconditioning or ischaemic postconditioning, making  it an attractive intervention in 
the context of CKD.  
Future work should focus on optimisation of ischaemic conditioning protocols to 
achieve greater tissue protection, including the use of combinations of conditioning 
strategies such as IPC combined with iPOST or pharmacological conditioning 
combined with IPC. I have performed preliminary work in this area using 2 RIPC 
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signals 24 hours apart to investigate whether summation of early and late RIPC can 
achieve greater tissue protection than early RIPC alone in a model of AKI (see 
supplementary data page 234-254). 
Finally future work should focus on translation of these findings into a human CKD 
and ESRD cohort. The first step in the widespread translation of ischaemic 
conditioning needs to involve a small ‘proof of concept’ trial in CKD and ESRD 
patients. A suitable model would be the forearm flow medicated vasodilatation model 
which is relatively simple and non invasive. This can be followed by larger 
intervention studies aimed at recruiting haemodialysis patients undergoing an elective 
PCI intervention followed by investigation of the role of iPOST in the setting of acute 
myocardial events. These trials could be much more powerful than trials in non CKD 
patients because CKD patients have 7 times the event rate following AMI, and thus 
smaller trials could still be powered for cardiovascular mortality. 
Taken together, CKD patients have the most to lose from cardiovascular disease and 
this thesis suggests that through novel cardioprotective strategies they may also have 
the most to gain. 
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Supplementary Data 
The use of Summation Remote Ischaemic 
Preconditioning to Protect the Kidney from 
Ischaemia/Reperfusion injury 
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Background	  
Ischaemic preconditioning was first described by Murry et al388 as a phenomenon which 
conferred tissue protection immediately after the preconditioning stimulus. This 
cytoprotective effect was temporary, with loss of protection seen if there was a delay of 
several hours between preconditioning protocol and injury. 6 years after Murry’s 
seminal paper, Marber et al.396 published work which demonstrated a ‘second window’ 
of tissue protection, which began 12-24 hours after the preconditioning stimulus and 
lasted for 24-48 hours. Remote ischaemic Preconditioning (RIPC) was first described 
by Przyklenk et al in 1993617. They described the phenomenon whereby several brief 
episodes of ischaemia and reperfusion in the circumflex artery in the dog could confer 
subsequent tissue protection on the territory supplied by the LAD artery.  This form of 
intramyocardial tissue protection was subsequently extended to non cardiac organs, 
such as the kidney377, small intestine618, liver618, skeletal muscle619 and brain620. Li et 
al.621 also showed that the second window exists for remote preconditioning. The group 
showed that the heart could be protected from lethal ischaemic injury using a RIPC 
protocol involving 3 cycles of femoral artery occlusion and reperfusion 24 hours before 
the index ischaemia.  This protection is broadly similar in magnitude to an IPC protocol 
(employing 3 cycles of 5 minutes LAD occlusion and reperfusion) employed 
immediately before the index ischaemia622.  Delayed remote preconditioning has 
notable benefits over standard IPC because the target organ does not need to be 
rendered ischaemic to confer protection, and because the window of protection is 
larger, the precise timing of the injury is less crucial. 
Mechanisms	  of	  delayed	  tissue	  protection	  from	  remote	  preconditioning	  
The mechanism by which RIPC confers tissue protection is not as fully understood as 
that of IPC or iPOST, and even less is understood about the different aspects of early 
and late remote preconditioning. The signal transduction of RIPC stimulus is complex. 
The signal has to get from the remote organ to the tissue of interest and then from the 
cell surface to the mitochondria. There are 2 different mechanistic pathways which are 
thought to exist to transfer the signal from the remote organ to the organ of interest; the 
humoral and neural pathway.  
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Humoral	  Pathway	  
The humoral pathway consists of a mediator, which is produced in response to several 
sub lethal episodes of ischaemia in a distant tissue bed, which is then transported via the 
circulation to the target organ.  Evidence in favour of this pathway comes form work 
which shows that reperfusion is required to ‘washout’ the substance to generate a 
signal623, along with work by Dickenson et al.624, which showed that the coronary 
effluent from an isolated preconditioned rabbit could reduce infarct size in an untreated 
isolated rabbit heart. Studies have sought to identify the humoral mediator, or 
mediators, responsible for the signal transduction of RIPC. Evidence from proteomic 
analysis of tissue effluents suggest that the factor is between 3.5-8kDa625, 626. While the 
composition of the mediator still remains unknown, several candidate molecules have 
been implicated in the inter organ signal transduction of RIPC, including opioids627, 
endocannabinoids628, noradrenaline629 and angiotensin630.  
 
Neural	  Pathway	  
Evidence in favour of a neural pathway comes from work by Gho et al.618 who 
demonstrated that myocardial protection following anterior mesenteric artery RIPC 
could be abolished by hexamethonium, a ganglion blocker. It was proposed that 
compounds released in response to brief periods of IR, stimulate afferent nerve fibres to 
transmit the signal to the target organ. Compounds which stimulate afferent nerves in 
response to brief periods of ischaemia leading to tissue protection, are thought to 
include adenosine, bradykinin and calcitonin gene-related peptide (CGRP). The role of 
adenosine as a mediator in the neural pathway comes from data by Ding et al.375 who 
showed that when the kidney was used to precondition the heart there was increased 
afferent renal nerve discharge. This was blocked by a selective adenosine antagonist, 
abolishing cardiac protection. Furthermore, sectioning the renal nerves before renal 
preconditioning also blocked the cardioprotective effect of renal RIPC on the heart. 
Liem et al.376 reported that local administration of adenosine into a mesenteric vascular 
bed conferred subsequent cardioprotection, which was blocked by hexamethonium. The 
role of bradykinin in RIPC is suggested by data which show that intra-mesenteric 
administration of bradykinin acted as an RIPC mimetic and that this effect was 
abolished in the presence of hexamethonium631.  
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Evidence for the role of CGRP in transduction of the RIPC signal comes from work 
which shows that RIPC stimulates sensory nerves in the intestinal vasculature to secrete 
CGRP into the blood-stream where it is carried to the heart632, 633. To summarise, 
mediators may be released into the blood stream and carried to a distant organ, 
mediators may be generated locally which stimulate afferent nerves to send a pro-
survival signal to the distant organ or finally preconditioning stimulates nerves to 
release factors into the blood stream.  
Intracellular	  signal	  transduction	  cascade	  
Once the mediators reach the cell surface, it is thought that they bind to G-protein cell 
surface receptors. Unlike IPC or iPOST, the intracellular signal transduction cascade 
from cell surface to the mPTP is unclear, but it appears to involve a similar cohort of 
compounds including the KATP channel634, nitric oxide635, ROS636, PKC633 and finally 
the mPTP637. 
Delayed	  RIPC	  
There is very little data specifically concerning late RIPC. However, it appears to be 
effective in humans in the flow mediated vasodilation model of endothelial function638. 
In rats, hind limb RIPC attenuated myocardial injury 24 hours later622. In the kidney, 
there is evidence that pharmacological late preconditioning can reduce tissue injury 
during experimental renal transplantation using the KATP channel opener, ciclosporin639. 
Summation preconditioning strategies 
Early and late pathways of preconditioning are thought to be mechanistically distinct, 
because of this research has been undertaken to identify whether these 2 stimuli can be 
combined to produce even greater tissue protection. Stambaugh et al.640 showed that an 
in vitro model of simulated myocardial ischaemia, combining early and late 
‘preconditioning’ strategies using adenosine agonists and KATP  channel openers to 
achieve early preconditioning and monophosphoryl lipid A to induce late PC, resulted 
in greater cellular protection than early PC alone.  
In vivo work by Sato et al.641 showed that combining iPOST with delayed IPC resulted 
in greater tissue protection following myocardial infarction than with either alone, and 
that the additional protection seen with delayed IPC could be abolished with a COX 2 
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inhibitor. Mullenheim et al.642 found that employing an IPC protocol to a rabbit heart 
resulted in tissue protection 24 hours later.  This protective effect could be improved 
with the addition of sevoflurane, an agent known to precondition, via opening of the 
KATP channel. This effect was abolished with the KATP channel blocker, 5-
hydroxydecanoate642. Furthermore, they reported that combining early and late IPC 
protocols protected the myocardium better than either alone643. Xin at al. reported that 
combining iPOST with remote preconditioning provided greater protection than either 
alone644. 
Clinical	  translation	  of	  Summation	  preconditioning	  
All published work on summation preconditioning has been focused on the 
myocardium as the target tissue. There has been no work on whether the kidney can 
achieve extra benefit through summation. This question is of clinical relevance 
particularly in the field of renal transplantation.  During harvesting, the kidney is 
exposed to both warm ischaemia during retrieval, and cold ischaemia during 
transportation of the organ and storage before it is exposed to reperfusion injury in the 
recipient following restoration of perfusion645. Ischaemia reperfusion injury at the time 
of transplantation is an important factor in both the short term outcome, with respect to 
delayed graft function646, and also long term graft outcome645-647. Remote 
preconditioning has been shown in a small trial to be effective in reducing renal injury 
in the transplant setting, with evidence of a sustained benefit in renal function to 24 
months648. Human clinical trials are in progress to investigate the effect of remote 
preconditioning in the context of cadaveric organ donation with the aim of reducing the 
effect of IRI to the kidney inherent in the procedure of renal transplantation.649 The 
Repair Trial648, a randomised multicentre trial currently recruiting, is investigating the 
effects of early, late and combined early and late RIPC on the outcome of live kidney 
donation. It is currently unknown whether the additional renal protection can be 
achieved by adding delayed remote preconditioning to classical early remote 
preconditioning. 
 
 239 
Aims	  
The aim of this experiment was to establish whether combining early and late RIPC 
strategies provided additional benefit over early RIPC alone in a rat model of AKI. 
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Methods	  
Forty five, six week old male Wistar Rats (Charles Rivers UK) were housed in an 
animal house with a 12 hour day night cycle and free access to water and standard chow 
for 1 week.  
All animals were anaesthetised using 100mg/kg ketamine (Fort Dodge animal Health) 
and 10mg/kg xylazine, (Rompun Bayer) injected intraperitoneally together with 
0.01mg/kg of Vetergesic S/C. All surgery was carried out under full aseptic conditions, 
on a homoeothermic control mat (Harvard). 
Once anaesthetised the fur over the left groin was shaved and a 5mm incision was made 
over the left femoral area. Blunt dissection through the muscle layers revealed the 
femoral neurovascular bundle. The femoral artery was isolated without damage to the 
nerve or vein, and a sterile tie (3-0 Sofsilk Syneture) was placed round the artery for 
easy identification at a later stage. The animals then were split into 3 groups  (see 
Figure 53). Group 1 and 2 were left for 30 minutes before the skin was closed using 
skin staples (3M Precise). This was a sham preconditioning protocol. Group 3 
underwent a preconditioning protocol; the femoral artery was reversibly occluded using 
an arterial clip for 5 minutes with 5 minutes reperfusion. This procedure was repeated 3 
times. Ischaemia to the hind leg was confirmed with the observation that the left foot 
became paler and colder than the right and upon reperfusion there was a dramatic 
reactive hyperaemia of the foot. All rats were then left to recover. After 48 hours, the 
rats were then anaesthetised as before. Group 1 underwent a sham preconditioning 
protocol as before, group 2 and 3 underwent a preconditioning protocol, using 3 cycles 
of 5 minutes left femoral artery occlusion and reperfusion. Following this, all animals 
had their fur over their abdomen shaved and a midline laparotomy incision was carried 
out using blunt tipped scissors. The small intestine was carefully pushed towards the 
animals left flank to expose the right kidney. The right kidney was decapsulated and 
mobilised. Sterile ties were placed around the renal pedicle and tied off. The right 
kidney was then rapidly removed. The left kidney was then exposed. The renal artery 
and vein were carefully dissected away from the surrounding tissue and an arterial 
clamp was used to occlude the renal artery. The left kidney underwent 45 minutes of 
ischaemia, which was confirmed with the observation of renal pallor. At the end of 45 
minutes, the clamp was released and reperfusion was confirmed with the observation of 
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prompt hyperaemia of the kidney. The abdominal musculature was then closed using 
suture (4-0 Polysorb Synture) and the overlying skin stapled with skin sutures. The 
animals were then left to recover, with close monitoring for signs of distress or 
suffering. 
After a further 48 hours the animals were anaesthetised using an IP injection of sodium 
thiopental at a dose of 58mg/kg (Link Pharmaceuticals). This was a smaller dose of 
anaesthetic than in previous experiments because the animals were more uraemic. Once 
the animals were anaesthetised, they were placed on a homoeothermic control unit 
(Harvard) and their temperature was measured using a rectal digital thermometer. A 
tracheostomy and arterial line was inserted as in previous experiments. The animals 
were not routinely ventilated; the tracheostomy was inserted as a precaution in case of 
respiratory arrest due to the anaesthetic. Blood pressure and pulse readings were 
collected. 200ul of blood was taken in a heparinised syringe for arterial blood gas 
measurement. Additionally, 1.5ml of blood was taken and spun at 6000g for 3 minutes 
in a centrifuge, to separate the serum from the cells. The serum was removed and 
placed in liquid nitrogen for storage. The serum was sent for biochemical analysis (Vet 
Lab services UK). 
 
Histological	  evaluation	  and	  TUNEL	  staining	  
At the end of the experiment, the left kidney was quickly removed and cut in into two 
halves which were fixed in immersion in 10% (wt/vol) formaldehyde in PBS (0.01 M; 
pH 7.4) at room temperature. After dehydration using graded ethanol, pieces of kidney 
were embedded in Paraplast (Sherwood Medical, Mahwah, NJ), cut in fine (8µm) 
sections and mounted on glass slides. Sections were then deparaffinized with xylene, 
counterstained with hematoxylin and eosin, and viewed under a light microscope 
(Dialux 22; Leitz, Milan, Italy). A scoring system was performed as previously 
described by Sharples et al.650. 
One hundred intersections were examined for each kidney, and a score from 0 to 3 was 
given for each tubular profile: 0, normal histology; 1, tubular cell swelling, brush border 
loss, and nuclear condensation with up to one third nuclear loss; 2, as for score 1, but 
greater than one third and less than two thirds tubular profiles showing nuclear loss; and 
3, greater than two thirds tubular profile showing nuclear loss. The histological score 
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for each kidney was calculated by addition of all scores, with a maximum score of 300.  
Sections were also examined for inflammation, with the number of polymorphonuclear 
(PMN) cells infiltrating the tissue counted per high power field. 
Sections were assessed quantitatively for apoptotic nuclei and graded for severity and 
extent of nuclear changes. TUNEL assay was performed by a pathologist who was 
blinded to the treatment animals had received. The TUNEL assay was conducted using 
a TUNEL detection kit according to the manufacturer’s instruction (HRP kit DBA; 
Apotag, Milan, Italy). 
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Figure 53. Schematic representation of the experimental protocol. 
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Results	  
45 male Wistar rats were used in the experiment. 8 animals died before the organs were 
harvested and therefore were excluded from the analysis. No animals died during the 
femoral surgery or in the perioperative period following the renal IRI. All 8 animals 
died between 36 hours and 48 hours after the renal IRI, presumably as a result of acute 
renal failure. 1 animal in the summation group died, 3 died in the RIPC group and 4 
died in the control group. This left 11, 12 and 14 animals included for analysis in the 
control, RIPC and summation RIPC groups respectively. 
At the beginning of the experiment, the 3 groups were similar in weight (see Table 18 
and Figure 54). 48 hours following renal IRI, the anaesthetised rats in the 3 groups had 
similar cardiovascular parameters, haematocrit, serum sodium and calcium levels. On 
arterial blood gas analysis there was a stepwise trend in a lower pH in the control group 
versus the RIPC group versus the summation RIPC group, which approached statistical 
significance (p=0.07). In parallel with the pH, there was a significant stepwise 
improvement in the base deficit seen between control, RIPC and summation RIPC 
groups (p=0.05). Serum potassium was significantly higher in the control group than 
the RIPC or summation RIPC group (p<0.0001).  Serum phosphate was significantly 
lower in the summation groups compared to the control or RIPC groups (p<0.001). The 
mean urea was 73.6, 62.8 and 44.5mmol/l in the sham, RIPC and summation RIPC 
groups respectively. Both the sham and RIPC groups had significantly higher urea 
concentrations than the summation RIPC group. A similar trend was seen in serum 
creatinine concentrations in the different groups. The mean creatinine was 506, 400 and 
276 µmol/l in the sham, RIPC and summation RIPC groups respectively. There was a 
stepwise fall in serum creatinine across the groups (p<0.001). The RIPC group had a 
significantly lower mean creatinine than the control group (p<0.05) and a significantly 
higher mean creatinine than the summation RIPC groups (p<0.05). 
Histological	  analysis	  
The mean ATN score was 112, 123 and 23 out of a possible 300 for the control, RIPC 
and summation RIPC groups respectively. Both the control group and the RIPC group 
had similar ATN scores and both were significantly higher than the summation RIPC 
group (see Image 8 and Table 18). 
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Polymorphonuclear	  cell	  infiltration	  into	  renal	  tissues	  
The mean number of PMN seen per high power field was 9.8, 11.4 and 3.5 in the 
control, RIPC and summation RIPC groups respectively. Both the control group and the 
RIPC group had similar numbers of PMN infiltration and both had significantly greater 
infiltration than the summation RIPC group (see Table 18 and Image 9) 
The mean number of TUNEL+ve cells seen per high-powered field was 3.30, 3.61 and 
0.81 in the control, RIPC and summation RIPC groups respectively. Both the control 
group and the RIPC group had similar numbers of TUNEL+ve cells seen per high-
powered field and both had significantly greater infiltration than the summation RIPC 
group. 
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Table 18. Results of summation preconditioning experiment.  Data presented as mean (SD), with p 
value presented as the results of a 1 way ANOVA using GraphPad software. 
!
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Figure 54. Biochemical analysis of results following control (n=11), RIPC (n=12) or summation RIPC(n=14)  protocols. 
Data presented as mean with SEM. Statistical analysis data presented as results of one way ANOVA with Bonteferroni’s 
multiple comparison testing as a post test. All statistical analysis calculated using GraphPad software. * p<0.05, 
**p<0.01  *** p<0.001 
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Image 8. Representative photographs of renal histopathology stained with hematoxylin and eosin.  
The top row is from the control group, the middle row is from  the RIPC group and the bottom row is 
from the summation RIPC group. The left  column shows renal sections at low power, the right column 
shows the sections at high power. 
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Image 9. Representative photographs of renal histopathology stained for TUNEL positive nuclei.  
The top row is from the control group, the middle row is from  the RIPC group and the bottom row is from 
the summation RIPC group. The left  column shows renal sections at low power, the right column shows the 
sections at high power. 
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Figure 55. Histological comparison of animals undergoing a sham RIPC protocol 
followed by renal IRI: control (n=10), animals undergoing an RIPC protocol 
followed by renal IRI: RIPC (n=10) and animals undergoing a summation RIPC 
protocol and renal IRI: summation RIPC (n=10). Top: the semi-quantative ATN 
score of the 3 groups. Middle: the number of polymorphonuclear cells seen at high 
power in the 3 groups. Bottom: the number of TUNEL positive cells pre high 
power field in the 3 groups. Graphs display mean with error bars representing 
SEM. Statistical analysis was performed using the one way ANOVA test, with 
Bonteforri post test for comparison of each pair of columns. *=p<0.05, **= 
p<0.01, *** =p<0.001. 
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Discussion	  
Acute renal failure is associated with a high risk of in hospital mortality, in excess of 
>30%651, with those patients who develop the most severe degree of acute renal failure 
having both the highest short and long term mortality. Despite many advances in 
medical practice, the in hospital mortality following acute renal failure has not 
significantly altered in several decades652. Furthermore, the incidence of AKI appears to 
be increasing over time653-656. There is a great unmet need to develop cytoprotective 
strategies to prevent AKI and improve patient outcomes. There is no published 
literature on combining any form of conditioning strategy to improve outcomes 
following renal IRI. 
Acute renal failure in humans is characterised by various perturbations of plasma 
biochemistry; hyperkalaemia, hyperphosphataemia, acidaemia in the context of an 
elevated serum creatinine and urea levels. Anaemia is not a feature of AKI, it is more 
commonly seen as a marker of chronicity in kidney disease. 
48 hours after unilateral nephrectomy and contralateral renal ischaemia reperfusion 
injury, the male Wistar rats developed a phenotype which shares many features of acute 
kidney injury seen in patients; hyperkalaemia, hyperphosphataemia, acidosis, uraemia, 
with an elevated serum creatinine but with no changes in serum sodium, calcium 
plasma haematocrit. Indeed, the mean potassium in the control group was 7, which 
carries with it a high risk of lethal cardiac arrhythmias, which could explain the higher 
rate of animals death in this group, as compared to the RIPC and summation RIPC 
group. 
The choice of unilateral nephrectomy followed by contralateral renal IRI, rather than 
the more commonly used model of bilateral renal IRI, was chosen for 3 reasons. Firstly, 
performing a unilateral nephrectomy before contralateral renal IRI enables harvesting 
of the kidney for future work on identifying the mechanism of immediate and delayed 
RIPC. At the point of harvesting, the kidney taken from the control group will not have 
been exposed to an RIPC signal, allowing the tissue to act as a baseline in future 
mechanistic work. The kidney removed from the RIPC group will have been exposed to 
an immediate RIPC signal from the hind limb preconditioning protocol and the kidney 
removed from the summation RIPC group will have been exposed to both an immediate 
and a delayed RIPC signal from the 2 episodes of femoral RIPC 48 hours apart. 
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Secondly, earlier attempts at this work were performed using bilateral renal ischaemia 
and in approximately 10% of cases one of the 2 kidneys failed to fully reperfuse. This 
was seen as a dusky colouration of the whole kidney, or part of the kidney, on release of 
the clamp, rather then a prompt hyperaemia seen in normal reperfusion. The mechanism 
for this likely to be due to traumatic damage to the endothelium during the occlusion of 
the artery or embolisation of thrombus formed at the time of ischaemia down the main 
renal artery leading to no reflow injury.  The effect of this would be development of a 
greater degree of acute renal failure in those rats which had not been fully reperfused, 
which was independent of duration of ischaemia or preconditioning protocol used. This 
would contribute to increased variability, leading to an increased risk of a type 2 error. 
By removing 1 kidney and occluding the other, it halved the chances of partial 
reperfusion and so led to a reduced intra group variability. 
A further reason for performing a unilateral nephrectomy before a contralateral renal 
IRI was so generate a more severe form of renal injury than bilateral renal IRI. The 
hypothesis was that summation RIPC would provide greater tissue protection than 
RIPC alone, and much greater protection than no RIPC. If the model generated only a 
moderate injury, then immediate RIPC alone may have maximally salvaged renal tissue 
and so summation RIPC may not have any additional shown benefit.  
Finally, there was a theoretical concern that during bilateral renal ischaemia, unless the 
clamps on each renal artery were removed at the same time, one of the kidneys may 
have been exposed to a form of remote post-conditioning from reperfusion of the 
contralateral kidney, potentially leading to some degree of protection from injury for 
the second kidney to be reperfused. This again could lead to increased variability in the 
tissue injury seen 48 h later. The potential effect of remote iPOST was abolished by 
unilateral nephrectomy before renal IRI. 
This is the first time that the same preconditioning protocol modality has been 
summated to achieve tissue protection. Other published work, almost without exception 
in the heart, has combined different modalities such as pharmacological preconditioning 
with IPC or IPC with iPOST. Combining identical stimuli is the most elegant way to 
establish the effects of summation, because other studies have looked at different 
triggering stimuli it may result in different intracellular signal transduction cascades 
being activated by the different stimuli. A speculative explanation for the ability of 
delayed RIPC to provide additional benefits over early RIPC is that delayed RIPC leads 
to de-novo synthesis of anti-apoptotic proteins and members of the cytoprotective 
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signalling cascades. This has been shown to occur in delayed IPC for compounds such 
as mitochondrial manganese superoxide dismutase (mMSOD)657, 658, heat stress 
proteins 60, 70 and 72396, iNOS 659, 660 and the RISK pathway itself 661.  
 
Histology	  
The semi-quantitative scoring system used to characterise the degree of ATN has been 
used extensively by our lab in the past650, 662-664. Acute tubular necrosis is the sine qua 
non of ischaemia reperfusion injury to the kidney. PMN infiltration is both a cause and 
effect of renal IRI, with neutrophil infiltration triggered by cytokine release during 
ischaemia followed by further inflammation triggered by neutrophil mediated ROS 
production. 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labelling) staining is a 
method for detecting DNA fragmentation that results from apoptotic signalling 
cascades, and as such is considered an indirect histological marker for apoptosis665.  
The histological analysis shows that summation RIPC resulted in significant tissue 
protection over delayed RIPC alone, as evidenced by a lower ATN score, less PMN 
infiltration and less apoptosis. Interestingly, no statistical difference was seen between 
the sham and RIPC groups. This is surprising given that the biochemical data supported 
the stepwise effect of protection seen between the 3 groups, and that the renoprotective 
effect of immediate RIPC has been shown in both human and animals models666, 667. 
This result is unlikely to be due to sampling error as 100 fields were analysed for each 
kidney sample. Further work with larger group sizes needs to be carried out to 
investigate the apparent discordance between the biochemistry and histology data in the 
sham and RIPC groups. 
 
Future	  work	  
1: Further experiments are required to investigate possible mechanisms for the tissue 
protection seen in both the RIPC and summation RIPC. Candidate markers for the early 
RIPC are the KATP channel, PKC, NO and ROS. The mediators involved in delayed 
RIPC are unknown, however a suitable place to start would be to look at mediators 
which are known to play a role in delayed IPC: HSP 60, 70 and 72, mSOD and iNOS. 
2: Investigation of the apparent discordance between the biochemical outcome data and 
the histological outcome data in the summation and RIPC groups. 
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3:Further work should also investigate the effect of delayed RIPC alone in the context 
of renal IRI. Ideally the current study should have included delayed RIPC alone as a 
fourth group. The reason for this is that all the initial studies on RIPC employed the 
RIPC strategy immediately before the prolonged injury. The concept of delayed RIPC 
is only a recent development and has yet be investigated as fully as early RIPC. 
Because of this, early RIPC is the default protocol for RIPC. It was because of this that 
the study planned to answer the question: could the effect of RIPC (early RIPC) be 
improved upon to confer greater protection?  It was not how summation RIPC would 
differ from early or late RIPC alone. In hindsight, answering the second question would 
have provided an insight into the contribution of delayed RIPC versus early RIPC.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 255 
References 
1. Brown GB. Biosynthesis of nucleic acids in the mammal. Fed Proc. 
1950;9:517-523 
2. Story DL, Shrader RE, Theriault LL, Lumijarvi DL, Shenoy TS, Savaiano 
DA, Shaffer RH, Ho CY, Clifford AJ. Effects of dietary protein, adenine, and 
allopurinol on growth and metabolism of rats. J Nutr. 1977;107:1044-1052 
3. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic 
renal failure. J Am Soc Nephrol. 1999;10:1606-1615 
4. Rubio VR, Wiedmeier T, Berne RM. Nucleoside phosphorylase: Localization 
and role in the myocardial distribution of purines. Am J Physiol. 
1972;222:550-555 
5. Compressed mortality file: Underlying cause of death, 1979 to 2005.  
6. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal 
K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard 
V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, 
Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, 
Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, 
Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics--2009 
update: A report from the american heart association statistics committee and 
stroke statistics subcommittee. Circulation. 2009;119:e21-181 
7. Incidence and prevalence: 2006 chart book on cardiovascular and lung 
diseases. 2006 
8. Jones DW, Chambless LE, Folsom AR, Heiss G, Hutchinson RG, Sharrett 
AR, Szklo M, Taylor HA, Jr. Risk factors for coronary heart disease in african 
americans: The atherosclerosis risk in communities study, 1987-1997. Arch 
Intern Med. 2002;162:2565-2571 
9. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles 
WH, Capewell S. Explaining the decrease in u.S. Deaths from coronary 
disease, 1980-2000. N Engl J Med. 2007;356:2388-2398 
10. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of 
adult hypertension in the united states 1999 to 2000: A rising tide. 
Hypertension. 2004;44:398-404 
11. 2003 european society of hypertension-european society of cardiology 
guidelines for the management of arterial hypertension. J Hypertens. 
2003;21:1011-1053 
12. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, 
Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-
pressure lowering and low-dose aspirin in patients with hypertension: 
Principal results of the hypertension optimal treatment (hot) randomised trial. 
Hot study group. Lancet. 1998;351:1755-1762 
13. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, 
Rogers NL, Teschan PE. Predictors of the progression of renal disease in the 
modification of diet in renal disease study. Kidney Int. 1997;51:1908-1919 
14. Effects of ramipril on cardiovascular and microvascular outcomes in people 
with diabetes mellitus: Results of the hope study and micro-hope substudy. 
Heart outcomes prevention evaluation study investigators. Lancet. 
2000;355:253-259 
 256 
15. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, 
Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk 
for vascular events. N Engl J Med. 2008;358:1547-1559 
16. The health benefits of smoking cessation: A report of the surgeon general. 
1990 
17. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum 
cholesterol, blood pressure, and mortality: Implications from a cohort of 
361,662 men. Lancet. 1986;2:933-936 
18. Dawber TR. The framingham study: The epidemiology of atherosclerotic 
disease. 1980 
19. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, 
McKillop JH, Packard CJ. Prevention of coronary heart disease with 
pravastatin in men with hypercholesterolemia. West of scotland coronary 
prevention study group. N Engl J Med. 1995;333:1301-1307 
20. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner 
D, Ettinger W, Heath GW, King AC, et al. Physical activity and public health. 
A recommendation from the centers for disease control and prevention and the 
american college of sports medicine. JAMA. 1995;273:402-407 
21. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, 
Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk 
factors associated with myocardial infarction in 52 countries (the interheart 
study): Case-control study. Lancet. 2004;364:937-952 
22. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among us 
children and adolescents, 2003-2006. JAMA. 2008;299:2401-2405 
23. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess 
deaths associated with underweight, overweight, and obesity. JAMA. 
2007;298:2028-2037 
24. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and 
cardiovascular disease. Recent Prog Horm Res. 2004;59:207-223 
25. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. 
Associations of diabetes mellitus with total life expectancy and life 
expectancy with and without cardiovascular disease. Arch Intern Med. 
2007;167:1145-1151 
26. Diabetes across the united states.  
27. Flegal KM, Ezzati TM, Harris MI, Haynes SG, Juarez RZ, Knowler WC, 
Perez-Stable EJ, Stern MP. Prevalence of diabetes in mexican americans, 
cubans, and puerto ricans from the hispanic health and nutrition examination 
survey, 1982-1984. Diabetes Care. 1991;14:628-638 
28. Wilson PW. Established risk factors and coronary artery disease: The 
framingham study. Am J Hypertens. 1994;7:7S-12S 
29. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--
measured and estimated glomerular filtration rate. N Engl J Med. 
2006;354:2473-2483 
30. Usrds 2010 annual data report: Atlas of endstage renal disease in the united 
states. 2010 
31. Prevalence of chronic kidney disease and associated risk factors--united states, 
1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56:161-165 
32. Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease 
risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 
2004;13:73-81 
 257 
33. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis 
in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701 
34. Clyne N, Lins LE, Pehrsson SK. Occurrence and significance of heart disease 
in uraemia. An autopsy study. Scand J Urol Nephrol. 1986;20:307-311 
35. Ikram H, Lynn KL, Bailey RR, Little PJ. Cardiovascular changes in chronic 
hemodialysis patients. Kidney Int. 1983;24:371-376 
36. Herzog CA. Poor long-term survival of dialysis patients after acute myocardial 
infarction: Bad treatment or bad disease? Am J Kidney Dis. 2000;35:1217-
1220 
37. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular 
disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-119 
38. McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, 
Khoury NE, Weaver WD, Sandberg KR, McCord J. Performance of multiple 
cardiac biomarkers measured in the emergency department in patients with 
chronic kidney disease and chest pain. Acad Emerg Med. 2002;9:1389-1396 
39. Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-
Visser MP. Impaired renal clearance explains elevated troponin t fragments in 
hemodialysis patients. Circulation. 2004;109:23-25 
40. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey 
KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS. 
Troponin t levels in patients with acute coronary syndromes, with or without 
renal dysfunction. N Engl J Med. 2002;346:2047-2052 
41. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, 
Miller WL, Murphy JG, Kopecky SL, Jaffe AS. Acute myocardial infarction 
and renal dysfunction: A high-risk combination. Ann Intern Med. 
2002;137:563-570 
42. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. 
Influence of concurrent renal dysfunction on outcomes of patients with acute 
coronary syndromes and implications of the use of glycoprotein iib/iiia 
inhibitors. J Am Coll Cardiol. 2003;41:718-724 
43. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-
converting enzyme inhibitor therapy in patients with end-stage renal disease 
and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201-208 
44. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff 
AM, Topol EJ, Ellis SG. Safety of abciximab during percutaneous coronary 
intervention in patients with chronic renal insufficiency. Am J Cardiol. 
2002;89:1209-1211 
45. Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: 
Epidemiology and prevention. Nat Rev Nephrol. 2011;7:145-154 
46. Schoebel FC, Gradaus F, Ivens K, Heering P, Jax TW, Grabensee B, Strauer 
BE, Leschke M. Restenosis after elective coronary balloon angioplasty in 
patients with end stage renal disease: A case-control study using quantitative 
coronary angiography. Heart. 1997;78:337-342 
47. Le Feuvre C, Dambrin G, Helft G, Beygui F, Touam M, Grunfeld JP, 
Vacheron A, Metzger JP. Clinical outcome following coronary angioplasty in 
dialysis patients: A case-control study in the era of coronary stenting. Heart. 
2001;85:556-560 
48. Dragu R, Behar S, Sandach A, Boyko V, Kapeliovich M, Rispler S, 
Hammerman H. Should primary percutaneous coronary intervention be the 
 258 
preferred method of reperfusion therapy for patients with renal failure and st-
elevation acute myocardial infarction? Am J Cardiol. 2006;97:1142-1145 
49. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, 
Wallentin L, Jernberg T. Influence of renal function on the effects of early 
revascularization in non-st-elevation myocardial infarction: Data from the 
swedish web-system for enhancement and development of evidence-based 
care in heart disease evaluated according to recommended therapies 
(swedeheart). Circulation. 2009;120:851-858 
50. Fujii H, Otani H, Okada T, Oka T, Osako M, Imamura H. Long-term results of 
chronic hemodialysis patients with isolated coronary artery bypass grafting 
performed by the same surgeon. A comparative study. J Cardiovasc Surg 
(Torino). 2002;43:617-624 
51. Suehiro S, Shibata T, Hattori K, Hirai H, Fujii H, Aoyama N, Ikuta T, 
Sakaguchi M, Kinoshita H. Early and long-term results of coronary artery 
bypass grafting in dialysis patients. Jpn J Thorac Cardiovasc Surg. 
2001;49:660-665 
52. Dacey LJ, Liu JY, Braxton JH, Weintraub RM, DeSimone J, Charlesworth 
DC, Lahey SJ, Ross CS, Hernandez F, Jr., Leavitt BJ, O'Connor GT. Long-
term survival of dialysis patients after coronary bypass grafting. Ann Thorac 
Surg. 2002;74:458-462; discussion 462-453 
53. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of 
long-term survival after revascularization in patients with chronic kidney 
disease presenting with acute coronary syndromes. Am J Cardiol. 
2003;92:509-514 
54. Koyanagi T, Nishida H, Kitamura M, Endo M, Koyanagi H, Kawaguchi M, 
Magosaki N, Sumiyoshi T, Hosoda S. Comparison of clinical outcomes of 
coronary artery bypass grafting and percutaneous transluminal coronary 
angioplasty in renal dialysis patients. Ann Thorac Surg. 1996;61:1793-1796 
55. Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Opsahl JA. A 
comparison of coronary angioplasty and coronary artery bypass grafting 
outcomes in chronic dialysis patients. Am J Kidney Dis. 1995;25:281-290 
56. Simsir SA, Kohlman-Trigoboff D, Flood R, Lindsay J, Smith BM. A 
comparison of coronary artery bypass grafting and percutaneous transluminal 
coronary angioplasty in patients on hemodialysis. Cardiovasc Surg. 
1998;6:500-505 
57. Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W, 
O'Neill WW, Wijns W, Serruys PW. Association of chronic kidney disease 
with clinical outcomes after coronary revascularization: The arterial 
revascularization therapies study (arts). Am Heart J. 2005;149:512-519 
58. Obrastzov WP, Strazhesko ND. Zur kenntnis der thrombose der 
koronararterien des herzens. Z Klin Med 1910;71:116-132 
59. Herrick JB. Clinical features of the sudden obstruction of the coronary 
arteries. Journal of the American Medical Association. 1912;LIX:2015-2022 
60. Wilson FN, Johnston FD, Rosenbaum FF, Erlanger H, Kossmann CE, Hecht 
H, Cotrim N, Menezes de Olivieira R, Scarsi R, PS B. The precordial 
electrocardiogram. Am Heart J. 1944;27 
61. Ladue JS, Wroblewski F. The significance of the serum glutamic oxalacetic 
transaminase activity following acute myocardial infarction. Circulation. 
1955;11:871-877 
 259 
62. Jennings RB, Baum JH, Herdson PB. Fine structural changes in myocardial 
ischemic injury. Arch Pathol. 1965;79:135-143 
63. Jennings RB, Ganote CE. Structural changes in myocardium during acute 
ischemia. Circ Res. 1974;35 Suppl 3:156-172 
64. Herdson PB, Sommers HM, Jennings RB. A comparative study of the fine 
structure of normal and ischemic dog myocardium with special reference to 
early changes following temporary occlusion of a coronary artery. Am J 
Pathol. 1965;46:367-386 
65. Meltzer LE, Kitchell JB. The incidence of arrhythmias associated with acute 
myocardial infarction. Prog Cardiovasc Dis. 1966:50 
66. Braunwald E. Control of myocardial oxygen consumption: Physiologic and 
clinical considerations. Am J Cardiol. 1971;27:416-432 
67. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Jr., 
Braunwald E. Factors influencing infarct size following experimental coronary 
artery occlusions. Circulation. 1971;43:67-82 
68. Becker LC, Ferreira R, Thomas M. Mapping of left ventricular blood flow 
with radioactive microspheres in experimental coronary artery occlusion. 
Cardiovasc Res. 1973;7:391-400 
69. Braunwald E, Maroko PR. Protection of the ischemic myocardium. 
Cardiovasc Dis. 1975;2:129-147 
70. Wende W, Bleifeld W, Meyer J, Stuhlen HW. Reduction of the size of acute, 
experimental myocardial infarction by verapamil. Basic Res Cardiol. 
1975;70:198-208 
71. Bleifeld W, Wende W, Bussmann WD, Meyer J. Influence of nitroglycerin on 
the size of experimental myocardial infarction. Naunyn Schmiedebergs Arch 
Pharmacol. 1973;277:387-400 
72. Burmeister WE, Reynolds RD, Lee RJ. Limitation of myocardial infarct size 
by atenolol, nadolol and propranolol in dogs. Eur J Pharmacol. 1981;75:7-10 
73. Hearse DJ, Yellon DM. The "border zone" in evolving myocardial infarction: 
Controversy or confusion? Am J Cardiol. 1981;47:1321-1334 
74. Hearse DJ. Models and problems in the study of myocardial ischemia and 
tissue protection. Eur Heart J. 1983;4 Suppl C:43-48 
75. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront 
phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of 
coronary occlusion in dogs. Circulation. 1977;56:786-794 
76. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial 
necrosis induced by temporary occlusion of a coronary artery in the dog. Arch 
Pathol. 1960;70:68-78 
77. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. 
[intracoronary administration of fibrinolysin in acute myocardial infarct]. Ter 
Arkh. 1976;48:8-19 
78. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of 
coronary-artery stenosis: Percutaneous transluminal coronary angioplasty. N 
Engl J Med. 1979;301:61-68 
79. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. 
Experimental observations and clinical implications. Circulation. 
1990;81:1161-1172 
80. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional 
myocardial functional and electrophysiological alterations after brief coronary 
artery occlusion in conscious dogs. J Clin Invest. 1975;56:978-985 
 260 
81. Diamond GA, Forrester JS, deLuz PL, Wyatt HL, Swan HJ. Post-extrasystolic 
potentiation of ischemic myocardium by atrial stimulation. Am Heart J. 
1978;95:204-209 
82. Ferreira R. The reduction of infarct size--forty years of research. Rev Port 
Cardiol. 2010;29:1037-1053 
83. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 
2007;357:1121-1135 
84. Bolli R, Becker L, Gross G, Mentzer R, Jr., Balshaw D, Lathrop DA. 
Myocardial protection at a crossroads: The need for translation into clinical 
therapy. Circ Res. 2004;95:125-134 
85. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne 
KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, 
Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to 
thrombolytic therapy for acute myocardial infarction: Results of a multicenter, 
randomized, placebo-controlled trial: The acute myocardial infarction study of 
adenosine (amistad) trial. J Am Coll Cardiol. 1999;34:1711-1720 
86. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment 
of acute myocardial infarction: An overview of randomized placebo-
controlled trials. Circulation. 1997;96:1152-1156 
87. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for 
ischaemia: Lost in translation. Dis Model Mech. 2010;3:35-38 
88. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, 
Judd RM. An improved mr imaging technique for the visualization of 
myocardial infarction. Radiology. 2001;218:215-223 
89. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. 
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J 
Med. 2006;355:2085-2098 
90. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, 
Burger HU, Scherhag A. Normalization of hemoglobin level in patients with 
chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084 
91. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, 
Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, 
McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, 
Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney 
disease. N Engl J Med. 2009;361:2019-2032 
92. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, 
Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, 
Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi 
S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, 
Wuthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and 
cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 
2009;360:1395-1407 
93. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. 
Atorvastatin in patients with type 2 diabetes mellitus undergoing 
hemodialysis. N Engl J Med. 2005;353:238-248 
94. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, 
Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, 
Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, 
Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, 
Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis 
 261 
D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen 
T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, 
Parish S, Simpson D, Sleight P, Young A, Collins R. The effects of lowering 
ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney 
disease (study of heart and renal protection): A randomised placebo-controlled 
trial. Lancet. 2011;377:2181-2192 
95. Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res. 
2005;28:191-202 
96. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors 
with myocardial ischemia/reperfusion injury, preconditioning, and 
postconditioning. Pharmacol Rev. 2007;59:418-458 
97. Shapiro LM, Mackinnon J, Beevers DG. Echocardiographic features of 
malignant hypertension. Br Heart J. 1981;46:374-379 
98. Tuzcu EM, Golz SJ, Lever HM, Salcedo EE. Left ventricular hypertrophy in 
persons age 90 years and older. Am J Cardiol. 1989;63:237-240 
99. Prisant LM. Hypertensive heart disease. J Clin Hypertens (Greenwich). 
2005;7:231-238 
100. Doyle AE. Does hypertension predispose to coronary disease? Conflicting 
epidemiological and experimental evidence. Am J Hypertens. 1988;1:319-324 
101. Vogt M, Motz W, Scheler S, Strauer BE. Disorders of coronary 
microcirculation and arrhythmias in systemic arterial hypertension. Am J 
Cardiol. 1990;65:45G-50G 
102. Rakusan K, Wicker P. Morphometry of the small arteries and arterioles in the 
rat heart: Effects of chronic hypertension and exercise. Cardiovasc Res. 
1990;24:278-284 
103. Attarian DE, Jones RN, Currie WD, Hill RC, Sink JD, Olsen CO, Chitwood 
WR, Jr., Wechsler AS. Characteristics of chronic left ventricular hypertrophy 
induced by subcoronary valvular aortic stenosis. Ii. Response to ischemia. J 
Thorac Cardiovasc Surg. 1981;81:389-395 
104. Snoeckx LH, van der Vusse GJ, Coumans WA, Willemsen PH, van der Nagel 
T, Reneman RS. Myocardial function in normal and spontaneously 
hypertensive rats during reperfusion after a period of global ischaemia. 
Cardiovasc Res. 1986;20:67-75 
105. Obata H, Tanaka H, Haneda T. Response of isolated perfused heart to 
ischemia after long-term treatment of spontaneously hypertensive rats with 
diltiazem. Jpn Circ J. 1990;54:89-99 
106. Anderson PG, Allard MF, Thomas GD, Bishop SP, Digerness SB. Increased 
ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ 
Res. 1990;67:948-959 
107. Batist G, Mersereau W, Malashenko BA, Chiu RC. Response to ischemia-
reperfusion injury in hypertrophic heart. Role of free-radical metabolic 
pathways. Circulation. 1989;80:III10-13 
108. Belichard P, Pruneau D, Rochette L. [arterial hypertension, myocardial 
hypertrophy and disorders of cardiac rhythm induced by ligation of the left 
coronary artery in the rat]. Arch Mal Coeur Vaiss. 1987;80:883-887 
109. Baxter GF, Yellon DM. Regression of left ventricular hypertrophy and 
susceptibility to reperfusion-induced arrhythmias after doca-salt hypertension 
in the rat. Cardioscience. 1992;3:245-250 
 262 
110. Ebrahim Z, Yellon DM, Baxter GF. Attenuated cardioprotective response to 
bradykinin, but not classical ischaemic preconditioning, in doca-salt 
hypertensive left ventricular hypertrophy. Pharmacol Res. 2007;55:42-48 
111. Inou T, Lamberth WC, Jr., Koyanagi S, Harrison DG, Eastham CL, Marcus 
ML. Relative importance of hypertension after coronary occlusion in chronic 
hypertensive dogs with lvh. Am J Physiol. 1987;253:H1148-1158 
112. Speechly-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning 
protects hypertrophied myocardium. Cardiovasc Res. 1994;28:1025-1029 
113. Issa ZF, Ujhelyi MR, Hildebrand KR, Zhou X, Rosenberger J, Groh WJ, 
Miller JM, Zipes DP. Intrathecal clonidine reduces the incidence of ischemia-
provoked ventricular arrhythmias in a canine postinfarction heart failure 
model. Heart Rhythm. 2005;2:1122-1127 
114. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: A 
role for interstitial fibrosis. Mol Cell Biochem. 1995;147:29-34 
115. Sharikabad MN, Aronsen JM, Haugen E, Pedersen J, Moller AS, Mork HK, 
Aass HC, Sejersted OM, Sjaastad I, Brors O. Cardiomyocytes from 
postinfarction failing rat hearts have improved ischemia tolerance. Am J 
Physiol Heart Circ Physiol. 2009;296:H787-795 
116. Hearse DJ, Ferrari R, Sutherland FJ. Cardioprotection: Intermittent ventricular 
fibrillation and rapid pacing can induce preconditioning in the blood-perfused 
rat heart. J Mol Cell Cardiol. 1999;31:1961-1973 
117. Jung O, Jung W, Malinski T, Wiemer G, Schoelkens BA, Linz W. Ischemic 
preconditioning and infarct mass: The effect of hypercholesterolemia and 
endothelial dysfunction. Clin Exp Hypertens. 2000;22:165-179 
118. Wang TD, Chen WJ, Mau TJ, Lin JW, Lin WW, Lee YT. Attenuation of 
increased myocardial ischaemia-reperfusion injury conferred by 
hypercholesterolaemia through pharmacological inhibition of the caspase-1 
cascade. Br J Pharmacol. 2003;138:291-300 
119. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on 
myocardial infarct size and the no-reflow phenomenon during coronary 
occlusion-reperfusion. Circulation. 1987;75:292-298 
120. Girod WG, Jones SP, Sieber N, Aw TY, Lefer DJ. Effects of 
hypercholesterolemia on myocardial ischemia-reperfusion injury in ldl 
receptor-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:2776-2781 
121. Ferdinandy P, Szilvassy Z, Horvath LI, Csont T, Csonka C, Nagy E, 
Szentgyorgyi R, Nagy I, Koltai M, Dux L. Loss of pacing-induced 
preconditioning in rat hearts: Role of nitric oxide and cholesterol-enriched 
diet. J Mol Cell Cardiol. 1997;29:3321-3333 
122. Le Grand B, Vie B, Faure P, Degryse AD, Mouillard P, John GW. Increased 
resistance to ischaemic injury in the isolated perfused atherosclerotic heart of 
the cholesterol-fed rabbit. Cardiovasc Res. 1995;30:689-696 
123. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The 
framingham study. JAMA. 1979;241:2035-2038 
124. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on 
survival following myocardial infarction in men vs women. The framingham 
study. JAMA. 1988;260:3456-3460 
125. Tosaki A, Engelman DT, Engelman RM, Das DK. The evolution of diabetic 
response to ischemia/reperfusion and preconditioning in isolated working rat 
hearts. Cardiovasc Res. 1996;31:526-536 
 263 
126. Ravingerova T, Neckar J, Kolar F. Ischemic tolerance of rat hearts in acute 
and chronic phases of experimental diabetes. Mol Cell Biochem. 
2003;249:167-174 
127. Ma G, Al-Shabrawey M, Johnson JA, Datar R, Tawfik HE, Guo D, Caldwell 
RB, Caldwell RW. Protection against myocardial ischemia/reperfusion injury 
by short-term diabetes: Enhancement of vegf formation, capillary density, and 
activation of cell survival signaling. Naunyn Schmiedebergs Arch Pharmacol. 
2006;373:415-427 
128. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning 
the diabetic heart: The importance of akt phosphorylation. Diabetes. 
2005;54:2360-2364 
129. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the 
heart of uremic patients. J Am Soc Nephrol. 1998;9:1018-1022 
130. Ghosh S, Standen NB, Galinianes M. Failure to precondition pathological 
human myocardium. J Am Coll Cardiol. 2001;37:711-718 
131. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon 
CP, Antman EM. Diabetes and mortality following acute coronary syndromes. 
JAMA. 2007;298:765-775 
132. Yang B, Larson DF, Watson RR. Modulation of inos activity in age-related 
cardiac dysfunction. Life Sci. 2004;75:655-667 
133. Kloner RA, Przyklenk K, Shook T, Cannon CP. Protection conferred by 
preinfarct angina is manifest in the aged heart: Evidence from the timi 4 trial. 
J Thromb Thrombolysis. 1998;6:89-92 
134. Csiszar A, Pacher P, Kaley G, Ungvari Z. Role of oxidative and nitrosative 
stress, longevity genes and poly(adp-ribose) polymerase in cardiovascular 
dysfunction associated with aging. Curr Vasc Pharmacol. 2005;3:285-291 
135. Bernecker OY, Huq F, Heist EK, Podesser BK, Hajjar RJ. Apoptosis in heart 
failure and the senescent heart. Cardiovasc Toxicol. 2003;3:183-190 
136. Willems L, Garnham B, Headrick JP. Aging-related changes in myocardial 
purine metabolism and ischemic tolerance. Exp Gerontol. 2003;38:1169-1177 
137. Dyachenko V, Rueckschloss U, Isenberg G. Aging aggravates heterogeneities 
in cell-size and stress-intolerance of cardiac ventricular myocytes. Exp 
Gerontol. 2006;41:489-496 
138. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial 
and nuclear DNA is extensive. Proc Natl Acad Sci U S A. 1988;85:6465-6467 
139. Di Lisa F, Bernardi P. Mitochondrial function and myocardial aging. A critical 
analysis of the role of permeability transition. Cardiovasc Res. 2005;66:222-
232 
140. Serviddio G, Bellanti F, Romano AD, Tamborra R, Rollo T, Altomare E, 
Vendemiale G. Bioenergetics in aging: Mitochondrial proton leak in aging rat 
liver, kidney and heart. Redox Rep. 2007;12:91-95 
141. Abete P, Cioppa A, Calabrese C, Pascucci I, Cacciatore F, Napoli C, 
Carnovale V, Ferrara N, Rengo F. Ischemic threshold and myocardial stunning 
in the aging heart. Exp Gerontol. 1999;34:875-884 
142. Tani M, Suganuma Y, Hasegawa H, Shinmura K, Hayashi Y, Guo X, 
Nakamura Y. Changes in ischemic tolerance and effects of ischemic 
preconditioning in middle-aged rat hearts. Circulation. 1997;95:2559-2566 
143. Tani M, Suganuma Y, Hasegawa H, Shinmura K, Ebihara Y, Hayashi Y, Guo 
X, Takayama M. Decrease in ischemic tolerance with aging in isolated 
 264 
perfused fischer 344 rat hearts: Relation to increases in intracellular na+ after 
ischemia. J Mol Cell Cardiol. 1997;29:3081-3089 
144. Loubani M, Ghosh S, Galinanes M. The aging human myocardium: Tolerance 
to ischemia and responsiveness to ischemic preconditioning. J Thorac 
Cardiovasc Surg. 2003;126:143-147 
145. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal 
disease. N Engl J Med. 1969;280:978-981 
146. Converse RL, Jr., Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-
Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal 
failure. N Engl J Med. 1992;327:1912-1918 
147. MacAllister R, Vallance P. Nitric oxide in essential and renal hypertension. J 
Am Soc Nephrol. 1994;5:1057-1065 
148. van de Borne P, Tielemans C, Vanherweghem JL, Degaute JP. Effect of 
recombinant human erythropoietin therapy on ambulatory blood pressure and 
heart rate in chronic haemodialysis patients. Nephrol Dial Transplant. 
1992;7:45-49 
149. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int. 
1997;51:1669-1677 
150. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary 
artery disease among new dialysis patients in the united states: A cross-
sectional study. J Am Soc Nephrol. 2001;12:1516-1523 
151. Sharp Collaborative G. Study of heart and renal protection (sharp): 
Randomized trial to assess the effects of lowering low-density lipoprotein 
cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 
2010;160:785-794 e710 
152. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan 
BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic 
hemodialysis patients. Kidney Int. 2000;58:353-362 
153. Kramer HJ, Saranathan A, Luke A, Durazo-Arvizu RA, Guichan C, Hou S, 
Cooper R. Increasing body mass index and obesity in the incident esrd 
population. J Am Soc Nephrol. 2006;17:1453-1459 
154. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. 
Body mass index and mortality in 'healthier' as compared with 'sicker' 
haemodialysis patients: Results from the dialysis outcomes and practice 
patterns study (dopps). Nephrol Dial Transplant. 2001;16:2386-2394 
155. Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are 
particularly hazardous and how do we measure them? Int J Epidemiol. 
2006;35:83-92 
156. Thum T, Anker SD. Obesity and risk of myocardial infarction: The interheart 
study. Lancet. 2006;367:1051-1052; author reply 1054 
157. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough 
K, Scalia R, Goldstein BJ. Adiponectin suppression of high-glucose-induced 
reactive oxygen species in vascular endothelial cells: Evidence for 
involvement of a camp signaling pathway. Diabetes. 2006;55:1840-1846 
158. Longnus SL, Segalen C, Giudicelli J, Sajan MP, Farese RV, Van Obberghen 
E. Insulin signalling downstream of protein kinase b is potentiated by 5'amp-
activated protein kinase in rat hearts in vivo. Diabetologia. 2005;48:2591-
2601 
159. Jalovaara K, Santaniemi M, Timonen M, Jokelainen J, Kesaniemi YA, Ukkola 
O, Keinanen-Kiukaanniemi S, Rajala U. Low serum adiponectin level as a 
 265 
predictor of impaired glucose regulation and type 2 diabetes mellitus in a 
middle-aged finnish population. Metabolism. 2008;57:1130-1134 
160. Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, 
Papademetriou V, Toutouzas P, Stefanadis C, Kallikazaros I. Relation of 
microalbuminuria to adiponectin and augmented c-reactive protein levels in 
men with essential hypertension. Am J Cardiol. 2005;96:946-951 
161. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo 
R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ. Adiponectin 
regulates albuminuria and podocyte function in mice. J Clin Invest. 
2008;118:1645-1656 
162. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and 
fatty liver disease: The roles of fetuin-a, adiponectin, and ampk. J Am Soc 
Nephrol. 2010;21:406-412 
163. Kadowaki T, Yamauchi T, Kubota N. The physiological and 
pathophysiological role of adiponectin and adiponectin receptors in the 
peripheral tissues and cns. FEBS Lett. 2008;582:74-80 
164. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, 
Giachelli CM. Phosphate regulation of vascular smooth muscle cell 
calcification. Circ Res. 2000;87:E10-17 
165. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow 
GM. Cardiac calcification in adult hemodialysis patients. A link between end-
stage renal disease and cardiovascular disease? J Am Coll Cardiol. 
2002;39:695-701 
166. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre 
PE. Clinical and echocardiographic disease in patients starting end-stage renal 
disease therapy. Kidney Int. 1995;47:186-192 
167. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum 
phosphorus and calcium x phosphate product with mortality risk in chronic 
hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607-617 
168. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young 
EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk 
for dialysis patients with different levels of serum calcium, phosphorus, and 
pth: The dialysis outcomes and practice patterns study (dopps). Am J Kidney 
Dis. 2008;52:519-530 
169. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. 
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J 
Am Soc Nephrol. 2004;15:2208-2218 
170. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, 
Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery 
calcification in young adults with end-stage renal disease who are undergoing 
dialysis. N Engl J Med. 2000;342:1478-1483 
171. Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone 
for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 
1994;4:1814-1819 
172. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Elevated 
serum parathyroid hormone is a cardiovascular risk factor in moderate chronic 
kidney disease. Int Urol Nephrol. 2011 
173. Coratelli P, Buongiorno E, Petrarulo F, Corciulo R, Giannattasio M, 
Passavanti G, Antonelli G. Pathogenetic aspects of uremic cardiomyopathy. 
Miner Electrolyte Metab. 1989;15:246-253 
 266 
174. Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C, de 
Vernejoul P, Crosnier J. Effect of parathyroidectomy on left-ventricular 
function in haemodialysis patients. Lancet. 1980;1:112-114 
175. Nanasato M, Goto N, Isobe S, Unno K, Hirayama H, Sato T, Matsuoka S, 
Nagasaka T, Tominaga Y, Uchida K, Murohara T. Restored cardiac conditions 
and left ventricular function after parathyroidectomy in a hemodialysis patient. 
Parathyroidectomy improves cardiac fatty acid metabolism assessed by 123i-
bmipp. Circ J. 2009;73:1956-1960 
176. Goto N, Tominaga Y, Matsuoka S, Sato T, Katayama A, Haba T, Uchida K. 
Cardiovascular complications caused by advanced secondary 
hyperparathyroidism in chronic dialysis patients; special focus on dilated 
cardiomyopathy. Clin Exp Nephrol. 2005;9:138-141 
177. Zhao G, Simpson RU. Interaction between vitamin d receptor with caveolin-3 
and regulation by 1,25-dihydroxyvitamin d3 in adult rat cardiomyocytes. J 
Steroid Biochem Mol Biol. 2010;121:159-163 
178. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, 
Bang BK. Intravenous calcitriol regresses myocardial hypertrophy in 
hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 
1999;33:73-81 
179. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Choi EJ, Chang YS, Bang 
BK. Calcitriol regresses cardiac hypertrophy and qt dispersion in secondary 
hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006;102:c21-29 
180. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner 
DG, Li YC. Cardiac hypertrophy in vitamin d receptor knockout mice: Role of 
the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol 
Metab. 2005;288:E125-132 
181. Artaza JN, Mehrotra R, Norris KC. Vitamin d and the cardiovascular system. 
Clin J Am Soc Nephrol. 2009;4:1515-1522 
182. Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU. 
1,25(oh)2-vitamin d3 actions on cell proliferation, size, gene expression, and 
receptor localization, in the hl-1 cardiac myocyte. J Steroid Biochem Mol Biol. 
2007;103:533-537 
183. Van Lente F. Markers of inflammation as predictors in cardiovascular disease. 
Clin Chim Acta. 2000;293:31-52 
184. Andress DL. Vitamin d in chronic kidney disease: A systemic role for 
selective vitamin d receptor activation. Kidney Int. 2006;69:33-43 
185. Al-Badr W, Martin KJ. Vitamin d and kidney disease. Clin J Am Soc Nephrol. 
2008;3:1555-1560 
186. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. 
Arterial media calcification in end-stage renal disease: Impact on all-cause and 
cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-1740 
187. Atkinson J, Poitevin P, Chillon JM, Lartaud I, Levy B. Vascular ca overload 
produced by vitamin d3 plus nicotine diminishes arterial distensibility in rats. 
Am J Physiol. 1994;266:H540-547 
188. Kent SP, Vawter GF, Dowben RM, Benson RE. Hypervitaminosis d in 
monkeys; a clinical and pathologic study. Am J Pathol. 1958;34:37-59 
189. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, 
Demer LL. Active serum vitamin d levels are inversely correlated with 
coronary calcification. Circulation. 1997;96:1755-1760 
 267 
190. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, 
Johnson HK, Zager PG. Mortality risk among hemodialysis patients receiving 
different vitamin d analogs. Kidney Int. 2006;70:1858-1865 
191. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr., 
Thadhani R. Activated injectable vitamin d and hemodialysis survival: A 
historical cohort study. J Am Soc Nephrol. 2005;16:1115-1125 
192. Hsu JJ, Tintut Y, Demer LL. Vitamin d and osteogenic differentiation in the 
artery wall. Clin J Am Soc Nephrol. 2008;3:1542-1547 
193. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular 
calcification in end-stage renal disease. Kidney Int. 2001;60:472-479 
194. Fraser JD, Otawara Y, Price PA. 1,25-dihydroxyvitamin d3 stimulates the 
synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma 
cells. Mutually exclusive expression of vitamin k-dependent bone proteins by 
clonal osteoblastic cell lines. J Biol Chem. 1988;263:911-916 
195. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome 
and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial 
Transplant. 1996;11:1277-1285 
196. Hausberg M, Tokmak F, Pavenstadt H, Kramer BK, Rump LC. Effects of 
moxonidine on sympathetic nerve activity in patients with end-stage renal 
disease. J Hypertens. 2010;28:1920-1927 
197. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, 
Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, 
Malatino LS. Plasma norepinephrine predicts survival and incident 
cardiovascular events in patients with end-stage renal disease. Circulation. 
2002;105:1354-1359 
198. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. 
Relation between cardiac sympathetic activity and hypertensive left 
ventricular hypertrophy. Circulation. 2003;108:560-565 
199. Peng T, Jiang X, Wang Y, Hand A, Gillies C, Cone RE, O'Rourke J. 
Sympathectomy decreases and adrenergic stimulation increases the release of 
tissue plasminogen activator (t-pa) from blood vessels: Functional evidence 
for a neurologic regulation of plasmin production within vessel walls and 
other tissue matrices. J Neurosci Res. 1999;57:680-692 
200. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship 
between muscle sympathetic nerve activity and large artery mechanical vessel 
wall properties in renal transplant patients. J Hypertens. 2002;20:501-508 
201. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, 
Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. 
Effect of renal sympathetic denervation on glucose metabolism in patients 
with resistant hypertension: A pilot study. Circulation. 2011;123:1940-1946 
202. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 
1999;354:407-413 
203. Wald DS, Law M, Morris JK. The dose-response relation between serum 
homocysteine and cardiovascular disease: Implications for treatment and 
screening. Eur J Cardiovasc Prev Rehabil. 2004;11:250-253 
204. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, 
Mayer EL, Selhub J, Kutner M, Jacobsen DW. Hyperhomocysteinemia 
confers an independent increased risk of atherosclerosis in end-stage renal 
disease and is closely linked to plasma folate and pyridoxine concentrations. 
Circulation. 1996;94:2743-2748 
 268 
205. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, 
Dworkin L, Rosenberg IH. Elevated fasting total plasma homocysteine levels 
and cardiovascular disease outcomes in maintenance dialysis patients. A 
prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554-2558 
206. Renke M, Tylicki L, Rutkowski P, Larczynski W, Neuwelt A, Aleksandrowicz 
E, Lysiak-Szydlowska W, Rutkowski B. The effect of n-acetylcysteine on 
blood pressure and markers of cardiovascular risk in non-diabetic patients 
with chronic kidney disease: A placebo-controlled, randomized, cross-over 
study. Med Sci Monit. 2010;16:PI13-18 
207. Heinz J, Kropf S, Domrose U, Westphal S, Borucki K, Luley C, Neumann 
KH, Dierkes J. B vitamins and the risk of total mortality and cardiovascular 
disease in end-stage renal disease: Results of a randomized controlled trial. 
Circulation. 2010;121:1432-1438 
208. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, 
Jogestrand T. Strong association between malnutrition, inflammation, and 
atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899-1911 
209. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for 
cardiovascular disease in chronic renal failure. Blood Purif. 2001;19:143-151 
210. Lowrie EG. Acute-phase inflammatory process contributes to malnutrition, 
anemia, and possibly other abnormalities in dialysis patients. Am J Kidney 
Dis. 1998;32:S105-112 
211. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for 
maintenance hemodialysis patients. Kidney Int. 1998;54:627-636 
212. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, Levey 
AS, Sarnak MJ. Relationship between c-reactive protein, albumin, and 
cardiovascular disease in patients with chronic kidney disease. Am J Kidney 
Dis. 2003;42:44-52 
213. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys 
MB. C-reactive protein and complement are important mediators of tissue 
damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740 
214. Stenvinkel P. Endothelial dysfunction and inflammation-is there a link? 
Nephrol Dial Transplant. 2001;16:1968-1971 
215. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. 
Oxidative stress in end-stage renal disease: An emerging threat to patient 
outcome. Nephrol Dial Transplant. 2003;18:1272-1280 
216. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. 
Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 
1999;17:99-106 
217. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative 
stress: Biological aspects, clinical consequences, and therapy. Semin Dial. 
2001;14:193-199 
218. Saint-Georges MD, Bonnefont DJ, Bourely BA, Jaudon MC, Cereze P, 
Chaumeil P, Gard C, D'Auzac CL. Correction of selenium deficiency in 
hemodialyzed patients. Kidney Int Suppl. 1989;27:S274-277 
219. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. 
Hemodialysis membrane-induced activation of phagocyte oxidative 
metabolism detected in vivo and in vitro within microamounts of whole blood. 
Kidney Int. 1985;28:158-167 
 269 
220. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S. Serum 
malondialdehyde and prevalent cardiovascular disease in hemodialysis. 
Kidney Int. 1999;56:1078-1083 
221. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-
tocopherol supplementation decreases the oxidative susceptibility of ldl in 
renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217-224 
222. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, 
Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with 
antioxidants of cardiovascular disease in endstage renal disease (space): 
Randomised placebo-controlled trial. Lancet. 2000;356:1213-1218 
223. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant 
acetylcysteine reduces cardiovascular events in patients with end-stage renal 
failure: A randomized, controlled trial. Circulation. 2003;107:992-995 
224. Schnider SL, Kohn RR. Glucosylation of human collagen in aging and 
diabetes mellitus. J Clin Invest. 1980;66:1179-1181 
225. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in 
nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl 
stress" in long-term uremic complications. Kidney Int. 1999;55:389-399 
226. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. Ages and their interaction 
with age-receptors in vascular disease and diabetes mellitus. I. The age 
concept. Cardiovasc Res. 1998;37:586-600 
227. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end 
products: A nephrologist's perspective. Am J Kidney Dis. 2000;35:365-380 
228. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial 
and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21:3-12 
229. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end 
products and mortality in hemodialysis patients. Kidney Int. 2002;62:301-310 
230. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander 
NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ. Skin 
autofluorescence, a measure of cumulative metabolic stress and advanced 
glycation end products, predicts mortality in hemodialysis patients. J Am Soc 
Nephrol. 2005;16:3687-3693 
231. Kielstein JT, Fliser D, Veldink H. Asymmetric dimethylarginine and 
symmetric dimethylarginine: Axis of evil or useful alliance? Semin Dial. 
2009;22:346-350 
232. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: A novel marker of risk 
and a potential target for therapy in chronic kidney disease. Curr Opin 
Nephrol Hypertens. 2008;17:609-615 
233. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, 
Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac 
dysfunction in humans and is actively metabolized by dimethylarginine 
dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459 
234. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-
Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM. Adma 
increases arterial stiffness and decreases cerebral blood flow in humans. 
Stroke. 2006;37:2024-2029 
235. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, 
Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration 
of asymmetrical dimethylarginine and mortality in patients with end-stage 
renal disease: A prospective study. Lancet. 2001;358:2113-2117 
 270 
236. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, 
Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric 
oxide synthase inhibition with asymmetrical dimethylarginine in humans. 
Circulation. 2004;109:172-177 
237. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, 
Cataliotti A, Bellanuova I, Boger R. Left ventricular hypertrophy, cardiac 
remodeling and asymmetric dimethylarginine (adma) in hemodialysis patients. 
Kidney Int. 2002;62:339-345 
238. Cooke JP. Asymmetrical dimethylarginine: The uber marker? Circulation. 
2004;109:1813-1818 
239. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an 
endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 
1992;339:572-575 
240. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser 
D. Marked increase of asymmetric dimethylarginine in patients with incipient 
primary chronic renal disease. J Am Soc Nephrol. 2002;13:170-176 
241. Leiper JM. The ddah-adma-nos pathway. Ther Drug Monit. 2005;27:744-746 
242. Martin MA, Gomez MA, Guillen F, Bornstein B, Campos Y, Rubio JC, de la 
Calzada CS, Arenas J. Myocardial carnitine and carnitine palmitoyltransferase 
deficiencies in patients with severe heart failure. Biochim Biophys Acta. 
2000;1502:330-336 
243. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and 
hemodialysis. Am J Kidney Dis. 2003;41:S116-122 
244. Guarnieri G, Toigo G, Crapesi L, Situlin R, Del Bianco MA, Corsi M, 
LoGreco P, Paviotti G, Mioni G, Campanacci L. Carnitine metabolism in 
chronic renal failure. Kidney Int Suppl. 1987;22:S116-127 
245. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yucel D. Effects of l-
carnitine infusions on inflammatory and nutritional markers in haemodialysis 
patients. Nephrol Dial Transplant. 2006;21:3211-3214 
246. Sakurabayashi T, Miyazaki S, Yuasa Y, Sakai S, Suzuki M, Takahashi S, 
Hirasawa Y. L-carnitine supplementation decreases the left ventricular mass in 
patients undergoing hemodialysis. Circ J. 2008;72:926-931 
247. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of l-carnitine 
supplementation in maintenance hemodialysis patients: A systematic review. J 
Am Soc Nephrol. 2002;13:708-714 
248. Chanutin A, Ferris EB. Experimental renal insufficiency produced by partial 
nephrectomy i. Control diet Arch Intern Med. 1932;49:767-787 
249. Garrido P, Reis F, Costa E, Teixeira-Lemos E, Parada B, Alves R, Piloto N, 
Sereno J, Figueiredo A, Pinto R, Carvalho L, Rocha-Pereira P, Belo L, Santos-
Silva A, Teixeira F. Characterization of a rat model of moderate chronic renal 
failure--focus on hematological, biochemical, and cardio-renal profiles. Ren 
Fail. 2009;31:833-842 
250. Liu ZC, Chow KM, Chang TM. Evaluation of two protocols of uremic rat 
model: Partial nephrectomy and infarction. Ren Fail. 2003;25:935-943 
251. Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada 
M. Sevelamer hydrochloride, a phosphate binder, protects against 
deterioration of renal function in rats with progressive chronic renal 
insufficiency. Nephrol Dial Transplant. 2003;18:2014-2023 
 271 
252. Shibata S, Miyakawa Y, Naruse T, Nagasawa T, Takuma T. A glycoprotein 
that induces nephrotoxic antibody: Its isolation and purification from rat 
glomerular basement membrane. J Immunol. 1969;102:593-601 
253. Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenine-
induced chronic renal failure in rats. Nephron. 1986;44:230-234 
254. Yokozawa T, Oura H, Okada T. Metabolic effects of dietary purine in rats. J 
Nutr Sci Vitaminol (Tokyo). 1982;28:519-526 
255. Yokozawa T, Oura H, Koizumi F. 2,8-dihydroxyadenine urolithiasis induced 
by dietary adenine in rats. Nippon Jinzo Gakkai Shi. 1985;27:371-378 
256. Bendich A, Brown G, Philips FS, Thiersch JB. The direct oxidation of adenine 
in vivo. J Biol Chem. 1950;183:267-277 
257. Ceballos-Picot I, Perignon JL, Hamet M, Daudon M, Kamoun P. 2,8-
dihydroxyadenine urolithiasis, an underdiagnosed disease. Lancet. 
1992;339:1050-1051 
258. Kamatani N, Hakoda M, Otsuka S, Yoshikawa H, Kashiwazaki S. Only three 
mutations account for almost all defective alleles causing adenine 
phosphoribosyltransferase deficiency in japanese patients. J Clin Invest. 
1992;90:130-135 
259. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin 
D. 1,25-dihydroxyvitamin d3 but not cinacalcet hcl (sensipar/mimpara) 
treatment mediates aortic calcification in a rat model of secondary 
hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1370-1377 
260. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, 
Rodriguez M. The effect of calcitriol, paricalcitol, and a calcimimetic on 
extraosseous calcifications in uremic rats. Kidney Int. 2008;73:300-307 
261. Wu-Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, 
Postl S, Morgan SJ, Reinhart GA. Role of phosphorus and vitamin d analogs 
in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 
2006;318:90-98 
262. Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X, Martin D, Yao W, 
Lane N, Shalhoub V. The calcimimetic amg 641 abrogates parathyroid 
hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur 
J Pharmacol. 2009;616:306-313 
263. Neven E, Dams G, Postnov A, Chen B, De Clerck N, De Broe ME, D'Haese 
PC, Persy V. Adequate phosphate binding with lanthanum carbonate 
attenuates arterial calcification in chronic renal failure rats. Nephrol Dial 
Transplant. 2009;24:1790-1799 
264. Matsui I, Hamano T, Mikami S, Fujii N, Takabatake Y, Nagasawa Y, Kawada 
N, Ito T, Rakugi H, Imai E, Isaka Y. Fully phosphorylated fetuin-a forms a 
mineral complex in the serum of rats with adenine-induced renal failure. 
Kidney Int. 2009;75:915-928 
265. Terai K, Mizukami K, Okada M. Comparison of chronic renal failure rats and 
modification of the preparation protocol as a hyperphosphataemia model. 
Nephrology (Carlton). 2008;13:139-146 
266. Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary 
deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol 
Dial Transplant. 2009;24:778-787 
267. Krog M, Ejerblad S, Eriksson I, Johansson H. Arterial calcifications in 
uraemic rats treated with 1-alpha-hydroxycholecalciferol and 
parathyroidectomy. Scand J Urol Nephrol. 1984;18:227-239 
 272 
268. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, 
Rodriguez M. Calcimimetic r-568 decreases extraosseous calcifications in 
uremic rats treated with calcitriol. J Am Soc Nephrol. 2006;17:795-804 
269. Mendoza FJ, Lopez I, Montes de Oca A, Perez J, Rodriguez M, Aguilera-
Tejero E. Metabolic acidosis inhibits soft tissue calcification in uremic rats. 
Kidney Int. 2008;73:407-414 
270. Neven E, Dauwe S, De Broe ME, D'Haese PC, Persy V. Endochondral bone 
formation is involved in media calcification in rats and in men. Kidney Int. 
2007;72:574-581 
271. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, 
Takeda K, Fukagawa M. Severe hyperparathyroidism with bone abnormalities 
and metastatic calcification in rats with adenine-induced uraemia. Nephrol 
Dial Transplant. 2006;21:651-659 
272. Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models 
of ckd: A review. Am J Nephrol. 2010;31:471-481 
273. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, 
Slatopolsky E. Sevelamer hydrochloride attenuates kidney and cardiovascular 
calcifications in long-term experimental uremia. Kidney Int. 2003;64:1653-
1661 
274. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats 
is increased by a low protein diet and prevented by treatment with 
ibandronate. Kidney Int. 2006;70:1577-1583 
275. Okada H, Kaneko Y, Yawata T, Uyama H, Ozono S, Motomiya Y, Hirao Y. 
Reversibility of adenine-induced renal failure in rats. Clin Exp Nephrol. 
1999:82-88 
276. Ganzoni AM, Oakes R, Hillman RS. Red cell aging in vivo. J Clin Invest. 
1971;50:1373-1378 
277. Michea L, Villagran A, Urzua A, Kuntsmann S, Venegas P, Carrasco L, 
Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates 
cardiac hypertrophy and prevents oxidative stress in uremic rats. 
Hypertension. 2008;52:295-300 
278. Ataka K, Maruyama H, Neichi T, Miyazaki J, Gejyo F. Effects of 
erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. 
Am J Nephrol. 2003;23:315-323 
279. Maruyama H, Ataka K, Gejyo F, Higuchi N, Ito Y, Hirahara H, Imazeki I, 
Hirata M, Ichikawa F, Neichi T, Kikuchi H, Sugawa M, Miyazaki J. Long-
term production of erythropoietin after electroporation-mediated transfer of 
plasmid DNA into the muscles of normal and uremic rats. Gene Ther. 
2001;8:461-468 
280. Hamada Y, Kono TN, Moriguchi Y, Higuchi M, Fukagawa M. Alteration of 
mrna expression of molecules related to iron metabolism in adenine-induced 
renal failure rats: A possible mechanism of iron deficiency in chronic kidney 
disease patients on treatment. Nephrol Dial Transplant. 2008;23:1886-1891 
281. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR. 
Ferric gluconate is highly efficacious in anemic hemodialysis patients with 
high serum ferritin and low transferrin saturation: Results of the dialysis 
patients' response to iv iron with elevated ferritin (drive) study. J Am Soc 
Nephrol. 2007;18:975-984 
 273 
282. Yokozawa T, Zheng PD, Oura H. Biochemical features induced by adenine 
feeding in rats. Polyuria, electrolyte disorders, and 2,8-dihydroxyadenine 
deposits. J Nutr Sci Vitaminol (Tokyo). 1984;30:245-254 
283. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima 
N, Doi T. 22-oxacalcitriol prevents progressive glomerulosclerosis without 
adversely affecting calcium and phosphorus metabolism in subtotally 
nephrectomized rats. Nephrol Dial Transplant. 2002;17:2132-2137 
284. Yokozawa T, Chung HY, Oura H. Urinary constituents and renal function in 
rats administered with adenine. Nippon Jinzo Gakkai Shi. 1987;29:1129-1135 
285. Podjarny E, Bernheim J, Hasdan G, Karsh D, Rashid G, Green J, Katz B. 
Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats 
after 5/6 nephrectomy. Nephrol Dial Transplant. 2007;22:1864-1872 
286. Yokozawa T, Oura H, Nakada T. Blood flow in renal tissue, blood pressure, 
and blood hormone levels in rats with adenine-induced renal failure. Nippon 
Jinzo Gakkai Shi. 1987;29:1145-1151 
287. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB. 
Chronic renal failure is associated with increased tissue deposition of 
lanthanum after 28-day oral administration. Kidney Int. 2005;67:1062-1069 
288. Yokozawa T, Chung HY, Lee TW, Oura H. Renal function and urinary 
prostaglandins in rats given an adenine diet. Nippon Jinzo Gakkai Shi. 
1989;31:671-675 
289. Mehls O, Ritz E, Gilli G, Schmidt-Gayk H, Krempien B, Kourist B, Wesch H, 
Prager P. Skeletal changes and growth in experimental uremia. Nephron. 
1977;18:288-300 
290. Shuvy M, Nyska A, Beeri R, Abedat S, Gal-Moscovici A, Rajamannan NM, 
Lotan C. Histopathology and apoptosis in an animal model of reversible renal 
injury. Exp Toxicol Pathol. 2010 
291. Raine AE, Seymour AM, Roberts AF, Radda GK, Ledingham JG. Impairment 
of cardiac function and energetics in experimental renal failure. J Clin Invest. 
1993;92:2934-2940 
292. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with imagej. 
Biophotonics International. 2004;11:36-42 
293. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in 
rats with renal insufficiency. Kidney Int. 1985;28:775-782 
294. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, 
Chedid K, London AM. Aortic and large artery compliance in end-stage renal 
failure. Kidney Int. 1990;37:137-142 
295. Gottdiener JS, Gross HA, Henry WL, Borer JS, Ebert MH. Effects of self-
induced starvation on cardiac size and function in anorexia nervosa. 
Circulation. 1978;58:425-433 
296. Kollai M, Bonyhay I, Jokkel G, Szonyi L. Cardiac vagal hyperactivity in 
adolescent anorexia nervosa. Eur Heart J. 1994;15:1113-1118 
297. Krinke G. The laboratory rat. Academic Press; 2000. 
298. Ramkissoon RA. Macroscopic identification of early myocardial infarction by 
dehydrogenase alterations. J Clin Pathol. 1966;19:479-481 
299. Kjekshus JK, Maroko PR, Sobel BE. Distribution of myocardial injury and its 
relation to epicardial st-segment changes after coronary artery occlusion in the 
dog. Cardiovasc Res. 1972;6:490-499 
 274 
300. Dikow R, Kihm LP, Zeier M, Kapitza J, T√∂rnig J, Amann K, Tiefenbacher 
C, Ritz E. Increased infarct size in uremic rats: Reduced ischemia tolerance? 
Journal of the American Society of Nephrology : JASN. 2004;15:1530-1536 
301. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute 
myocardial infarction among patients on long-term dialysis. N Engl J Med. 
1998;339:799-805 
302. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, 
Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human 
heart. Circulation. 2005;112:2143-2148 
303. Ceriani L, Verna E, Giovanella L, Bianchi L, Roncari G, Tarolo GL. 
Assessment of myocardial area at risk by technetium-99m sestamibi during 
coronary artery occlusion: Comparison between three tomographic methods of 
quantification. Eur J Nucl Med. 1996;23:31-39 
304. Kaul S, Pandian NG, Okada RD, Pohost GM, Weyman AE. Contrast 
echocardiography in acute myocardial ischemia: I. In vivo determination of 
total left ventricular "area at risk". J Am Coll Cardiol. 1984;4:1272-1282 
305. Ortiz-Perez JT, Meyers SN, Lee DC, Kansal P, Klocke FJ, Holly TA, 
Davidson CJ, Bonow RO, Wu E. Angiographic estimates of myocardium at 
risk during acute myocardial infarction: Validation study using cardiac 
magnetic resonance imaging. Eur Heart J. 2007;28:1750-1758 
306. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, 
Finn JP, Klocke FJ, Judd RM. Relationship of mri delayed contrast 
enhancement to irreversible injury, infarct age, and contractile function. 
Circulation. 1999;100:1992-2002 
307. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher C, 
Ritz E. Increased infarct size in uremic rats: Reduced ischemia tolerance? J 
Am Soc Nephrol. 2004;15:1530-1536 
308. Dikow R, Wasserhess C, Zimmerer K, Kihm LP, Schaier M, Schwenger V, 
Hardt S, Tiefenbacher C, Katus H, Zeier M, Gross LM. Effect of insulin and 
glucose infusion on myocardial infarction size in uraemic rats. Basic Res 
Cardiol. 2009;104:571-579 
309. Greaves SC, Gamble GD, Collins JF, Whalley GA, Sharpe DN. Determinants 
of left ventricular hypertrophy and systolic dysfunction in chronic renal 
failure. Am J Kidney Dis. 1994;24:768-776 
310. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular 
hypertrophy in the predialysis population: Identifying opportunities for 
intervention. Am J Kidney Dis. 1996;27:347-354 
311. Huting J, Kramer W, Schutterle G, Wizemann V. Analysis of left-ventricular 
changes associated with chronic hemodialysis. A noninvasive follow-up study. 
Nephron. 1988;49:284-290 
312. Lipkin GW, Tucker B, Giles M, Raine AE. Ambulatory blood pressure and 
left ventricular mass in cyclosporin- and non-cyclosporin-treated renal 
transplant recipients. J Hypertens. 1993;11:439-442 
313. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, 
Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass 
index increase in early renal disease: Impact of decline in hemoglobin. Am J 
Kidney Dis. 1999;34:125-134 
314. Fellner SK, Lang RM, Neumann A, Korcarz C, Borow KM. Cardiovascular 
consequences of correction of the anemia of renal failure with erythropoietin. 
Kidney Int. 1993;44:1309-1315 
 275 
315. London GM. Brachial arterial pressure to assess cardiovascular structural 
damage: An overview and lessons from clinical trials. J Nephrol. 2008;21:23-
31 
316. Dahan M, Siohan P, Viron B, Michel C, Paillole C, Gourgon R, Mignon F. 
Relationship between left ventricular hypertrophy, myocardial contractility, 
and load conditions in hemodialysis patients: An echocardiographic study. Am 
J Kidney Dis. 1997;30:780-785 
317. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, 
Reboldi G, Porcellati C. Prognostic significance of serial changes in left 
ventricular mass in essential hypertension. Circulation. 1998;97:48-54 
318. Rahman M, Griffin V, Kumar A, Manzoor F, Wright JT, Jr., Smith MC. A 
comparison of standardized versus "usual" blood pressure measurements in 
hemodialysis patients. Am J Kidney Dis. 2002;39:1226-1230 
319. Agarwal R. Blood pressure and mortality among hemodialysis patients. 
Hypertension. 2010;55:762-768 
320. Chaudhuri A, Sutherland SM, Begin B, Salsbery K, McCabe L, Potter D, 
Alexander SR, Wong CJ. Role of twenty-four-hour ambulatory blood pressure 
monitoring in children on dialysis. Clin J Am Soc Nephrol. 2011;6:870-876 
321. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB. 
Regression of left ventricular hypertrophy in hypertensive dialyzed uremic 
patients on long-term antihypertensive therapy. Kidney Int. 1993;44:881-886 
322. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. 
Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave 
reflection in end-stage renal disease. Comparative effects of ace inhibition and 
calcium channel blockade. Circulation. 1994;90:2786-2796 
323. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, 
Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller 
B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, 
Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS. In-center 
hemodialysis six times per week versus three times per week. N Engl J Med. 
2010;363:2287-2300 
324. Ozkahya M, Ok E, Cirit M, Aydin S, Akcicek F, Basci A, Dorhout Mees EJ. 
Regression of left ventricular hypertrophy in haemodialysis patients by 
ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol 
Dial Transplant. 1998;13:1489-1493 
325. Charra B, Calemard M, Laurent G. Importance of treatment time and blood 
pressure control in achieving long-term survival on dialysis. Am J Nephrol. 
1996;16:35-44 
326. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of 
hypertension on cardiomyopathy, morbidity and mortality in end-stage renal 
disease. Kidney Int. 1996;49:1379-1385 
327. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. 
Morphology of coronary atherosclerotic lesions in patients with end-stage 
renal failure. Nephrol Dial Transplant. 2000;15:218-223 
328. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the 
united states with coronary revascularization procedures. Kidney Int. 
1999;56:324-332 
329. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R. 
Influence of coronary collateral vessels on myocardial infarct size in humans. 
 276 
Results of phase i thrombolysis in myocardial infarction (timi) trial. The timi 
investigators. Circulation. 1991;83:739-746 
330. Sezer M, Ozcan M, Okcular I, Elitok A, Umman S, Umman B, Tayyareci Y, 
Olcay A, Nisanci Y, Bilge AK, Meric M. A potential evidence to explain the 
reason behind the devastating prognosis of coronary artery disease in uraemic 
patients: Renal insufficiency is associated with poor coronary collateral vessel 
development. Int J Cardiol. 2007;115:366-372 
331. Passauer J, Bussemaker E, Range U, Plug M, Gross P. Evidence in vivo 
showing increase of baseline nitric oxide generation and impairment of 
endothelium-dependent vasodilation in normotensive patients on chronic 
hemodialysis. J Am Soc Nephrol. 2000;11:1726-1734 
332. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with 
chronic renal disease. Kidney Int. 2000;58:1261-1266 
333. Amann K, Miltenberger-Miltenyi G, Simonoviciene A, Koch A, Orth S, Ritz 
E. Remodeling of resistance arteries in renal failure: Effect of endothelin 
receptor blockade. J Am Soc Nephrol. 2001;12:2040-2050 
334. Amann K, Neususs R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of 
vascular architecture independent of blood pressure in experimental uremia. 
Am J Hypertens. 1995;8:409-417 
335. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall 
thickening, capillary rarefaction and interstitial fibrosis in the heart of rats 
with renal failure:The effects of ramipril, nifedipine and moxonidine. J Am 
Soc Nephrol. 1996;7:667-675 
336. Amann K, Munter K, Wessels S, Wagner J, Balajew V, Hergenroder S, Mall 
G, Ritz E. Endothelin a receptor blockade prevents capillary/myocyte 
mismatch in the heart of uremic animals. J Am Soc Nephrol. 2000;11:1702-
1711 
337. Tok D, Gullu H, Erdogan D, Topcu S, Ciftci O, Yildirim I, Muderrisoglu H. 
Impaired coronary flow reserve in hemodialysis patients: A transthoracic 
doppler echocardiographic study. Nephron Clin Pract. 2005;101:c200-206 
338. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary 
density in the myocardium of uremic rats--a stereological study. Kidney Int. 
1992;42:1079-1085 
339. Amann K, Ritz E. Reduced cardiac ischaemia tolerance in uraemia - what is 
the role of structural abnormalities of the heart? Nephrol Dial Transplant. 
1996;11:1238-1241 
340. Amann K, Neimeier KA, Schwarz U, Tornig J, Matthias S, Orth SR, Mall G, 
Ritz E. Rats with moderate renal failure show capillary deficit in heart but not 
skeletal muscle. Am J Kidney Dis. 1997;30:382-388 
341. Tornig J, Amann K, Nichols C, Schwarz U, Zeier M, Mall G, Ritz E. 
Differential effects of antihypertensive treatment on abnormal cardiac 
structure in uremia [abstract]. J Am Soc Nephrol. 1994;5:796 
342. Amann K, Hofstetter J, Campean V, Koch A, Gross ML, Veelken R, Ritz E. 
Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits 
in the hearts of rats with moderate renal failure. Virchows Arch. 
2006;449:207-214 
343. Nabokov AV, Amann K, Wessels S, Munter K, Wagner J, Ritz E. Endothelin 
receptor antagonists influence cardiovascular morphology in uremic rats. 
Kidney Int. 1999;55:512-519 
 277 
344. Langendorf R, Pirani CL. The heart in uremia; an electrocardiographic and 
pathologic study. Am Heart J. 1947;33:282-307 
345. Weber KT, Brilla CG, Janicki JS. Myocardial remodeling and pathologic 
hypertrophy. Hosp Pract (Off Ed). 1991;26:73-80 
346. Amann K, Mall G, Ritz E. Myocardial interstitial fibrosis in uraemia: Is it 
relevant? Nephrol Dial Transplant. 1994;9:127-128 
347. Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with 
renal failure. Am J Kidney Dis. 1993;21:113-118 
348. Rump LC, Amann K, Orth S, Ritz E. Sympathetic overactivity in renal 
disease: A window to understand progression and cardiovascular 
complications of uraemia? Nephrol Dial Transplant. 2000;15:1735-1738 
349. Ellison KE, Gandhi G. Optimising the use of beta-adrenoceptor antagonists in 
coronary artery disease. Drugs. 2005;65:787-797 
350. Gaasch WH, Zile MR, Hoshino PK, Weinberg EO, Rhodes DR, Apstein CS. 
Tolerance of the hypertrophic heart to ischemia. Studies in compensated and 
failing dog hearts with pressure overload hypertrophy. Circulation. 
1990;81:1644-1653 
351. Mohmand B, Malhotra DK, Shapiro JI. Uremic cardiomyopathy: Role of 
circulating digitalis like substances. Front Biosci. 2005;10:2036-2044 
352. Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-Okdi N, Elkareh J, 
Gupta S, Gohara S, Fedorova OV, Cooper CJ, Xie Z, Malhotra D, Bagrov AY, 
Shapiro JI. Spironolactone attenuates experimental uremic cardiomyopathy by 
antagonizing marinobufagenin. Hypertension. 2009;54:1313-1320 
353. Wittnich C, Chiu RC, McArdle AH. Protection of ischemic myocardium: The 
roles of nutrition and myocardial glycogen. Can J Surg. 1982;25:534-537 
354. Schaefer S, Ramasamy R. Glycogen utilization and ischemic injury in the 
isolated rat heart. Cardiovasc Res. 1997;35:90-98 
355. Gobel FL, Norstrom LA, Nelson RR, Jorgensen CR, Wang Y. The rate-
pressure product as an index of myocardial oxygen consumption during 
exercise in patients with angina pectoris. Circulation. 1978;57:549-556 
356. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after 
temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508 
357. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E. 
Ultrastructural evidence of microvascular damage and myocardial cell injury 
after coronary artery occlusion: Which comes first? Circulation. 1980;62:945-
952 
358. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O. 
Microvascular compression during myocardial ischemia: Mechanistic basis for 
no-reflow phenomenon. Am J Physiol. 1994;266:H1541-1550 
359. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J, Ito H, 
Kitabatake A, Sato T, Kamada T. Role of adenosine in hyperemic response of 
coronary blood flow in microembolization. Am J Physiol. 1986;250:H509-518 
360. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc 
Res. 2009;81:412-419 
361. Ingwall JS. Atp and the heart. 2002:3-6 
362. Bittl JA, Ingwall JS. Reaction rates of creatine kinase and atp synthesis in the 
isolated rat heart. A 31p nmr magnetization transfer study. J Biol Chem. 
1985;260:3512-3517 
363. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical 
energy to support cardiac function. Circ Res. 2004;95:135-145 
 278 
364. Matthews PM, Taylor DJ, Radda GK. Biochemical mechanisms of acute 
contractile failure in the hypoxic rat heart. Cardiovasc Res. 1986;20:13-19 
365. Trentham DR, Eccleston JF, Bagshaw CR. Kinetic analysis of atpase 
mechanisms. Q Rev Biophys. 1976;9:217-281 
366. Van Belle H, Goossens F, Wynants J. Formation and release of purine 
catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol. 
1987;252:H886-893 
367. Hilderman T, McKnight K, Dhalla KS, Rupp H, Dhalla NS. Effects of long-
term dietary restriction on cardiovascular function and plasma catecholamines 
in the rat. Cardiovasc Drugs Ther. 1996;10 Suppl 1:247-250 
368. Belloni FL, Hintze TH. Glibenclamide attenuates adenosine-induced 
bradycardia and coronary vasodilatation. Am J Physiol. 1991;261:H720-727 
369. Smolenski RT, Kalsi KK, Zych M, Kochan Z, Yacoub MH. Adenine/ribose 
supply increases adenosine production and protects atp pool in adenosine 
kinase-inhibited cardiac cells. J Mol Cell Cardiol. 1998;30:673-683 
370. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of 
intracoronary adenosine as an adjunct to primary angioplasty in acute 
myocardial infarction. Circulation. 2000;101:2154-2159 
371. Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor 
involvement in a delayed phase of myocardial protection 24 hours after 
ischemic preconditioning. Circulation. 1994;90:2993-3000 
372. Bernardo NL, Okubo S, Maaieh MM, Wood MA, Kukreja RC. Delayed 
preconditioning with adenosine is mediated by opening of atp-sensitive k(+) 
channels in rabbit heart. Am J Physiol. 1999;277:H128-135 
373. Boutros A, Wang J. Ischemic preconditioning, adenosine and bethanechol 
protect spontaneously hypertensive isolated rat hearts. J Pharmacol Exp Ther. 
1995;275:1148-1156 
374. Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' 
are not mediated by adenosine receptors in rat hearts. Circulation. 
1993;87:1642-1648 
375. Ding YF, Zhang MM, He RR. Role of renal nerve in cardioprotection 
provided by renal ischemic preconditioning in anesthetized rabbits. Sheng Li 
Xue Bao. 2001;53:7-12 
376. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ. Sites of action of 
adenosine in interorgan preconditioning of the heart. Am J Physiol Heart Circ 
Physiol. 2002;283:H29-37 
377. Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T, 
Kinoshita M. Renal ischemia/reperfusion remotely improves myocardial 
energy metabolism during myocardial ischemia via adenosine receptors in 
rabbits: Effects of "remote preconditioning". J Am Coll Cardiol. 1999;33:556-
564 
378. Donato M, D'Annunzio V, Berg G, Gonzalez G, Schreier L, Morales C, 
Wikinski RL, Gelpi RJ. Ischemic postconditioning reduces infarct size by 
activation of a1 receptors and k+(atp) channels in both normal and 
hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2007;49:287-292 
379. Kaur S, Jaggi AS, Singh N. Molecular aspects of ischaemic postconditioning. 
Fundam Clin Pharmacol. 2009;23:521-536 
380. Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, Guyton RA, 
Vinten-Johansen J. Remote postconditioning. Brief renal ischemia and 
reperfusion applied before coronary artery reperfusion reduces myocardial 
 279 
infarct size via endogenous activation of adenosine receptors. Basic Res 
Cardiol. 2005;100:404-412 
381. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, Zhao ZQ, 
Guyton RA, Headrick JP, Vinten-Johansen J. Postconditioning reduces infarct 
size via adenosine receptor activation by endogenous adenosine. Cardiovasc 
Res. 2005;67:124-133 
382. Perrett D, Bhusate L, Patel J, Herbert K. Comparative performance of ion 
exchange and ion-paired reversed phase high performance liquid 
chromatography for the determination of nucleotides in biological samples. 
Biomed Chromatogr. 1991;5:207-211 
383. Dzeja PP, Vitkevicius KT, Redfield MM, Burnett JC, Terzic A. Adenylate 
kinase-catalyzed phosphotransfer in the myocardium : Increased contribution 
in heart failure. Circ Res. 1999;84:1137-1143 
384. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left 
ventricular systolic dysfunction after acute myocardial infarction: Prevalence, 
clinical characteristics, and prognostic importance. Am J Cardiol. 
2006;97:13F-25F 
385. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from 
coronary heart disease in subjects with type 2 diabetes and in nondiabetic 
subjects with and without prior myocardial infarction. N Engl J Med. 
1998;339:229-234 
386. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams 
GR. Impact of the metabolic syndrome on mortality from coronary heart 
disease, cardiovascular disease, and all causes in united states adults. 
Circulation. 2004;110:1245-1250 
387. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo 
JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term 
outcomes of st-segment elevation myocardial infarction and non-st-segment 
elevation myocardial infarction in patients with chronic kidney disease: A 
report from the national cardiovascular data acute coronary treatment and 
intervention outcomes network registry. Circulation. 2010;121:357-365 
388. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay 
of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136 
389. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief 
periods of myocardial ischemia cause no cumulative atp loss or necrosis. Am J 
Physiol. 1986;251:H1306-1315 
390. Gumina RJ, Gross GJ. If ischemic preconditioning is the gold standard, has a 
platinum standard of cardioprotection arrived? Comparison with nhe 
inhibition. J Thromb Thrombolysis. 1999;8:39-44 
391. Yellon DM, Downey JM. Preconditioning the myocardium: From cellular 
physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151 
392. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: Reperfusion-
induced arrhythmias. Am J Physiol. 1987;253:H1470-1476 
393. Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. Ischemic 
preconditioning suppresses ventricular tachyarrhythmias after myocardial 
revascularization. Circulation. 2002;106:3091-3096 
394. DeFily DV, Chilian WM. Preconditioning protects coronary arteriolar 
endothelium from ischemia-reperfusion injury. Am J Physiol. 1993;265:H700-
706 
 280 
395. Gross GJ, Kersten JR, Warltier DC. Mechanisms of postischemic contractile 
dysfunction. Ann Thorac Surg. 1999;68:1898-1904 
396. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein 
elevation 24 hours after brief ischemia or heat stress is associated with 
resistance to myocardial infarction. Circulation. 1993;88:1264-1272 
397. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion 
injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 
1994;94:1621-1628 
398. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning 
protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart 
Circ Physiol. 2005;288:H971-976 
399. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: 
Taking a risk for cardioprotection. Heart Fail Rev. 2007;12:217-234 
400. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of 
death agonist bad in response to survival factor results in binding to 14-3-3 not 
bcl-x(l). Cell. 1996;87:619-628 
401. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, 
Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G. Bax and adenine 
nucleotide translocator cooperate in the mitochondrial control of apoptosis. 
Science. 1998;281:2027-2031 
402. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (pi3k)-
akt pathway suppresses bax translocation to mitochondria. J Biol Chem. 
2002;277:14040-14047 
403. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, 
Wagner EF, Cook SJ. Activation of erk1/2 by deltaraf-1:Er* represses bim 
expression independently of the jnk or pi3k pathways. Oncogene. 
2003;22:1281-1293 
404. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/akt pathway promotes 
translocation of mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci 
U S A. 2001;98:11598-11603 
405. Kennedy SG, Kandel ES, Cross TK, Hay N. Akt/protein kinase b inhibits cell 
death by preventing the release of cytochrome c from mitochondria. Mol Cell 
Biol. 1999;19:5800-5810 
406. Terada K, Kaziro Y, Satoh T. Analysis of ras-dependent signals that prevent 
caspase-3 activation and apoptosis induced by cytokine deprivation in 
hematopoietic cells. Biochem Biophys Res Commun. 2000;267:449-455 
407. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, 
Frisch S, Reed JC. Regulation of cell death protease caspase-9 by 
phosphorylation. Science. 1998;282:1318-1321 
408. Balakirev M, Khramtsov VV, Zimmer G. Modulation of the mitochondrial 
permeability transition by nitric oxide. Eur J Biochem. 1997;246:710-718 
409. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. 
Activation of nitric oxide synthase in endothelial cells by akt-dependent 
phosphorylation. Nature. 1999;399:601-605 
410. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, Critz 
SD. Protein kinase g transmits the cardioprotective signal from cytosol to 
mitochondria. Circ Res. 2005;97:329-336 
411. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not 
pharmacologic preconditioning is abrogated following genetic ablation of the 
tnfalpha gene. Cardiovasc Res. 2002;55:553-560 
 281 
412. Mann DL. Stress-activated cytokines and the heart: From adaptation to 
maladaptation. Annu Rev Physiol. 2003;65:81-101 
413. Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H, 
Sekikawa K, Seishima M. Improved myocardial ischemia/reperfusion injury 
in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol. 
2002;39:1229-1235 
414. Belosjorow S, Bolle I, Duschin A, Heusch G, Schulz R. Tnf-alpha antibodies 
are as effective as ischemic preconditioning in reducing infarct size in rabbits. 
Am J Physiol Heart Circ Physiol. 2003;284:H927-930 
415. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor-alpha 
confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. 
Circulation. 1998;97:1392-1400 
416. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, 
Sivasubramanian N, Entman ML, Mann DL. Endogenous tumor necrosis 
factor protects the adult cardiac myocyte against ischemic-induced apoptosis 
in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A. 
2000;97:5456-5461 
417. Krown KA, Yasui K, Brooker MJ, Dubin AE, Nguyen C, Harris GL, 
McDonough PM, Glembotski CC, Palade PT, Sabbadini RA. Tnf alpha 
receptor expression in rat cardiac myocytes: Tnf alpha inhibition of l-type 
ca2+ current and ca2+ transients. FEBS Lett. 1995;376:24-30 
418. Busquets S, Aranda X, Ribas-Carbo M, Azcon-Bieto J, Lopez-Soriano FJ, 
Argiles JM. Tumour necrosis factor-alpha uncouples respiration in isolated rat 
mitochondria. Cytokine. 2003;22:1-4 
419. Schulz R, Heusch G. Tumor necrosis factor-alpha and its receptors 1 and 2: 
Yin and yang in myocardial infarction? Circulation. 2009;119:1355-1357 
420. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. 
Identification of a novel role for sphingolipid signaling in tnf alpha and 
ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 
2002;34:509-518 
421. Gao Q, Zhang SZ, Cao CM, Bruce IC, Xia Q. The mitochondrial permeability 
transition pore and the ca2+-activated k+ channel contribute to the 
cardioprotection conferred by tumor necrosis factor-alpha. Cytokine. 
2005;32:199-205 
422. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The 
myocardial jak/stat pathway: From protection to failure. Pharmacol Ther. 
2008;120:172-185 
423. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MA, 
Das DK. Role of stat3 in ischemic preconditioning. J Mol Cell Cardiol. 
2001;33:1929-1936 
424. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of stat-
3 and akt is required during the trigger phase of ischaemic preconditioning. 
Cardiovasc Res. 2008;79:127-133 
425. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: Its 
fundamental role in mediating cell death during ischaemia and reperfusion. J 
Mol Cell Cardiol. 2003;35:339-341 
426. Gross ER, Hsu AK, Gross GJ. The jak/stat pathway is essential for opioid-
induced cardioprotection: Jak2 as a mediator of stat3, akt, and gsk-3 beta. Am 
J Physiol Heart Circ Physiol. 2006;291:H827-834 
 282 
427. Fryer RM, Hsu AK, Gross GJ. Mitochondrial k(atp) channel opening is 
important during index ischemia and following myocardial reperfusion in 
ischemic preconditioned rat hearts. J Mol Cell Cardiol. 2001;33:831-834 
428. Holmuhamedov EL, Wang L, Terzic A. Atp-sensitive k+ channel openers 
prevent ca2+ overload in rat cardiac mitochondria. J Physiol. 1999;519 Pt 
2:347-360 
429. Akao M, Ohler A, O'Rourke B, Marban E. Mitochondrial atp-sensitive 
potassium channels inhibit apoptosis induced by oxidative stress in cardiac 
cells. Circ Res. 2001;88:1267-1275 
430. Lipton AJ, Johnson MA, Macdonald T, Lieberman MW, Gozal D, Gaston B. 
S-nitrosothiols signal the ventilatory response to hypoxia. Nature. 
2001;413:171-174 
431. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, Wuthrich RP. 
Interpretation of erythropoietin levels in patients with various degrees of renal 
insufficiency and anemia. Kidney Int. 2004;66:1206-1211 
432. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul 
Pharmacol. 2005;42:233-241 
433. Rafiee P, Shi Y, Su J, Pritchard KA, Jr., Tweddell JS, Baker JE. 
Erythropoietin protects the infant heart against ischemia-reperfusion injury by 
triggering multiple signaling pathways. Basic Res Cardiol. 2005;100:187-197 
434. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. 
Mechanisms of erythropoietin-mediated cardioprotection during ischemia-
reperfusion injury: Role of protein kinase c and phosphatidylinositol 3-kinase 
signaling. FASEB J. 2005;19:1323-1325 
435. Diwan V, Kant R, Jaggi AS, Singh N, Singh D. Signal mechanism activated 
by erythropoietin preconditioning and remote renal preconditioning-induced 
cardioprotection. Mol Cell Biochem. 2008;315:195-201 
436. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, 
Semenza GL. Hearts from rodents exposed to intermittent hypoxia or 
erythropoietin are protected against ischemia-reperfusion injury. Circulation. 
2003;108:79-85 
437. Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK. Anemia is an independent 
predictor of mortality after percutaneous coronary intervention. J Am Coll 
Cardiol. 2004;44:541-546 
438. Haworth RA, Hunter DR. The ca2+-induced membrane transition in 
mitochondria. Ii. Nature of the ca2+ trigger site. Arch Biochem Biophys. 
1979;195:460-467 
439. Hunter DR, Haworth RA. The ca2+-induced membrane transition in 
mitochondria. I. The protective mechanisms. Arch Biochem Biophys. 
1979;195:453-459 
440. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability 
transition pore as a target for preconditioning and postconditioning. Basic Res 
Cardiol. 2009;104:189-202 
441. Di Lisa F, Bernardi P. A capful of mechanisms regulating the mitochondrial 
permeability transition. J Mol Cell Cardiol. 2009;46:775-780 
442. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition 
pore in heart disease. Biochim Biophys Acta. 2009;1787:1402-1415 
443. Crompton M, Costi A. Kinetic evidence for a heart mitochondrial pore 
activated by ca2+, inorganic phosphate and oxidative stress. A potential 
 283 
mechanism for mitochondrial dysfunction during cellular ca2+ overload. Eur J 
Biochem. 1988;178:489-501 
444. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial 
permeability transition pore opening: A new paradigm for myocardial 
preconditioning? Cardiovasc Res. 2002;55:534-543 
445. Argaud L, Gateau-Roesch O, Chalabreysse L, Gomez L, Loufouat J, Thivolet-
Bejui F, Robert D, Ovize M. Preconditioning delays ca2+-induced 
mitochondrial permeability transition. Cardiovasc Res. 2004;61:115-122 
446. Ylitalo KV, Ala-Rami A, Liimatta EV, Peuhkurinen KJ, Hassinen IE. 
Intracellular free calcium and mitochondrial membrane potential in 
ischemia/reperfusion and preconditioning. J Mol Cell Cardiol. 2000;32:1223-
1238 
447. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the 
reperfusion phase. Basic Res Cardiol. 2007;102:445-452 
448. Korge P, Honda HM, Weiss JN. Protection of cardiac mitochondria by 
diazoxide and protein kinase c: Implications for ischemic preconditioning. 
Proc Natl Acad Sci U S A. 2002;99:3312-3317 
449. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The 
mechanism by which the mitochondrial atp-sensitive k+ channel opening and 
h2o2 inhibit the mitochondrial permeability transition. J Biol Chem. 
2006;281:20801-20808 
450. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, 
Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase 
kinase-3beta mediates convergence of protection signaling to inhibit the 
mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549 
451. Costa AD, Garlid KD. Intramitochondrial signaling: Interactions among 
mitokatp, pkcepsilon, ros, and mpt. Am J Physiol Heart Circ Physiol. 
2008;295:H874-882 
452. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, 
Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, 
Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, 
Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute 
myocardial infarction. N Engl J Med. 2008;359:473-481 
453. Carr-White G, Koh T, DeSouza A, Haxby E, Kemp M, Hooper J, Gibson D, 
Pepper J. Chronic stable ischaemia protects against myocyte damage during 
beating heart coronary surgery. Eur J Cardiothorac Surg. 2004;25:772-778 
454. Heusch P, Skyschally A, Leineweber K, Haude M, Erbel R. The interaction of 
coronary microembolization and ischemic preconditioning: A third window of 
cardioprotection through tnf-alpha. Arch Med Sci. 2007;2:83-92 
455. Szilvassy Z, Ferdinandy P, Szilvassy J, Nagy I, Karcsu S, Lonovics J, Dux L, 
Koltai M. The loss of pacing-induced preconditioning in atherosclerotic 
rabbits: Role of hypercholesterolaemia. J Mol Cell Cardiol. 1995;27:2559-
2569 
456. Iliodromitis EK, Zoga A, Vrettou A, Andreadou I, Paraskevaidis IA, 
Kaklamanis L, Kremastinos DT. The effectiveness of postconditioning and 
preconditioning on infarct size in hypercholesterolemic and normal 
anesthetized rabbits. Atherosclerosis. 2006;188:356-362 
457. Kocic I, Konstanski Z, Kaminski M, Dworakowska D, Dworakowski R. 
Experimental hyperlipidemia prevents the protective effect of ischemic 
 284 
preconditioning on the contractility and responsiveness to phenylephrine of 
rat-isolated stunned papillary muscle. Gen Pharmacol. 1999;33:213-219 
458. Tang XL, Takano H, Xuan YT, Sato H, Kodani E, Dawn B, Zhu Y, Shirk G, 
Wu WJ, Bolli R. Hypercholesterolemia abrogates late preconditioning via a 
tetrahydrobiopterin-dependent mechanism in conscious rabbits. Circulation. 
2005;112:2149-2156 
459. Csonka C, Csont T, Onody A, Ferdinandy P. Preconditioning decreases 
ischemia/reperfusion-induced peroxynitrite formation. Biochem Biophys Res 
Commun. 2001;285:1217-1219 
460. Onody A, Csonka C, Giricz Z, Ferdinandy P. Hyperlipidemia induced by a 
cholesterol-rich diet leads to enhanced peroxynitrite formation in rat hearts. 
Cardiovasc Res. 2003;58:663-670 
461. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. 
Hyperlipidemia attenuates the infarct size-limiting effect of ischemic 
preconditioning: Role of matrix metalloproteinase-2 inhibition. J Pharmacol 
Exp Ther. 2006;316:154-161 
462. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(atp) channel 
opening is an endogenous mechanism of protection against the no-reflow 
phenomenon but its function is compromised by hypercholesterolemia. J Am 
Coll Cardiol. 2002;40:1339-1346 
463. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. 
Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning 
during coronary angioplasty. Chest. 2005;128:1623-1628 
464. Tatsumi T, Matoba S, Kobara M, Keira N, Kawahara A, Tsuruyama K, 
Tanaka T, Katamura M, Nakagawa C, Ohta B, Yamahara Y, Asayama J, 
Nakagawa M. Energy metabolism after ischemic preconditioning in 
streptozotocin-induced diabetic rat hearts. J Am Coll Cardiol. 1998;31:707-
715 
465. Ravingerova T, Stetka R, Pancza D, Ulicna O, Ziegelhoffer A, Styk J. 
Susceptibility to ischemia-induced arrhythmias and the effect of 
preconditioning in the diabetic rat heart. Physiol Res. 2000;49:607-616 
466. Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ. Influence of 
diabetic state and that of different sulfonylureas on the size of myocardial 
infarction with and without ischemic preconditioning in rabbits. Exp Clin 
Endocrinol Diabetes. 2002;110:212-218 
467. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes 
ischemic preconditioning: Role of glucose, insulin, and osmolality. Am J 
Physiol Heart Circ Physiol. 2000;278:H1218-1224 
468. Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute 
hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. 
1998;275:H721-725 
469. Wynne, Hausenloy DJ, Mocanu M, DM. Y. Adenosine preconditioning 
attenuates ischemia and reperfusion injury in young adult but not aged rat 
cardiomyocytes J Mol Cell Cardiol. 2007:s177 
470. del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection 
against stunning in conscious diabetic sheep: Role of glucose, insulin, 
sarcolemmal and mitochondrial katp channels. Cardiovasc Res. 2002;55:642-
659 
 285 
471. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination 
of benfotiamine and fenofibrate in diabetes-induced vascular endothelial 
dysfunction and nephropathy in the rat. Mol Cell Biochem. 2009;320:149-162 
472. Miki T, Miura T, Tsuchida A, Nakano A, Hasegawa T, Fukuma T, Shimamoto 
K. Cardioprotective mechanism of ischemic preconditioning is impaired by 
postinfarct ventricular remodeling through angiotensin ii type 1 receptor 
activation. Circulation. 2000;102:458-463 
473. Moolman JA, Genade S, Tromp E, Opie LH, Lochner A. Ischaemic 
preconditioning does not protect hypertrophied myocardium against 
ischaemia. S Afr Med J. 1997;87 Suppl 3:C151-156 
474. Riess ML, Camara AK, Rhodes SS, McCormick J, Jiang MT, Stowe DF. 
Increasing heart size and age attenuate anesthetic preconditioning in guinea 
pig isolated hearts. Anesth Analg. 2005;101:1572-1576 
475. Juhaszova M, Rabuel C, Zorov DB, Lakatta EG, Sollott SJ. Protection in the 
aged heart: Preventing the heart-break of old age? Cardiovasc Res. 
2005;66:233-244 
476. Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic 
preconditioning in middle-aged and old rabbits. J Am Coll Cardiol. 
2001;38:1741-1747 
477. Abete P, Ferrara N, Cioppa A, Ferrara P, Bianco S, Calabrese C, Cacciatore F, 
Longobardi G, Rengo F. Preconditioning does not prevent postischemic 
dysfunction in aging heart. J Am Coll Cardiol. 1996;27:1777-1786 
478. Fenton RA, Dickson EW, Meyer TE, Dobson JG, Jr. Aging reduces the 
cardioprotective effect of ischemic preconditioning in the rat heart. J Mol Cell 
Cardiol. 2000;32:1371-1375 
479. Schulman D, Latchman DS, Yellon DM. Effect of aging on the ability of 
preconditioning to protect rat hearts from ischemia-reperfusion injury. Am J 
Physiol Heart Circ Physiol. 2001;281:H1630-1636 
480. Tani M, Honma Y, Hasegawa H, Tamaki K. Direct activation of 
mitochondrial k(atp) channels mimics preconditioning but protein kinase c 
activation is less effective in middle-aged rat hearts. Cardiovasc Res. 
2001;49:56-68 
481. Katakam PV, Jordan JE, Snipes JA, Tulbert CD, Miller AW, Busija DW. 
Myocardial preconditioning against ischemia-reperfusion injury is abolished 
in zucker obese rats with insulin resistance. Am J Physiol Regul Integr Comp 
Physiol. 2007;292:R920-926 
482. Sharma M, Rai SK, Tiwari M, Chandra R. Effect of hyperhomocysteinemia on 
cardiovascular risk factors and initiation of atherosclerosis in wistar rats. Eur J 
Pharmacol. 2007;574:49-60 
483. Balakumar P, Rohilla A, Singh G, Singh K, Singh M. Modulation of 
cardioprotective effect of ischemic pre- and postconditioning in the 
hyperhomocysteinemic rat heart. Methods Find Exp Clin Pharmacol. 
2009;31:71-79 
484. Singh G, Rohilla A, Singh M, Balakumar P. Possible role of jak-2 in 
attenuated cardioprotective effect of ischemic preconditioning in 
hyperhomocysteinemic rat hearts. Yakugaku Zasshi. 2009;129:523-535 
485. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, 
and independent of lipid lowering, protects the myocardium by up-regulating a 
pro-survival pathway. J Am Coll Cardiol. 2003;41:508-515 
 286 
486. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by 
insulin at reperfusion requires early administration and is mediated via akt and 
p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191-1198 
487. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson 
RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect 
of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007 
488. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is 
protective against myocardial ischemia/reperfusion injury when given either 
as a preconditioning mimetic or at reperfusion in an isolated rat heart model. 
Cardiovasc Drugs Ther. 2005;19:9-11 
489. Medi C, Montalescot G, Budaj A, Fox KA, Lopez-Sendon J, FitzGerald G, 
Brieger DB. Reperfusion in patients with renal dysfunction after presentation 
with st-segment elevation or left bundle branch block: Grace (global registry 
of acute coronary events). JACC Cardiovasc Interv. 2009;2:26-33 
490. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal 
disease in randomized controlled trials of cardiovascular disease. JAMA. 
2006;296:1377-1384 
491. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease 
from clinical trials in coronary artery disease. Kidney Int. 2006;70:2021-2030 
492. Andrikopoulos P, Fraser SP, Patterson L, Ahmad Z, Burcu H, Ottaviani D, 
Diss JK, Box C, Eccles SA, Djamgoz MB. Angiogenic functions of voltage-
gated na+ channels in human endothelial cells: Modulation of vascular 
endothelial growth factor (vegf) signalling. J Biol Chem. 2011 
493. Manintveld OC, Te Lintel Hekkert M, van den Bos EJ, Suurenbroek GM, 
Dekkers DH, Verdouw PD, Lamers JM, Duncker DJ. Cardiac effects of 
postconditioning depend critically on the duration of index ischemia. Am J 
Physiol Heart Circ Physiol. 2007;292:H1551-1560 
494. Braunwald E, Kloner RA. Myocardial reperfusion: A double-edged sword? J 
Clin Invest. 1985;76:1713-1719 
495. Smith CC, Mocanu MM, Bowen J, Wynne AM, Simpkin JC, Dixon RA, 
Cooper MB, Yellon DM. Temporal changes in myocardial salvage kinases 
during reperfusion following ischemia: Studies involving the cardioprotective 
adipocytokine apelin. Cardiovasc Drugs Ther. 2007;21:409-414 
496. Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM. Preconditioning the 
diabetic human myocardium. J Cell Mol Med. 2009;Volume 14: pages 1740–
1746 
497. Botsford MW, Lukas A. Ischemic preconditioning and arrhythmogenesis in 
the rabbit heart: Effects on epicardium versus endocardium. J Mol Cell 
Cardiol. 1998;30:1723-1733 
498. Buyukates M, Kalaycioglu S, Oz E, Soncul H. Effects of ischemic 
preconditioning in human heart. J Card Surg. 2005;20:241-245 
499. Das B, Sarkar C. Similarities between ischemic preconditioning and 17beta-
estradiol mediated cardiomyocyte katp channel activation leading to 
cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the 
intact rabbit heart. J Cardiovasc Pharmacol. 2006;47:277-286 
500. Fu LL, Xia Q, Shen YL, Wong TM. [involvement of endogenous opioids in 
cardioprotective effects of ischemic preconditioning in the isolated rat heart]. 
Sheng Li Xue Bao. 1998;50:603-610 
501. Galagudza M, Kurapeev D, Minasian S, Valen G, Vaage J. Ischemic 
postconditioning: Brief ischemia during reperfusion converts persistent 
 287 
ventricular fibrillation into regular rhythm. Eur J Cardiothorac Surg. 
2004;25:1006-1010 
502. Parratt J, Vegh A. Pronounced antiarrhythmic effects of ischemic 
preconditioning. Cardioscience. 1994;5:9-18 
503. Matejikova J, Ravingerova T, Pancza D, Carnicka S, Kolar F. Mitochondrial 
katp opening confers protection against lethal myocardial injury and 
ischaemia-induced arrhythmias in the rat heart via pi3k/akt-dependent and -
independent mechanisms. Can J Physiol Pharmacol. 2009;87:1055-1062 
504. Miura T, Ishimoto R, Sakamoto J, Tsuchida A, Suzuki K, Ogawa T, 
Shimamoto K, Iimura O. Suppression of reperfusion arrhythmia by ischemic 
preconditioning in the rat: Is it mediated by the adenosine receptor, 
prostaglandin, or bradykinin receptor? Basic Res Cardiol. 1995;90:240-246 
505. Driamov S, Bellahcene M, Ziegler A, Barbosa V, Traub D, Butz S, Buser PT, 
Zaugg CE. Antiarrhythmic effect of ischemic preconditioning during low-flow 
ischemia. The role of bradykinin and sarcolemmal versus mitochondrial atp-
sensitive k(+) channels. Basic Res Cardiol. 2004;99:299-308 
506. Usrds 2009 annual data report: Atlas of end-stage renal disease in the united 
states. 2009 
507. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Sudden 
cardiac death in end-stage renal disease patients: A 5-year prospective 
analysis. Hypertension. 2010;56:210-216 
508. Bigger JT, Jr., Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The 
relationships among ventricular arrhythmias, left ventricular dysfunction, and 
mortality in the 2 years after myocardial infarction. Circulation. 1984;69:250-
258 
509. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, Taylor AJ. 
Myocardial fibrosis predicts appropriate device therapy in patients with 
implantable cardioverter-defibrillators for primary prevention of sudden 
cardiac death. J Am Coll Cardiol. 2011;57:821-828 
510. Vegh A, Szekeres L, Parratt JR. Transient ischaemia induced by rapid cardiac 
pacing results in myocardial preconditioning. Cardiovasc Res. 1991;25:1051-
1053 
511. Vanagt WY, Cornelussen RN, Poulina QP, Blaauw E, Vernooy K, Cleutjens 
JP, van Bilsen M, Delhaas T, Prinzen FW. Pacing-induced dys-synchrony 
preconditions rabbit myocardium against ischemia/reperfusion injury. 
Circulation. 2006;114:I264-269 
512. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-
Johansen J. Inhibition of myocardial injury by ischemic postconditioning 
during reperfusion: Comparison with ischemic preconditioning. Am J Physiol 
Heart Circ Physiol. 2003;285:H579-588 
513. Sato H, Jordan JE, Zhao ZQ, Sarvotham SS, Vinten-Johansen J. Gradual 
reperfusion reduces infarct size and endothelial injury but augments neutrophil 
accumulation. Ann Thorac Surg. 1997;64:1099-1107 
514. Vinten-Johansen J. Controlled coronary hydrodynamics at the time of 
reperfusion reduces postischemic injury. Coron Artery Dis. 1992;3:1081-1094 
515. Hori M, Kitakaze M, Sato H, Takashima S, Iwakura K, Inoue M, Kitabatake 
A, Kamada T. Staged reperfusion attenuates myocardial stunning in dogs. 
Role of transient acidosis during early reperfusion. Circulation. 1991;84:2135-
2145 
 288 
516. Przyklenk K. Lethal myocardial "reperfusion injury": The opinions of good 
men. J Thromb Thrombolysis. 1997;4:5-6 
517. Schaper W, Schaper J. Reperfusion injury: An opinionated view. J Thromb 
Thrombolysis. 1997;4:113-116 
518. Eltze T, Boer R, Wagner T, Weinbrenner S, McDonald MC, Thiemermann C, 
Burkle A, Klein T. Imidazoquinolinone, imidazopyridine, and 
isoquinolindione derivatives as novel and potent inhibitors of the poly(adp-
ribose) polymerase (parp): A comparison with standard parp inhibitors. Mol 
Pharmacol. 2008;74:1587-1598 
519. Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H, Zvara DA, Xu Z. 
Adenosine a2a and a2b receptors work in concert to induce a strong protection 
against reperfusion injury in rat hearts. J Mol Cell Cardiol. 2009;47:684-690 
520. Penna C, Mancardi D, Tullio F, Pagliaro P. Postconditioning and intermittent 
bradykinin induced cardioprotection require cyclooxygenase activation and 
prostacyclin release during reperfusion. Basic Res Cardiol. 2008;103:368-377 
521. Zatta AJ, Kin H, Yoshishige D, Jiang R, Wang N, Reeves JG, Mykytenko J, 
Guyton RA, Zhao ZQ, Caffrey JL, Vinten-Johansen J. Evidence that 
cardioprotection by postconditioning involves preservation of myocardial 
opioid content and selective opioid receptor activation. Am J Physiol Heart 
Circ Physiol. 2008;294:H1444-1451 
522. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, 
Heusch G. Ischemic postconditioning: Experimental models and protocol 
algorithms. Basic Res Cardiol. 2009;104:469-483 
523. Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R, Perrelli MG, 
Mancardi D, Pagliaro P. Postconditioning cardioprotection against infarct size 
and post-ischemic systolic dysfunction is influenced by gender. Basic Res 
Cardiol. 2009;104:390-402 
524. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, Kerendi F, 
Guyton RA, Vinten-Johansen J. Postconditioning attenuates myocardial 
ischemia-reperfusion injury by inhibiting events in the early minutes of 
reperfusion. Cardiovasc Res. 2004;62:74-85 
525. Gritsopoulos G, Iliodromitis EK, Zoga A, Farmakis D, Demerouti E, Papalois 
A, Paraskevaidis IA, Kremastinos DT. Remote postconditioning is more 
potent than classic postconditioning in reducing the infarct size in anesthetized 
rabbits. Cardiovasc Drugs Ther. 2009;23:193-198 
526. Fujita M, Asanuma H, Hirata A, Wakeno M, Takahama H, Sasaki H, Kim J, 
Takashima S, Tsukamoto O, Minamino T, Shinozaki Y, Tomoike H, Hori M, 
Kitakaze M. Prolonged transient acidosis during early reperfusion contributes 
to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ 
Physiol. 2007;292:H2004-2008 
527. Zhao JL, Yang YJ, You SJ, Cui CJ, Gao RL. Different effects of 
postconditioning on myocardial no-reflow in the normal and 
hypercholesterolemic mini-swines. Microvascular research. 2007;73:137-142 
528. Iliodromitis EK, Georgiadis M, Cohen MV, Downey JM, Bofilis E, 
Kremastinos DT. Protection from post-conditioning depends on the number of 
short ischemic insults in anesthetized pigs. Basic Res Cardiol. 2006;101:502-
507 
529. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, 
Warltier DC. Isoflurane protects against myocardial infarction during early 
reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: 
 289 
Evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology. 
2005;102:102-109 
530. Zhao H, Sapolsky RM, Steinberg GK. Interrupting reperfusion as a stroke 
therapy: Ischemic postconditioning reduces infarct size after focal ischemia in 
rats. J Cereb Blood Flow Metab. 2006;26:1114-1121 
531. Liu X, Chen H, Zhan B, Xing B, Zhou J, Zhu H, Chen Z. Attenuation of 
reperfusion injury by renal ischemic postconditioning: The role of no. 
Biochem Biophys Res Commun. 2007;359:628-634 
532. Zeng Z, Huang HF, Chen MQ, Song F, Zhang YJ. Postconditioning prevents 
ischemia/reperfusion injury in rat liver transplantation. 
Hepatogastroenterology. 2010;57:875-881 
533. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy 
DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R. Postconditioning 
and protection from reperfusion injury: Where do we stand? Position paper 
from the working group of cellular biology of the heart of the european society 
of cardiology. Cardiovasc Res. 2010;87:406-423 
534. Burley DS, Baxter GF. Pharmacological targets revealed by myocardial 
postconditioning. Curr Opin Pharmacol. 2009;9:177-188 
535. Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent 
activation of bradykinin b2 receptors and mitochondrial katp channels trigger 
cardiac postconditioning through redox signaling. Cardiovasc Res. 
2007;75:168-177 
536. Xi L, Das A, Zhao ZQ, Merino VF, Bader M, Kukreja RC. Loss of myocardial 
ischemic postconditioning in adenosine a1 and bradykinin b2 receptors gene 
knockout mice. Circulation. 2008;118:S32-37 
537. Piper HM, Balser C, Ladilov YV, Schafer M, Siegmund B, Ruiz-Meana M, 
Garcia-Dorado D. The role of na+/h+ exchange in ischemia-reperfusion. Basic 
Res Cardiol. 1996;91:191-202 
538. Inserte J, Barba I, Hernando V, Garcia-Dorado D. Delayed recovery of 
intracellular acidosis during reperfusion prevents calpain activation and 
determines protection in postconditioned myocardium. Cardiovasc Res. 
2009;81:116-122 
539. Ruiz-Meana M, Pina P, Garcia-Dorado D, Rodriguez-Sinovas A, Barba I, 
Miro-Casas E, Mirabet M, Soler-Soler J. Glycine protects cardiomyocytes 
against lethal reoxygenation injury by inhibiting mitochondrial permeability 
transition. J Physiol. 2004;558:873-882 
540. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are 
refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol. 
2008;51:1393-1398 
541. Sivaraman V, Mudalagiri NR, Di Salvo C, Kolvekar S, Hayward M, Yap J, 
Keogh B, Hausenloy DJ, Yellon DM. Postconditioning protects human atrial 
muscle through the activation of the risk pathway. Basic Res Cardiol. 
2007;102:453-459 
542. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, 
Schulz R, Heusch G. Ischemic postconditioning in pigs: No causal role for 
risk activation. Circ Res. 2009;104:15-18 
543. Musiolik J, van Caster P, Skyschally A, Boengler K, Gres P, Schulz R, 
Heusch G. Reduction of infarct size by gentle reperfusion without activation 
of reperfusion injury salvage kinases in pigs. Cardiovasc Res. 2010;85:110-
117 
 290 
544. Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects 
against reperfusion injury via the safe pathway. Cardiovasc Res. 2009;84:201-
208 
545. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, 
Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and 
stat3-deficient mice. Circ Res. 2008;102:131-135 
546. Heusch G, Boengler K, Schulz R. Cardioprotection: Nitric oxide, protein 
kinases, and mitochondria. Circulation. 2008;118:1915-1919 
547. Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S, Gattullo D, 
Losano G, Pagliaro P. Post-conditioning induced cardioprotection requires 
signaling through a redox-sensitive mechanism, mitochondrial atp-sensitive 
k+ channel and protein kinase c activation. Basic Res Cardiol. 2006;101:180-
189 
548. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. 
Postconditioning inhibits mitochondrial permeability transition. Circulation. 
2005;111:194-197 
549. Meier JM, Urban P, Goy JJ. Postconditioning inhibits mitochondrial 
permeability transition. Future Cardiol. 2005;1:457-460 
550. Halkos ME, Kerendi F, Corvera JS, Wang NP, Kin H, Payne CS, Sun HY, 
Guyton RA, Vinten-Johansen J, Zhao ZQ. Myocardial protection with 
postconditioning is not enhanced by ischemic preconditioning. Ann Thorac 
Surg. 2004;78:961-969; discussion 969 
551. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, 
Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, 
Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M. Long-term 
benefit of postconditioning. Circulation. 2008;117:1037-1044 
552. Wang G, Zhang S, Joggerst SJ, McPherson J, Zhao DX. Effects of the number 
and interval of balloon inflations during primary pci on the extent of 
myocardial injury in patients with stemi: Does postconditioning exist in real-
world practice? J Invasive Cardiol. 2009;21:451-455 
553. Chen R, Luo WJ, Jiang HH, Long L, Huang RM, Luo FY. [cardiopulmonary 
protection of ischemic postconditioning in cardiac surgery in children with 
tetralogy of fallot]. Zhongguo Dang Dai Er Ke Za Zhi. 2009;11:273-276 
554. Luo W, Li B, Lin G, Huang R. Postconditioning in cardiac surgery for 
tetralogy of fallot. J Thorac Cardiovasc Surg. 2007;133:1373-1374 
555. Li B, Chen R, Huang R, Luo W. Clinical benefit of cardiac ischemic 
postconditioning in corrections of tetralogy of fallot. Interact Cardiovasc 
Thorac Surg. 2009;8:17-21 
556. Luo W, Li B, Lin G, Chen R, Huang R. Does cardioplegia leave room for 
postconditioning in paediatric cardiac surgery? Cardiol Young. 2008;18:282-
287 
557. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in 
coronary flow reserve and st-segment resolution during percutaneous coronary 
intervention for acute myocardial infarction: A benefit of postconditioning. 
Catheter Cardiovasc Interv. 2008;72:212-220 
558. Zhao WS, Xu L, Wang LF, Zhang L, Zhang ZY, Liu Y, Liu XL, Yang XC, 
Cui L. A 60-s postconditioning protocol by percutaneous coronary 
intervention inhibits myocardial apoptosis in patients with acute myocardial 
infarction. Apoptosis. 2009;14:1204-1211 
 291 
559. Xue F, Yang X, Zhang B, Zhao C, Song J, Jiang T, Jiang W. Postconditioning 
the human heart in percutaneous coronary intervention. Clin Cardiol. 
2010;33:439-444 
560. Luo W, Li B, Chen R, Huang R, Lin G. Effect of ischemic postconditioning in 
adult valve replacement. Eur J Cardiothorac Surg. 2008;33:203-208 
561. Lonborg J, Kelbaek H, Vejlstrup N, Jorgensen E, Helqvist S, Saunamaki K, 
Clemmensen P, Holmvang L, Treiman M, Jensen JS, Engstrom T. 
Cardioprotective effects of ischemic postconditioning in patients treated with 
primary percutaneous coronary intervention, evaluated by magnetic resonance. 
Circ Cardiovasc Interv. 2010;3:34-41 
562. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, Wang HS, Li WM, Xu 
L, Ni ZH, Liu SH, Zhang L, Jia HM, Vinten-Johansen J, Zhao ZQ. Reduction 
in myocardial infarct size by postconditioning in patients after percutaneous 
coronary intervention. J Invasive Cardiol. 2007;19:424-430 
563. Ma XJ, Zhang XH, Luo M, Li CM, Shao JH. [effects of preconditioning and 
postconditioning on emergency percutaneous coronary intervention in patients 
with acute myocardial infarction]. Zhonghua Yi Xue Za Zhi. 2007;87:114-117 
564. Ma XJ, Zhang XH, Li CM, Luo M. Effect of postconditioning on coronary 
blood flow velocity and endothelial function in patients with acute myocardial 
infarction. Scand Cardiovasc J. 2006;40:327-333 
565. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood 
flow velocity and endothelial function and lv recovery after myocardial 
infarction. J Interv Cardiol. 2006;19:367-375 
566. Crisostomo PR, Wang M, Wairiuko GM, Terrell AM, Meldrum DR. 
Postconditioning in females depends on injury severity. J Surg Res. 
2006;134:342-347 
567. Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, Marais de W, 
Csont T, Ferdinandy P. Cholesterol diet-induced hyperlipidemia impairs the 
cardioprotective effect of postconditioning: Role of peroxynitrite. Am J 
Physiol Heart Circ Physiol. 2009;297:H1729-1735 
568. Przyklenk K, Maynard M, Greiner D, Whittaker P. Abstract 1905: Restoration 
of normoglycemia re-establishes the infarct-sparing effect of postconditioning 
in diabetic mice. Circulation Supplement. 2008;118 
569. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial 
ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob 
mice. Am J Physiol Heart Circ Physiol. 2008;295:H1580-1586 
570. Oikawa M, Yaoita H, Watanabe K, Maruyama Y. Attenuation of 
cardioprotective effect by postconditioning in coronary stenosed rat heart and 
its restoration by carvedilol. Circ J. 2008;72:2081-2086 
571. Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E, Giricz 
Z, Janaky T, van Rooyen J, Csont T, Ferdinandy P. Lovastatin interferes with 
the infarct size-limiting effect of ischemic preconditioning and 
postconditioning in rat hearts. Am J Physiol Heart Circ Physiol. 
2008;294:H2406-2409 
572. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, Stumpner J, 
Roewer N, Kehl F. Desflurane-induced postconditioning is mediated by beta-
adrenergic signaling: Role of beta 1- and beta 2-adrenergic receptors, protein 
kinase a, and calcium/calmodulin-dependent protein kinase ii. Anesthesiology. 
2009;110:516-528 
 292 
573. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The 
influence of mitochondrial katp-channels in the cardioprotection of 
preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth 
Analg. 2005;101:1252-1260 
574. Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, 
Setsuda M, Makino K, Yamakado T, Nakano T. Impact of nicorandil to 
prevent reperfusion injury in patients with acute myocardial infarction: 
Sigmart multicenter angioplasty revascularization trial (smart). Circ J. 
2006;70:1099-1104 
575. Dow J, Bhandari A, Kloner RA. The mechanism by which ischemic 
postconditioning reduces reperfusion arrhythmias in rats remains elusive. J 
Cardiovasc Pharmacol Ther. 2009;14:99-103 
576. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the 
myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 
2005;100:397-403 
577. Jagtap P, Szabo C. Poly(adp-ribose) polymerase and the therapeutic effects of 
its inhibitors. Nat Rev Drug Discov. 2005;4:421-440 
578. Pacher P, Szabo C. Role of poly(adp-ribose) polymerase 1 (parp-1) in 
cardiovascular diseases: The therapeutic potential of parp inhibitors. 
Cardiovasc Drug Rev. 2007;25:235-260 
579. Virag L, Szabo C. The therapeutic potential of poly(adp-ribose) polymerase 
inhibitors. Pharmacol Rev. 2002;54:375-429 
580. Mabley JG, Wallace R, Pacher P, Murphy K, Szabo C. Inhibition of 
poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin 
d. Int J Mol Med. 2007;19:947-952 
581. Geraets L, Moonen HJ, Wouters EF, Bast A, Hageman GJ. Caffeine 
metabolites are inhibitors of the nuclear enzyme poly(adp-ribose)polymerase-
1 at physiological concentrations. Biochem Pharmacol. 2006;72:902-910 
582. Kun E, Kirsten E, Mendeleyev J, Ordahl CP. Regulation of the enzymatic 
catalysis of poly(adp-ribose) polymerase by dsdna, polyamines, mg2+, ca2+, 
histones h1 and h3, and atp. Biochemistry. 2004;43:210-216 
583. Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, Swanson RA. 
Direct phosphorylation and regulation of poly(adp-ribose) polymerase-1 by 
extracellular signal-regulated kinases 1/2. Proc Natl Acad Sci U S A. 
2006;103:7136-7141 
584. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, 
Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, 
Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular 
characterization of mitochondrial apoptosis-inducing factor. Nature. 
1999;397:441-446 
585. Szabo C. Poly(adp-ribose) polymerase activation by reactive nitrogen species-
-relevance for the pathogenesis of inflammation. Nitric Oxide. 2006;14:169-
179 
586. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in 
myocardial ischaemia-reperfusion injury and preconditioning. Br J 
Pharmacol. 2003;138:532-543 
587. Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion 
injury. Annu Rev Physiol. 1990;52:561-576 
588. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and 
disease. Physiol Rev. 2007;87:315-424 
 293 
589. Bowes J, McDonald MC, Piper J, Thiemermann C. Inhibitors of poly (adp-
ribose) synthetase protect rat cardiomyocytes against oxidant stress. 
Cardiovasc Res. 1999;41:126-134 
590. Docherty JC, Kuzio B, Silvester JA, Bowes J, Thiemermann C. An inhibitor 
of poly (adp-ribose) synthetase activity reduces contractile dysfunction and 
preserves high energy phosphate levels during reperfusion of the ischaemic rat 
heart. Br J Pharmacol. 1999;127:1518-1524 
591. Liaudet L, Szabo E, Timashpolsky L, Virag L, Cziraki A, Szabo C. 
Suppression of poly (adp-ribose) polymerase activation by 3-aminobenzamide 
in a rat model of myocardial infarction: Long-term morphological and 
functional consequences. Br J Pharmacol. 2001;133:1424-1430 
592. Yang Z, Zingarelli B, Szabo C. Effect of genetic disruption of poly (adp-
ribose) synthetase on delayed production of inflammatory mediators and 
delayed necrosis during myocardial ischemia-reperfusion injury. Shock. 
2000;13:60-66 
593. Thiemermann C, Bowes J, Myint FP, Vane JR. Inhibition of the activity of 
poly(adp ribose) synthetase reduces ischemia-reperfusion injury in the heart 
and skeletal muscle. Proc Natl Acad Sci U S A. 1997;94:679-683 
594. Bowes J, Ruetten H, Martorana PA, Stockhausen H, Thiemermann C. 
Reduction of myocardial reperfusion injury by an inhibitor of poly (adp-
ribose) synthetase in the pig. Eur J Pharmacol. 1998;359:143-150 
595. Zhao YJ, Wang JH, Fu B, Ma MX, Li BX, Huang Q, Yang BF. Effects of 3-
aminobenzamide on expressions of poly (adp ribose) polymerase and 
apoptosis inducing factor in cardiomyocytes of rats with acute myocardial 
infarction. Chin Med J (Engl). 2009;122:1322-1327 
596. Wayman N, McDonald MC, Thompson AS, Threadgill MD, Thiemermann C. 
5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate 
ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol. 
2001;430:93-100 
597. Toth-Zsamboki E, Horvath E, Vargova K, Pankotai E, Murthy K, Zsengeller 
Z, Barany T, Pek T, Fekete K, Kiss RG, Preda I, Lacza Z, Gero D, Szabo C. 
Activation of poly(adp-ribose) polymerase by myocardial ischemia and 
coronary reperfusion in human circulating leukocytes. Mol Med. 2006;12:221-
228 
598. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, Dauerman H, 
Kumar S, Slomowitz N, Grip L, McCabe CH, Salzman AL. A randomized, 
placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, 
and pharmacodynamics of a potent inhibitor of poly(adp-ribose) polymerase 
(ino-1001) in patients with st-elevation myocardial infarction undergoing 
primary percutaneous coronary intervention: Results of the timi 37 trial. J 
Thromb Thrombolysis. 2009;27:359-364 
599. Liaudet L, Yang Z, Al-Affar EB, Szabo C. Myocardial ischemic 
preconditioning in rodents is dependent on poly (adp-ribose) synthetase. Mol 
Med. 2001;7:406-417 
600. Virag L, Szabo C. Purines inhibit poly(adp-ribose) polymerase activation and 
modulate oxidant-induced cell death. FASEB J. 2001;15:99-107 
601. Garnier P, Ying W, Swanson RA. Ischemic preconditioning by caspase 
cleavage of poly(adp-ribose) polymerase-1. J Neurosci. 2003;23:7967-7973 
602. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, 
Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, 
 294 
Schellens JH, de Bono JS. Inhibition of poly(adp-ribose) polymerase in 
tumors from brca mutation carriers. N Engl J Med. 2009;361:123-134 
603. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips 
LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, 
Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski 
JE, Doroshow JH. Phase 0 clinical trial of the poly (adp-ribose) polymerase 
inhibitor abt-888 in patients with advanced malignancies. J Clin Oncol. 
2009;27:2705-2711 
604. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, 
Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert 
AH, Harris AL, Newell DR, Curtin NJ. Temozolomide pharmacodynamics in 
patients with metastatic melanoma: Dna damage and activity of repair 
enzymes o6-alkylguanine alkyltransferase and poly(adp-ribose) polymerase-1. 
Clin Cancer Res. 2005;11:3402-3409 
605. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-
McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler 
RK, Matulonis U, Wickens M, Tutt A. Oral poly(adp-ribose) polymerase 
inhibitor olaparib in patients with brca1 or brca2 mutations and recurrent 
ovarian cancer: A proof-of-concept trial. Lancet. 2010;376:245-251 
606. Slominska EM, Smolenski RT, Szolkiewicz M, Leaver N, Rutkowski B, 
Simmonds HA, Swierczynski J. Accumulation of plasma n-methyl-2-
pyridone-5-carboxamide in patients with chronic renal failure. Mol Cell 
Biochem. 2002;231:83-88 
607. Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, 
Rutkowski P, Swierczynski J. N-methyl-2-pyridone-5-carboxamide: A novel 
uremic toxin? Kidney Int Suppl. 2003:S19-21 
608. Hasselwander O, Young IS. Oxidative stress in chronic renal failure. Free 
Radic Res. 1998;29:1-11 
609. Rutkowski P, Slominska EM, Wolyniec W, Smolenski RT, Szolkiewicz M, 
Swierczynski J, Rutkowski B. Nicotinamide metabolites accumulate in the 
tissues of uremic rats. J Ren Nutr. 2008;18:56-59 
610. Slominska EM, Smolenski RT, Osborne F, Swierczynski J, Yacoub MH. The 
effect of n-methyl-2-pyridone-5-carboxamide--a nicotinamide catabolite on 
poly adp-rybosylation and oxidative stress injury in endothelial cells. 
Nucleosides Nucleotides Nucleic Acids. 2005;24:259-262 
611. Kun E, Kirsten E, Ordahl CP. Coenzymatic activity of randomly broken or 
intact double-stranded dnas in auto and histone h1 trans-poly(adp-
ribosylation), catalyzed by poly(adp-ribose) polymerase (parp i). J Biol Chem. 
2002;277:39066-39069 
612. Juszczak E. Medical statistics online help: Sample size & power for clinical 
trials. 
http://www.google.co.uk/url?sa=t&source=web&cd=1&ved=0CC8QFjAA&u
rl=http%3A%2F%2Fwww.oxfordradcliffe.nhs.uk%2Fresearch%2Fprojects%2
Fdocuments%2Fmedical-statistics-online-
help.pdf&rct=j&q=www.oxfordradcliffe.nhs.uk%2F...%2Fmedical-statistics-
online-
help.pdf&ei=F83HTbq9NY25hAfZ8o37Aw&usg=AFQjCNH5NKJSgsmwsH
d40lX54uuuF1DkcA&sig2=sinZhxZH9n9oTF3JIJf3lQ&cad=rja. 2001 
613. Xiao CY, Chen M, Zsengeller Z, Szabo C. Poly(adp-ribose) polymerase 
contributes to the development of myocardial infarction in diabetic rats and 
 295 
regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol 
Exp Ther. 2004;310:498-504 
614. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of 
poly(adp-ribose) polymerase activation in the development of myocardial and 
endothelial dysfunction in diabetes. Diabetes. 2002;51:514-521 
615. Suarez-Pinzon WL, Mabley JG, Power R, Szabo C, Rabinovitch A. Poly (adp-
ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune 
diabetes in nod mice by inducing apoptosis of islet-infiltrating leukocytes. 
Diabetes. 2003;52:1683-1688 
616. Drel VR, Xu W, Zhang J, Pavlov IA, Shevalye H, Slusher B, Obrosova IG. 
Poly(adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts 
multiple manifestations of experimental type 1 diabetic nephropathy. 
Endocrinology. 2009;150:5273-5283 
617. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 
'preconditioning' protects remote virgin myocardium from subsequent 
sustained coronary occlusion. Circulation. 1993;87:893-899 
618. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. 
Myocardial protection by brief ischemia in noncardiac tissue. Circulation. 
1996;94:2193-2200 
619. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: 
Reduction of myocardial infarct size by partial reduction of blood supply 
combined with rapid stimulation of the gastrocnemius muscle in the rabbit. 
Circulation. 1997;96:1641-1646 
620. Ren C, Gao X, Steinberg GK, Zhao H. Limb remote-preconditioning protects 
against focal ischemia in rats and contradicts the dogma of therapeutic time 
windows for preconditioning. Neuroscience. 2008;151:1099-1103 
621. Li G, Labruto F, Sirsjo A, Chen F, Vaage J, Valen G. Myocardial protection 
by remote preconditioning: The role of nuclear factor kappa-b p105 and 
inducible nitric oxide synthase. Eur J Cardiothorac Surg. 2004;26:968-973 
622. Li SJ, Wu YN, Kang Y, Yin YQ, Gao WZ, Liu YX, Lou JS. Noninvasive limb 
ischemic preconditioning protects against myocardial i/r injury in rats. J Surg 
Res. 2009 
623. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: United at 
reperfusion. Pharmacol Ther. 2007;116:173-191 
624. Dickson EW, Lorbar M, Porcaro WA, Fenton RA, Reinhardt CP, Gysembergh 
A, Przyklenk K. Rabbit heart can be "preconditioned" via transfer of coronary 
effluent. Am J Physiol. 1999;277:H2451-2457 
625. Lang SC, Elsasser A, Scheler C, Vetter S, Tiefenbacher CP, Kubler W, Katus 
HA, Vogt AM. Myocardial preconditioning and remote renal preconditioning-
-identifying a protective factor using proteomic methods? Basic Res Cardiol. 
2006;101:149-158 
626. Serejo FC, Rodrigues LF, Jr., da Silva Tavares KC, de Carvalho AC, 
Nascimento JH. Cardioprotective properties of humoral factors released from 
rat hearts subject to ischemic preconditioning. J Cardiovasc Pharmacol. 
2007;49:214-220 
627. Patel HH, Moore J, Hsu AK, Gross GJ. Cardioprotection at a distance: 
Mesenteric artery occlusion protects the myocardium via an opioid sensitive 
mechanism. J Mol Cell Cardiol. 2002;34:1317-1323 
628. Hajrasouliha AR, Tavakoli S, Ghasemi M, Jabehdar-Maralani P, Sadeghipour 
H, Ebrahimi F, Dehpour AR. Endogenous cannabinoids contribute to remote 
 296 
ischemic preconditioning via cannabinoid cb2 receptors in the rat heart. Eur J 
Pharmacol. 2008;579:246-252 
629. Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B. Limb ischemia 
preconditions the heart against reperfusion tachyarrhythmia. Am J Physiol. 
1997;273:H1707-1712 
630. Singh D, Chopra K. Evidence of the role of angiotensin at(1) receptors in 
remote renal preconditioning of myocardium. Methods Find Exp Clin 
Pharmacol. 2004;26:117-122 
631. Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac 
preconditioning at a distance. Am J Physiol Heart Circ Physiol. 
2000;278:H1571-1576 
632. Li YJ, Xiao ZS, Peng CF, Deng HW. Calcitonin gene-related peptide-induced 
preconditioning protects against ischemia-reperfusion injury in isolated rat 
hearts. Eur J Pharmacol. 1996;311:163-167 
633. Wolfrum S, Nienstedt J, Heidbreder M, Schneider K, Dominiak P, Dendorfer 
A. Calcitonin gene related peptide mediates cardioprotection by remote 
preconditioning. Regul Pept. 2005;127:217-224 
634. Kristiansen SB, Henning O, Kharbanda RK, Nielsen-Kudsk JE, Schmidt MR, 
Redington AN, Nielsen TT, Botker HE. Remote preconditioning reduces 
ischemic injury in the explanted heart by a katp channel-dependent 
mechanism. Am J Physiol Heart Circ Physiol. 2005;288:H1252-1256 
635. Tokuno S, Hinokiyama K, Tokuno K, Lowbeer C, Hansson LO, Valen G. 
Spontaneous ischemic events in the brain and heart adapt the hearts of 
severely atherosclerotic mice to ischemia. Arterioscler Thromb Vasc Biol. 
2002;22:995-1001 
636. Weinbrenner C, Schulze F, Sarvary L, Strasser RH. Remote preconditioning 
by infrarenal aortic occlusion is operative via delta1-opioid receptors and free 
radicals in vivo in the rat heart. Cardiovasc Res. 2004;61:591-599 
637. Zhang SZ, Wang NF, Xu J, Gao Q, Lin GH, Bruce IC, Xia Q. Kappa-opioid 
receptors mediate cardioprotection by remote preconditioning. Anesthesiology. 
2006;105:550-556 
638. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield 
JE, MacAllister RJ. Remote ischemic preconditioning provides early and late 
protection against endothelial ischemia-reperfusion injury in humans: Role of 
the autonomic nervous system. J Am Coll Cardiol. 2005;46:450-456 
639. Shihab FS, Bennett WM, Andoh TF. Role of cellular cholesterol in 
pharmacologic preconditioning with cyclosporine in experimental kidney 
transplantation. Am J Nephrol. 2010;31:134-140 
640. Stambaugh K, Elliott GT, Jacobson KA, Liang BT. Additive effects of late 
preconditioning produced by monophosphoryl lipid a and the early 
preconditioning mediated by adenosine receptors and katp channel. 
Circulation. 1999;99:3300-3307 
641. Sato H, Bolli R, Rokosh GD, Bi Q, Dai S, Shirk G, Tang XL. The 
cardioprotection of the late phase of ischemic preconditioning is enhanced by 
postconditioning via a cox-2-mediated mechanism in conscious rats. Am J 
Physiol Heart Circ Physiol. 2007;293:H2557-2564 
642. Mullenheim J, Ebel D, Bauer M, Otto F, Heinen A, Frassdorf J, Preckel B, 
Schlack W. Sevoflurane confers additional cardioprotection after ischemic late 
preconditioning in rabbits. Anesthesiology. 2003;99:624-631 
 297 
643. Mullenheim J, Schlack W, Frassdorf J, Heinen A, Preckel B, Thamer V. 
Additive protective effects of late and early ischaemic preconditioning are 
mediated by the opening of katp channels in vivo. Pflugers Arch. 
2001;442:178-187 
644. Xin P, Zhu W, Li J, Ma S, Wang L, Liu M, Wei M, Redington AN. Combined 
local ischemic postconditioning and remote perconditioning recapitulate 
cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart 
Circ Physiol. 2010;298:H1819-1831 
645. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the 
transplanted kidney. Transplantation. 1997;64:945-947 
646. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: 
Risk factors and implications for renal allograft survival. Transplantation. 
1997;63:968-974 
647. Halloran PF, Aprile MA, Farewell V, Ludwin D, Smith EK, Tsai SY, Bear 
RA, Cole EH, Fenton SS, Cattran DC. Early function as the principal correlate 
of graft survival. A multivariate analysis of 200 cadaveric renal transplants 
treated with a protocol incorporating antilymphocyte globulin and 
cyclosporine. Transplantation. 1988;46:223-228 
648. MacAllister RJ. Clinical trial: Renal protection against ischaemia-reperfusion 
in transplantation. 2010 
649. Koneru. Clinical trial: Remote ischemic preconditioning in abdominal organ 
transplantation (ripcot). NCT00975702. 2009 
650. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, 
Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. 
Erythropoietin protects the kidney against the injury and dysfunction caused 
by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115-2124 
651. Nephrology ASo. American society of nephrology renal research report. J Am 
Soc Nephrol. 2005;16:1886-1903 
652. Agrawal M, Swartz R. Acute renal failure. Am Fam Physician. 2000;61:2077-
2088 
653. Silvester W, Bellomo R, Cole L. Epidemiology, management, and outcome of 
severe acute renal failure of critical illness in australia. Crit Care Med. 
2001;29:1910-1915 
654. Liano F, Pascual J. Epidemiology of acute renal failure: A prospective, 
multicenter, community-based study. Madrid acute renal failure study group. 
Kidney Int. 1996;50:811-818 
655. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining 
mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 
2006;17:1143-1150 
656. Hsu CY, McCulloch CE, Fan D, Ordonez JD, Chertow GM, Go AS. 
Community-based incidence of acute renal failure. Kidney Int. 2007;72:208-
212 
657. Hoshida S, Kuzuya T, Fuji H, Yamashita N, Oe H, Hori M, Suzuki K, 
Taniguchi N, Tada M. Sublethal ischemia alters myocardial antioxidant 
activity in canine heart. Am J Physiol. 1993;264:H33-39 
658. Zhai X, Zhou X, Ashraf M. Late ischemic preconditioning is mediated in 
myocytes by enhanced endogenous antioxidant activity stimulated by oxygen-
derived free radicals. Ann N Y Acad Sci. 1996;793:156-166 
659. Takano H, Manchikalapudi S, Tang XL, Qiu Y, Rizvi A, Jadoon AK, Zhang 
Q, Bolli R. Nitric oxide synthase is the mediator of late preconditioning 
 298 
against myocardial infarction in conscious rabbits. Circulation. 1998;98:441-
449 
660. Patel HH, Hsu AK, Gross GJ. Cox-2 and inos in opioid-induced delayed 
cardioprotection in the intact rat. Life Sci. 2004;75:129-140 
661. Bell RM, Clark JE, Hearse DJ, Shattock MJ. Reperfusion kinase 
phosphorylation is essential but not sufficient in the mediation of 
pharmacological preconditioning: Characterisation in the bi-phasic profile of 
early and late protection. Cardiovasc Res. 2007;73:153-163 
662. Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-
Filipe H, Thiemermann C. Tempol, a membrane-permeable radical scavenger, 
reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney 
Int. 2000;58:658-673 
663. Kumar S, Allen DA, Kieswich JE, Patel NS, Harwood S, Mazzon E, 
Cuzzocrea S, Raftery MJ, Thiemermann C, Yaqoob MM. Dexamethasone 
ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol. 
2009;20:2412-2425 
664. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, 
Thiemermann C. Pretreatment with epo reduces the injury and dysfunction 
caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 
2004;66:983-989 
665. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell 
death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 
1992;119:493-501 
666. Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, 
Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote ischemic 
preconditioning reduces myocardial and renal injury after elective abdominal 
aortic aneurysm repair: A randomized controlled trial. Circulation. 
2007;116:I98-105 
667. Lazaris AM, Maheras AN, Vasdekis SN, Karkaletsis KG, Charalambopoulos 
A, Kakisis JD, Martikos G, Patapis P, Giamarellos-Bourboulis EJ, Karatzas 
GM, Liakakos TD. Protective effect of remote ischemic preconditioning in 
renal ischemia/reperfusion injury, in a model of thoracoabdominal aorta 
approach. J Surg Res. 2009;154:267-273 
 
 
